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ABSTRACT  
Background Since the initiation of drug utilisation research in the 1960s, the 
research in this area has continued to grow over the years, and in 2015 this 
search term reached over 20,000 hits in Medline. Whilst this area of research 
is known to be used in assessing the rational use of drugs, including 
prescribing, less is known about it in the neonatal population. In the UK, a 
drug utilisation study across neonatal units was conducted in 2009, but 
several limitations were observed that hinders a true representation of drug 
use patterns on a national level. Also, this study highlighted future research 
needs in one of the most challenging areas in neonatal medicine, which is 
managing patent ductus arteriosus (PDA). Ibuprofen is one of the drugs used 
to manage PDA; however, the rising reports of its adverse effects from 
observational studies requires further evaluation on when to use this agent, 
especially with the emergence of paracetamol as a suggestive alternative. In 
light of these existing gaps in knowledge, this thesis has been formulated to 
address a general question of ‘Where are we at when it comes to rational 
prescribing of drugs in one of the most vulnerable populations towards  
adverse effects from drugs?’. The aim was designed to assess the rational 
use of drugs in neonates at the very first step of the drug use process, which 
is prescribing. As a result, several questions were answered, and others set 
for future research.    
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Methods An updated literature review was undertaken to provide an overall 
picture of neonatal drug utilisation studies across different regions. Then, this 
was narrowed to the UK setting by a retrospective pharmaco-epidemiological 
study investigating drug use patterns in England and Wales from 2010 to 
2017 using the National Neonatal Research Database (NNRD), a large 
database from participating neonatal units across the UK. Having identified 
the drug use patterns and changes on drug use over time from 2010 to 2017, 
a follow up analysis to investigate the changes in drugs used in PDA was 
undertaken to explore the current practice in this condition. This was followed 
by a systematic review and meta-analyses of adverse effects of ibuprofen 
when used in preterm neonates with PDA to illuminate the safety profile of 
this popular agent. As a final explorative step, investigating the drugs’ 
prescribing contents were looked at across neonatal drug formularies and/or 
clinical practice guidelines across UK neonatal units.   
Results The findings of the drug utilisation literature review have shown that 
drug use patterns are similar globally, especially in Europe, with antibiotics 
remaining the most frequently prescribed drugs. In the retrospective 
pharmaco-epidemiological study, 638,843 neonates across 187 neonatal 
units in England and Wales (from 2010 to 2017) were included in the final 
analysis. The number of drugs prescribed per neonate (median (range, IQR)) 
was 2 (0-69, 0-3), with extremely preterm neonates received the highest 
number of drugs, 17 (0-69, 12-25). Across the entire cohort, the most 
frequently prescribed drug was benzylpenicillin, prescribed to 355,679 (56%) 
of neonates at least once during their hospital stay, closely followed by 
gentamicin which was prescribed to 347,713 (54%) of neonates. Drug 
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changes over time have also been explored; those with an overall increase in 
their use over the eight-year period across the entire cohort were sodium, 
benzylpenicillin, gentamicin, and pulmonary surfactants, whereas those with 
overall decrease were cefotaxime, domperidone, ranitidine, and ocular 
chloramphenicol. Across England and Wales, 18,181 (30%) of very and 
extremely preterm neonates had a record of PDA from 2010 to 2017. The 
analysis of different PDA treatment modalities has shown that ibuprofen was 
prescribed at least once to 27% of neonates with PDA, indomethacin to eight 
percent, and surgery to six percent, whereas 65% of neonates with PDA 
have not been recorded with any treatment (indomethacin and/or ibuprofen 
and/or surgery). A total of 90 studies were included in the systematic review 
of adverse effects of ibuprofen, with the largest number of neonates (3,831) 
receiving ibuprofen were recruited within 26 retrospective studies and 
accounted for half of the extracted adverse effects (2,264/4,700). Ibuprofen 
was discontinued in 56 neonates because of GI bleeding and renal toxicity. 
Inconsistencies in the dosage regimen of drugs with harm potential (e.g., 
gentamicin, caffeine) were found in the collected drug formularies. 
Conclusion Understanding how drugs are prescribed and the pattern of their 
use over time in any neonatal care setting is important as a primary step 
towards rational prescribing. This thesis provides a benchmark for referral 
when prioritising research agendas in neonates, especially in the UK.  
However, the resources (such as NNRD) used to assess drug utilisation 
need to be improved to provide more in-depth understanding of drug use in 
neonates and to detect any inappropriate/irrational prescribing in this 
population.        
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CHAPTER 1 INTRODUCTION  
In critical care settings such as neonatal care, any inappropriate use of drugs 
is a great risk, especially to vulnerable neonates at the start of their lives (1). 
The World Health Organisation (WHO) estimates that more than 50% of 
drugs are prescribed, dispensed or sold inappropriately (2). This has driven 
researchers towards exploring the best ways to rationalise the use of drugs. 
In response, this thesis aims to address some of the gaps concerning the 
rational use of drugs in the neonatal population.  
 Rational use of medicines in neonates 
The WHO defines the rational use of medicines as “the use of medicines so 
that individual patients receive medicines that are appropriate to their clinical 
needs, in doses in accordance with their own individual requirements, for the 
appropriate period of time, and at the lowest or reasonable cost to both the 
individual and the community” (3). This definition has been cited over the 
years and used extensively in research to evaluate the process of drug use 
within any healthcare system or organisation.  
Prescribing is the first step in any medication use process. The complexity of 
prescribing to the neonatal population stems from several factors that include 
the lack of licensed formulations and limited evidence-based information on 
dosing and indication of drugs suitable for this population (1). Lack of 
universally standardised and accepted guidelines on drug prescribing and 
individualising drug therapy in neonatal care adds a further challenge when 
prescribing to neonates (4,5). The concept of ‘one size fits all’ cannot be 
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applied when deciding on dosage considerations in this population. This is 
due to the rapid changes in neonates’ body surface area and weight that 
necessitates continual dosing alterations (4,5).  
Another obstacle when prescribing in neonates, particularly in preterm 
neonates, is the immaturity of their organs, which alters the pharmacokinetics 
and pharmacodynamics (PKPD) of the drugs and may consequently 
predispose them to various adverse drug reactions (5). The potential 
significant harm from inappropriate prescribing in neonates adds a further 
twist to the problem. This is emphasised by an observational study that 
reported a three-fold increase in the potential adverse events that occurred 
as a result of medication errors in neonatal care settings compared to adult 
settings (6). This study included paediatric inpatients, of which 16% were 
neonates. Overall, they reported that 79% of the potential adverse events 
were at the prescribing stage. However, the nature of the potential adverse 
events, including those that occurred in neonates, were not stated in the 
study.  
Hence, prescribing constitutes a crucial step in the drug use process. It 
needs to be rationalised, especially in the neonatal population who are at 
greater risk of harmful effects of the drugs. 
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 Drug utilisation research in neonatal medicine 
Drug utilisation research (DUR) is a tool that can be used as a benchmark to 
explore the prescribing patterns in a healthcare system and to assist 
researchers in prioritising the research agenda for improving practice (7). It is 
defined as the research into “the marketing, distribution, prescription, and use 
of drugs in a society, with special emphasis on the resulting medical, social 
and economic consequences” (8). Since its introduction, several terms were 
developed to further define the methods and domains used in this area of 
research, such as pharmaco-epidemiology, pharmaco-surveillance and 
pharmaco-vigilance. Pharmaco-epidemiology is the application of 
epidemiology to investigate the clinical use of drugs in a particular population. 
DUR is an essential part of pharmaco-epidemiological studies to provide an 
insight into the pattern of drug use and drug prescribing. DUR uses either a 
descriptive approach to portray a drug use pattern in a population or an 
analytical approach to further illuminate drug use by linking these data to 
morbidity, quality of healthcare, and treatment outcomes (8). 
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1.2.1 Previous reviews of drug utilisation in neonates 
So far, three systematic reviews have been conducted with an overall aim of 
providing an insight into drug prescribing patterns in neonates (9–11). 
However, two of those reviews have yielded a small number of studies that 
investigated drug use in neonatal care units (≤ 20 studies) (9,10). The most 
recent review of the literature in this field was published by Allegaert et al. 
(11). It provides an updated overview of the characteristics, objectives, 
methods, and patterns of drug use in hospitalised neonates (11). In this 
paper, Allegaert et al. updated a previous systematic review search by Rosli 
et al. and found an increasing number of studies investigating drug utilisation 
in neonates. This review further extended their findings to descriptively 
include patterns of certain drug classes that are used in neonates, such as 
opioids, gastro-intestinal (GI) drugs, respiratory stimulants, and anti-
epileptics.   
Despite the availability of these reviews that summarise the drug utilisation 
studies across different neonatal care settings, there remain limited 
comparisons of different prescribing practices between different regions of 
the world (Table 1). This is pivotal as studies describing drug use in neonates 
are accumulating, and emerging evidence suggests wide variation in 
practices across the globe (11).  
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SR to provide an overview of 
medicine use worldwide which 
includes identifying most 
frequently prescribed drugs 
SR to determine drug prescribing 
patterns for hospitalised neonates 
which includes identifying most 
frequently prescribed drugs 
Review to update a previous 
SR (Rosli et al. 2017) with a 
focus on research objectives, 
methods and patterns 
Number of studies 19 20 
30 in addition to Rosli et al., 
(Total: 50) 
Search strategy 
• Databases: Google Scholar, 
MEDLINE/PubMed, Scopus 
and EMBASE 
• Dates: 2000 to 2016 
• Search terms: MeSH terms: 
neonate, NICU, drug 
utilisation, prescription 
pattern 
• Databases: Medline, CINAHL, 
EMBASE, and PubMed 
• Dates: From inception to August 
2016 
• Search terms: Combination of 
neonates(s), newborn, infants 
WITH drug utilization, defined 
daily doses, and anatomical 
therapeutic chemical 
classification 
• Databases: Medline Ovid, 
Web of Science, 
EMBASE 
• Dates: Updated the 
search of Rosli et al. 
(2016) from August 2016 
to August 2018 
• Search terms: Refer to 
Rosli et al. (2016) 
Limitation(s) 
• Only English language 
studies 
• Excluded single class of 
drugs (such as antibiotics) 
• Only English language studies 
• Excluded conference abstracts 
• Overview of the literature 
on drug use research 
methods and objectives 
without highlighting the 
most frequently 
prescribed drugs across 
regions 
MeSH, medical subject heading; SR, systematic review 
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 Drug utilisation studies in the UK 
1.3.1 Overview of neonatal population and care in the UK  
1.3.1.1 Birth statistics from England and Wales 
There were 657,076 live births in England and Wales in 2018, a decrease of 
3.2% since 2017 and 10% decrease since the most recent peak of live births 
in 2012 (12) (Figure 1). 
Prematurity is the leading cause of death in children under five years (13). 
The WHO estimates that 15 million neonates are born prematurely, every 
year with one million deaths because of complications of preterm birth (13). 
In the UK, approximately 60,000 neonates are born prematurely per year 
(one in every 13 neonates born in the UK) (14).  
The calculated rate of preterm births in England and Wales was found to be 
almost constant, ranging from 75 per 1,000 live births in 2014 to 79 per 1,000 
live births in 2018 (Figure 2). 




Figure 1. Number of live births in England and Wales 
Source: The Office for National Statistics (ONS) (15)  
 




Figure 2. Number of preterm births (< 37 weeks gestation) in England and Wales  
 Source: The Office for National Statistics (ONS) (16)
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1.3.1.2 Neonatal mortality from the UK 
Neonatal mortality rate indicates the number of deaths during the first 28 
completed days of life per 1000 live births in a given year or other period 
(17). The neonatal mortality rate was lowest in England and Wales in 2014, 
with a rate of 2.5 per 1,000 live births (12). The rate following that year has 
increased reaching 2.8 per 1,000 live births in 2018 (Figure 3).  
A recent perinatal mortality surveillance report was released by the UK 
maternal, newborn and infant clinical outcome review programme in October 
2019 (18). In 2017, 12.2% of neonatal deaths were due to extreme 
prematurity classified as a primary cause of death. Other reasons are shown 
in Figure 4.
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Figure 3. Neonatal mortality rate in England and Wales 
Source: The Office for National Statistics (ONS) (15)  
 




Figure 4. Causes of neonatal death across UK and crown dependencies 
in 2017 using the Cause of Death & Associated Conditions (CODAC) 
classification a. Neonatal deaths according to CODAC ‘level 1’ 
classification b. Neonatal deaths according to CODAC ‘level 2’ 
classification
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1.3.1.3 Neonatal care in the UK 
The National Neonatal Audit Programme (NNAP) in 2019 estimated that one 
in seven neonates in the UK received neonatal care due to prematurity, low 
birth weight (LBW), or need for other specialist treatment (19). Most of these 
admissions, around 60%, are for those born at full term gestation (20,21).  
Across the UK, there are approximately 195 neonatal units with three 
different levels of service within the National Health Service (NHS) (22,23). 
Each of these levels functions to provide the specialist care that is tailored 
towards the needs of neonates (24). These levels are categorised according 
to the complexity of care provided by the British Association of Perinatal 
Medicine (BAPM) according to 2011 definition into special care unit (SCU-
level one), local neonatal unit (LNU-level two), and neonatal intensive care 
unit (NICU-level three) (24).  
Level one (SCU) of neonatal care provides care for singleton births born at 
gestational age (GA) > 32 weeks and birth weight (BW) > 1000 g. However, 
neonates born between 30-32 weeks can be admitted to this level provided 
that their BW is > 1000 g and not requiring intensive care. This level is known 
for its initial and short-term care and involve stabilisation of neonates prior to 
their transfer to other unit levels (LNUs or NICUs), or caring for neonates in 
need of special or post-surgical care following their return from those units. 
Services provided can include neonates requiring phototherapy, having an 
intravenous (IV) cannula, needing observation or continuous monitoring and 
those on feeding by nasogastric or jejunal or gastrostomy.  
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Level two (LNU) is a high dependency unit providing additional services to 
those provided by SCUs and is dedicated to providing care for singleton 
births with GA > 27 weeks, multiple births with GA > 28 weeks provided that 
their BW > 800 g. LNU provides limited intensive care and is responsible for 
ongoing post-surgical care and care for transferred neonates from other 
network neonatal units. Also, this level is responsible for stabilising neonates 
before their NICU transfer. This level includes neonates requiring non-
invasive respiratory support, parenteral nutrition (PN) and continuous drug 
infusions (except prostaglandin and/or insulin).  
Level three (NICU) represents the highest level in terms of neonatal care for 
neonates who are mostly unwell and unstable. Similarly, this level provides 
all the services provided by SCUs and LNUs in addition to other complex 
services. This unit level provides neonatal services for neonates with GA ≥ 23 
weeks, and any neonate requiring complex or prolonged intensive care. 
Neonatal units in the UK are organised as collaborative regional operational 
delivery networks to provide high quality specialist neonatal care and improve 
the survival of neonates admitted to neonatal units (25,26). These networks 
involve collaboration between tertiary and non-tertiary neonatal units to 
transfer neonates in need for a high level of care to a tertiary unit vs. step-
down transfer for those requiring less level of care to a non-tertiary unit within 
the same network (27). This was emphasized following the recommendation 
by the department of health to reorganise neonatal services into clinical 
networks in 2003 (25).  
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1.3.2 Paucity of drug utilisation studies in the UK 
There are a limited number of drug utilisation studies in the UK, and only two 
were found across the literature (28,29). The most recent one was conducted 
in 2009. A scoping survey was used as a data collection tool to collect the 
results over two week period from 116 neonatal units. This study reported 
that the most frequently prescribed drugs were gentamicin, followed by 
benzylpenicillin and vitamin K. This study was limited mainly by the low 
response rate. Only 42% of units responded (n=49) to the survey, limiting the 
ability to generalise the findings of this study.  
The second study was also a prospective study, by Conroy et al., aimed to 
determine the extent of use of unlicensed or off label drugs in a single 
neonatal unit (29).  
1.3.3 Neonatal drug formularies and clinical practice guidelines 
Quality, which is considered a determinant of irrational practice, is assessed 
through the comparison of current practices against the local drug 
formularies and guidelines (7). Drug use across neonatal care units 
(including dosing, formulations, and direction) differs widely. This is related to 
the setting, availability, and accessibility of the drug depending on the 
country, licensing and off-labelling status, and national and international 
guidelines (9,10). This will consequently affect the available prescribing 
information within any neonatal drug formulary or any clinical practice 
guidelines.  
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The previous study by Conroy et al. exploring the nature of off label and 
unlicensed drugs have reported that benzylpenicillin accounted for the 
highest number off-label prescription in terms of its dosage (29). 
Benzylpenicillin prescribed 120 mg/kg/day, followed by 240 mg/kg/day is 
higher than the licensed dose (50-75 mg/kg/day). This suggests differences 
in terms of the recommendations of the product licence and the current 
prescribing practice. Interestingly, this study has pointed out the fact that 
different doses of benzylpenicillin contained within different commonly used 
neonatal prescribing formularies. However, this study was a single centre 
study so these findings may not be generalisable.  
In the UK, the British National Formulary for Children (BNF-C), published by 
the British Medical Association and the Royal Pharmaceutical Society, is 
considered the standard of drug prescribing and dosing guide. It meets the 
WHO standards for national formularies (28) and widely used in the UK. 
Neonatal units often have their own local or regional resources in which they 
use it in conjunction with the BNF-C.  
No study has explored whether prescribing information in those formularies 
and other clinical practice guidelines is similar or different to national 
guidelines. 
1.3.4 A dilemma in neonatal pharmacotherapy: Medical management of 
patent ductus arteriosus (PDA) in preterm neonates 
PDA is a cardiovascular complication of prematurity in which the ductus 
arteriosus fails to close after birth. The ductus arteriosus is a vital blood 
vessel that connects the aorta and the pulmonary artery to allow blood flow 
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between these arteries during fetal life. Normally, the ductus arteriosus 
closes within a few days after birth as the lungs expand and blood is 
redirected from the right side of the heart, through the lung, back to the left 
side of the heart and out to the body (30). In PDA, the ductus arteriosus 
remains open leading to increased risk of complications such as heart failure 
and reduced blood flow to vital organs (e.g. kidney and GI tract). It has been 
estimated that PDA affects approximately 25% of preterm neonates born at 
GA < 33 weeks (31). In most term neonates (GA ≥ 37 weeks) PDA closes by 
72 hours, whereas it takes longer in preterm neonates (32).  
Small to moderate PDA tends to close spontaneously, therefore treatment is 
not required, especially in those born at GA > 28 weeks (33). However, larger 
PDA may require medical or surgical intervention as they are also associated 
with adverse outcomes (33). Several treatment strategies have been 
investigated in terms of their efficacy and safety in the management of PDA. 
Treatment strategies can be divided into three main categories: conservative, 
pharmacological and surgical. Conservative treatment includes fluid 
restriction, ventilator support, and increased positive end expiratory pressure. 
Several recent studies have shown that non-intervention strategies (i.e. 
conservative strategy) were not associated with an increase risk in morbidity 
and/or mortality (34–37). Conservative strategy has proven its 
successfulness in neonates with a BW > 1000 g with few risk factors of 
having PDA (33,38). Pharmacological treatment is often reserved to preterm 
neonates with LBW and diagnosed with PDA as persistent PDA in this 
population is associated with a higher risk of mortality (33). Two non-steroidal 
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anti-inflammatory drugs (NSAIDs), indomethacin and ibuprofen, have been 
approved for PDA closure. This is due to their inhibitory effect on the release 
of prostaglandins, which play a role in maintaining ductal patency. Both have 
been associated with similar closure rates but differ in terms of their adverse 
effect profile (detail in section 1.3.4.1). Paracetamol is the most recent drug 
used in PDA, as it has a similar effect of NSAIDs in decreasing circulating 
prostaglandins but with different mechanism by acting at the peroxidase site 
of prostaglandin H2 synthetase (33). Paracetamol was found to be most 
effective when started in preterm neonates during their first week of life (39). 
Despite its better tolerability when compared to ibuprofen, paracetamol is 
associated with increased level of hepatic enzymes (38). Surgical ligation 
strategy can be considered when pharmacological measures failed to close 
PDA, often beyond the fourth week of life (40). This strategy is also 
considered in neonates where PDA results in cardiac, renal or respiratory 
failure (38).  
1.3.4.1 Why is the management of PDA a dilemma?   
There is a long-standing debate concerning the optimum management of 
PDA in preterm neonates. The most important questions of ‘when’ and 
‘whether’ to treat PDA, especially in extremely preterm neonates (GA < 28 
weeks). This question remains unanswered despite more than four decades 
of investigating the outcomes of different treatment strategies (41–44). The 
use of pharmacological interventions (indomethacin, ibuprofen, and most 
recently paracetamol) is one of the most extensively researched areas in 
Page | 18  
 
PDA. However, much uncertainty still exists about the long-term benefits of 
attempting to close the PDA with these agents. 
The most recent Cochrane systematic review on the safe and effective use of 
ibuprofen in PDA was published in February 2020 (45). The systematic 
review updated previous reviews and supported their conclusion by indicating 
that ibuprofen is as effective as indomethacin in PDA closure. The review has 
also concluded that ibuprofen remains the drug of choice as it was found to 
be associated with a lower risk of NEC and transient renal insufficiency when 
compared to indomethacin. Another recent Cochrane review published in 
January 2020 investigated the efficacy and safety of paracetamol when used 
in PDA (46). This review concluded that paracetamol is as effective as 
ibuprofen in PDA closure and was associated with lower risk of GI bleeding 
when compared to ibuprofen. One of the reasons for the lack of clear 
evidence is the fact that clinical trials have not yet fully addressed the issue 
of clinically relevant, long term benefits in their research question (47,48). A 
recent review by Bentiz and Bhombal interestingly aimed to focus on long 
term benefits of NSAIDs in PDA closure. This review conducted a meta-
analysis of 51 RCTs (1980-2016) that used NSAIDs (indomethacin, 
ibuprofen) and paracetamol in PDA. It concluded that there was no significant 
difference in long term outcomes, including neurodevelopmental outcomes, 
when managing PDA with or without the use of these drugs (48).  
PDA was flagged as one of the areas in need for further research by 
clinicians who participated in the Turner et al. survey in 2009 (28). Over a 
decade has passed and PDA management continues to be debated. Several 
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systematic reviews have investigated the efficacy of pharmacological agents 
in PDA closure. However, not many have focussed on the problems related 
to use of these agents in preterm neonates.   
1.3.4.2 Adverse effects of ibuprofen in neonates with PDA 
To date, there is not enough evidence to suggest that one pharmacological 
management strategy is superior to another in the management of PDA (49). 
Therefore, quantifying the risks of adverse effects associated with 
pharmacological agents may assist neonatologists in their clinical judgement 
for selecting the appropriate management strategy when treating PDA, or 
indeed in deciding whether to use or not to use pharmacological 
management.  
Despite the fact that ibuprofen is the preferred pharmacological agent when 
compared to indomethacin, there have been several observational studies 
that have reported adverse effects following its use. Ibuprofen was found to 
be associated with several reports of pulmonary hypertension (50–52), GI 
bleeding (53), and acute renal failure (54). Currently, there is no systematic 
review that provides comprehensive information of all the reported adverse 
effects associated with ibuprofen use in preterm neonates. Several Cochrane 
systematic reviews were conducted to derive a useful conclusion on the 
efficacy and safety of ibuprofen for use as a guidance for neonatologists 
when managing PDA in preterm neonates. These reviews only included 
RCTs or quasi-randomised trials. Some were conducted to collate studies 
where ibuprofen was used for PDA prophylaxis (55–58) and others where 
ibuprofen was used for PDA treatment (47,59–61). 
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 Thesis aim and objectives  
This thesis intends to shed light on some of the topics surrounding drug 
utilisation in neonates in the UK. The main aim sets out to assess the rational 
use of drugs in neonatal care units within areas in the UK. Several objectives 
emerged to achieve this aim based on the previous introductory sections 
which are summarised in Figure 5. 
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Figure 5. Aim and objectives of the presented thesis 
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 Outline of subsequent chapters 
The next chapter is an updated review of neonatal drug utilisation studies 
and a comparison of the patterns of drug use across different regions. In light 
of findings from this review, drug utilisation patterns across neonatal units in 
England and Wales using a national database was then investigated in 
general and the results of this study are reported in Chapter 3. Chapter 4 
reports the results of drug utilisation patterns that are used for PDA using the 
same national database. Chapter 5 reveals the findings of a systematic 
review and meta-analyses of adverse effects of ibuprofen when used in PDA 
management. This is followed by another study presented in Chapter 6, 
which describes the available prescribing information in the collected 
neonatal drug formularies and/or clinical practice guidelines from neonatal 
units in the UK. The findings of each study are discussed within the context 
of each chapter, but the overall implications for practice and future research 
are discussed in-depth in Chapter 7.  
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CHAPTER 2 REVIEW OF DRUG UTILISATION 
STUDIES IN NEONATAL UNITS 
This work has been published in the International Journal of Environmental 
Research and Public Health in August 2020, vol.17, issue 16. A copy is 
attached in 9.1. 
 Introduction  
Drug utilisation research (DUR) is needed particularly in neonatal medicine 
due to several factors that constitute a challenge to prescribers when 
deciding on the safest medicines for neonates. These challenges include the 
lack of universally standardised and accepted guidelines on drug prescribing 
and individualising drug therapy in neonatal intensive care units (NICUs) 
(4,5). Consequently, this can cause a large variation in drug prescribing 
patterns. Also, the lack of licensed formulations and limited evidence-based 
information on dosing and indication of drugs suitable for this population is 
another challenging factor many prescribers may face (1). Scoping literature 
reviews are important in this field as there are many studies that reported on 
medication use in their settings worldwide. 
 A review on drug use patterns will collate all the relevant prescribing 
information to understand the differences in prescribing patterns, if they exist, 
between and within different geographic regions. Hence, the aim of this study 
was to conduct an up-to-date review of the literature to find out the most 
frequently prescribed drugs across neonatal units worldwide.   
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 Methods 
2.2.1 Search strategy 
I constructed the search strategy with the help of the senior librarian at the 
University of Nottingham (Ms. Ruth Curtis). The search was checked by two 
people to ensure its robustness. Three databases, EMBASE, CINAHL, and 
Medline were searched from their inception to July 2020 without any other 
limits. A combination of both ‘free text’ and Medical subject headings ‘MeSH 
terms’ was applied for each database separately to attain a comprehensive 
literature search. The search was based on the following PICo (Population, 
Interest/intervention, Context) summarised in Table 2. 





Neonates, infants or 
newborns 
(all gestation age 
groups) 
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2.2.2 Search terms 
Various free-text keywords were created and used to complement the MesH 
terms. For the population search terms, an infant* or newborn* or neonate* 
were used and are defined as those who were born during the first 28 days 
after birth. For the interest/intervention, free-text keywords, a combination of 
drug use and drug utili?ation was applied. The term util?ation was used to 
cover both different spellings of this term; utilisation or utilization. The free 
text keywords for the context or setting free in this review were neonatal 
intensive care unit* and neonatal unit*. This setting was used as the aim of 
this review was to provide an updated drug utilisation literature review at the 
level of neonatal intensive care units only. All the previously mentioned free 
text keywords were used in addition to the MeSH terms identified in each 
database separately. The full search strategy is detailed in 9.2 Following the 
retrieval of the records, titles were reviewed to remove any duplicates before 
starting to screen the abstracts for inclusion. This was done manually (using 
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2.2.3 Inclusion and exclusion criteria  
Inclusion criteria: Studies of drug utilisation were included in this review if 
they fulfilled all the following criteria: 
• Included neonates treated in neonatal units  
• Provided information on drug use patterns and/or prescriptions 
patterns  
• Provided information on the most frequently prescribed drugs. This 
includes general or overall, frequently prescribed drugs or 
pharmacologic groups, off-label and or unlicenced drugs, specific 
pharmacologic groups  
Exclusion criteria: Studies were excluded for the following reasons: 
• Conference abstracts with insufficient data on drug utilisation 
• Drug utilisation studies not reporting the most frequently prescribed 
drugs  
• Drug use in children (age > 28 days) 
• Editorials and review articles 
• Maternal drug use studies 
• Systematic reviews 
• Studies in non-English language that could not be translated 
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2.2.4 Data extraction and analysis 
 All included studies were tabulated (using Microsoft Excel, Version 15 
Microsoft Corporation) to summarise the most frequently prescribed drugs 
reported in those studies. To ensure completeness, data extraction was 
performed by two reviewers: myself and Dr Ojha (Clinical Associate 
Professor of Neonatology, University of Nottingham and the PhD supervisor). 
The data extracted included the following: 
• Location of the study  
• Inclusion and exclusion criteria 
• Demographics of the included neonates (number, mean gestational 
age (GA), mean birth weight (BW), gender)  
• The number of drugs prescribed per neonate  
• Ten most frequently prescribed drugs or pharmacologic groups 
Quality assessment of the studies was not performed as there is no 
appropriate tool for the type of the studies that are included. All studies 
included in this review were descriptively summarised and presented in 
tables or figures. Stata SE 16 (64-bit) software was used to summarise some 
of the data extracted (sample size and duration of the studies). Where the 
standard deviation (SD) of the number of the drugs received per neonate not 
available, it was imputed from the available summary statistics (mean, 
median, interquartile range (IQR), range) and sample size using the process 
described by Hozo et al. (62). The correlation between proportion of included 
preterm neonates and number of drugs per neonate was calculated using the 
Pearson’s correlation coefficient test in Stata. 




2.3.1 Search results  
The initial search resulted in 715 titles and abstracts. Duplicates were then 
removed and titles and abstract screened and 92 studies were selected for 
full text evaluation. Of these, 15 were excluded and a further seven were 
added (by searching the reference list of other studies). Thus, a total of 84 
studies are included in this review (Figure 6). 
 




Figure 6. Selection of the studies for inclusion in the review of drug 
utilisation studies
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2.3.2 Drug utilisation studies: An overview 
Eighty-four studies included in this review were classified into four groups 
(Figure 7).  
Studies were conducted in 26 different countries across six different 
continents (Figure 8). India (n=14) and the United States (n=13) accounted 
for the largest number of drug utilisation studies. There was one study that 
involved several European countries (21 participated) (63) and one study 
conducted in Germany and Brazil (64). 
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Figure 7. Classification of the studies included in this review 
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Figure 8. The geographical location of drug utilisation studies included in this review
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Table 3 summarises the key demographics of the 84 studies. The studies 
had a wide range of sample size with a median (IQR) of 220 (113-1491). This 
reflects the large variation in the duration of the study period (range 1-264, 
IQR 3-18 months). The retrospective studies utilised large databases with 
routinely collected data and thus included more neonates and data over a 
longer span of time. For instance, the two main large studies were conducted 
in the United States of America (USA) over nine and five year periods by 
Clark et al. and Hsieh et al. respectively (65,66). There were 52 single centre 
studies out of 84 included studies.  
Table 3. Summary of key demographic data (84 studies) 
Demographic 
data 
Median Range IQR 
Sample size* 220 34-450386 113-1491 
Duration of the 
studies in 
months ** 
6 1-264 3-18 
*calculated for 77 studies only, 7 studies did not report the sample size 
**calculated for 79 studies only, 5 studies did not report the duration of the 
study period 
 
Figure 9 shows the data of 69 studies that mentioned the sample size and its’ 
duration in months. However, four studies were excluded from this graph due 
to their large sample size (high outliers) (65–68). 
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Figure 9. Sample size vs Duration of studies (months) of 69 studies
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2.3.2.1 Drug utilisation studies investigating drug use in general  
Sixty studies aimed to investigate drug use in the neonatal population and 
were conducted between 1983 to 2020. The majority of those studies were 
prospective in their design (43 studies, 73%) (4,5,28,29,63,69–106), with the 
remaining 17 studies (27%) utilising retrospective data extraction 
(65,66,68,107–120).  
The participants’ gender was not reported in 20 of the 60 studies. Where 
reported, most had more boys than girls (37 of 40 studies). Three studies had 
equal number of boys and girls.  
More than half of the studies (34 of 60, 57%) reported the proportion of 
prematurity among the participants (Figure 10). Two out of the 34 studies 
enrolled only preterm neonates. In addition one study by Puia-Dumitrescu et 
al. reported drugs received by neonates born at gestational age (GA) of 22-
24 weeks only (120).
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Figure 10. Percentage of preterm neonates among participants in drug utilisation studies in neonates
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All the studies had similar inclusion criteria which was based on including all 
neonates admitted into the neonatal care units who received at least one 
drug. However, the exclusion criteria varied. The majority of studies excluded 
certain items from their analyses such vitamin K, intravenous (IV) fluids, total 
parenteral nutrition (TPN), and fluids to keep the patency of the venous 
access (e.g. heparin and sodium chloride for flush). The details of inclusion 
and exclusion for each included study are given in 9.3. 
Drug use per neonate: 14 studies out of the 60 studies reported the mean ( 
SD) of the number of drugs prescribed per neonate. Seven studies reported 
the mean, but provided no information on the SD. The SD for these seven 
studies were imputed by estimation from the mean, median, range and 
sample size, where possible (62). However, it is worth noting that this formula 
has been developed with no assumptions on the distribution of the data. A 
total of 21 studies with their reported means and reported or imputed 
standard deviations of the average number of drugs prescribed per neonate 
in each study and divided by each continent are plotted in Figure 11.
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One study by Du et al. is plotted twice (Du-A, and Du-B) as it compared drug 
use in two different periods and reported different sample sizes and means 
(109). The pooled mean and the pooled SD from 29 studies out of 60 studies 
on drug use in general included in this review were 4 (2.4). Those 29 studies 
include 14 studies that reported the mean (SD) and 15 studies with imputed 
values of either mean and or SD based on the formula.  
The remaining 39 studies were not included in this plot for the following 
reasons: 
• 15 studies reported the median instead of the mean. The medians 
reported in those studies ranged between 3.5 and 9 
• One study by Aranda et al. did not report the sample size (107) 
• 17 studies reported neither the mean nor the median  
• Six studies reported the mean only without reporting the range. 
Therefore, the standard deviation could not be estimated using the 
formula (4,5,72,76,79,117). The means reported in those studies 
ranged between 1.2 and 11.1  
There were 27 studies reporting the maximum number of drugs received by 
at least one neonate. Kumar et al. reported the highest drug burden with at 
least one neonate receiving 62 drugs (115), while eight other studies 
reported that the maximum number of drugs per neonate was >  30 in their 
population.




Figure 11. The number of unique drugs prescribed per neonate
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2.3.2.1.1 Most frequently prescribed drugs  
Among the studies that reported drug use in general, 48 of 60 studies 
reported the most frequently prescribed drugs. Thirty studies out of the 60 
reported the most frequently prescribed pharmacologic groups instead of 
individual drugs, 20 studies reported most frequently prescribed off-label 
and/or unlicensed drugs, and eight studies reported most frequently 
prescribed antibiotics.  
All the 48 studies that reported most frequently prescribed drugs have 
reported at least one antibiotic agent among the ten most frequently 
prescribed drugs across NICU admissions (Figure 12). Penicillins and 
gentamicin were among the ten most frequently prescribed drugs in the 
majority of studies; 41 and 34 studies, respectively. Most studies had either 
penicillin or gentamicin as the most frequently reported antibiotics in their list 
except for six studies. Of these, two reported antibiotics (without specifying 
which antibiotic) (5,78) and the other four had cefotaxime, ceftriaxone, 
vancomycin, tobramycin, amikacin, cefoperazone-sulbactam and piperacillin-
tazobactam amongst their most frequently prescribed drugs 
(88,104,106,109). Caffeine was among the ten most frequently prescribed 
drugs cited by 25 studies.  
There were 21 studies reporting a drug from other therapeutic class as its 
most frequently used. These were calcium gluconate (two studies (70,107)), 
multivitamins (three studies (63,75,96)), vitamin K (seven studies 
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(4,81,97,101,106,111,121)) caffeine (two studies (80,88)), chlorhexidine 
powder (one study (89)), theophylline (one study (122)), epinephrine (one 
study (102)), parenteral nutrition (one study (116)), cholecalciferol (one study 
(123)), fentanyl (one study (124)) and vitamin D (one study(68)). Of the two 
studies that reported caffeine as the first most frequently prescribed drug, 
86.8% of included neonates in Cuzzolin et al. were preterm (80) while Jong 
et al. did not report the preterm proportion in their cohort (88). 
The following sections detail the most frequently prescribed drugs in each 
geographic region. The overall summary of the most frequently prescribed 
drugs per each geographic region is outlined in Table 4.   




Figure 12. Twenty most frequently prescribed drugs in neonatal units reported by 48 studies (*include: 
benzylpenicillin/penicillin/ampicillin/amoxicillin/piperacillin)
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Table 4. Overall summary of the most frequently prescribed drugs in each geographic region (48 studies) 
Geographic region (number of studies) 
(ref) 
Most frequently prescribed drugs 
(number of studies citing the drug among the  
ten most frequently prescribed drugs) 
Europe (24 studies) 
(28,29,63,68,70,74,75,80,83,84,88,89,91,92,95,96,99,101,103,110,111,113,118,122) 
Caffeine (18 studies), gentamicin (17 studies), 
ampicillin (11 studies), furosemide (9 studies), 
multivitamins (9 studies), vitamin K (11 studies), 
benzylpenicillin (8 studies), amikacin (6 studies), 
morphine (5 studies), paracetamol (6 studies) 
North America (ten studies) 
(65,66,71,102,107,109,115,116,119,120) 
Ampicillin (8 studies), gentamicin (8 studies), 
furosemide (6 studies), surfactant (6 studies), penicillin 
(5 studies), vancomycin (6 studies), caffeine citrate (6 
studies), cefotaxime (4 studies), dopamine (5 studies), 
calcium gluconate (4 studies) 
Asia (six studies) 
(4,5,69,78,104,106) 
 
Phenobarbitone (4 studies), vitamin K (4 studies), 
amikacin (3 studies), aminophylline (3 studies), 
ceftriaxone (2 studies), ceftazidime (2 studies), 
gentamicin (2 studies), phenytoin (2 studies), 
penicillin/sulbactam (2 studies), caffeine (1 study) 
Latin America and Caribbean (four studies) 
(76,85,108,117) 
Fentanyl (4 studies), gentamicin (3 studies), 
vancomycin (3 studies), multivitamins (3 studies), 
amikacin (2 studies), ampicillin (2 studies) 
furosemide (2 studies), aminophylline (2 studies), 
morphine (1 study), metamizole (1 study) 
Middle East (two studies) 
(73,97) 
Gentamicin, ampicillin, amoxicillin and vitamins 
(reported by both studies) 
Australasia (two studies) 
(81,98) 
Vancomycin and gentamicin (reported by both studies) 
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2.3.2.1.1.1 Frequently prescribed drugs in Europe  
Twenty-four studies in Europe have reported the most frequently prescribed 
drugs in their NICUs, whereas three studies have reported the most 
frequently prescribed pharmacologic class instead of drugs.  
Appendix 9.4 details the ten most frequently prescribed drugs reported by 
each of those 24 studies. However, some studies have reported less than ten 
most frequently prescribed drugs; a study by Alonso et al. reported only four 
frequently prescribed drugs (70).  
One study by Girardi et al. compared the frequently prescribed drugs in two 
different groups of neonates categorised according to their body weights, and 
therefore it was plotted and reported twice (70). Also, another study by Lass 
et al. have reported the most frequently prescribed drugs in term and preterm 
neonates and therefore the results were plotted twice for both groups in this 
review (92). However, if the same drug was reported in the two groups, it was 
counted once. 
The most frequently prescribed drug in Europe was found to be caffeine or 
caffeine citrate (18 studies), followed by gentamicin (17 studies) and 
ampicillin (12 studies).  
Two studies were conducted in the UK and both of them reported gentamicin 
to be the most frequently prescribed drug in neonates followed by 
benzylpenicillin (28,29). 
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2.3.2.1.1.2 Frequently prescribed drugs in North America  
Ten studies in North America have reported the most frequently prescribed 
drugs in their NICUs whereas two studies reported the most frequently 
prescribed pharmacologic class instead of drugs (detailed in 9.5). There were 
two studies that compared drug use in two different periods and hence the 
drugs in those studies were counted twice (107,109).  
The most frequently reported prescribed drugs in North America were 
ampicillin and gentamicin, which were reported by nine and eight studies 
respectively. Aranda et al. (107) reported it in both periods which are 
included in their study. This was followed by furosemide and surfactants, 
which were reported by six studies, with also Aranda et al. reporting it twice. 
A study by Du et al. reported surfactants twice in both periods of the study 
among the ten most frequently prescribed drugs. 
2.3.2.1.1.3 Frequently prescribed drugs in Asia  
Six studies from Asia described the most frequently prescribed drugs  
whereas five studies reported the most frequently prescribed pharmacologic 
class instead of drugs (detailed in 9.6). Two studies reported antibiotics 
without specifying the individual drugs as frequently prescribed drugs. These 
antibiotics are detailed in section 2.3.3.1.3. Phenobarbitone and vitamin K 
were reported by most of the studies, five and four studies respectively, 
followed by amikacin, which was reported by three studies.  
Choure et al. have reported ‘others’ as most frequently prescribed drugs 
without any information on what drugs were included in this category (78) . 
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2.3.2.1.1.4 Frequently prescribed drugs in Latin America and Caribbean  
Four studies from this region reported the most frequently prescribed drugs  
whereas two studies reported the most frequently prescribed pharmacologic 
class instead of drugs (detailed in 9.7). Marino et al. compared the drug use 
in four different groups of neonates characterised according to their BW 
(117). Fentanyl was the most frequently prescribed drug in Latin America and 
the Caribbean as reported by all of the studies. This was followed by 
gentamicin, vancomycin, and multivitamins, which were reported by three 
studies as amongst the ten most frequently prescribed drugs.   
2.3.2.1.1.5 Frequently prescribed drugs in the Middle East  
Only two out of the 56 studies were conducted in the Middle East (both in 
Israel) and they reported the most frequently prescribed drugs in their NICUs 
(73,97). Gentamicin, ampicillin, amoxicillin and vitamins were among the ten 
most frequently prescribed drugs reported by both studies.  
2.3.2.1.1.6 Frequently prescribed drugs in Australasia  
Only two studies  were conducted in this continent that reported the most 
frequently prescribed drugs (80,98). Vancomycin and gentamicin were 
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2.3.2.1.2 Most frequently prescribed pharmacologic groups 
As described earlier, 30 studies out of the 60 included studies reported the 
frequently prescribed pharmacologic groups in their NICUs using different 
methods in their classification. Most used the World Health Organisation-
Anatomical Therapeutic Chemical (WHO-ATC) classification system (19 of 
30 studies, 63%). Four studies listed the pharmacologic class of the drugs. 
One study by Kumar et al. has classified the pharmacologic groups based on 
the most frequent indication and the physiologic effects of the drug (115). 
The remaining six studies have not stated their classification method.  
Among the studies that used the WHO-ATC system, anti-microbials for 
systemic use were the most frequently prescribed pharmacologic group in 
the majority (14 studies, 81%), followed by agents for gastro-intestinal (GI) 
and metabolism (four studies), and agents for the central nervous system 
(one study). Among the four studies that listed the pharmacological groups 
according to their pharmacologic class, three studies reported that 
antimicrobials were the most frequently prescribed group and one study by 
Ashwin et al. identified that penicillins were the most frequently prescribed 
pharmacologic group. A study by Kumar et al. reported that the GI agents 
were the most frequently prescribed pharmacologic group (115).  
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2.3.3 Drug utilisation studies investigating antibiotics only  
Characteristics of the studies: 11 studies aimed to evaluate antibiotic use 
only in their neonatal units (64,125–134). The studies varied in their design 
between prospective (seven studies) (125,126,128,130,131,133,134), 
retrospective (two studies) (64,129), and two studies used both prospective 
and retrospective study design (127,132). Enrolled neonates ranged between 
84 to 5,619. The inclusion and exclusion criteria of those studies are detailed 
in 9.8. 
2.3.3.1 Most frequently prescribed antibiotics 
Seven of the 11 studies reported on the most frequently prescribed 
antibiotics. In addition, several antibiotics appeared in the list of the most 
frequently prescribed drugs that did not focus on antibiotics only. In total, 59 
studies reported the most frequently prescribed antibiotics used in their 
NICUs and their data are presented per each continent.   
2.3.3.1.1 Most frequently prescribed antibiotics in Europe 
Twenty-three studies in Europe have cited antibiotics among their most 
frequently prescribed drugs. Each study reported more than one antibiotic, 
and hence they are all counted accordingly. The most frequently prescribed 
antibiotics in Europe are gentamicin (17 studies) followed by ampicillin (12 
studies) (Figure 13).




Figure 13. Most frequently prescribed antibiotics in Europe (cited as one of the 10 most frequently prescribed drug 
in those studies)
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2.3.3.1.2 Most frequently prescribed antibiotics in North America 
Twelve studies in North America reported the most frequently prescribed 
antibiotics in their settings. Two studies by Aranda et al. and Du et al. have 
investigated drug use pattern in two different periods and reported the same 
antibiotics in both periods (Figure 14). 
 




Figure 14. Most frequently prescribed antibiotics in North America (cited as one of the 10 most frequently 
prescribed drug in those studies; *cited twice by the same study in two different periods) 
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2.3.3.1.3 Most frequently prescribed antibiotics in Asia 
Eleven studies in Asia reported the most frequently prescribed antibiotics. 
One study out of those 11 have reported the most frequently prescribed 
antibiotics in the participating units by their broad pharmacological groups 
instead of individual names of the antibiotics. This study was conducted in 
two units at two different hospitals and reported that aminoglycosides were 
among the most frequently prescribed antibiotics in both units (130). 
Amikacin was reported by most of the studies (nine studies) followed by 
cefotaxime (eight studies) and gentamicin (six studies) (Figure 15). The 
single study from China (106) reported the use of cefoperazone-sulbactam, 
and piperacillin-tazobactam as the most frequently used for all gestational 
age groups. 




Figure 15. Most frequently prescribed antibiotics in Asia (cited as one of the 10 most frequently prescribed drug in 
those studies)
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2.3.3.1.4 Most frequently prescribed antibiotics in Latin America and 
Caribbean 
Seven studies in this continent reported the most frequently prescribed 
antibiotics. The data from the study conducted by Marino et al. is counted 
once in this review if the same drug was reported more than once. The most 
frequently prescribed antibiotics were gentamicin, ampicillin and vancomycin 
(all reported by four studies) (Figure 16).




Figure 16. Most frequently prescribed antibiotics in Latin America and Caribbean (cited as one of the 10 most 
frequently prescribed drug in those studies)
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2.3.3.1.5 Most frequently prescribed antibiotics in other regions 
The Middle East: Two studies conducted in Israel reported antibiotics among 
their frequently prescribed drugs in their NICUs (73,97). Both studies cited 
gentamicin, ampicillin, and amoxicillin among the ten frequently prescribed 
drugs. The recent study by Nir-Neuman et al. (97) has reported meropenem 
in addition to the previously mentioned antibiotics. 
Australasia: Two studies in Australasia reported the most frequently 
prescribed antibiotics and have included gentamicin, vancomycin, ampicillin 
and benzylpenicillin in both lists (80,98).  
Africa: One study in Zimbabwe by Chimhini et al. reported gentamicin, 
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2.3.4 Drug utilisation studies investigating off-label and or unlicensed 
drugs only  
Characteristics of the studies: Six studies aimed to evaluate only off-label 
and/or unlicensed drugs use across NICUs (135–140) (detailed in 9.9). Three 
studies were retrospective (136,138,139), and three  were prospective 
(135,137,140). Number of included neonates ranged from 38 to 910. The 
percentage of preterm neonates was 53.9% in one study by Kouti et al. 
(136), whereas three studies reported more term neonates in the included 
population (137,139,140). The remaining two studies have not stated the 
percentage of neonatal prematurity in their included population (135,138).  
Most frequently prescribed off-label and /or unlicensed drugs: 20 studies that 
assessed drug utilisation, in general, have reported also most frequently 
prescribed off-label and/or unlicensed drugs. In total, the number of studies 
reporting most frequently prescribed off-label and or unlicensed drugs in this 
review is 26 studies. The studies varied between listing most frequently 
prescribed off label drugs only or most frequently prescribed both off-label 
and unlicensed (Table 5). Most of the studies (17 studies, 65%) have listed 
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n % References 
Frequently prescribed off-




Both frequently prescribed 








Some studies have not distinguished whether the most frequently prescribed 
drugs were off-label or unlicensed. Therefore, the results presented here are 
extracted from studies that clearly reported the most frequently prescribed 
off-label or unlicensed drugs. Table 6 and Table 7 summarise the most 
frequently prescribed off-label and unlicensed drugs, respectively.  
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Table 6. Five most frequently prescribed off-label drugs (15 studies) 











British National Formulary for Children (2011-2012) 
and Neofax (2011) 
Antibiotics (meropenem), NSAIDs 








British National Formulary of drugs, 
2005 version and Neofax 2008 (for doses) 
Anti-infectives, anti-convulsants, 
circulatory agents, pulmonology 






National Formulary of India (4th edition, 2011) Anti-infectives, agents for 
respiratory, agents for central 
nervous system, alimentary agents 





Saudi Arabia Saudi FDA approval for use in neonates by using the 
product monograph 
Anti-infectives, alimentary agents 
and metabolism, agents for the 





Israel Drug summary brochure Ampicillin, gentamicin, 
aminophylline, phytomenadione, 
glycerin 




Canada Health Canada-approved product 














SPC approved by Spanish and European Medicine 
Agency 







SPC approved by Spanish and European Medicine 
Agency 














France SPC of French formulary 
(Theriaque 2013) 
Calcium folinate, amikacin sulphate, 
ferrous fumarate, rifamycin, sodium 
chloride 
De Lima Costa 2018 
(82) 









Ethiopia European Medicine Agency electronic medicine 
compendium 
Antibiotics (ampicillin, vancomycin), 
NSAIDs, medicines for seziure 
CPS, Canadian Compendium of Pharmaceuticals and Specialties; FDA, Food and drug administration; SPC, Summary of product 
characteristics 
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Table 7. Five most frequently prescribed unlicensed drugs (six studies) 
Study ID Country Reference in classification 





Spain SPC approved by Spanish and 
European Medicine Agency 




Spain  SPC approved by Spanish and 
European Medicine Agency 




France SPC of French formulary 
(Theriaque, 2013) 
Glucose monohydrate, norepinephrine, 
ketamine hydrochloride, glucose phosphate, 
phenobarbital 
De lima costa 
2018 
(82) 
Brazil FDA criteria 
https://www.accessdata.fda.gov/script
s/cder/daf/ index.cfm 




Israel Drug’s information leaflet approved in 
the Ministry of Health’s drug registry 





Ethiopia European Medicine Agency electronic  
medicine compendium 
Paracetamol, phenobarbital, aminophylline 
FDA, Food and drug administration; SPC, Summary of product characteristics 
Page | 62  
 
2.3.5 Drug utilisation investigating specific pharmacologic groups  
2.3.5.1 Characteristics of the studies 
Seven studies evaluated drug use on specific pharmacological groups 
(detailed in 9.10). Three studies evaluated the use of sedatives, analgesics 
and narcotics in their NICUs (67,141,142). One prospective study evaluated 
the use of anti-epileptics (143), and one study (published as a conference 
abstract) evaluated the use of cardiovascular agents (144). One study have 
evaluated the drugs used in neonates diagnosed with Bronchopulmonary 
dysplasia (BPD) (145). One study have evaluated the use of only IV drugs in 
neonates (146).  
2.3.5.2 Analgesics and sedatives 
Three studies investigated the use of analgesics and sedatives in the 
neonatal population and reported that fentanyl, morphine, midazolam and 
paracetamol were among the five most frequently prescribed analgesics and 
sedatives (67,141,142).    
2.3.5.3 Anti-convulsants 
A study by Ahmad et al. evaluated the changing pattern of anti-convulsants 
over time, from 2005 to 2014, in 341 NICUs (9,134 neonates) in the USA 
(143). This retrospective study found that phenobarbital was the most 
frequently prescribed drug from 2005 to 2014 (96.3% - 99.4%). This was 
followed by phenytoin (11.6% - 13.8 %) from 2005 to 2012, and levetiracetam 
(14.3%) was prescribed more than phenytoin (11%) from 2013 to 2014. 
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2.3.5.4 Cardiovascular agents 
A study by Hallik et al. evaluated the use of cardiovascular agents across 89 
different European NICUs and reported that inotropes (dopamine followed by 
dobutamine and adrenaline), diuretics and indomethacin/ibuprofen were the 
most frequently prescribed cardiovascular agents (144). 
2.3.5.5 Drugs used in Bronchopulmonary dysplasia (BPD) 
A retrospective study by Bamat et al. that involved multicentre (43 NICUs, 
3252 neonates) in the United States aimed to explore the most frequently 
used drugs among neonates with symptomatic BPD. This study reported 
sodium chloride followed by furosemide and potassium chloride as the top 
three drugs used in BPD (145).  
2.3.5.6 Intravenous drugs  
A prospective survey by De Basagoiti et al. conducted over one month in 
nine Spanish NICUs with an aim of  exploring the most frequently prescribed 
IV drugs (146). This study reported the most frequently used IV drugs by their 
pharmacological class and found that anti-infectives followed by 
cardiovascular drugs and drugs used in central nervous system were the 
most frequently prescribed IV drugs. 
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2.3.5.7 Drug utilisation in high- and middle-income regions 
This section compares the use of analgesics, anti-convulsants, and 
surfactants use between high- and middle-income regions.  
Use of analgesia: 27 studies in this review cited one or more analgesics 
among the ten most frequently prescribed drugs in their NICUs (Figure 17) 
(29,66–69,74,76,78,80,89,98,101,102,108–
111,113,115,117,118,120,124,141,142,147,148). In high income regions 
(Europe, North America, Middle east, Australasia), the most frequently 
prescribed analgesic was fentanyl, followed by morphine and paracetamol. In 
middle income regions (Asia, Latin America), the most frequently prescribed 
drug was fentanyl, followed by paracetamol. 
Use of anti-epileptics: 11 studies (4,5,69,76,78,104,108,117,124) reported 
the use of one or more anti-epileptic agents among the ten most frequently 
prescribed drugs in their NICUs (Figure 18). In both high- and middle-income 
regions, phenobarbital was the most frequently prescribed anti-convulsant.  




Figure 17. Most frequently prescribed analgesics in a. high income 
regions b. middle income regions (cited as one of the 10 most 
frequently prescribed drug in those studies) 
 




Figure 18. Most frequently prescribed anti-convulsants in a. high 
income regions b. middle income region (cited as one of the 10 most 
frequently prescribed drug in those studies)
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Use of surfactants: 12 studies (65,66,91,93,95,109–111,113,113,119,120) in 
high income regions reported different types of surfactants among the ten 
most frequently prescribed drugs in their NICUs (Figure 19). However, only 
one study, Marino et al. (117), conducted in Brazil reported pulmonary 
surfactants as one of their ten most frequently prescribed drugs. This study 
has reported pulmonary surfactants in four different groups of neonates 
divided according to their BW and surfactants were reported as the most 
frequently prescribed drugs in neonates with BW < 2500 g.  
 




Figure 19. Use of surfactants in high income region (cited as one of the 10 most frequently prescribed drug in 
those studies)
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 Discussion and conclusion  
To date, this is the most comprehensive review of the literature that provides 
widespread and updated information on the most frequently prescribed drugs 
across various NICUs worldwide, with a comparison between different 
geographic regions.    
2.4.1 Comparison with other reviews 
This review has added 35 studies to the previous systematic reviews and 
their dates of publication ranged from 1983 to the most recent study in 2020.  
Availability of resources is a major determinant in provision of neonatal care. 
This is evident in the wide disparities in survival of neonates, especially 
preterm neonates between different regions of the world. The United Nations 
Inter-agency Group for Child Mortality Estimation reported that in 2017 the 
annual neonatal mortality rate (NMR) was highest in west and central Africa, 
at 30.2 deaths per 1000 livebirths and in south Asia (which included India) at 
26.9 per 1000 livebirths and lowest in the high-income countries, 3.0 per 
1000 livebirths. Together, south Asia and sub-Saharan Africa accounted for 
79% of the total burden of neonatal deaths (149). With such disparities, it is 
important to study the differences in all aspects of care between different 
regions of the world. In this review I have investigated any reported 
differences in drug utilisation patterns. 
When looking at drug utilisation studies globally, this review has captured 
studies from most parts of the world with India, which has the highest number 
of preterm births, contributing the largest number of the studies followed by 
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the USA. There have been WHO-led concern that the WHO South-East Asia 
region, which includes India, is likely to be the most at risk part of the world 
for the emergence of resistant to microorganisms (150).  
In terms of the methodologies of the included studies, they remained limited 
due to lack of information to assess the rational use of drugs such as dose, 
indication or duration of use. Most studies were restricted to a single centre 
and included a limited sample size. However, larger studies such as those 
from the Paediatrix Medical group in the USA (65,66) are powered by their 
electronic patient records. Such records may enable further large-scale 
evaluations of drug utilization; however, this requires efforts to improve 
electronic patients records to appropriately assess the rational prescribing in 
neonatal medicine. Such improvement should be directed towards use of 
standardized nomenclature and categorization of drugs, collection of data on 
indications, dosage, adverse effects and medication errors. 
2.4.2  Drug use in general 
 Half of the studies (27 studies) that investigated drug use in general were 
conducted in 11 European countries. In addition to those 11 European 
countries, a collaborative study presented in this review was performed which 
involved several European countries (21 participated) (63). 
None of the previous systematic reviews have summarised the sample size, 
the duration of studies, or proportion of premature neonates in the included 
cohorts. In this current review, the median (range, IQR) sample size of 
neonates in 77 studies that reported the sample size was 220 (34-450386, 
113-1491). This huge variation can be attributed to the study designs 
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(prospective vs. retrospective) and the study duration, which can affect the 
number of neonates enrolled. There were 17 single centre studies (out of 84 
studies) with less than one hundred neonates included that may limit a firm 
conclusion with regard to the drug utilisation in such settings. The larger 
studies that included many thousands of neonates were enabled by 
retrospective analyses of routinely collected clinical data from large 
healthcare providers in the United States (65). In the UK, a critical review by 
Foster and Young assessed the usefulness of secondary data (i.e. routinely 
collected patient data and stored electronically) for research purposes on a 
neonatal level (151). This critical review highlighted the possibility at present 
of using secondary data for research purposes in the UK due to the existence 
of the National Health Service (NHS), which holds thousands of electronic 
neonatal records collected over a long period of time. Black et al. pointed out 
the usefulness of such data in several research areas such as identifying the 
development and causes of certain diseases, assessment of the healthcare 
interventions, and trends in the use of healthcare. The benefit of such data 
can be manifested in service planning and operational management of a 
healthcare system as added by Higgins et al. However, one should take into 
account several issues concerning parents’ consent, use of patient-
identifiable data, and the accuracy and security of electronic records when 
using such data in research (151).  
The population included in the studies within this review are quite 
heterogeneous. Most studies include all neonatal unit admissions with varied 
proportion of preterm neonates. More than half of the studies reported the 
percentage of included neonates who were born prematurely (34 studies). 
Page | 72  
 
Twenty-one out of those studies (64%) reported that more than half of the 
participants were preterm, with a range of 52%-87% of NICUs admissions 
included in the study. One would expect a higher number of drugs used in 
preterm neonates as reported by individual studies (77,82,87,115,121,124). 
The studies; however, did not directly report the number of drugs per patient 
for term vs. preterm neonates.  
The pooled mean (SD) of the number of drugs per neonate from 29 studies 
was 4 (2.4) unique drugs per patient. The highest mean was reported by 
Neubert et al. as 11.1 unique drugs per patient (95). As discussed by the 
authors, the inclusion of high proportion of preterm and very preterm 
neonates (69%) and the specialisation of the neonatal unit may have 
contributed to the high number of drugs prescribed per neonates when 
compared to other studies. Another possible explanation for this may be the 
greater availability of medicines in the healthcare setting of this study, as it 
was conducted in a high-income country. Also, the inclusion of drugs given 
routinely in the delivery room prior to neonates being transferred to the unit 
were collected retrospectively and that could increase the number of drugs 
prescribed. Unlike some studies which have excluded the routinely used 
drugs at the delivery room (108,109,119), Neubert et al. retrospectively 
collected this data and included it in their analysis.  
2.4.3 Frequently prescribed drugs  
Overall, penicillins and gentamicin were among the ten most frequently cited 
drugs in the majority of the studies. These results support the data from 
previous systematic reviews (9,10). This was not unexpected as most 
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neonates admitted for intensive care are treated for presumed infections, and 
often penicillins and aminoglycosides are the first line antibiotics used.  
In most regions, ampicillin and gentamicin were among the ten most 
frequently prescribed drugs in their neonatal units. There is an exception; in 
Asia, amikacin and cefotaxime were among the ten most frequently 
prescribed drugs in their neonatal units. Few studies reported drugs other 
than an antibiotic as the one in most common usage e.g. caffeine featured at 
the top of the list in two studies. This can be attributed to the high proportion 
of preterm neonates in the study; however, this was confirmed by only one 
study captured in this review (80) where 87% of included neonates were born 
preterm. Variations in which drugs were excluded from analysis in each study 
accounts for some other drugs which were not antibiotics appearing as the 
most frequently prescribed, such as parenteral nutrition, vitamin K and 
multivitamins which, due to their ubiquitous use, were excluded from most 
studies. 
The current review found limited studies conducted in the Middle East region 
that cited most frequently prescribed drugs in their neonatal units with only 
two studies were found, both in Israel (73,97). Both studies were also 
prospective and reported that gentamicin and ampicillin were among the five 
most frequently prescribed drugs in their centres. The limited data on drug 
use is a matter of concern, especially in a vulnerable population such as 
neonates. The need to investigate the drug use pattern in such regions is 
important to explore where the main misuse, if any, of drugs exists. Also, it 
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will identify existing gaps and whether adherence to guidelines is 
implemented.  
Surfactants are recommended by the WHO for ventilated and intubated 
neonates with respiratory distress syndrome (152). However, in the low- and 
middle-income regions, lack of human or material resources may hinder the 
use of those agents compared to countries in high income regions. This is 
supported by this review as seven studies in high income regions cited 
surfactants as one of the ten most frequently prescribed drugs, whereas only 
one study conducted in a middle-income region cited the use of surfactants 
as frequently prescribed drugs. 
2.4.4 Antibiotic use 
 This review has reported the most frequently prescribed antibiotics in 59 
studies that ranked the use of antibiotics in their NICUs. Overall, the use of 
antibiotics was similar in Europe, North America and Latin America, with 
ampicillin and gentamicin to be among the most frequently prescribed 
antibiotics. This finding broadly supports the work of a previous systematic 
review by Rosli et al. that concluded ampicillins and aminoglycosides were 
the commonest antibiotic groups reported by the included studies (10). This 
is again is not an unexpected finding as the burden of infections remains 
high; neonatal sepsis or meningitis accounted for 6.8% neonatal death 
globally in 2015 (153). High risk of death and poor outcomes in survivors 
warrants the reliance on empirical antibiotic usage based on the sensitive but 
nonspecific clinical diagnosis of possible infections, particularly in preterm 
neonates, and the antibiotics given to clinically well neonates born with risk-
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factors for early-onset sepsis. Unfortunately, the selective pressure exerted 
by this widespread use is driving antimicrobial antibiotic resistance. The wide 
use of antibiotics in the neonatal population is mainly to manage neonatal 
sepsis as either a prophylactic or treatment measure. However, an observed 
difference between these findings and Asia was found in this review. Many 
neonates in hospitals in south Asia are now treated with carbapenems as a 
first-line therapy for sepsis or presumed sepsis (154). This was reflected in 
this review, with the more frequent appearance of antibiotics such as third 
generation cephalosporins (cefotaxime, ceftriaxone) and meropenem, and 
tazobactam in studies from Asia and Latin America. Cefotaxime was cited as 
the most frequently prescribed antibiotic instead of penicillins in studies 
conducted in Asia, followed by amikacin. Cefotaxime can also be used in the 
management of neonatal sepsis due to its broad-spectrum cover for both 
gram positive and negative organisms. Cephalosporins are mainly eliminated 
via the kidneys with their clearance and half-life being dependent on 
neonates’ development. The half-life of cefotaxime and ceftazidime 
decreases with the increase in gestational and postnatal age with an 
opposite trend of the clearance of those agents (155). This warrants careful 
monitoring when it comes to deciding the dosage regimen for neonates. Data 
from South Asia reflect a high burden on neonatal sepsis and a distinct 
pathogen profile with predominance of Gram-negative organisms and lower 
prevalence of group B streptococci as compared to high income countries 
(156). In this review of neonatal sepsis in South Asia, Chaurasia et al. 
reported that 50–88% of common isolates from health facilities are resistant 
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to first-line antibiotics ampicillin and gentamicin and often to third-generation 
cephalosporins such as cefotaxime. 
One unanticipated finding was that ceftriaxone appeared among the ten most 
frequently cited drugs in three studies in Asia (69,104,134). Ceftriaxone was 
also cited among the ten most frequently prescribed antibiotics in an African 
NICU in Zimbabwe (132). Ceftriaxone has been associated with several 
concerns about its safety use in neonates. This antibiotic is highly protein 
bound with an ability of displacing bilirubin from its albumin binding sites, 
resulting in accumulation of bilirubin in brain tissues, and consequently 
kernicterus in neonates (155). Furthermore, the FDA has issued a warning in 
2007 restricting its use in neonates, especially when used concomitantly with 
calcium-containing IV products (157). This is because this combination has 
been associated with life threatening cardiopulmonary adverse drug 
reactions due to the precipitation of calcium salts in the lungs and kidney 
(158).  
Another interesting finding seen in antibiotics use in Asia is the combination 
of cefoperazone-sulbactum, which was cited by two studies in India among 
their most frequently prescribed antibiotics (5,134) and in one recent study in 
China (106). This antibiotic is a combination of B-lactam antibiotic and b-
lactamase inhibitor and it is used for nosocomial sepsis caused by multi-drug 
resistant pathogens in NICUs (159). This combination is not routinely used in 
the neonatal population due to the limited data on its use in neonates. A 
study by Ovali et al. was the first study to show the effectiveness of this 
combination to be used as an alternative to carbapenems in the management 
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of nosocomial sepsis in NICUs without any apparent adverse effects (159). 
However, the emergence of this agent among the frequently prescribed 
drugs may suggest the emergence of antibiotic resistance, which warrants 
further evaluation and application of strategies to improve antibiotic 
prescribing.  
To date, there is a lack of standard guidelines for empiric choice of antibiotics 
in neonatal sepsis, especially late onset sepsis. This is evident as the last 
published Cochrane review in 2005 concluded inadequacy of randomised 
trials for the empiric choice of antibiotic for late onset sepsis (160,161). This 
can explain the variety of antibiotics regimens used for neonatal sepsis 
worldwide and even in NICUs within the same country. Broad spectrum 
antibiotics are often being prescribed by neonatologists, as it is difficult to 
differentiate signs of preterm sepsis from those of prematurity (160). This is 
also compounded by the fact that clinical and laboratory findings (such as C-
reactive protein and white blood cells count) are not sensitive during the first 
hours following birth (105). Therefore, these reasons can be attributed to the 
high rate of antibiotic use which can accelerate resistance, especially with 
broad spectrum antibiotics. Overuse of antibiotics, especially in early 
neonatal life, can distort the gut microbiota which is pivotal for the 
developmental of the immune system and digestive function, leading to 
dysbacteriosis (162). A recent systematic review was conducted with the aim 
of investigating the effect of antibiotic therapy in neonates on gut microbiota 
and/or antibiotic resistance (162). This systematic review included 48 studies 
(three RCTs and 45 observational studies) and concluded that prolonged 
antibiotic therapy was associated with reduced gut microbial diversity (i.e. 
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disrupts the microbiota) and increased antibiotic resistance. Antibiotic use 
pattern in China is distinctively different from any other setting around the 
globe. A recent Lancet global health commentary has reported that China is 
accounted for the lowest antibiotic use (7.8%) among 56 countries (23,572 
patients) that participated in a global study that describe paediatric patterns 
of WHO’s Access, Watch, and Reserve classification of antibiotics (113). The 
pattern of antibiotic use in China is different when compared to other 
countries due to several reasons. First, gentamicin is banned in China for 
children who are below 8 years, unlike many countries in which it is used for 
gram negative bacteria in children and neonates. Another reason is the 
limited access of penicillin in China due to their policy of skin testing prior to 
penicillin use and the unavailability of those agents in many hospitals in 
China. A final reason is the high willingness of physicians to prescribe 
macrolide and third generation cephalosporins in China based on a latest 
survey on knowledge, attitude, and practice of antibacterial agents among 
Chinese paediatricians (113). The search in the present review have yielded 
one recent study conducted in a Chinese NICU (106) that supported this 
difference in drug use pattern in China. This study concluded that the three 
most frequently prescribed drugs were vitamin K1, hepatitis B vaccine, and 
cefoperazone-sulbactum. Authors suggest that this is driven by the high 
levels of ampicillin resistance and prohibition of gentamicin use due to the 
high risk of hearing loss in the population.  
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2.4.5 Lack of evidence for antiepileptic use in neonates  
There is insufficient evidence from literature supporting the use of anti-
epileptics in neonates. Only two RCTs were found to assess 
pharmacotherapy of anti-epileptics and were reported by a Cochrane review 
published in 2004 (163). With regards to this current review, four studies in 
Asia have cited phenobarbitone among the ten most frequently prescribed 
drugs in their NICUs. Phenobarbitone remains the mainstay in the 
management of neonatal seizures as cited in the literature (143,164). A 
recent large retrospective cohort study in the USA by Ahmad et al. was 
conducted with the aim of investigating the change of antiepileptic use over 
time (143). This study concluded that phenobarbitone was used in 98% of the 
cohort, with a minor decrease overtime compared to phenytoin use, which 
decreased significantly from the period 2005 to 2014. This downward trend 
was met with an opposing trend in levetiracetam use during the same period. 
A possible explanation for the recent increase in levetiracetam use is the 
favourable safety profile in several studies compared to phenobarbitone 
(165). Levetiracetam is currently suggested to be possibly used as a second-
line agent following phenobarbital due to its efficacy and safety, but evidence 
is still lacking with regards to its use as monotherapy or a first-line agent.  
The fact that phenobarbitone appears to be cited among the ten most 
frequently prescribed drugs in the majority of the studies in Asia indicates the 
prevalence of neonatal seizures in this region. The four studies that were 
conducted in Asia have reported that perinatal asphyxia was found to be one 
of the common morbidities and mortalities of the included neonates 
Page | 80  
 
(4,69,78,104). Annually, three million neonatal deaths are due to prematurity, 
asphyxia and sepsis on a global scale (166). Perinatal asphyxia is a major 
cause of neonatal mortality in Asian countries. This was evident in a study 
that analysed the causes of 3,772 neonatal deaths in Nepal, Bangladesh, 
Malawi and India between 2001 and 2011 (167). This study has found that 
more than one third of neonatal deaths in urban India were attributed to 
asphyxia. Perinatal asphyxia could trigger seizures in neonates, which can 
eventually lead to the use of anti-epileptic drugs. Hence, this could explain 
the frequent use of phenobarbitone compared to other drugs. Furthermore, 
phenobarbitone and other first-generation antiepileptics (e.g. phenytoin) are 
readily accessed in low- and middle-income countries due to their lower cost 
compared to the higher cost newer generation anti-epileptic drugs (e.g. 
levetiracetam) which explains the high use of first generation anti-epileptic 
drugs in Asia (168).
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2.4.6 Strengths and limitations 
This is the most updated review to provide comprehensive data on the most 
frequently prescribed drugs, from 1983 to July 2020, in different regions. It 
included all studies without any restriction on language or search dates. The 
robust search strategy that was constructed with a senior clinical librarian has 
added another strength to this review. The data extraction, which was done 
by two reviewers, is considered another strength that ensures completion of 
the extracted data. This review has summarised the overall drug use in 
neonates worldwide in terms of the geographic location, the included sample 
size, duration of the studies, average drug use per neonate, and the most 
frequently prescribed drugs of all of the studies that aimed to evaluate drug 
use in general. Unlike the systematic review by Rosli et al. (10), the high 
number of the studies yielded in this review would provide a thorough picture 
of drug use across the globe and in different geographic regions.  
The analysis of data extracted from the included studies is limited by the 
heterogeneity of the included populations, variations in study designs and 
different methods of reporting the findings. One source of weakness in this 
review is excluding two studies in German as one could not be obtained 
(169), and the other one was received as a scanned copy which hindered its 
translation to English (170). Due to the lack of uniformity among the included 
studies in terms of the labelling and licensing definitions, the identification of 
the most frequently prescribed off-label and/or unlicensed drugs was not 
feasible, which added another limitation to this review and hence they were 
reported descriptively per each study. 
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2.4.7 Conclusion 
Despite the descriptive nature of this systematic review, it provides valuable 
insight into the frequently used drugs across different NICUs worldwide. 
Globally, the pattern of drug use across neonatal units is similar, especially in 
Europe, with antibiotics being the most frequently prescribed drugs. The high 
usage of antibiotics is still an ongoing concern that needs to be tackled to 
rationalise the use of those agents worldwide, especially with the introduction 
of combined antibiotics, which has led towards the emergence of resistance 
in some countries. This review also highlighted the lack of details such as 
paucity on information of indication, dose, duration of use or adverse effects 
calling for improvement in data collection and analysis of drug utilisation data 
when conducted on a neonatal level. Such research is important, particularly 
when conducted collaboratively across national and continental boundaries 
to improve rational use of medicine in neonates.  
In the UK, there is a need for larger updated studies on drug use in neonates 
due to the limitations of previously conducted studies. A further study with 
more focus on drug use in neonatal units at a national level will provide a 
better description of the most frequently prescribed drugs and the current 
practice in the UK. 
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CHAPTER 3 DRUG UTILISATION PATTERNS IN 
NEONATAL UNITS IN ENGLAND AND WALES 
 Introduction 
Assessing the rational process behind drug therapy is the fundamental goal 
of drug utilisation research, which involves either quantitative or qualitative 
methods. Quantitative methods aim to measure prescribing, dispensing, or 
the consumption of medicines in a population using primary or secondary 
data sources (171). As very little was found in the previous review chapter 
regarding the question of the pattern of drug utilisation in neonatal units in the 
UK, the present study was designed to fill the gaps and extend the body of 
literature. This chapter describes a retrospective pharmaco-epidemiological 
study in England and Wales over a long period of time and on a national level 
using prospectively collected data stored in the National Neonatal Research 
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 Study design  
This is a retrospective pharmaco-epidemiological study to explore the 
utilisation of drugs across neonatal units in England and Wales over eight 
years (2010 to 2017). The study uses a database of routinely-recorded, 
prospectively collected data (NNRD), which is approved by the National 
Research Ethics Service in the UK to permit the use of de-identified data for 
research (REC Number: 16/1093). A description of the database is detailed 
in section 3.4.  
3.2.1 Ethical approval process 
This study was registered prospectively at ClinicalTrials.gov (NCT03773289). 
The protocol for this study was approved by the Health Research Authority 
(HRA) following a favourable opinion from the Yorkshire & The Humber – 
Leeds East Research Ethics Committee and Health and Care Research 
Wales (IRAS project ID: 248088, REC reference: 18/YH/0209; Date of 
approval: 25 May 2018) (attached in 9.11). 
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 Aim and objectives 
The overall aim of this study was to investigate historic pattern of drug 
utilisation in neonatal units in England and Wales.  
• Objective 1: What are the most frequently prescribed drugs?  
• Objective 2: Have prescribing patterns changed from 2010 to 2017? 
• Objective 3: Are there any variations in prescribing according to 
gestational age and birth weight and treatment location?  
• Post-hoc objective: Are there any differences in antibiotic prescribing 
according to gestational age group? 
Page | 86  
 
 Methods  
3.4.1 Overview of the data used in this study  
3.4.1.1 Sources of neonatal data in the UK  
The routine collection of neonatal data in the UK started in 1990 through a 
study called The Neonatal Survey, which has become a resource for 
providing clinical information on neonates (172). However, the data provided 
by this survey covers some regions of England only (Leicestershire & 
Rutland, Derbyshire, Nottinghamshire, Lincolnshire, South Yorkshire, South 
Humberside and Northamptonshire). In addition, the reports produced by The 
Neonatal Survey do not provide drug records from the collaborating neonatal 
units.  
Another electronic platform that is used in the UK is the Hospital Episode 
Statistics (HES) database. HES is a database of all admissions, Acute care 
and Emergency (A and E) attendances, and outpatient appointments in the 
National Health Service (NHS) hospitals in England only. This database was 
established in 1989 with an aim of recording every episode of admission in 
England and the care delivered (173). This database contains key clinical 
information (diagnoses and operations), patient information (age groups, 
gender, and ethnicity), administrative information (dates and methods of 
admission and discharge), and finally, geographical information (treating 
centre and area of living) (174). However, it does not capture any information 
regarding drug treatment in neonates.    
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Since the main aim of this study was to identify the most frequently 
prescribed drugs in the neonatal population and investigate patterns of drug 
use over time, the use of both the Neonatal Survey and HES were not 
appropriate. The NNRD, established in 2007 by the Neonatal Data Analysis 
Unit (NDAU), is an approved research database which can be used to meet 
the aim and objectives of this study. 
3.4.1.2 NNRD and justification for its use in this study 
Neonatal clinical data are entered daily into a national electronic platform by 
healthcare professionals providing care to neonates across the UK. This 
platform is known as Badger.net, which holds neonatal electronic health 
records of all admissions to NHS neonatal units and is managed by an 
authorised hosting company, Clevermed Ltd (Level 6, Edinburgh Quay, 133 
Fountainbridge, Edinburgh, EH3 9QG, www.clevermed.com). Since the 
establishment of the NDAU in 2007, based at the Chelsea and Westminster 
Hospital campus of Imperial College London, the collection of electronic 
neonatal data for research and quality assessment was facilitated (175). 
Neonatal Data Analysis Unit (NDAU) extract data quarterly from all NHS 
neonatal units, combine it, and undertake initial data management and 
cleaning to produce the NNRD. 
At present, the NNRD holds data on around one million neonates and ten 
million days of care (176). The database includes a variable where names of 
individual drugs prescribed to neonates are entered daily. In addition, there 
are other data items which capture drug use, such as drugs used in 
resuscitation at birth, surfactant at delivery, and drugs given for specific 
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conditions, such as for patent ductus arteriosus (PDA). Therefore, the NNRD 
was selected for its ability to provide a detailed insight into drug use across 
neonatal units in the UK and fulfil the aim and objectives of this study, as it is 
currently considered the only national neonatal database providing clinical 
information on neonates admitted at different neonatal unit levels and their 
drug use across the UK. For this study, all data on neonatal unit admissions 
over an eight-year period (01 January 2010 to 31 December 2017) in 
England and Wales was utilised for the purpose of analysis. However, the 
data from Scotland and Northern Ireland were not included. This is because 
a different ethics process was required and Northern Ireland do not use the 
Badger.net. Therefore, I have focused on data from England and Wales only.  
3.4.1.3 Dataset used in this study and statistical software 
Data in the NNRD are broadly organised in two files – Episode data and 
Daily data – and were extracted by NDAU and provided to us in this form. 
Episode data represent an admission to a neonatal care unit. Each row in the 
episode data corresponds to one admission (i.e. one episode of care in a 
single unit regardless of how many days a neonate stays at the unit). A 
neonate may have several episodes of care if they are transferred between 
units. Daily data represent a day of care for a neonate and each row in the 
daily data file corresponds to one day of care. Figure 20 and Figure 21 detail 
the variables requested from NDAU to be extracted from NNRD.   
All data management and statistical analysis were carried out using Stata SE 
16 (64-bit) (Stata Corp. College Station, TX, USA) for Windows 2010 
Enterprise Edition (Microsoft Corporation, Seattle, USA).
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Figure 20. Variables extracted from the NNRD Episode file  
 
 




Figure 21. Variables extracted from the NNRD Daily data file 
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3.4.2 Study population  
All neonates admitted to a neonatal unit in England or Wales from 01 
January 2010 to 31 December 2017 were eligible for inclusion. Neonates 
with the following criteria were excluded:  
• Neonates with missing or contradictory information in their demographic 
data (gestational age (GA), birth weight (BW), gender, month of birth) 
• Neonates admitted to a non-neonatal unit  
• Neonates with missing episodes at the start or in the middle of their care 
• Neonates whose first admission is not within the study period 
• Neonates with GA < 22 weeks or > 44 weeks 
• Neonates with extreme BW for GA Z-scores (detailed in section 3.4.3.4) 
WHO definitions were adopted to categorise neonates according to different 
GA groups and BW groups (13,177) (Table 8).
Table 8. Definitions of gestational age and birth weight categories 
according to WHO 
 
Gestational age category Birth weight category 
Term:  
born at ≥ 37 weeks 
Normal birth weight: 
born ≥ 2500 g 
Moderate to late preterm: 
born between 32-36 weeks 
Low birth weight (LBW): 
born < 2499 g 
Very preterm: 
born between 28-31 weeks 
Very low birth weight (VLBW): 
born < 1500 g 
Extremely preterm: 
born at < 28 weeks 
Extremely low birth weight (ELBW): 
born < 1000 g 
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3.4.3 Overview of data management  
A summary of the steps taken to derive the final study dataset for the 
purpose of analysis is provided in Figure 22, followed by a detailed 
explanation.









*exceptions are mentioned in drugs coding section  
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3.4.3.1 Initial data management 
Episode and Daily data were received from NDAU as two separate.csv files, 
and an anonymised identification number (anon-id) was used to enable 
linkage between the two files. Some of the variables were coded as ‘integers’ 
(i.e. numbers) while others were coded as ‘strings’ (i.e. text). The initial data 
management was supported by my supervisor Dr Lisa Szatkowski (Associate 
Professor in Medical Statistics, School of Medicine, University of Nottingham) 
using her computer as initial data processing required a computer with 
sufficient processing power to be able to open the extremely large files. This 
process involved importing the .csv dataset into Stata and saving it in a Stata 
format. Both Episode and Daily datasets were then divided into 20 smaller 
files of approximately equal numbers of neonates. This was done as I was 
not able to run the analysis on one complete file on my computer due to lack 
of adequate processing power. It was therefore necessary for me to perform 
the key steps of analysis on one Episode/Daily data file and then repeat it on 
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3.4.3.2 Drugs coding 
Drug data entered in the NNRD data are in text format with different spellings 
and alternate names (generic/brand). For example, amoxicillin appears as 
two different spellings, ‘amoxicillin’ and ‘amoxycillin’, and paracetamol is 
entered using the brand name ‘calpol’ as well as the generic ‘paracetamol’. 
Hence, it was essential to harmonise and code drugs before starting the 
analysis. As a first step, every single drug entry in the Daily data file was 
identified and extracted. The number of unique drugs identified from the raw 
data was 659. These were extracted and copied to an Excel file to start the 
process of coding. This process involved three different steps applied as 
necessary (Figure 23).  
 
Figure 23. Stepwise drugs coding process 
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In the first step, all drug entries were corrected in terms of their spelling. 
Secondly, drugs entered using brand name entries were converted to their 
generic names. Following those two steps, the drugs were then categorised 
according to two main categories for the purpose of analyses: 
• Broad group category: Drugs were renamed according to their 
broader category and their primary use in the neonatal population 
• Individual category: Drugs were renamed according to their original 
scientific/generic name with appropriate UK spellings  
I performed the initial cleaning and categorisation which was subsequently 
checked by my supervisor Dr Ojha. The British National Formulary for 
Children (BNF-C, September 2018 update) and specific product 
characteristics (www.medicines.org.uk) were used as a reference for 
categorisation. Some examples of the drug cleaning and categorisation are 
shown in Table 9.  
Table 9. Examples of coding and categorising drugs 
Drug entry (as presented in 
original dataset) 
Broad group Individual drug 
ibuprofen 





Indomethacin indometacin (indomethacin) 
indomethacin 
morphine - oral 
Analgesics Morphine (oral) 
oral morphine 
oral morphine - level 1 
oral morphine - level 3 
oral morphine - level 4 
oramorph 
oromorph 
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Some drugs were not categorised according to the references stated above, 
but instead according to their use as reported in the literature. An example of 
this is oral sucrose which is effective as an analgesic for procedural pain in 
neonates (178). Another example is paracetamol, which can be used in 
neonates as an analgesic but more recently shown to be effective in PDA 
management (179). However, paracetamol was classified as analgesic as it 
was not clear at this stage from the data if it was used for PDA or as an 
analgesic. The broad pharmacological groups of the drugs are listed in 
Figure 24 whereas the full drug list with their codes and categories along with 
the corresponding references is detailed in 9.12. 
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Figure 24. Broad pharmacological group categories
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3.4.3.3 Neonatal units coding 
The neonatal unit providing each episode of care was coded according to 
their level (level one, two, or three) as defined by the NHS Neonatal 
Specialist Commissioning Group network’s definition of different neonatal 
levels of care (180,181) and British Association of Perinatal Medicine (BAPM) 
categories of care (24) .  
These are:  
• Level one: SCU (special care unit) for initial and short-term care for 
neonates born at GA > 32 weeks 
• Level two: LNU (local neonatal unit) for high dependency care for 
neonates born between 28-32 weeks 
• Level three: NICU (neonatal intensive care unit) for complex care for 
neonates born at GA < 28 weeks 
One unit was identified as a non-neonatal unit and coded as level 0 of care 
after checking with NDAU. All neonates labelled with admission to this unit 
were excluded from the study.
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3.4.3.4 Episode file management 
The Episode file contains information on basic characteristics of neonates’ 
demographics, such as GA in weeks, BW in grams, month and year of birth, 
gender of the baby, and the place of birth. The Episode data file was 
therefore used as the key file to create a new dataset of demographic data 
for each neonate, which was later merged into the Daily file to enable 
analyses.  
Before merging, an initial attempt was made to ensure that the data in the 
Episode file were consistent and there were no duplicates, conflicts, or 
missing records in any entry of the demographic variables. A summary of the 
steps followed to ensure completeness of data in the Episode data file is 
presented in Figure 25. 
 
Figure 25. Steps followed to ensure completeness and consistency in 
demographic variables in the Episode data file 
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Neonates with GA < 22 weeks or > 44 weeks were marked to be excluded. 
Neonates with extreme BW for GA Z scores were also identified for 
exclusion. A Z score is a standard deviation (SD) score that allows a 
comparison of a child to the reference population (182). In this study, Z 
scores were calculated to exclude neonates with a BW for GA Z score 
greater or less than 4 SD as performed in the recent published study using 
the same database wherein neonates with incongruous BW were also 
excluded (27). Z scores were calculated using the ‘Zanthro’ function in Stata 
to generate the acceptable BW bounds, based on the UK-WHO growth 
charts-neonatal and infant close monitoring (NCIM) (183). Appendix 9.13 
details the calculated ±4 SD Z score bounds for boys and girls for each 
week of GA at birth (184). Weight data in UK reference charts are available 
from 23 weeks’ gestation only. Since there are no reference BW data for 
neonates at 22 weeks of gestation, BW records for neonates born at this 
gestation were examined manually and compared to the ±4 SD bounds for 
neonates born at GA of 23 weeks. This manual inspection concluded that the 
BW of all neonates born at 22 weeks’ gestation fell within the acceptable 
weight range for neonates born at 23 weeks and so these neonates were not 
marked for exclusion. 
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3.4.3.5 Daily file management 
Management of the Daily data file included simple ‘housekeeping’ tasks such 
as labelling variables and dropping variables not needed at this point in order 
to reduce the data file size. 
3.4.3.6 Derivation of the final study dataset 
At this stage, the clean Daily data file and the demographic data file were 
merged. Figures for the number of neonates excluded, both in total and 
according to each specific exclusion criterion, were created. 
3.4.4 Specific methods for each objective 
3.4.4.1 Objective 1: What are the most frequently prescribed drugs?   
For this objective, the following steps were undertaken:  
1. Merged the newly created demographic data file to the Daily data file 
using the anonymous Identification number (anon_id) variable to link 
individuals and excluded neonates based on the previously mentioned 
list.  
2. Dropped any irrelevant variables from the data file to reduce its size and 
speed the analysis process.  
3. Created a new variable for each individual drug and group of drugs, 
coded as ‘one’ if the drug/group was prescribed on each day of care and 
coded as ‘zero’ if it was not prescribed.  
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4. For each neonate, created a binary variable indicating whether each 
individual drug or group of drugs was prescribed at least once during 
their care.  
5. For each neonate, created a continuous variable counting the number of 
days each individual drug or group of drugs was prescribed during their 
care.   
I have tabulated two scenarios below from the data analysing the prescribing 
of analgesics (as an example) to explain the function of the created variables 
(Figure 26). Intravenous (IV) morphine and paracetamol are two examples 
that were coded as analgesics in those presented scenarios. The anon_id 
was removed and replaced by ‘a’ and ‘b’ for the purpose of confidentiality.




Figure 26. Variables created to identify drug prescribing  
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3.4.4.1.1 Mean number of drugs and proportion of drugs free days 
A secondary aim was to quantify the mean number of drugs per neonate and 
the proportion of drug free days. To achieve this, for each neonate I created 
a variable counting the total number of different individual drugs prescribed, 
and a variable counting the number of days when no drugs were prescribed.  
3.4.4.1.2 Drugs excluded from the analyses  
In line with other drug utilisation studies, some drugs and other substances 
were excluded from the analyses. These include IV fluids to prevent clotting 
of vascular lines (heparin sodium, sodium chloride for flush), standard IV 
replacement solutions (electrolytes, glucose), parenteral nutrition solutions, 
milk formula, and all types of vitamins and topical dermatological agents that 
contain combined antibiotics and/or corticosteroids. Also, some substances 
were classified as unrecognised as they could not be identified and were 
excluded from the analysis (detailed in 9.14). 
3.4.4.1.3 The total days of use of drugs  
This was calculated by multiplying the number of neonates who were 
prescribed a particular drug at least once during their neonatal stay by the 
average number of days of exposure. The drugs were then ranked based on 
the total number of days of use from the highest number of days of use to the 
lowest and the results of the top ten drugs are presented.
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3.4.4.2 Objective 2: Have prescribing patterns changed over time? 
The methods used to answer the three parts of this objective build on those 
described above and are detailed below.  
3.4.4.2.1 Changes over time in which drugs are most frequently used 
relative to other drugs 
For this, I have taken the ten most frequently prescribed drugs identified from 
objective 1 and analysed them by year of admission using the absolute 
number and proportion of neonates who have been prescribed each 
individual drug at least once from 2010 to 2017.  
3.4.4.2.2 Changes over time in the average number of days that 
neonates are given particular drugs  
Again, the ten most frequently prescribed drugs were identified as per the 
first objective. Then, the absolute numbers and proportion of neonates 
prescribed those drugs at least once were tabulated by year of admission 
from 2010 to 2017 to illustrate the change in prescribing patterns. In addition, 
the median, range and interquartile range for the number of days each drug 
was prescribed were calculated by year of admission from 2010 to 2017, and 
this was also repeated for each GA group. 
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3.4.4.2.3 Changes in drug use over time for the entire cohort and for 
very and extremely preterm neonates 
In order to explore the change in drug use over time for the full cohort (i.e. 
neonates of all GA), the percentage of neonates who were prescribed a 
particular drug at least once in a particular year (e.g. 2010) among all 
neonates who were admitted in that year (e.g. 2010) was calculated. This 
was repeated for each year in the study period (from 2010 to 2017). 
Following this step, the minimum, maximum, and range of the percentage of 
neonates who received the drug at least once in each study year was 
determined. These ranges were ranked from the largest to the smallest value 
(detailed in 9.15). However, only the data on drugs with a range of greater 
than one percent were extracted to attain a manageable number of drugs to 
describe in more detail. This cut off was chosen for the full cohort. Following 
this, the percentages of neonates prescribed the drugs at least once from 
2010 to 2017 were plotted.  
Similarly, the change in drug use over time was investigated among very and 
extremely preterm neonates separately. As the ranges of the percentages of 
neonates who received the drug at least once in these subgroups were 
larger, a higher percentage cut off was selected to attain a manageable 
number of drugs to describe in more detail for these two cohorts. For very 
preterm neonates, drugs that had a range of more than 3% (detailed in 9.16) 
and for extremely preterm neonates, drugs that had a range of more than 5% 
(detailed in 9.17) are presented. All the calculations were done using 
Microsoft Excel (version 16, 64 bit). 
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In this analysis, research drugs were excluded as the change in the use of 
those drugs over time is related to the start and the end of each trial, and 
hence will not provide a meaningful interpretation of the change in their use 
over time. Those drugs are detailed in 9.12.  
3.4.4.3 Objective 3: Are there any variations in prescribing according to 
gestational age and birth weight of neonates and treatment 
location? 
For this objective, the analyses carried out for objective 1 were repeated for 
sub-groups of the study population defined by GA groups, BW group and unit 
level, using the group definitions listed in Table 8 and Section 3.4.3.3.  
For the analyses at unit level, only those neonates who received all their 
neonatal care in one unit were included. Neonates who were treated in more 
than one unit were excluded, as were any neonates where the care level of 
the treating unit could not be identified.
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3.4.4.4 Post-hoc objective: Are there any differences in antibiotic 
prescribing for each gestational age group? 
This objective focuses on four questions; the methods for each are detailed 
below. Initially, a general coding of the antibiotics was undertaken similar to 
that described in objective 1 (step 4), but this was done only for the group of 
antibiotics. After that, the following analysis steps were undertaken for each 
question. 
3.4.4.4.1 How many different antibiotics are prescribed per neonate 
during their hospital stay? 
A binary variable was created for each individual antibiotic where each row, 
representing a day of care, was coded as ‘one’ if a neonate was prescribed 
that antibiotic on that day. Then, by generating a variable called total 
antibiotics (total abx), the number of different antibiotics that were prescribed 
per neonate who were prescribed antibiotics at least once during their 
hospital stay was calculated.  
3.4.4.4.2 How many days of antibiotics are prescribed per neonate? 
The number of days on which neonates were prescribed antibiotics was 
analysed by first generating a binary variable (antibiotics_baby) identifying 
neonates who were prescribed antibiotics on at least one day. Another 
variable was created (antibiotics_baby_days) to count the number of days 
antibiotics were prescribed per baby.  
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3.4.4.4.3 On what percentage of neonatal care days are antibiotics 
prescribed amongst neonates who have been prescribed 
antibiotics for at least one day? 
This percentage was calculated for each neonate by dividing the number of 
days where antibiotics were prescribed by the total number of days of care. 
Figure 27 depicts two scenarios extracted from the dataset to illustrate the 
function of the above-mentioned variables used to identify antibiotics 
prescribing.  
3.4.4.4.4 How many courses of antibiotics were prescribed, where 
antibiotics were prescribed for at least 5 days continuously? 
For this analysis, a course of antibiotics was defined as five consecutive days 
of prescribing per neonate. A gap of at least two days was required between 
courses to call them different courses of antibiotics. The total number of 
courses of antibiotics prescribed, overall and in each GA, group was counted. 




Figure 27. Variables created to identify antibiotic prescribing
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 Results 
3.5.1 Derivation of the study dataset for the analyses 
The total number of neonates for whom records were received from NDAU 
was 643,233. Of these, a total of 4,390 (0.7%) neonates were excluded from 
analysis for one or more reasons (Figure 28).





Figure 28. Number of neonates excluded from the analyses 
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For the analysis at unit level (objective 3), 52,566 (8%) neonates were 
excluded where they were treated in more than one unit or because the level 
of care could not be identified (Figure 29). 586,277 neonates were therefore 
included in the analyses of drug use by unit level. 
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3.5.2 Population characteristics 
After exclusions, a total of 638,843 neonates admitted to 187 neonatal units 
across England and Wales from January 2010 to December 2017 were 
included in the study (Table 10). 44% of neonates (n=283,553) were female 
and 59% were born at term (n=379,410).  
A histogram was done to inspect the normality of the data sets and mean/median 
were chosen for normal/skewed distribution, respectively. Following the inspection 
of the histogram it was clearly not normally distributed data set in terms of the GA,  
BW, and length of hospital stay. Therefore, median (IQR) was chosen to summarise 
these variables.  
The median (IQR) GA in weeks and median (IQR) BW in grams were 37 
weeks (35-40) and 2890 (2168-3500), respectively. The median length of 
neonatal unit stay was five days (IQR 3-13). As expected, length of stay was 
longer for neonates born the most premature. 66% of neonates were 
discharged to home and 1% (n=8,666) died. Mortality was highest among 
extremely preterm neonates, 22% (n=4,234) of whom died.   
Appendix 9.18 describes the demographic characteristics of neonates by BW 
category.  
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(< 28 weeks) 
Very preterm 
(28-31 weeks) 




(≥ 37 weeks) 
Number of neonates 
 n (%) 
638,843 (99.3) 19,159 (3) 42,106 (7) 198,168 (31) 379,410 (59) 
Gestational age (weeks) 
median (IQR) 
37 (35-40) 26 (24-27) 30 (29-31) 35 (33-36) 39 (38-40) 
Birth weight (grams) 
median (IQR) 
2890 (2168-3500) 814 (677-965) 1375 (1160-1590) 2240 (1910-2595) 3362 (2955-3760) 
Female 
n (%) 
283,553 (44) 8,739 (46) 19,148 (46) 90,540 (46) 165,126 (44) 
Length of hospital stay 
in days 
median (IQR) 





Home 419,671 (66) 13,481 (70) 39,209 (93) 153,996 (77) 212,985 (56) 
Died 8,666 (1) 4,234 (22) 1,347 (3) 1,255 (1) 1,830 (1) 
Ward 192,766 (30) 387 (2) 525 (2) 39,469 (20) 152,385 (40) 
Transfer 16,022 (3) 968 (5) 943 (2) 3,140 (2) 10,974 (3) 
Missing 1,715 (<0.01) 89 (1) 82 (<0.01) 308 (<0.01) 1,236 (<0.01) 
IQR, interquartile range; SD, standard deviation  
 
Page | 117  
 
3.5.2.1 Characteristics of the study population based on receiving 
treatment in one neonatal unit 
Of the population included, 44% (n= 255,738) of neonates were admitted to 
NICUs, followed by 42% (n=248,108) to LNUs and 14% (n=82,431) to SCUs. 
The median (IQR) of the GA in weeks and BW in grams were 38 weeks (35-
40) and 2960 g (2270-3530), respectively. The median length of neonatal unit 
stay was approximately the same for all three levels of care (Table 11).  
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Table 11. Characteristics of neonates who received care in only one neonatal unit  
 
All neonatal units 
Level 1 neonatal 
units (SCU) 
Level 2 neonatal 
units (LNU) 
Level 3 neonatal 
units (NICU) 
Number of neonates n (%) 
586,277 82,431 (14) 248,108 (42) 255,738 (44) 
Gestational age (weeks) 
median (IQR)  
38 (35-40) 38 (35-40) 38 (35-40) 38 (35-40) 
Gestational age group (n)  586,277 82,431 248,108 255,738 
Term n (%) 366,252 (62) 51, 016 (62) 151,310 (61) 163,926 (64) 
Moderate to late preterm n (%) 181,875 (31) 28,919 (35) 81,410 (33) 71,546 (28) 
Very preterm n (%) 29,093 (5) 2,256 (3) 13,591 (5) 13,246 (5) 
Extremely preterm n (%) 9,057 (2) 240 (0.3) 1,797 (1) 7,020 (3) 
Birth weight (grams) 
median (IQR) 
2960 (2270-3530) 2975 (2320-3550) 2940 (2246-3522) 2960 (2280-3525) 
Female n (%) 
260,174 (44) 36,045 (44) 109,741 (44) 114,388 (45) 
Length of hospital stay (days) 
median (IQR) 
4 (2-10) 5 (3-10) 5 (3-11) 4 (2-10) 
Discharge 
destination 
n (%)   
Home   374,475 (64) 51,379 (62) 159,598 (64) 163,498 (64) 
Died  6,366 (1) 317 (0) 1,324 (1) 4,725 (2) 
Ward  190,448 (33) 29,407 (36) 83,110 (34) 77,931 (31) 
Transfer  13,441 (2) 1,244 (2) 3,901 (1) 8,296 (3) 
Missing  1,547 (0) 84 (0) 175 (0) 1,288 (0) 
SCU, special care unit; LNU, local care unit; NICU, neonatal intensive care unit; IQR, interquartile range; SD, standard deviation  
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3.5.2.2 Characteristics of the study population based on drug 
prescribing 
Of the population included, 30% of neonates were not prescribed any drug 
(not including the excluded drugs) during their neonatal stay (Table 12). As 
expected, neonates who have not been prescribed any drugs had higher GA 
and BW compared to those who had drugs during their neonatal stay. Also, 
the median length of neonatal unit stay of neonates who did not have any 
drugs was three days (IQR 2-5), which was lower than those who had the 
drugs (median 7, IQR 3-18) (p<0.001).  
Further analyses was done to extract the diagnosis at the admission of 
neonates who have not been prescribed any drugs (Table 13). Across all the 
cohort, 22% (n=137,578) of neonates had no entries of any diagnosis at 
admission. Whereas 39% (n=74,698) of neonates who have not prescribed 
any drugs had no entries of diagnosis at admission. At least 13% of neonates 
who have not prescribed any drugs were diagnosed with prematurity, 
followed by hypoglycaemia (10%), and ‘other’ (10%). Some entries were 
excluded from the list of diagnosis as they were signs and symptoms (1%, 
n=2,730), unclear entries (2%, n=4,036), entries related to social issues and 
delivery (3%, n=6,610), or maternal related conditions (5%, n=10,140).   
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Table 12. Characteristics of the study population based on drugs prescribing 
Demographic comparison Prescribed drugs Not prescribed drugs 
P value for difference 
between groups 
Number of neonates 
 n (%) 
445,322 (70%) 193,521 (30%) - 
Gestational age (weeks) 
median (IQR) 
37 (34-40) 38 (36-40) P<0.001* 
Birth weight (grams) 
mean (SD) 
2732 (966) 2998 (740) P<0.001** 
Female 
n (%) 
189,692 (43%) 93,861 (49%) P<0.001*** 
Length of neonatal stay in days 
median (IQR) 
7 (3-18) 3 (2-5) P<0.001* 
Discharge 
destination n (%) 
 
Home 298,375 (67%) 121,296 (63%) 
P<0.001*** 
Died 7,955 (2%) 711 (0.4%) 
Ward 125,532 (28%) 67,234 (35%) 
Transfer 13,023 (3%) 3,002 (1%) 
Missing 427 (0.1%) 1,278 (0.6%) 
*Mann-Whitney test; **Two sample t-test; ***Pearson Chi-square test 
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Table 13. Diagnosis at admission of neonates who were not prescribed any drugs 
Conditions based on diagnosis at admission variable 
Neonates with no drug prescriptions 
(n=193,521) 
n (%) 
Prematurity 25,368 13 
Hypoglycaemia 20,212 10 
Other* 18,540 10 
Neonatal jaundice  14,943 8 
Intrauterine growth restriction 13,622 7 
Respiratory diseases 12,110 6 
Syndrome of infant of mother with gestational diabetes 9,536 5 
Feeding issues 9,113 5 
Hypothermia or disturbances in temperature regulation of new-born  6,761 4 
Low birth weight  6,386 3 
Risk of infections 5,807 3 
Weight loss 5,056 3 
Infections** 4,737 3 
Birth asphyxia 4,429 2 
Congenital malformation 4,145 2 
Neonatal abstinence syndrome 2,650 1 
CVD and all related heart defects conditions 2,363 1 
Unspecified conditions 1,988 1 
Disorders of fluid, electrolyte and acid-base balance 1,808 1 
Cleft lip and cleft palate 1,226 1 
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Perinatal haematological disorders 1,025 1 
Fetal macrosomia 823 0.4 
Fetus affected by maternal condition  751 0.4 
Neonatal aspiration syndromes 676 0.4 
Confirmed or suspected major trisomy (Down's, Edward's, Patau's) 566 0.3 
Haemolytic disease of fetus and new-born 478 0.3 
Birth trauma  439 0.2 
Neonates with birth weight> 4.5 kg 412 0.2 
Disturbances of cerebral status of new-born 346 0.2 
Abnormal findings (blood, diagnostic imaging) 278 0.1 
Diseases of other systems (immune, muscle tone/musculoskeletal, circulatory, genital 
organs) 
253 0.1 
Coagulation defects, purpura and other haemorrhagic conditions 181 0.1 
Injuries 149 0.1 
Neonatal seizures 135 0.1 
Other conditions (adrenal, gingiva, pleural, intestine, kidney and ureter, urinary) 128 0.1 
Intrauterine hypoxia 115 0.1 
Intestinal obstruction  97 0.1 
Transitory endocrine and metabolic disorders specific to fetus and new-born 93 0.04 
Fetal blood loss 90 0.1 
Metabolic disorders*** 86 0.04 
Diabetes mellitus  76 0.04 
Haemolytic anaemias 68 0.04 
Cerebro-vascular diseases 63 0.03 
Neoplasms (benign, malignant) 60 0.03 
Complications (surgical, related to puerperium, labour)  45 0.02 
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Neonatal haemorrhage 42 0.02 
Hernia  39 0.02 
Persistent pulmonary hypertension of the newborn 34 0.02 
Gastroesophageal reflux disease 31 0.02 
Hypotension 28 0.01 
Renal failure 27 0.01 
Skin related issues 20 0.01 
Hydrops fetalis 14 0.01 
Hypertensive diseases 13 0.01 
Disorders of the nervous system 6 0 
Drug toxicity 4 0 
Vitamin deficiency  4 0 
Retinopathy of prematurity  1 0 
Oral candidiasis 1 0 
Neonatal death 1 0 
CVD, cardiovascular disease 
*Other: literally written as ‘other’ without any further details   
**   include respiratory syncytial virus, suspected sepsis, conjunctivitis, fungal/skin/viral infections, suspected urinary tract infections, 
gastroenteritis  
*** include alkalosis, acidosis, hypo/ernatraemia, hypo/erkalaemia, hypochloraemia   
Page | 124  
 
3.5.2.3 Admissions per year  
Overall, the total number of admissions increased from 60,437 (9% of the 
total) in 2010 to 99,541 (16% of total) in 2017, which can be attributed to the 
increase in the number of term admissions (Figure 30). The number of term 
neonates increased from 32,567 (54% of total admission in the year) in 2010 
to 63,760 (64% of total admissions) in 2017. Moderate to late preterm 
neonates were 34% of the total admission in 2010 (n=20,573) and their 
percentage reduced to 28% of all admissions (n=27,943) in 2017. There was 
a slight decrease over time in the percentage of admissions in the year who 
were born at very preterm (from 8% (n=5,057) in 2010 to 6 % (n=5,437) in 
2017). Although the actual number of extremely preterm neonates increased, 
there was a decrease in their percentage among the total admission for each 
year from 4% (n=2,240) in 2010 to 2% (n=2,401) in 2017. The number of 
neonates admitted each year by GA group is detailed in Table 14.   
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Moderate to late 
preterm 
Very preterm Extremely preterm All gestational age 
n % n % n % n % n % 
2010 32,567 9 20,573 10 5,057 12 2,240 12 60,437 10 
2011 37,883 10 22,260 11 5,161 12 2,407 13 67,711 10 
2012 42,176 11 23,970 12 5,200 12 2,463 13 73,809 12 
2013 44,727 12 24,433 12 5,269 13 2,406 13 76,835 12 
2014 47,870 13 25,248 13 5,188 12 2,337 12 80,643 13 
2015 51,088 13 26,148 13 5,331 13 2,414 13 84,981 13 
2016 59,339 16 27,593 14 5,463 13 2,491 13 94,886 15 
2017  63,760 17 27,943 14 5,437 13 2,401 13 99,541 16 
Total 379,410 198,168 42,106 19,159 638,843 
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Figure 30. Percentage of total admissions to neonatal units by gestational age group at birth in England and Wales 
(2010-2017)
Page | 127  
 
3.5.3 Results for objective 1: What are the most frequently prescribed 
drugs in neonatal units in England and Wales
Among the 638,843 included neonates, the most frequently prescribed 
pharmacological group was antibiotics. 66% (n=423,918) of neonates 
prescribed at least one antibiotic during their neonatal stay. The second most 
frequently prescribed group was electrolytes and minerals, prescribed to 26% 
of neonates. The miscellaneous group of drugs included emollients, ocular 
lubricants, and wound dressings (detailed in 9.12) was the 10th most 
frequently prescribed pharmacological group (Figure 31).  
The most frequently prescribed drug was benzylpenicillin, prescribed to 56% 
(n=355,679) of neonates at least once during their neonatal stay, closely 
followed by gentamicin which was prescribed to 54% (n=347,713) of 
neonates. Sodium was prescribed to 24% of neonates (n=56,109) at least 
once during their neonatal stay (Figure 32). The top 50 most frequently 
prescribed drugs are listed in descending order in 9.19 for all and each GA.




Figure 31. Ten most frequently prescribed pharmacological groups in neonatal units in England and Wales (2010-
2017) 
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Figure 32. Ten most frequently prescribed individual drugs in neonatal units in England and Wales (2010-2017) 
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There was a total of 377 different individual drugs prescribed from 2010 to 
2017 in neonatal units across England and Wales, after omitting those 
labelled as excluded drugs. The median (range, IQR) number of drugs 
prescribed per neonate across neonatal units was 2 (0-69, 0-3). Extremely 
preterm neonates were prescribed the largest number of drugs and this 
number decreased with increasing GA (Table 15). The median number of 
drugs prescribed by neonates was similar for each year of admission 
(Appendix 9.20). 
Overall, half of all days of care were drug free, but there were large 
differences by GA group (Figure 33). For neonates born extremely preterm, 
just 3% of days were drug free on average. Moderate to late preterm 
neonates had the highest proportion of drug free days, 70% on average.  
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Figure 33. Drug free days (white proportion of the bars represent percentage of total neonatal care days that were 
drug free)
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Caffeine was prescribed to 69,060 neonates at least once and the cumulative 
number of days of use was 1,381,200. This was followed by benzylpenicillin 
and gentamicin as they were prescribed for a total 1,067,037 and 1,043,139 
days, respectively (Figure 34). 
Appendix 9.21 shows the calculated total number of days of use of the top 50 
drugs ranked from the highest to lowest number of days of use.




Figure 34. Most frequently prescribed drugs in neonatal units in England and Wales (2010-2017) (measured as the 
number of days of use of individual drug
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3.5.4 Results for objective 2: Have prescribing patterns changed over 
time? 
3.5.4.1 Changes over time in which drugs are most frequently used 
relative to other drugs  
The ten most frequently prescribed drugs identified in section 3.5.3 are here 
analysed further to investigate changes in the frequency of their prescribing 
over time.  
Figure 35 and Figure 36 show that the number of neonates prescribed 
benzylpenicillin, gentamicin and pulmonary surfactants at least once, has 
increased over time. Of the total admissions in each year, the percentage of 
neonates prescribed benzylpenicillin and gentamicin at least once during 
their neonatal stay increased from 51% to 60% and from 52% to 57%, 
respectively from 2010 to 2017 (Figure 36). The percentage of neonates 
receiving pulmonary surfactants increased from 4% to 6% from 2010 to 2017.  
The absolute number and percentage of neonates who have been prescribed 
the remaining seven top ten drugs remained fairly constant over the study 
period. However, the percentages in Figure 36 are misleading as of the 
number of term admissions have increased significantly over the years. This 
inflation can lead to an apparent decrease in the use of drugs that are given 
only to preterm neonates. Therefore, I have done sub-group analysis for the 
change in drug use over time in very and extremely preterm neonates’ cohort 
(detailed in 3.5.4.4 and 3.5.4.5). 




Figure 35. Absolute numbers of neonates prescribed the most frequently prescribed drugs by year of admission  




Figure 36. Percentage of neonates prescribed the most frequently prescribed drugs by year of admission
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3.5.4.2 Changes over time in the average number of days that neonates 
are given particular drugs  
Caffeine and phosphate supplements were prescribed for the highest median 
number of days compared to other drugs, with a median (IQR) of 20 (9-37) 
and 15 (6-34) days, respectively (Table 16). Table 17 shows the median 
number of days of exposure (IQR) for the ten most frequently prescribed 
individual drugs, for each GA group. The median number of days on which 
neonates were prescribed these drugs amongst neonates prescribed the 
drug on at least one day was higher with increasing prematurity. This was 
found, for example, with gentamicin, in which number of days was higher in 
extremely preterm neonates compared to term neonates, with a median 
(IQR) of 8 (4-14) and 3 (2-4) respectively. This was also true for caffeine, in 
which the number of days of drug exposure decreased from 48 (37-60) to 1 
(1-3) in extremely preterm and term neonates, respectively. 
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n, number of neonates (population size) 
Pulmonary surfactants are not reported since they are prescribed as one dose only 
All figures are median (interquartile range) 
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Benzylpenicillin 3 (2-4) 3 (2-4) 3 (2-4) 4 (3-5) 4 (3-6) 
Gentamicin 3 (2-5) 3 (2-4) 3 (2-4) 4 (3-6) 8 (4-14) 
Sodium 4 (2-8) 3 (2-4) 3 (2-5) 13 (5-27) 39 (15-63) 
Cefotaxime 4 (2-6) 3 (2-5) 3 (2-5) 5 (3-8) 7 (4-12) 
Caffeine 20 (9-37) 1 (1-3) 7 (4-10) 22 (14-31) 48 (37-60) 
Iron 
supplements 
15 (6-34) 6 (2-14) 5 (2-11) 16 (8-28) 47 (29-67) 
Morphine (IV) 3 (2-7) 3 (2-5) 2 (1-4) 3 (1-5) 8 (3-19) 
Flucloxacillin 4 (3-7) 3 (2-5) 4 (2-6) 5 (3-7) 7 (4-12) 
Phosphate 
supplements 
19 (9-38) 5 (2-11) 8 (5-14) 19 (10-31) 40 (20-61) 
n, number of neonates (population size) 
All figures are median (interquartile range) 
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3.5.4.3 Change in drug use in the full cohort (all GA) 
There were 20 drugs that had a calculated range of change in frequency of 
use between the years in the study period greater than one percent (detailed 
in 9.15). The percentage of neonates receiving the drug at least once 
increased for some drugs (n=5) and decreased for others (n=12) while four 
drugs showed a fluctuation in use over the years (n=3).   
Overall decrease: 12 drugs had an overall decrease in their use over the 
years. This change in use could be attributed to either safety issues or 
factors related to their use in different neonatal gestational age groups. I 
have divided them into three groups of drugs: those with a decrease in their 
use that may be due to safety concerns, those where the decrease may be 
due to changes in the proportion of admitted neonates over the years based 
on their GA, and those where the decrease may be associated with lack of 
evidence of effectiveness.  
Safety concerns: the percentage of neonates who have been prescribed 
cefotaxime, domperidone, ranitidine, and ocular chloramphenicol (Figure 
37.a) at least once decreased from 2010 to 2017. This may be related to 
safety concerns associated with their use in neonates, which is detailed in 
the discussion. The percentage of neonates who have been prescribed 
cefotaxime decreased over time in general from 15.6% (9,417 neonates) in 
2010 to 12.1 % (12,001 neonates) in 2017, with 3.5% absolute decrease 
from 2010 to 2017. The percentage of neonates who have been prescribed 
domperidone at least once decreased from 4% (2,406 neonates) in 2010 to 
0.4% (377 neonates) in 2017, i.e. a 3.6 % absolute decrease in use. The 
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percentage of neonates who have been prescribed ranitidine at least once 
decreased from 5.1% (3,100 neonates) in 2010 to 2.5 % (2,504 neonates) in 
2017, with a 2.6% absolute decrease from 2010 to 2017. Percentage of 
neonates who have been prescribed ocular chloramphenicol decreased 
steadily from 2.6% (1,567 neonates) in 2010 to 1.5% (1,525 neonates) in 
2017, with 1.1% absolute decrease from 2010 to 2017.  
Changes in population composition: The percentage of neonates who have 
been prescribed flucloxacillin, vancomycin, metronidazole, caffeine, feed 
thickeners, and supplements (iron, phosphates) at least once have 
decreased from 2010 to 2017 (Figure 37.b). All these drugs are known to be 
prescribed to preterm neonates and their decrease in use might be attributed 
to the change in the population composition of the study cohort, detailed in 
the discussion.    




Figure 37. Drugs with an overall decrease in the percentage of neonates 
receiving it at least once from 2010 to 2017 a. safety concerns b. 
changes in population
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Lack of evidence: The percentage of neonates who have been prescribed 
topical nystatin at least once decreased from 5.1% (4,096 neonates) in 2014 
to 3.9% (3,868 neonates) in 2017, with 1.3% absolute decrease from 2010 to 
2017, which might be attributed to the lack of evidence that supports its 
effectiveness in the neonatal population.   
Overall increase: Five drugs were found to have an overall increase in their 
use over time; sodium, benzylpenicillin, gentamicin, amikacin, and pulmonary 
surfactants (Figure 38).  
The percentage of neonates who have been prescribed sodium at least once 
increased from 16.6% (10,038 neonates) in 2010 to 27.3% (27,198 
neonates) in 2017, with 10.7% absolute increase from 2010 to 2017. 
Amongst the antibiotics, benzylpenicillin had the highest percentage of 
increase over time. The percentage of neonates who have been prescribed 
benzylpenicillin at least once increased from 51% (30,828 neonates) in 2010 
to 59.4% (59,088 neonates) in 2017, with 8.4% absolute increase from 2010 
to 2017. With regard to pulmonary surfactants, the percentage of neonates 
who have been prescribed these agents at least once increased from 3.9% 
(2,351 neonates) in 2010 to 6% (5,938 neonates) in 2017, with 2.1% 
absolute increase from 2010 to 2017.   
Fluctuated: The percentage of neonates receiving amoxicillin, probiotics, 
and chlorhexidine at least once fluctuated over time (Figure 39).
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Figure 38. Drugs with an overall increase in the percentage of neonates receiving it at least once from 2010 to 2017
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Figure 39. Drugs fluctuated in the percentage of neonates receiving it at least once from 2010 to 2017
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3.5.4.4 Change in drug use among very preterm neonates 
There were 26 drugs that had a calculated range value greater than three 
percent (detailed in 9.16). Some of these drugs had an overall increase in 
their use (n=10) or an overall decrease in their use (n=1). Others displayed 
fluctuations in use over the years (n=15). Those with fluctuations in their use 
are detailed in 9.22.   
Overall decrease: Percentage of very preterm neonates who have been 
prescribed domperidone at least once each admission year was found to be 
continuously decreased from 17.8% (899 neonates) in 2010 to 2.6% (139 
neonates) in 2017, with 15.2% absolute decrease from 2010 to 2017 (Figure 
40). 
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Figure 40. Overall decrease in the percentage of very preterm neonates receiving domperidone at least once from 
2010 to 2017
Page | 149  
 
Overall increase: 10 drugs were found to have an overall increase in the 
percentage of very preterm neonates receiving it at least once (Figure 41). 
The percentage of very preterm neonates who have been prescribed caffeine 
at least once had increased from 76.5% (3,868 neonates) in 2010 to 91% 
(4,945 neonates) in 2017, with 14.5% absolute increase from 2010 to 2017. 
This was followed by benzylpenicillin in which the percentage of neonates 
that have been prescribed this drug at least once was 76.4% (3,865 
neonates) in 2010 to 88.3% (4,801 neonates) in 2017, and with 11.9% 
absolute increase from 2010 to 2017. The percentage of very preterm 
neonates who have been prescribed pulmonary surfactants at least once 
also noticeably increased from 17.4% (880 neonates) in 2010 to 34.7% 
(1,885 neonates) in 2017, with 17.3% absolute increase from 2010 to 2017.  
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Figure 41. Drugs with an overall increase in the percentage of very preterm neonates receiving it at least once from 
2010 to 2017 
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3.5.4.5 Change in drug use among extremely preterm neonates 
There were 43 drugs that had a calculated range value greater than five 
percent (detailed in 9.17). Some of these drugs had an overall increase in the 
percentage of extremely preterm neonates receiving it at least once (n=11) or 
an overall decrease in the percentage of extremely preterm neonates 
receiving it at least once (n=1). Others displayed fluctuations in the 
percentage of extremely preterm neonates receiving it at least once (n=31). 
Those with fluctuations in their use are tabulated in 9.23. 
Overall decrease: The percentage of extremely preterm neonates who have 
been prescribed domperidone at least once have decreased from 31.2% 
(699 neonates) in 2010 to 5.8% (139 neonates) in 2017, with 25.4% absolute 
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Figure 42. Overall decrease in the percentage of extremely preterm neonates receiving domperidone at least once 
from 2010 to 2017
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Overall increase: One of the most obvious drugs that can be extracted from 
Figure 43 in terms of its increase in prescribing in this cohort is pulmonary 
surfactants. Despite the three minor decrease in the percentage of neonates 
being prescribed those agents in 2012, 2016 and 2017, the use of those 
agents has been found to be increased over time. The percentage of 
extremely preterm neonates who have been prescribed paracetamol at least 
once increased from 18.8% (420 neonates) in 2010 to 37.8% (907 neonates) 
in 2017, with 19% absolute increase from 2010 to 2017. Similarly, in the very 
preterm neonates, the percentage of extremely preterm neonates who have 
been prescribed caffeine at least once increased from 79.5% (1,781 
neonates) in 2010 to 93.6% (2,248 neonates) in 2017, with 14.1% absolute 
increase from 2010 to 2017.  
 




Figure 43. Drugs with an overall increase in the percentage of extremely preterm neonates receiving it at least once 
from 2010 to 2017
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3.5.5 Results for objective 3: Are there any variations in prescribing 
according to gestational age and birth weight of neonates and 
treatment location? 
GA category: Benzylpenicillin and gentamicin were the most frequently 
prescribed drugs in term and moderate to late preterm neonates, whereas 
caffeine was the most frequently prescribed drug in very preterm and 
extremely preterm neonates (Figure 44). The average duration of drug 
exposure in days for the most frequently prescribed drugs was similar in each 
gestational age group (detailed in 9.24).  
BW category: Benzylpenicillin and gentamicin were the most frequently 
prescribed drugs in normal, LBW and VLBW neonates. Caffeine was the 
most frequently prescribed drug in extremely LBW neonates (Figure 45). 
The average duration of drug exposure in days for the most frequently 
prescribed drugs was similar in each BW group (detailed in 9.25).  
Unit level: There was no difference in the most frequently prescribed drugs 
according to the unit level of care; benzylpenicillin and gentamicin were the 
most frequently prescribed drugs in all unit levels (Figure 46).  




Figure 44. Most frequently prescribed drugs by gestational age group  
  




Figure 45. Most frequently prescribed drugs by birth weight group  
 




 Figure 46. Most frequently prescribed drugs by unit level
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3.5.6 Results for post-hoc objective: Are there any differences in 
antibiotic prescribing for each gestational age group? 
The median number of antibiotics prescribed per neonate was two (IQR 2-2) 
(Table 18). The median number of different antibiotics prescribed to one 
neonate decreased with increasing GA, where extremely preterm neonates 
were prescribed a median of five different antibiotics (IQR 4-7). 
The overall median (IQR) number of days of antibiotics across all GA was 3 
(2-5) (Table 18). The number of days of antibiotics, as well as the length of 
hospital stay, increased with the level of prematurity. In extremely preterm 
neonates the median length of hospital stay and median number of days on 
antibiotics per neonate were 86 and 19, respectively. In term neonates, the 
median length of hospital stay and median number of days of antibiotics 
decreased to four and three, respectively.  
Overall, neonates who were prescribed antibiotics for at least one day were 
prescribed antibiotics for an average of 60% of their hospital stay, and this 
percentage increased to 100% in term neonates.  
The highest absolute number of courses of antibiotics lasting at least five 
days was amongst term neonates (65,487 neonates) (Table 18). Extremely 
preterm neonates had the highest number of antibiotic courses per neonate, 
with a median (IQR) of 2 (1-3).  
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Table 18. Antibiotic analysis for all and each gestational age groups 









Number of neonates prescribed 
antibiotics at least once 
423,918 18,245 40,113 136,753 228,807 



































Percentage of neonatal care days 











Number (%) of neonates who 
received at least one course* of 
antibiotics 
136,859 (21%) 15,073 (79%) 22,167 (53%) 34,132 (17%) 65,487 (17%) 
Number of courses* of antibiotics 












All figures are Median (IQR) 
* antibiotic course: antibiotics prescribed for at least 5 consecutive days. If there was a gap of ≥2 days between stopping and re-
starting antibiotics, they were counted as two different courses  
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 Discussion  
This drug utilisation study is the first study to provide a benchmark for drug 
use across neonatal units in England and Wales. With the aim of exploring 
historic patterns of drug use across England and Wales neonatal units, 
several objectives were answered, and new questions have emerged which 
need to be answered in future research.  
This discussion focuses on comparing the findings in the present study with 
the UK as well as international drug utilisation studies, that used a similar 
approach. It also includes a discussion on the quality of data and issues with 
the use of NNRD in DUR, strengths and limitations of this study. The 
suggestions for future work will be highlighted in the final discussion chapter 
of this thesis.   
3.6.1 Comparison with other studies: Population characteristics 
Two prospective studies have been conducted in the UK for the purpose of 
exploring drug use in neonates (28,29). One investigated the frequency of 
off-label and unlicensed drugs use in a single NICU (29) whereas the more 
recent study by Turner et al. aimed to investigate the most frequently 
prescribed drugs in several NICUs across the UK and highlighted therapeutic 
gaps in the field of neonatal pharmacotherapy (28). However, the latter study 
did not report any information regarding the sample size or the characteristics 
of the population, and only reported the number of NICUs that participated in 
the survey (37 units). Conroy et al. included a small number of neonates (70 
neonates). It was prospective in design and conducted over a short period of 
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time in a single NICU. In addition to those two prospective studies, a recent 
multi-European study by Mesek et al. conducted to assess the drug 
prescribing patterns using a single-day point prevalence survey (65). In this 
study, 15 neonatal units from the UK contributed; however, the data of the 
UK could not be extracted. This is because the results in this study were 
reported by each European geographic region rather than single countries.  
When turning to drug utilisation studies worldwide, two studies in the USA 
have used an approach similar to the present study in exploring drug use in 
neonatal units, by using large national datasets and setting out similar aims 
(66,185) which allows better comparison in terms of their findings to the 
present study. In the current study, 44% of included neonates were female; 
this matches the findings of Clark et al. (185) and Hsieh et al. (66) where 
both showed 44% of neonates were female. This is also similar to my 
findings in Chapter 2 where there were more males in 33 out of 56 drug 
utilisation studies included in the review. The median GA of the neonates 
included in the present study was 37 weeks (IQR 35-40) and this can be 
attributed to the high percentage of term neonates (59%) in the studied 
population. In the previous studies conducted in the USA, the median GA of 
the included neonates was 35 (IQR 33-38), which represents moderate to 
late preterm neonates (66,185). Neonates with ELBW accounted for 3.5% of 
the entire cohort in the present study. This percentage was lower than that 
the study by Hsieh et al. where 6.5% of the included neonates were ELBW. 
The length of neonatal hospital stay in this present study increased with the 
decrease in the GA of the neonatal population (longest for extremely preterm 
neonates). This is expected, as the medical complications related to 
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prematurity and the intensive care required for preterm neonates results in a 
longer hospital stay compared to term ones (105). This finding cannot be 
compared to the previous studies in the USA as the length of hospital stay 
was not reported for each GA group. However, in the present study, the 
median length of hospital stay for the entire cohort was lower (median 5 
days, IQR 3-13) than the previous study by Hsieh et al. (median 10 days, 
IQR 5-21). This could be explained by the fact that the majority of neonates 
in the current study were term, who usually have the shortest length of 
hospital stay. In Hsieh’s study the breakdown of admissions by GA group 
was not reported. However, it might be speculated that the longer neonatal 
hospital stay in Hsieh’s study is due to a proportionally more babies admitted 
of a younger GA who would be expected to have longer lengths of stay. 
3.6.2 Comparison with other studies: Drug use profile 
Several methods have been reported in the literature quantifying drug use in 
neonates. Two studies in the USA, that used large datasets, represented 
drug use descriptively in three ways (courses, exposure, and frequencies), 
and interestingly, both reported no significant difference in the rank of the 
frequently prescribed drugs when comparing the three methods (66,185). In 
the current study, counts and proportions were used to rank the drugs and 
represent the frequencies of drug use across the population. Courses were 
defined differently by both studies that were conducted in the USA. In Clark 
et al. a course of a drug was defined as the number of times a unique 
medication was recorded for a single patient with a specific start date. 
Whereas in Hsieh et al. the course of a drug was defined as number of times 
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a unique drug name was reported in in the database. The limited information 
available in the NNRD database did not allow me to calculate the courses of 
each drug apart from antibiotics where an accepted definition of a course of 
antibiotics could be used. With regard to exposure, this term was defined 
exactly the same by both Clark et al. and Hsieh et al. as the number of 
unique drug names that were reported for each patient, which can be 
similarly applied to the counting method in the present study. I have used the 
term frequency to represent the raw count of each unique drug if it was 
prescribed at least once to a neonate. However, regardless of these 
inconsistencies in the terms used to define drug use, the results were similar 
when comparing the present study with Clark et al. and Hsieh et al.  With 
regards to the drug use profile findings, the present study supports that as 
the prematurity of neonates increases,  the total number of drugs a neonate 
is exposed to increases (115,119,186). The median number of drugs 
prescribed per neonate in England and Wales was lower (median 2, range 0-
69) than Hsieh et al. (mean 4, range 1-14), which is a study with a similar 
setting, design, and approximately similar sample size to the current study 
(66). A lower median number of drugs per neonate may, again, be due to the 
larger percentage of the neonates in the present study being term-born, the 
group that was prescribed the smallest median number of drugs compared to 
the other GA groups. Gulati et al. assessed the changes in drug use patterns 
in preterm neonates and very low birth weight neonates and reported a lower 
number of prescribed drugs per neonate (median 9, IQR 5-15) (114). This 
might be due to the included criteria of preterm neonates in Gulati which was 
confined to very low birth weight neonates with completed data (5,529 
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neonates included), whereas in the presented study the cohort of preterm 
neonates was larger.  
The top of the list of most frequently prescribed pharmacological groups was 
antibiotics, with 66% of neonates being prescribed at least one antibiotic 
during their neonatal stay; this is consistent with 23 studies from the previous 
literature review that found anti-infectives were the most frequently 
prescribed group of drugs in their NICUs (Chapter 2). With regards to the 
most frequently prescribed individual drugs, the present study supports 
evidence from two studies from the USA that utilised large databases in 
exploring drug utilisation in their NICUs (66,185). Penicillin and gentamicin 
were the most frequently prescribed drugs in the present study as well as the 
aforementioned studies. Also, this finding broadly supports the work of one of 
the two previous UK studies, in which gentamicin, followed by 
benzylpenicillin, were amongst the most frequently prescribed drugs (28). 
This was not an unexpected finding as most neonates are treated for 
presumed infections, especially early onset sepsis, with penicillin and 
aminoglycosides being the first line antibiotics used in Europe and North 
America (Chapter 2). Both are narrow spectrum antibiotics that are usually 
used to treat early onset sepsis. A review by Russell et al. reported that 70% 
of neonatal units in the UK use narrow spectrum antibiotics 
(penicillin/gentamicin) for treating early onset sepsis empirically, according to 
an audit across UK neonatal units (187). Clinicians often opt to use 
antibiotics empirically due to the fact that early onset sepsis is a life-
threatening condition if not treated promptly.  
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Other antibiotics found among the top ten most frequently prescribed drugs in 
the present study were cefotaxime and flucloxacillin. Flucloxacillin is a narrow 
spectrum antibiotic used often in the empirical management of late onset 
sepsis in neonates, alongside cefotaxime. In addition, it is used in the 
management of skin and soft tissue infections, cellulitis, bone infections, and 
pneumonia. Cefotaxime, a broad spectrum third generation cephalosporin, is 
often used in treatment of neonatal sepsis. In Chapter 2, among the included 
studies, cefotaxime was reported amongst the ten most frequently prescribed 
antibiotics in Europe by three studies (74,101,122). However, none of those 
studies were conducted in the UK, and the two prospective studies that were 
conducted in the UK in 1999 (29) and 2009 (28) have not cited this drug 
among the ten most frequently prescribed drugs in the participating neonatal 
units. The concern with such an agent is the emergence of antibiotic 
resistance, and the appearance of this drug amongst the ten frequently 
prescribed drugs in the current study needs to be explored further to avoid 
the misuse of broad spectrum of antibiotics.  
In the present study, comparing the number of antibiotics received by 
neonates in different GA groups showed that term neonates had the shortest 
length of hospital stay (median 4, IQR 3-7) with most of those days spent on 
antibiotics (median percentage of days on antibiotics 100, IQR 60-100). Term 
neonates are frequently admitted for suspected sepsis and/or treated 
empirically with antibiotics for this condition. They are then often, very 
quickly, discharged to the postnatal wards where they may or may not 
continue on antibiotics. Hence the majority of their time on neonatal units is 
spent on antibiotics.  
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Extremely preterm neonates were found to be prescribed the highest number 
of different antibiotics (median 5, IQR 4-7) and the highest number of days on 
antibiotics per neonate (median 19, IQR 9-33). Extremely preterm neonates 
are more prone to sepsis and require frequent sepsis screening, which leads 
to more antibiotics being prescribed.  
Analgesics were amongst the ten most frequently prescribed 
pharmacological groups, with IV morphine ranked amongst the ten most 
frequently prescribed drugs. The popularity of this opioid analgesic has been 
observed in the literature as it was cited by eight studies (high income 
countries) amongst the ten most frequently prescribed drugs included in 
Chapter 2. Morphine is used as pain relief and for sedation during invasive 
mechanical ventilation in preterm neonates. However, it is known to be 
associated with respiratory depression, which can lead to prolonged 
mechanical ventilation and prolonged time to full enteral feeding (188). Two 
randomised controlled trials have been conducted to assess the use of 
morphine in preterm neonates in terms of its efficacy and safety (189,190). 
Both of those trials have not supported the routine use of morphine in 
ventilated preterm neonates in the short term. Simons et al. reported the lack 
of efficacy of morphine to improve pain relief (190). Use of morphine as a 
short-term analgesic for painful procedures was recently explored in the 
Poppi Study (191) when the study was prematurely stopped due to the 
profound respiratory adverse effects of morphine without any suggestion of 
efficacy. Despite this body of evidence showing lack of efficacy and high risk 
of adverse effects, in the current study, I found a widespread use of morphine 
especially among preterm neonates. The proportion of neonates being 
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prescribed intravenous morphine increased with a decrease in GA (5% in 
term vs. 66% in extremely preterm neonates). This suggests that further 
research and quality improvement work is needed to support evidence-based 
use of morphine and other opioid analgesics (such as fentanyl) in these 
cohorts.  
Other drugs, not including antibiotics and analgesics, that are cited amongst 
the ten frequently prescribed drugs in this study were caffeine and 
surfactants, which are discussed in the next section (variation according to 
neonatal characteristics).  
3.6.3 Variation in prescribed drugs according to neonatal 
characteristics 
Caffeine was the most frequently prescribed drug in very and extremely 
preterm neonates in the current study. These results reflect those of Clark et 
al. who also cited caffeine citrate as the most frequently prescribed drug in 
preterm neonates born at GA < 32 weeks, followed by surfactants and 
vancomycin (185). Additionally, two prospective studies included in Chapter 2 
(80,88) have cited caffeine amongst the most frequently prescribed drug in 
their neonatal units. One of those studies by Cuzzolin et al. was a multicentre 
study (36 NICUs) which included a majority of preterm neonates amongst the 
included population (191/220, 86.8%) with more than half of the neonates 
being ELBW and VLBW (140/220, 63.7%) (80). Caffeine is the mainstay 
pharmacological treatment of apnoea of prematurity in preterm neonates 
because of its longer half-life and wider therapeutic range, which leads to 
reduced drug monitoring and higher cost-effectiveness compared to other 
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methylxanthines (e.g. theophylline) (192,193). Apnoea of prematurity is a 
common condition in those born prematurely, especially at lower gestational 
ages (194). Also, apnoea of prematurity incidence is inversely correlated with 
BW, affecting nearly all neonates born weighing < 1000g (195). 
When comparing the variation among units of levels of care, there were no 
differences in the most frequently prescribed drugs; gentamicin and 
benzylpenicillin were the most prescribed drugs overall in all units and each 
unit level. Another drug that was frequently cited across all unit levels is 
pulmonary surfactants. Surfactants were found to be amongst the ten most 
frequently prescribed drugs in level two units and ranked as number 11 in 
level three units. Level two and level three units care for neonates who 
require a higher level of ventilatory support, and the admitted gestational 
ages are usually between 28-32 weeks and GA< 28 weeks respectively. 
Exogenous pulmonary surfactants are usually indicated for the prevention 
and treatment of respiratory distress syndrome (RDS), a condition that is 
reported frequently with decreased GA; it is caused by structural immaturity 
of the lungs and insufficient production of surfactants (113,196). Hence, the 
use of those agents is expected in unit levels that care for neonates with 
lower GA and those presenting with medical complications.  
3.6.4 Change in drug use over time 
The change in drug use over time was observed across the entire cohort, 
and amongst very and extremely preterm cohorts, these observations will be 
discussed in this section for drugs highlighted in the results of this study.  
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3.6.4.1 Drugs used for GI conditions 
 There was an overall decrease in the percentage of neonates who were 
prescribed domperidone at least once across the entire cohort and among 
very and extremely preterm neonates. The decrease in the use of 
domperidone, usually given for gastro-oesophageal reflux disease (GORD), 
maybe a response to the restriction of its use in children following a report by 
the European Medicines Agency (EMA), released in 2014, with regard to its 
association with cardiac side effects (197). Also, a systematic review 
conducted in 2014 looked at the management of GORD in a paediatric 
population. It concluded that there is no robust evidence of using 
domperidone in neonates in terms of its efficacy and safety (198). This 
decrease in domperidone use was also observed by Cuzzolin et al. (80).  
Ranitidine is another drug used for GORD. Its use has decreased across the 
entire cohort. This may be due to safety concerns about its use as well. 
Ranitidine use has been associated with NEC and increased risk of infections 
and death in VLBW neonates as published in a study by Terrin et al. (199). 
Furthermore, there are no studies to date that have advocated its efficacy 
and safety in neonates (200). A systematic review conducted in 2014 on the 
pharmacologic management of children with GORD concluded that weak 
evidence exists for using H2 antagonist (such as ranitidine) or proton pump 
inhibitors (such as omeprazole/ lansoprazole) in managing GORD in children 
(including neonates) (198). However, Clark et al. and Du et al. have reported 
an increase in ranitidine use over the period from 1997 to 2004 (185,186). 
Page | 171  
 
These studies assessed drug use prior to the publications that associated 
use of ranitidine with NEC and infections.  
Feed thickeners, also used to manage GORD, are commonly used in 
neonates, in particular preterm neonates, as GORD is common in preterm 
neonates and can be exacerbated by the immaturity of the oesophagus and 
the lower oesophageal sphincter (201). The overall percentage of neonates 
prescribed feed thickeners decreased over time across the entire cohort, 
which might be attributed to the change in population composition (an 
increase in number of term babies in the database every year) rather than an 
actual shift in drug use (202).  
3.6.4.2 Drugs used for respiratory conditions 
Caffeine is a respiratory stimulant that is used for apnoea of prematurity. As 
the number of term neonates included in the cohort each year increased, 
across the entire cohort, the overall percentage of neonates who were 
prescribed caffeine at least once decreased from 2010 to 2017. However, the 
percentage of very and extremely preterm neonates who received caffeine 
increased over time. The vital role of caffeine in preterm neonates has 
become apparent following the Caffeine for Apnoea trial (CAP), the largest 
randomised controlled trial conducted to date on the efficacy and safety of 
caffeine in preterm neonates (203). The results of this trial supported the 
prophylactic use of caffeine for apnoea of prematurity as it reduces the 
frequency of Bronchopulmonary Dysplasia (BPD). This was followed by a 
Cochrane review in 2010 evaluating the effect of prophylactic effect of 
caffeine and included the CAP trial. However, the Cochrane review included 
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only three randomised trials and concluded against the use of prophylactic 
caffeine for preterm neonates at risk of apnoea due to insufficient available 
evidence on the effectiveness of this agent in decreasing episodes of apnoea 
or short term outcomes (e.g. use of mechanical ventilation, bradycardia, 
episodes of hypoxaemia) (204). This review was followed by series of 
retrospective studies and randomised trials supporting, overall, the initiation 
of caffeine especially within the first three days of life (192). A systematic 
review and meta-analysis by Park et al. assessed the early (0-2 days of life) 
vs. late use of caffeine (≥ 3 days of life). This meta-analysis has supported 
the early initiation of caffeine as it was associated with decreased incidence 
of death, and BPD without significantly affecting the duration of mechanical 
ventilation (205). Another more recent systematic review released in 2017 by 
Kua and Lee included 14 studies comparing early caffeine administration (< 3 
days) with late caffeine, placebo or theophylline. The meta-analysis of cohort 
studies and randomised trials in this review showed a reduction in BPD rate 
and shorter duration of mechanical ventilation (206). The accumulating 
evidence in favour of using caffeine early had led to the increase in its use in 
extremely and very preterm infants.  
Pulmonary surfactants have been used for the prevention and treatment of 
respiratory distress syndrome, which is common in preterm neonates who 
are deficient in surfactant production. The surfactant prescriptions included in 
this study do not include surfactants given in delivery rooms as those are 
reported separately in the NNRD. In the included data, overall, the 
percentage of neonates receiving pulmonary surfactants increased from 
2010 to 2017. In the cohort of very preterm neonates only, the percentage of 
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neonates who have been prescribed pulmonary surfactants at least once 
increased over time as expected. However, the percentage of extremely 
preterm neonates who were given pulmonary surfactants fluctuated over time 
with a general increase from 2010 to 2017, apart from three minor decreases 
in 2012, 2016 and 2017. This overall increased recording of use may reflect 
the shift in clinical practice from routinely giving surfactants to preterm 
neonates in the delivery suite (which would not be recorded in this dataset) to 
provide early support with continuous positive airway pressure followed by 
surfactant administration in the neonatal unit if needed. This later 
administration would be recorded in the database and may have been 
captured as the increasing trend in use of surfactant on neonatal units. Some 
increase in recorded use may also be due to improvement in data entry 
practices over the years.  
Evidence supporting the use of surfactants as prophylactic measures for 
preterm neonates suggests it reduces the risk of pneumothorax, pulmonary 
interstitial emphysema, and mortality according to a systematic review 
published in 2012 (207). However, this systematic review highlighted that 
some large trials included have supported the use of continuous positive 
airway pressure as early stabilisation with selective use of surfactants as a 
treatment strategy rather than prophylactic surfactant use. The use of 
antenatal steroids also has a role to reduce the risk of RDS and the use of 
surfactants, which has not been addressed in terms of analysis in the present 
study.  
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3.6.4.3 Antibiotics and drugs used in infections 
Benzylpenicillin and gentamicin, are frequently prescribed to term neonates 
for the empirical treatment of neonatal sepsis, so the increase in the 
proportion of term neonates corresponds to the increase in percentage 
neonates being prescribed those drugs at least once over the years in the 
present study across the entire cohort. Interestingly, the percentage of very 
preterm neonates who have been prescribed benzylpenicillin also increased 
from 2010 to 2017, whereas the use of this agent fluctuated among 
extremely preterm neonates.  
Percentage of neonates who have been prescribed amikacin increased from 
2011 to 2017 across the entire cohort. This aminoglycoside antibiotic is 
active against gram-negative bacteria resistant to gentamicin and has a half-
life of 7-14 hours in neonates (GA < 30 weeks) (208). Prescribers may often 
opt to use amikacin as an alternative agent in managing neonatal sepsis 
resistant to gentamicin (209). This raises the possibility of the emergence of 
bacterial resistance and warrants further studies exploring the use of 
amikacin in neonatal units in the UK.  
There is a decrease in the percentage of neonates prescribed some 
antibiotics such as flucloxacillin, vancomycin, and metronidazole. These 
trends might be related to the increase in the number of term born infants 
included in the dataset as at least some of these are more frequently used in 
preterm neonates. Therefore, the use of the whole population as a 
denominator to calculate the proportion of neonates being prescribed these 
drugs to explore their change in use over time might lead to such results. 
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Vancomycin is used for the empirical management of late-onset sepsis due 
to its coverage of Coagulase-negative staphylococci, which are found in the 
majority of methicillin-resistant infections (210). Late-onset sepsis affects 
10% of neonates, with more than 25% in those being VLBW (211). 
Flucloxacillin is also used in the management of late-onset sepsis, with an 
increase in its use as GA decreases (212). This was also shown in the 
results of this study as the percentage of neonates who received flucloxacillin 
increased with decreasing GA (2% term vs. 52% extremely preterm). 
Necrotising enterocolitis (NEC) also mostly affects preterm neonates and 
metronidazole is often used in its management. Cefotaxime is another 
antibiotic that the present study revealed the steady decrease in the 
percentage of neonates receiving it over time, apart from two minor increases 
in 2016 and 2017. This decrease might be associated with the emerging 
findings of the increased risk of fungal infections (candidiasis) in neonates 
with the use of third generation cephalosporins (213,214). Two retrospective 
studies by Hsieh et al. and Gulati et al. investigating the patterns in drug use 
have also reported a decrease in the use of third generation cephalosporins 
in the included neonatal care units and attributed the decrease to the 
emerging information of the increase risk of candida infections with third 
generation cephalosporins (66,114).  
The percentage of neonates who were prescribed ocular chloramphenicol 
decreased over time across the entire cohort from 2010 to 2017.This may be 
due to safety issues. The use of systemic chloramphenicol has been 
associated with toxicity in neonates, with symptoms such as grey baby 
syndrome, haemopoietic disturbances, and bone marrow aplasia (215). 
Page | 176  
 
However, debates and insufficient evidence exist with regard to the use of 
the topical formulation (i.e. ocular) for treating neonatal conjunctivitis. The 
topical form can be absorbed directly through the nasal mucosa or swallowed 
and absorbed into the intestine. This small amount might also be of concern 
as aplastic anaemia (also known as bone marrow aplasia) may be dose-
independent (216). This uncertainty and insufficient evidence for the safety in 
using the topical form of chloramphenicol might be the drive behind the 
decrease of its use in neonatal units in England and Wales.  
Lack of evidence may be attributed to the decrease in the percentage of 
neonates who have been prescribed topical nystatin which was captured in 
the database 2014 onwards. Topical nystatin is usually used as a 
prophylactic agent against invasive fungal infections, especially in preterm 
neonates and those born with VLBW. Invasive fungal infections are more 
common in such cohorts due to several risk factors, such as the use of 
multiple courses of antibiotics, severe illness at birth, and the use of a central 
catheter (14). A Cochrane systematic review in 2015 (14) assessed the 
effectiveness of prophylactic oral/topical non-absorbed antifungals (nystatin 
or miconazole) on the incidence of invasive fungal infection, mortality, and 
morbidity in very preterm or VLBW neonates. It concluded that there is 
insufficient data to provide conclusive evidence that supports the efficacy of 
those agents and recommended larger high-quality trials to resolve the 
uncertainty of the findings. 
The use of some antibiotics such as amoxicillin fluctuated over time. In 
addition, the percentage of neonates who have been prescribed probiotics 
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also fluctuated over time. Probiotic use increased between 2013 to 2014 and 
then fell in 2015 and 2016. This demonstrates the continuing debate about 
the routine use of probiotics in neonates. The Cochrane review published in 
2014 compared the efficacy and safety of prophylactic use of probiotics in the 
prevention of severe NEC or sepsis, or both, in preterm neonates (217). This 
review strongly supported the use of probiotics to prevent severe NEC and all 
cause of mortality in preterm neonates. However, several reports of probiotic 
sepsis published in 2015 and 2016 and one neonatal death due to fungal 
infection from a contaminated probiotic raised concern regarding their use 
(218,219). Furthermore, the use of probiotics in the UK may have been 
discouraged following the results of a large multicentre trial in the UK in 2016 
(PIPs trial), (220,221). This trial has concluded the ineffectiveness of using 
probiotics in preventing NEC and late-onset sepsis in very preterm neonates. 
Another randomised trial conducted in the UK, ELFIN trial, to enhance the 
validity of the available evidence on the use of lactoferrin supplements in 
neonates, especially preterm ones (222). Enteral lactoferrin is a supplement 
that promotes the growth of probiotic bacteria and is involved in several 
mechanisms of the immune system. It has been proposed as an alternative 
to compensate for the little/no intake of the mammalian lactoferrin that 
presents in human breast milk during the early neonatal period. As a result of 
this trial, the use of enteral lactoferrin was discouraged in very preterm 
neonates as those supplements did not show any reduction in the risk of late-
onset infections and associated morbidity (NEC, ROP, BPD) or mortality in 
this cohort.  
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3.6.4.4 Other drugs 
The percentage of neonates being prescribed chlorhexidine fluctuated during 
the study period across the entire cohort. Chlorhexidine is a topical antiseptic 
that is widely used in NICUs to prevent nosocomial infections. Although some 
fluctuations in recorded use may be due to inconsistency in data entry into 
electronic patients records, the dilemma in the effective and safe use of 
antiseptics, including chlorhexidine, in neonates, may have contributed to 
some variation in use. An evidence-based review by Sathiyamurthy et al. 
concluded that chlorhexidine is associated with local reactions compared to 
other antiseptics (iodine) which is associated with an increased risk of 
systematic absorption and toxicity (223). In June 2014, the UK Medicines and 
Healthcare products Regulatory Agency (MHRA) urged physicians to use 
chlorhexidine with maximum care in preterm neonates due to several reports 
of erythema and local burns in extremely preterm neonates (224,225).  
The percentage of extremely preterm neonates who were prescribed insulin 
at least once increased from 2010 to 2017. Insulin is used in extremely 
preterm neonates as they are more prone to hyperglycaemia (226). The 
increase might be related to the increase in the records of insulin in the 
database. Other reasons that may drive increased use of insulin may be 
related to more intensive nutritional strategies with higher concentrations of 
parenteral nutrition given to extremely preterm neonates leading to the 
increased chance of glucose intolerance and need for insulin. Increase in the 
percentage of extremely preterm neonates who have been prescribed 
dexamethasone (from 13.3% in  2010 to 20.2% in 2017) may also drive 
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higher insulin use. Dexamethasone, which can cause hyperglycaemia as one 
of its adevrse effects, is often prescribed in the prevention and treatment of 
BPD in preterm neonates. Several Cochrane reviews conducted in 2009, 
2010, 2014 and the most recent in 2017 (227–230) investigated the 
effectiveness and safety of administring postnatal corticosteriods in pereterm 
neonates at risk of developing BPD. The authors of these reviews concluded 
that dexamethasone is effective in facilitating extubation and reducing BPD in 
preterm neonates, but the risk of the adverse effects of such agents may not 
outweigh the benefit.  
It is worth highlighting the fact that not all the drugs that are actually 
prescribed are meticulously entered into NNRD. But as data entry has 
improved in general over the years, the entry of routinely used drugs, such as 
sodium supplements, might have increased which then shows as an increase 
in the percentage of neonates who have been prescribed this supplement. In 
very preterm neonates, the increase in the percentage of neonates being 
prescribed drugs such as immunisations and topical agents such as 
phenylephrine have increased over time, which may also be due to 
improvement in data entries and recording over the years. Supplements such 
as iron and phosphate are known for their prevalent use in preterm neonates 
as this cohort are usually born with low stores of phosphate and iron. 
Therefore, the percentage of extremely preterm neonates who have been 
prescribed those supplements increased in the study period.  
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3.6.5 NNRD data quality 
Secondary data sources in drug utilisation studies have been used to 
estimate incidence, prevalence, duration of drug use, and investigate drug 
use patterns over periods of time (231). The NNRD was used to answer 
several questions that were proposed in this drug utilisation study, as so far 
this is the only database that captures information about drug prescriptions to 
neonates from almost all neonatal units in the UK. This database is a 
repository of pre-defined clinical data that is extracted by NDAU quarterly on 
all neonatal admissions to the NHS from any point of care in England, Wales, 
and Scotland. It is worth highlighting that by 2012, all neonatal units in those 
three countries contributed their data into the NNRD to cover the whole 
population admitted to neonatal units. A recent validation study in England  
set out to assess the validity of the NNRD in terms of the population 
coverage from 2008 to 2014 by assessing the accuracy and the 
completeness of the data held in this database (202). The completeness was 
assessed by calculating the percentage of 7 data items of patients’ 
characteristics that includes GA, sex, and BW, and reported over 90% 
completeness. This study also linked the NNRD with independently collected 
data from the Office for National Statistics and the Probiotics in Preterm 
babies Study (PiPS) to assess the accuracy of the data and compared the 
agreement between 44 prespecified items in both databases. The specificity 
of the NNRD was found to be > 85% for all outcomes and the sensitivity 
ranged between 50-100%. So, it can be concluded that the completeness 
and the quality of data held in the NNRD is high, which assures its 
applicability for research purpose use (202). 
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Despite these assurances on data quality and completeness, this study 
revealed several drawbacks of the NNRD when used for drug utilisation 
studies. First, not all neonates who received drugs are admitted to neonatal 
units and thus, their data are not included in the NNRD. This is because 
many neonates are treated in postnatal wards, discharged from postnatal 
wards, or discharged from neonatal units and returned to the hospital to be 
treated by a paediatric unit and as such, their data is not included in the 
NNRD.  
The second observation made while analysing this data is the limitation of the 
drug data available in this database, which can impede a firm conclusion with 
regards to the rational use of the drugs in this population; this is the ultimate 
goal of any drug utilisation study and as such, is deemed pertinent. Although 
the name of drugs is recorded daily, limited information was available on the 
route of administration, such as some drugs were coded as ‘morphine-iv’ and 
‘beclomethasone-inhaler’, while most others were missing such information. 
There was no information recorded on the dose given, actual duration, 
adverse effects, and most importantly the indication of drug use.  
Thirdly, poor coding of the drugs is another drawback of the NNRD, as all 
drugs were coded in free text with several incorrect spellings as illustrated in 
the coding section of this study. Also, there were many unrecognised drug 
entries encountered while extracting the drugs, and all were excluded from 
the analysis. For example, 41 neonates were prescribed ‘supplements’ and 
four neonates were prescribed an ‘unlisted drug’. So, there was no 
standardisation of coding such as those by WHO-ATC classification system 
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that was observed in other drug utilisation studies that appeared in the 
previous review chapter. Diagnosis coding had some drawbacks that was 
observed while analysing the characteristics of neonates with no drugs. First, 
22% (n=137,578) of the included neonates across the entire cohort and 39% 
(n=74,698) of those who were not prescribed any drugs had no entries of 
diagnosis at admission. The reason for missing such necessary entry is 
worth to be explored. Also, the term ’other’ in diagnosis at admission was 
used in at least 7% (n=46,373) of the entire cohort and in at least 10 % 
(n=18,540) of neonates who have not been prescribed any drugs. Using a 
general broad entry, such as other, requires further exploration to understand 
what this term exactly includes.  
The fourth observation related to the data quality that may constitute a 
limitation of this work is the fact that admission criteria appear to have 
changed over the study period. This is demonstrated by the increase in the 
number of neonates admitted every year, especially those born at term 
gestations. Consequently, the interpretation of some drugs used, especially 
those that are used mostly in preterm neonates is not representative of actual 
change in use when the whole cohort is considered together. 
Lastly, data entered at the point of care (i.e. Bager.net platform) by a variety 
of staff, who might not necessarily be those who prescribed the drug or be 
appropriately trained in data entry (175). How drugs are entered into the 
dataset may between units and from one year to another and some changes 
in drug use over time might be due to these variations rather than actual 
change is use. 
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While some data are known to be accurate and complete such as those 
related to the population characteristics as per the validation study mentioned 
earlier (202), the accuracy and completeness of other important data points 
for a drug utilisation study such as those related to the drugs have not been 
evaluated or validated.  
Despite these limitations, NNRD provides a unique opportunity to conduct 
large scale data analysis and this study has utilised this to produce an overall 
picture of drug utilisation in neonatal units in England and Wales.  
3.6.6 What does this study add? 
This is the largest study to date reporting on drug utilisation in neonates in 
England and Wales. It is the first study that has used a national database to 
explore drug use in neonates and to lay the groundwork for future 
researchers interested in this field. Furthermore, this study has explored the 
usefulness, as well as the drawbacks, of the NNRD when used in drug 
utilisation research. The variety of designs and methods used in drug 
utilisation studies in neonates have been pointed out in a systematic review 
by Rosli et al. (2017), which highlighted the need for future research to 
identify the best measure in quantifying drug utilisation in this age group (10). 
For the UK, there were no studies that investigated drug use patterns in 
neonates on a national level. And since there is still no gold standard to 
quantify drug consumption in neonates as pointed by Rosli et al., the use of 
secondary data sources can provide an initial step towards exploring drug 
use in neonatal units in the UK. The results of this study are generalisable as 
it is a multicentre study and includes data from more than half a million 
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neonates and captured medication use over an eight year period. Previous 
studies conducted in the UK, both prospective, included either a small 
sample size (one NICU) (29) or had a low response rate from participating 
units (28). Thus, both had insufficient data to describe drug use in neonatal 
units in the UK to be generalisable. Another strength is that the present study 
has sub-analysed drug use across the neonatal population according to 
different GA, BW, and level of care. This was not observed in the UK studies 
or drug utilisation studies in the USA that have used a national dataset. Drug 
utilisation in neonates is dynamic and is prone to changes with different 
neonatal GA or BW as it was seen from the findings of the current study. This 
is because each age or BW group of neonates is admitted with different 
conditions and requires tailored neonatal care.  
In summary, this study lays the groundwork for future research on the use of 
drugs in neonates. It has identified the most frequently prescribed drugs 
across neonatal units in England and Wales and whether these drugs have 
changed in frequency of use over an eight-year period.  
In the UK, one of the main therapeutic gaps that requires research, as 
identified by previous drug utilisation studies and highlighted by clinicians, is 
PDA (28). PDA pharmacological management is one of the most challenging 
areas in neonatal therapeutics. Several studies exist in the literature aiming 
towards finding the optimal management of this condition that affects preterm 
neonates. Indomethacin, ibuprofen and more recently paracetamol are the 
most studied drugs that are used in management of PDA, with several 
controversies that exist around them in terms of their efficacy and safety. 
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Therefore, I chose to further explore drug use in PDA across the same time 
period, to look at the prescribing pattern of those three drugs and whether it 
has changed over time. This will be further detailed in the next chapter 
(Chapter 4).  
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CHAPTER 4 DRUG UTILISATION IN PATENT 
DUCTUS ARTERIOSUS (PDA) ACROSS NEONATAL 
UNITS IN ENGLAND AND WALES   
 Introduction 
Management of PDA remains one of the most debated and challenging areas 
in neonatal therapeutics. As discussed in Chapter 1, PDA can be managed 
pharmacologically with indomethacin, ibuprofen, and most recently 
paracetamol. Surgery may, sometimes, be used in case of failure or 
contraindication of those agents.    
In Chapter 3, I found that among extremely preterm neonates, 21% were 
prescribed ibuprofen at least once; this drug was ranked as number 25 in the 
top 50 drugs (detailed in 9.19). PDA, although present at birth at all 
gestational age, is a condition that mostly adversely affects very and 
extremely preterm neonates. Delayed closure of PDA in very preterm 
neonates is associated with several complications including intraventricular 
haemorrhage (IVH), necrotising enterocolitis (NEC), BPD, and higher 
mortality (232). In addition, small to moderate PDA tends to close 
spontaneously especially in those born over 28 weeks and often left without 
any treatment (33).  
In addition to ibuprofen, as shown in Chapter 3, 8% and 25% of very and 
extremely preterm neonates respectively were prescribed paracetamol at 
least once. Paracetamol may have been prescribed either as an analgesic or 
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for PDA treatment although its use as an analgesic is limited as is thought to 
have a poor effect in postoperative pain and procedures in neonates (233).  
In this chapter, I aimed to do an analysis of different treatment modalities 
used in PDA management in extremely and very preterm neonates across 
neonatal units in England and Wales and to investigate if their use has 
changed over time.  
 Study design  
This was a retrospective pharmacoepidemiologic study to explore drug 
utilisation in PDA management from 2010 to 2017 across neonatal units in 
England and Wales. The same dataset National Neonatal Research 
Database (NNRD) that was used as in Chapter 3.  
 Aim and objectives  
The aim of this study was an analysis of different treatment modalities used 
in PDA management in extremely and very preterm neonates across 
neonatal units in England and Wales and to investigate if their use has 
changed over time. 
Five main objectives were set out to approach this aim. 
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• Objective 1: What is the prevalence of PDA in <32 weeks neonates 
across neonatal units in England and Wales, and has it changed over 
time? 
• Objective 2: What is the prevalence of no treatment in neonates who have 
a record of PDA, and has it changed over time? 
• Objective 3: What is the prevalence of use of each PDA treatment 
strategy across neonatal units in England and Wales from 2010 to 2017 
and has it changed over time? 
• Objective 4: What is the prevalence of use of paracetamol in neonates 
with PDA across neonatal units in England and Wales? 
• Objective 5: What is the duration of treatment for the drugs used for 
treating PDA? 
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 Methods  
A detailed overview of the study dataset is described in the previous chapter 
of drug utilisation patterns in neonatal units in England and Wales (Chapter 
3).  
4.4.1 Study dataset and population characteristics 
All neonates admitted to a neonatal unit in England or Wales from 01 
January 2010 to 31 December 2017 with a GA < 32 weeks (very and 
extremely preterm neonates only) were eligible for inclusion. This restriction 
in GA was selected as PDA mostly affects very and extremely preterm 
neonates. Neonates who met exclusion criteria as in Chapter 3 were 
excluded from this analysis too. The population demographics were 
summarised for the entire cohort, neonates with PDA, neonates without PDA.
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4.4.2 Specific methods for each objective 
4.4.2.1 Objective 1: What is the prevalence of PDA in <32 weeks 
neonates across neonatal units in England and Wales, and has 
it changed over time? 
For this objective, the following steps were undertaken: 
1. The Daily dataset was inspected for variables that indicate a record of 
PDA. This could either involve an actual record of the PDA in one of 
the diagnosis variables or one of the treatments (record of drugs/ 
surgery) in one of the variables that indicate a treatment of PDA. 
Three variables were identified in the daily dataset, and those include 
the ‘diagnosis day’ variable, ‘treatment for PDA’ variable, and the 
‘drugs day’ variable.  
2. The Episode dataset was inspected for variables that also could 
indicate a record of PDA whether from diagnosis or treatment aspects 
(‘diagnosis at admission’ variable and the ‘principal diagnosis at 
discharge’ variables).  
3. Created different binary variables for each source of information which 
were coded as zero and one. ‘Zero’ was generated to indicate that a 
neonate does not have a PDA diagnosis record or has not been 
treated with ibuprofen/indomethacin/surgery at any point of their 
neonatal stay. ‘One’ was generated to indicate a diagnosis or a 
treatment of PDA (drugs/surgery) of a neonate at any point during 
their neonatal stay.  
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4. Converted the daily dataset into one row per neonate dataset, and 
only neonates who had a GA of less than 32 were kept. The Episode 
dataset is a one row per neonate dataset; therefore, this conversion 
was not required but neonates who had a GA  32 weeks were 
dropped from it.  
5. Merged the information of the PDA from episode and daily datasets to 
create a final PDA dataset to identify records of PDA that could assist 
in calculating the prevalence of it. 
6. Created variable to merge all the sources of information that indicate a 
neonate has a record of PDA in one variable based on either 
diagnosis or treatment variables.  
Appendix 9.26 details the variables used to calculate the number of neonates 
who have PDA records based on diagnosis and/or treatment indicating the 
presence of a PDA. Following these steps, prevalence of PDA was 
calculated. These steps were also repeated to demonstrate the PDA 
prevalence for each GA. 
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4.4.2.2 Objective 2: What is the prevalence of no treatment in neonates 
who had PDA, and has it changed over time? 
Neonates included in this analysis were only those with a record of PDA. For 
this analysis paracetamol was included as a treatment strategy as it can be 
used for PDA. Prevalence of any treatment was calculated based on either 
including or excluding paracetamol as a treatment strategy in addition to 
other treatment strategies (indomethacin, ibuprofen and surgery). Then for 
each cohort the corresponding prevalence of no treatment was calculated. 
Similar variables created for each treatment strategy in the previous 
objectives (2 and 3) were used.  
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4.4.2.3 Objective 3: What is the prevalence of use of each PDA 
treatment strategy across neonatal units in England and Wales 
from 2010 to 2017, and has it changed over time? 
For this objective, neonates who have been identified to have a PDA record 
from the first objective were analysed only. Then the following steps were 
followed:  
1. Created variables to identify neonates who had records of ibuprofen or 
indomethacin at least once during their neonatal stay. And this was either 
identified from ‘drugs day’ variable or ‘treatment for PDA’ variable.  
2. Created a variable to identify neonates who had records of surgery from 
‘treatment for PDA’ variable. 
3. Counted the variables used to calculate the number of neonates who had 
any treatment strategy for PDA (detailed in 9.27).  
4. The number of neonates receiving any treatment strategy either alone or 
in combination was counted across the entire cohort and across each GA.  
5.  The prevalence of each treatment received was calculated by dividing 
the number of neonates having a record of each treatment strategy by the 
total number of neonates admitted each month with a record of PDA. 
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4.4.2.4 Objective 4: What is the prevalence of use of paracetamol in 
neonates with PDA across neonatal units in England and 
Wales? 
This was done by first comparing paracetamol prevalence in neonates who 
had PDA records and those who don’t and making the assumption that 
neonates with any record of paracetamol only (i.e. neonates have no records 
of indomethacin/surgery/ibuprofen or text diagnosis) does not indicate that a 
neonate have PDA. This was assumed as only one percent of neonates 
(n=478) across the entire cohort had a record of ibuprofen or indomethacin or 
surgery as treatment for PDA without having recorded text diagnosis. 
Appendix 9.28 details the variables used to extract records of paracetamol 
across the entire cohort. Then the prevalence in (%) of paracetamol use in 
neonates with and without PDA was calculated.   
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4.4.2.5 Objective 5: What is the duration of treatment for the drugs 
used for treating PDA? 
The analysis was done across the entire cohort (all neonates < 32 weeks) for 
indomethacin, ibuprofen, and paracetamol. The same codes that were used 
in objective three to extract the free text of the drugs were used. Then the 
following steps were followed:  
1. Sorted the data by two variables: anonymised ID of the neonate and the 
‘daydateanon’ variables. The daydateanon, is a variable that shows the 
time difference between time of birth and each particular date in the 
database. From this variable the first day of life of each neonate can be 
estimated, which can be considered as the ‘chronological age’ of the 
neonate.  
2. Created a variable to identify first day of prescribing of each drug amongst 
those who were prescribed that drug.  
3. The total number of days of prescribing variable was created for each 
drug.  
4. Variables in steps (two and three) were kept and all duplicates were 
dropped. 
5. All the steps from one to four were repeated for all daily data files. 
6. The created demographic data file was merged into the daily data file to 
summarise demographics of the neonates for this question.  
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 Results 
4.5.1 Study dataset and population characteristics 
Study dataset: The total number of neonates for whom records were initially 
received was 643,233. The final number of very and extremely preterm 
neonates included in this study was 61,265, as detailed in Figure 47. 
 
Figure 47. Derivation of the study dataset for patent ductus arteriosus 
analysis
Page | 197  
 
Population characteristics: Total number of very and extremely preterm 
neonates included in this study was 61,265. Of these, 18,181 (30%) had a 
diagnosis of PDA identified within the database (Table 19). Neonates with 
PDA records had smaller GA and lower BW when compared to those with no 
records of PDA. Also, a higher percentage of neonates with PDA records 
died (11%) before discharge compared to those without any PDA records 
(8%).
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Table 19. Population characteristics of neonates (<32 weeks gestation) with and without record of PDA 
Demographic comparison All PDA No PDA 
P value 
(PDA vs. No PDA) 
Number, n (%) 61,265 18,181 (30) 43,084 (70)  
GA (weeks) 
Median (IQR) 








 ( 1050-1565) 
<0.001** 




Home  52,690 (86) 14,620 (81) 38,070 (88) 
<0.001*** 
Died 5,581 (9) 2,109 (11) 3,562 (8) 
Ward  912 (1) 410 (2) 502 (1) 
Transfer  1,911 (3) 1,054 (6) 857 (2) 
Missing  171 (0) 78 (0) 93 (0) 
BW, birth weight; GA, gestational age; PDA, patent ductus arteriosus  
*Mann-Whitney test; **Two sample t-test; ***Pearson Chi-square test 
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4.5.2 Results for objective 1: What is the prevalence of PDA in <32 
weeks neonates across neonatal units in England and Wales, and 
has it changed over time? 
The overall prevalence of PDA in this study period was 30% (Table 19).  
Despite month to month variations, overall, the prevalence of PDA has not 
changed from 2010 to 2017 (Figure 48). A detailed table of neonates who 
have PDA based on the diagnosis and/or treatment indicating a PDA on each 
month of admission is attached in appendix 9.29.  
Figure 49 shows the prevalence of PDA by GA weeks and shows that 
prevalence increased with decreasing GA except in 22- and 23-weeks 
neonates who had a lower prevalence.   




Figure 48. PDA prevalence (by month of admission) in <32 weeks neonates from 2010 to 2017 in England and 
Wales 




Figure 49. Prevalence of PDA across different GA
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4.5.3 Results for objective 2: What is the prevalence of no treatment in 
neonates who have a record of PDA, and has it changed over 
time? 
Table 20 shows how many neonates did or did not have any treatment for 
PDA. When including paracetamol as a treatment strategy, 49% of neonates 
with a diagnosis of PDA received some treatment. 
Table 20. The prevalence of treatment for PDA among neonates < 32 
weeks gestation who had a diagnosis of PDA (n=18,181) 
 Prevalence of any 
treatment, n (%) 
Prevalence of no 









8,981 (49%) 9,200 (51%) 
 
In Figure 50 any treatment which included ibuprofen and/or indomethacin 
and/or surgery showed little variation over time. Whereas when paracetamol 
was not counted as one of the treatment strategies, the prevalence of 
neonates who have not received any treatment increased over time. 
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Figure 50. Prevalence of no treatment in neonates with a record of PDA
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4.5.4 Results for objective 3: What is the prevalence of use of each 
PDA treatment strategy across neonatal units in England and 
Wales, and has it changed over time?  
In this section, use of indomethacin, ibuprofen, and PDA surgery are 
presented. Paracetamol use is described in section 4.5.5.  
Overall, as shown in Table 21, amongst neonates who have records of PDA, 
35% (6,384 neonates) had at least one treatment strategy. More were treated 
with ibuprofen (4,926 (27%)) as compared to indomethacin (1,417 (8%)) or 
surgery (1,037 (6%)). Figure 51 shows the prevalence of use of each 
treatment strategy across each GA. The use of treatment increased with 
decreasing GA. Use of treatment strategies in combinations (including 
paracetamol) in neonates with PDA by GA is given in appendix 9.30. 
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Had PDA surgery 
n (%) 
22 27 12 (44%) 1 (4%) 11 (41%) 2 (7%) 
23 997 557 (56%) 126 (13%) 420 (42%) 144 (14%) 
24 2,339 1,327 (57%) 286 (12%) 1,038 (44%) 295 (13%) 
25 2,636 1,310 (50%) 316 (12%) 1,002 (38%) 215 (8%) 
26 2,900 1,160 (40%) 261 (9%) 892 (31%) 157 (5%) 
27 2,807 910 (32%) 208 (7%) 702 (25%) 104 (4%) 
28 2,479 597 (24%) 122 (5%) 466 (19%) 66 (3%) 
29 1,772 320 (18%) 61 (3%) 249 (14%) 37 (2%) 
30 1,276 130 (10%) 20 (2%) 104 (8%) 10 (1%) 
31 948 61 (6%) 16 (2%) 42 (4%) 7 (1%) 
22-27 weeks 11,706 5,276 (45%) 1,198 (10%) 4,065 (35%) 917 (8%) 
28-31 weeks 6,475 1,108 (17%) 219 (3%) 861 (13%) 120 (2%) 
22-31 weeks 18,181 6,384 (35%) 1,417 (8%) 4,926 (27%) 1,037 (6%) 
PDA, patent ductus arteriosus 
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Figure 51. Prevalence of each treatment strategy according to each GA 
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Overall, there were several fluctuations in use of PDA treatment strategies in 
the study period (Figure 52). From January 2010 to April 2011 as there was 
an increase in the percentage of neonates with records of ibuprofen use with 
a decline in the percentage of neonates with records of indomethacin use. 
Following April 2011, several fluctuations in the prevalence of use of each 
modality. Figure 52 shows an overall decline in the use of surgery as 
treatment strategy over time.   
Table with prevalence of recorded use of indomethacin and ibuprofen at each 
month of admission is given in 9.31 . 




Figure 52. Prevalence in the percentage of different treatment strategies of PDA over time in England and Wales 
neonatal units from January 2010 to December 2017
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4.5.5 Results for objective 4: What is the prevalence of use of 
paracetamol in neonates with PDA across neonatal units in 
England and Wales? 
As shown in Table 22, 27% (4,889 neonates) of neonates with PDA had 
paracetamol use recorded at some point during their neonatal stay. However, 
only 8% (3,280 neonates) of neonates without PDA had paracetamol use 
recorded. 
Table 22. Prevalence of use of paracetamol in neonates with and 
without PDA  




With PDA  18,181 4,889 (27) 
Without PDA 43,084 3,280 (8) 
Total  61, 265 8,169 (13) 
PDA, patent ductus arteriosus 
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Figure 53 shows that there was a noticeable increase in the number of 
neonates with a record of PDA who were treated with paracetamol from 
March 2015 onwards. The prevalence of paracetamol used in neonates 
without PDA diagnosis recorded was lower but also appears to be increasing.  
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Figure 53. Prevalence of paracetamol used in neonates with PDA and those without PDA across neonatal units in 
England and Wales
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4.5.6 Results for objective 5: What is the duration of treatment for the 
drugs used for treating PDA? 
Table 23 details the total number of days of use of, day of life and corrected 
GA when indomethacin, ibuprofen, or paracetamol were first given.  
Table 23. Duration of the drugs used for PDA 
 Indomethacin Ibuprofen Paracetamol** 
Number of neonates 
prescribed the drug  
1,417 4,926 8,169 








Day of life when drug 







Corrected GA when 
the drug was first 
prescribed (weeks)* 
27 (23-52,25-29) 27 (23-63,26-29) 34 (23-68,31-37) 
*Median (range, IQR) 
**includes all records of paracetamol irrespective of whether the neonate did or did 
not have a record of patent ductus arteriosus (PDA) 
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 Discussion and conclusion  
PDA is a key clinical example for exploring evidence-based pharmacotherapy 
in neonatal practice. It has been the subject of numerous clinical trials and its 
optimal management is an unresolved debate.   
4.6.1 The prevalence of PDA 
In the present study, 30% of neonates born at <32 weeks gestation had a 
record of PDA and/or a treatment indicating the presence of a PDA. 
Previously published reports estimate that on day three of life neonates with 
GA< 32 weeks the prevalence of PDA is  20 to 50% (234–236). Similar to 
other reports (237), I also found that the prevalence of PDA increased with 
decreasing GA (15% at 28-31 weeks compared to 61% at 22-27 weeks). 
Prevalence of PDA was lower at 22 and 23 gestational age which may be 
due to lower survival at these gestations or incomplete records. A previous 
analysis of NNRD data showed that record completeness is much lower for 
23 week neonates as compared to those who are more mature (202).  
4.6.2 Change in the prevalence of no treatment over time 
I found that, in the study period, there was an increase in the percentage of 
neonates who did not received any treatment for PDA. The ductus closes 
without any treatment in most babies especially those who are less 
immature, have BW > 1000 g, and who do not have respiratory distress 
syndrome (RDS) (237,238). However, late ductal closure in preterm 
neonates or those with RDS does not always happen spontaneously and 
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interventions are needed. However, a growing body of evidence suggests 
that inducing ductal closure in preterm neonates, particularly in the first two 
weeks after birth, does not improve the long term outcomes (237,239).   
4.6.3 Change in use of ibuprofen and indomethacin over time 
I found that more neonates with a diagnosis of PDA were treated with 
ibuprofen as compared to indomethacin and surgery. The popularity of 
ibuprofen reflects the evidence, published as several Cochrane reviews (59) 
(45,47,60,240) that show that  ibuprofen is as effective as indomethacin and 
is associated with a lower risk of necrotising enterocolitis (NEC) and transient 
renal insufficiency when used for PDA closure. 
I found variations in the use of the three treatment strategies. Use of 
ibuprofen increased in 2010-2011 possibly following the publication of the 
first Cochrane review (59). In April 2011, amongst neonates who had a 
record of PDA, 40% (79 neonates) had ibuprofen and only 2% (three 
neonates) had indomethacin. This pattern is however not consistent. My 
results show several fluctuations in the use of each treatment modality 
reflecting the continuous debates and the dilemma in the PDA management. 
Interestingly, use of indomethacin increased again from April 2011 until the 
mid of 2012 and with a parallel decrease in use of ibuprofen. By this time, 
other evidence was emerging describing higher risks of BPD with use of 
ibuprofen as compared to indomethacin. Jones et al. (241), in a systematic 
review, reported that IV ibuprofen was associated with approximately 30% 
increase in the risk of BPD compared to intravenous indomethacin [RR:1.28 
(95% CI 1.03 to 1.60)] or placebo [RR 1.29 (95% CI 0.99 to 1.70)]. Further 
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fluctuations with decrease in use of indomethacin and increase in use of 
ibuprofen from November 2012 continue to reflect the ongoing debate. The 
revised Cochrane review (59) reiterated that ibuprofen is the drug of choice 
for treatment of PDA and that there was no statistically significant increase in 
the risk of chronic lung disease, a finding that  contradicted Jones et al. 
Thereafter, we see periods of fluctuations but an overall increase in the use 
of ibuprofen as compared to indomethacin.   
4.6.4 Change is use of surgery over time 
Surgical intervention is generally reserved for those whose ductus fails to 
close despite pharmacological treatment, those who have contraindications 
to pharmacological treatment, or those who have a large duct which may 
pose a greater risk such as poor neurodevelopmental outcome, BPD and 
severe retinopathy of prematurity (ROP) (235). I found that only 6% of 
neonates (n=1,037) with PDA had surgery either alone or in combination with 
pharmacologic treatment(s). There was a decline in the percentage of 
neonates with a diagnosis of PDA who had surgery between 2010 (183 
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4.6.5 Use of paracetamol  
Paracetamol can be used as an analgesic as well as for PDA closure. In this 
study, 13% (n=8,169) neonates out of the entire cohort had paracetamol. 
Among those who had a record of a PDA, 27% (n=4,889) had paracetamol 
whereas 8% (n=3,280) of neonates without PDA diagnosis had paracetamol. 
As it was not possible to link the drug with the indication of use, I am unable 
to be certain that paracetamol was used for PDA closure or for analgesia.  
Although limited, evidence suggests that paracetamol has a poor analgesic 
effect in preterm neonates (242). Allegaert et al. evaluated the efficacy of 
paracetamol for postoperative pain in neonates and found three prospective 
studies. This review concluded that paracetamol has a very poor analgesic 
effect when used for postprocedural pain such as heel prick and retinopathy 
of prematurity screening (233). My findings support the limited use of 
paracetamol in preterm neonates as I found very few neonates who did not 
have a PDA but had use of paracetamol recorded.  
In addition, some neonates may have received the paracetamol for PDA 
closure, but a diagnosis of PDA was not recorded. On the other hand, some 
neonates with a record of PDA may have had the paracetamol as an 
analgesic.  
Assuming that in neonates with a record of PDA, paracetamol was used for 
PDA closure, from March 2015, there is an increase in the number of 
neonates treated with paracetamol. In March 2015, the first Cochrane review 
that investigated the efficacy and safety of paracetamol in preterm neonates 
with PDA was published (243). It concluded that oral paracetamol is as 
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effective as oral ibuprofen in PDA closure. However, this review also 
highlighted the importance of assessing the long-term outcomes of 
paracetamol when used in preterm neonates. Further updates in in 2018 
(244) and 2020 (46) had similar conclusions.   
4.6.6 Duration of pharmacological treatment 
The median number of days of indomethacin use was 3 (range 1-22, IQR  2-
5). Different dosage regimens of indomethacin have been used in studies 
across the literature. A review by Pacifici et al. reported several studies that 
used indomethacin for three days while others used it for six days (245). 
Most studies used three days regimen rather than six days and attained a 
higher rate of PDA closure of ≥91% (246,247). Interestingly, in my study, 
there was a neonate who had indomethacin use recorded for 22 days. This 
was a very preterm neonate with PDA, respiratory distress, and BPD and is 
likely to be a data entry error.  
The median number of days of ibuprofen use was 3 (range 1-55, IQR  2-4). 
This supports the approved regimen for PDA treatment with ibuprofen which 
consists of three doses given 24 hours apart (248). An extremely preterm 
neonate had 55 days of ibuprofen, and following data inspection, this 
neonate was also diagnosed with BPD at 36 weeks, in addition to PDA, RDS 
and septicaemia. This is also likely to be a data entry error.  
The median number of days of paracetamol use was also 3 (range 1-101, 
IQR 1-7). Singh and Gooding (2016) summarised the available literature on 
the role of paracetamol in PDA closure including two RCTs and 14 
observational studies  (249). The range of paracetamol duration (in days) 
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reported in those studies was 1 to 11 days, with half of the studies (eight 
studies) reporting three or 3-6 days as duration of the treatment. 
The median first day on which indomethacin was given was day eight (range 
1-173, IQR 4-15) at the median corrected GA 27 (range 23-52, IQR 25-29) 
weeks. Ibuprofen, similarly, was given first on day 10 (range 1-257, IQR 6-
15) and at the median corrected GA of 27 (range 23-63, IQR 26-29) weeks. 
These results suggest that most clinicians deferring the pharmacological 
treatment of PDA to the second week of life, possibly waiting for spontaneous 
ductal closure. Ductal closure is delayed in preterm neonates. By day 7, 36% 
and 32% of 27- 28 weeks and 25-26 weeks neonates, respectively will have 
spontaneous ductal closure (250). Another study reported that 75% of ≤ 27 
weeks neonates (or weighing < 1000 g) with persistent PDA will attain 
spontaneous ductal closure by hospital discharge (31,32). The median first 
day on which paracetamol was given was day 56 (6-8 weeks of life). This 
maybe related to neonates receiving paracetamol following immunisation.  
With high rates of spontaneous ductal closure that discourage the early 
treatment and the fear of co-morbidities associated with persistent PDA, the 
optimal time to treat PDA remains a dilemma. A recent retrospective study in 
Sweden investigated whether the timing of indomethacin or ibuprofen is 
associated with a higher risk of BPD or secondary PDA surgery or death 
before three months of age in extremely preterm neonates (252). This study 
concluded that the timing of pharmacological treatment with indomethacin or 
ibuprofen is not associated with death or secondary PDA surgery and also 
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the late start of PDA treatment (beyond seven days of postnatal age) was 
associated with a lower risk of BPD.  
4.6.7 Limitations and strengths 
This is the first study to provide an overall picture of PDA prevalence across 
neonatal units in England and Wales. Also, it has compared the different 
approaches (no treatment vs. treatment) used to manage this condition in 
terms of their prevalence and whether they have changed over time. I further 
extended the analyses to provide an overview of the prevalence of 
pharmacological agents used for PDA and the change in their pattern of use 
over time.  
However, limitations of the NNRD and limited data access hinder full analysis 
to describe current practice. It was not possible to link the use of drugs with 
their specific indications. This was not an issue for indomethacin and 
ibuprofen, drugs that are exclusively use for PDA closure. For paracetamol, 
however, I was unable to discern if the neonates who had this drug received 
it for PDA closure or for analgesia. Also, the increase in the use of 
paracetamol might be related to neonates being received immunisation 
during their hospital stay, which often lasts longer due to their prematurity. 
This is another area that required to be further explored from the data set.  
The quality of data entered into the NNRD also raised some issues. The 
human factor of data entry error cannot be neglected (e.g. indomethacin 
used for 22 days or ibuprofen for 55 days).  
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Another limitation is that I was unable to gather any information of the dose, 
regimen, or route of administration of the drugs. Also, as I did not have 
access to results of any echocardiography or other clinical assessment, I 
have no information on how PDA was diagnosed, basis for decisions to treat 
or not, and whether the treatment was successful.  
4.6.8 Conclusion  
In summary, this study is a useful overview of how PDA is managed across 
neonatal units in England and Wales, but further research is needed to define 
details. Some additional areas for future work which are highlighted in 
Chapter 7.  
Although these results show that pharmacological treatment is often used in 
PDA management, the debate about whether to treat at all continues. In this 
context, understanding the limitations and dangers of using drugs is an 
important aspect. Ibuprofen is associated with less risk of NEC and transient 
renal impairment compared to indomethacin (60,240) but it does have 
significant side effects. Cochrane and other systematic reviews include RCTs 
or quasi-experimental randomised trials and mostly focus on the efficacy of 
the intervention. They report the most known and anticipated adverse effects. 
These do not give the complete profile of adverse effects of any treatment 
modality. Several observational studies published in 2012 have reported 
cases of pulmonary hypertension (51) and GI bleeding (53) associated with 
ibuprofen use which might lead clinicians to prefer alternative treatment or no 
treatment. In the next chapter I present an in-depth systematic review of the 
adverse effects of ibuprofen when used in preterm neonates with PDA.  
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CHAPTER 5 SYSTEMATIC REVIEW AND META-
ANALYSES OF ADVERSE EFFECTS OF IBUPROFEN 
IN PRETERM NEONATES WITH PDA 
 Introduction  
5.1.1 Pharmacological management of PDA and their adverse effects: 
Is it worth a review? 
Indomethacin and ibuprofen are pharmacological agents used in PDA 
management (253–258). Indomethacin has been used since it received’ 
Food and Drug Administration (FDA) approval in 1985. Ibuprofen lysine was 
approved by the FDA in 2006. Both are non-selective cyclooxygenase 
inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs). They block the 
biosynthesis of prostaglandin from arachidonic acid (253). It is believed that 
their mechanism of action manifests through the reduction of plasma 
concentration of Prostaglandin E2 (PGE2) (259). PGE2 is known to be the 
most potent circulatory prostaglandin responsible for the patency of the 
ductus especially in premature neonates (33). The immature ductus in 
preterm neonates (particularly those < 28 gestational weeks) is more 
sensitive to the vasodilating effects of PGE2 (256). Hence, NSAIDs including 
ibuprofen may be used for the closure of PDA.  
The rising frequency of adverse effects such as renal (e.g. oliguria, rise in 
serum creatinine), gastro-intestinal (GI) (e.g. NEC, haemorrhage), and 
cerebrovascular events (e.g. intraventricular haemorrhage (IVH)) (15) 
associated with indomethacin use in neonates triggered the researchers to 
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use an alternative i.e. ibuprofen. These adverse effects are attributed to the 
reduction in renal and mesenteric blood flow caused by indomethacin (261). 
Also, indomethacin reduces cerebral blood flow velocity and cerebral 
oxygenation (260). Unlike indomethacin, ibuprofen is not associated with a 
reduction in mesenteric and cerebral blood flow and has a smaller effect on 
renal perfusion when compared to indomethacin (262). Other adverse effects 
such as hyperbilirubinemia are also cause of a concern. Both ibuprofen and 
indomethacin are highly protein bound (253). However, the small dose of 
indomethacin used in neonates is unlikely to reach drug concentration that 
displaces bilirubin from albumin binding sites (263). With ibuprofen, an 
increase risk of hyperbilirubinemia occurs due to its high percent (99%) of 
protein binding which can displace bilirubin from albumin (255,264).  
5.1.2 Defining medication harm in neonates: Adapted definitions in 
this review 
The definition of medication harm is a challenge (265). Falconer et al. 
collated key studies that define or classify terminology used for medication 
harm. This review concluded diversity in terminology which may hinder 
appropriate extrapolation and comparison of data (266). In my study, the 
terms “Adverse drug reactions (ADRs)”, “toxicity”, and “adverse effects” are 
used to describe medication harm. ADR is defined by the WHO as “a 
response to a drug which is noxious and unintended and which occurs at 
doses normally used in man for prophylaxis, diagnosis, or therapy of disease, 
or the modification of physiologic function”(267). It can be taken from this 
definition, that there is a causal relationship between the medication and the 
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reactions. However, in neonates, this may be difficult to apply or assume. 
This is because ADR definition-related assumptions (known doses and 
pharmacology, quantification of interactions, the anticipation of side effects or 
secondary effects, etc.) cannot be speculated (268). Hence, further broader 
definition of ADRs may be better adopted in this population as suggested by 
Allegaert and Anker. They describe ADR as “an unintended and harmful 
effect resulting from the use of medications intended for diagnostic or 
therapeutic reasons (irrespective of the dose)” (268).  
The rationale of using the term “adverse effects” in this review is to follow the 
overall framework methodology suggested by Adverse Effects Subgroup of 
the Cochrane Collaboration (269). This term was introduced in 1966 to 
describe harms related to drugs, chemicals or biological agents when used in 
accepted dosage (270). Toxicity is a type of ADRs that occur when there is 
an over ingestion of the drug, elevated blood levels or enhanced drug effects 
(e.g. impaired metabolism, drug-drug or drug-disease interactions) (271).  
The term adverse event is used in clinical trials and covers both drug-related 
and non-drug related events. According to the WHO, an adverse drug event 
is defined as ‘ any untoward medical occurrence that may present during 
treatment with a pharmaceutical product but that does not necessarily have a 
causal relation to the treatment’ (267). Adverse drug event extends beyond 
ADRs to include harm that is related from medication errors (e.g. under 
doses, overdoses, etc.) (272). All ADRs are adverse events but not vice 
versa (266).  
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5.1.3 Aim of the systematic review 
The aim of this systematic review is to identify all the reported adverse 
effects associated with ibuprofen use for PDA closure in preterm neonates, 
and to quantify, where possible, their risk per 100 patients.  
This review aims to be comprehensive, with minimal restriction of language, 
study design, settings, and include all existing published and grey literature. 
This review is guided by the following PICO model (Population, Intervention, 
Comparator and Outcomes) summarised in Table 24. 
Table 24. Summary of the PICO used in this systematic review 
Population Intervention Comparator Outcomes 
Preterm 
neonates 
(born at  





administered by any 














Patients and indications for use of ibuprofen 
There have been several studies that investigated the efficacy of ibuprofen in 
PDA management. They have compared the use of ibuprofen as a treatment 
or prophylaxis for PDA closure. In this review, I have considered use of 
ibuprofen as “prophylactic” where it was administered to all neonates with or 
without PDA diagnosis who were included based on certain criteria (e.g. 
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gestational age (GA) at birth or birth weight (BW)). Studies where ibuprofen 
is given only after a confirmation of echocardiographic or clinical diagnosis of 
PDA is classified as study using ibuprofen “as a treatment”.   
Comparators 
Studies have compared the use of ibuprofen with various alternatives: 
ibuprofen vs. indomethacin; ibuprofen vs. placebo/no treatment; ibuprofen vs. 
paracetamol. In addition, some have compared different dose regimens or 
different modes of administration of ibuprofen (such as intravenous vs. oral).   
Adverse effects outcomes 
 The specific product characteristics (SPC) of ibuprofen when used in 
preterm neonates, lists several adverse effects (273). The most common are 
related to renal and blood systems (e.g. increase in serum creatinine and 
thrombocytopenia). Some other adverse effects such as BPD is also 
classified as possible adverse effect. However, the causality of such adverse 
effects is hard to determine in preterm neonates as they may be due to 
prematurity itself. Such effects cannot be differentiated from those that may 
have been caused by the direct effect of ibuprofen administration.  
 Methods 
I followed the methodology detailed in Cochrane Collaboration Handbook 
and systematic reviews of adverse effects frame work (269,274,275) . The 
adverse effects systematic review framework was developed to provide a 
detailed approach on conducting systematic reviews of adverse effects. It 
was structured through a consensus of expert reviewers and members of 
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adverse effects Subgroup of the Cochrane Collaboration. For this study, a 
protocol was established and registered in Prospero (ID: 67600; registration 
number: CRD 42018067600).  
5.2.1 Search strategy 
5.2.1.1 Information sources 
A systematic literature search was carried out to identify all relevant papers 
describing the adverse effects or ADRs of ibuprofen in premature neonates. 
The search strategy was developed and tested with the help of the 
specialised paediatric clinical librarian, Cathryn James, of the University 
Hospitals of Derby and Burton NHS Trust.  
Eight databases [EMBASE, MEDLINE, PubMed, International 
Pharmaceutical Abstracts (IPA), Cochrane Library, CINAHL, British Nursing 
Index (BNI), and clinicaltrials.gov] were searched from 1964 to 31 January 
2019 without any other limits. This start date was selected because ibuprofen 
was developed in 1964 (276). A combination of both ‘free text’ and Medical 
subject headings ‘MeSH terms’ was applied for each database separately to 
attain a comprehensive literature search. The results of the search were then 
combined via the End-note software (Thomson Reuters, version X7.7.1) to 
remove duplications. Duplicates that were not removed by electronic de-
duplication were subsequently removed manually. Information on studies in 
progress, or research reported in the grey literature was sought by searching 
clinical trials.gov and greylit.org, respectively. In addition, further attempts to 
identify studies were made by contacting the authors of published conference 
abstracts and examining the reference lists of all retrieved articles.  
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5.2.1.2 Search terms  
Various ‘free text’ keywords, as well as MeSH terms were used as search 
terms across the selected databases to provide a comprehensive search. For 
the population search terms, premature or preterm infants are defined as 
infants who were born prior to GA of 37 weeks (WHO 2016) (5). Therefore 
‘prematurity, preterm, premature*, premmie*, preemie*’ were used to 
represent population free text key words search terms. 
For the intervention free text key words search terms, a combination of both 
generic and most commonly used brand names of ibuprofen was applied in 
the search strategy. Most commonly used brand names of ibuprofen were 
‘ibumetin, motrin, nuprin, advil, nurofen, brufen’. These were used  in addition 
to the generic name ‘ibuprofen’.  
For the adevrse effects outcomes free text keywords search terms, were as 
recommended by the Cochrane Adverse Effects Methods Group (CAEM) for 
systematic reviews of adverse effects (269). For example, ‘toxicity* or 
adverse drug reaction* or side effect* or adverse effect*’. 
All of the previously mentioned free text key words were used in addition to 
the MeSH terms identified in each database separately. The full search 
strategy is detailed in 9.32.  
5.2.1.3 Study selection  
Both title and abstracts of the search results were screened independently by 
two reviewers for initial inclusion, and any disagreements were resolved by 
consensus or a third reviewer. Ms. Janine Abramson (Research Nurse, 
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School of Medicine, University of Nottingham) was the second reviewer and 
disagreeements were resolved by my supervisor, Dr Ojha. The two reviewers 
(Ms. Abramson and I) then assessed the full texts for inclusion.  
5.2.1.4 Inclusion and exclusion criteria  
All studies in which ibuprofen is used for treatment or prophylaxis of PDA 
closure and reported adverse effects/ADRs without any restriction in the 
study design and publication type were included. This includes randomised 
controlled trials (RCTs), case reports, case series, and prospective and 
retrospective cohort studies. Systematic reviews, laboratory studies such as 
pharmacokinetic or pharmacodynamics (PKPD) evaluations, studies in adults 
(more than 18 years old of age), studies in the paediatric population but 
where ibuprofen was used for indications other than PDA closure, studies 
where information about adverse effects in premature neonates could not be 
extracted separately were excluded. In addition, reviews, editorials, 
preliminary reports and letters which did not include any primary data on 
ibuprofen adverse effects when used for PDA closure were also excluded. 
Conference poster abstracts were assessed for primary data of ibuprofen 
adverse effects when used in premature neonates, and the authors were 
contacted by email for more information if those data were relevant to the 
review question. 
5.2.2 Data synthesis and statistical analysis of the studies  
All included studies were tabulated (using Microsoft Excel, Version ‘15’ 
Microsoft Corporation) to summarise the number of neonates who had 
received ibuprofen and the number of adverse effects reported.  
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The risk of adverse effects per 100 patients was calculated from the RCTs 
and prospective cohort studies only. The risk was calculated by dividing the 
number of patients with a particular adverse effect by the total number of 
patients who received ibuprofen and then multiplying it by 100. This was 
done following the methodology of previous systematic reviews of drug 
toxicity (277).  
Due to the sufficient number of the included RCTs, meta-analyses were 
performed, using RevMan (version 5.3), to obtain an overall measure of the 
risk of adverse effects. To ensure homogeneity, RCTs were grouped together 
according to the types of comparators. The risk ratio was calculated with 95% 
confidence interval (CI). Statistical heterogeneity was measured using I². This 
statistical test measures the variation across the studies in a percentage 
figure. Fixed effect model was used in the forest plots where I² was less than 
50 %, and random effect model was used where I² is more than 50% (25). 
 
5.2.3 Quality assessment  
Two reviewers (Ms. Abramson or Dr Ojha and I) assessed all of  the RCTs 
included in the review independently for risk of bias (ROB) using the 
Cochrane ‘Risk of bias’ tool (278). The domains for assessment included the 
following: 
• Sequence generation (selection bias) 
• Allocation concealment (selection bias) 
• Blinding of participants and personnel (performance bias) 
• Blinding of outcome assessment (detection bias) 
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• Incomplete outcome data (attrition bias)  
• Selective reporting (reporting bias) 
• Any other bias (defined as any bias related to the funding/sponsorship 
and other issues related to the methodology) 
Non-randomised trials (observational studies) were assessed by two 
reviewers (Ms. Abramson or Dr Ojha and I) using Joanna Briggs Institute 
(JBI) appraisal tools to assess the quality of the observational studies (e.g. 
case reports, cohort studies, case series, etc.) (279). Any discrepancies were 
resolved through discussion and adjudication by a third reviewer. However, it 
is of note that the decisions made by using this tool are subjective and it is 
recommended that all studies are included after assessing their quality (279).  
5.2.4 Data extraction  
I extracted all data using a structured proforma. To ensure completeness, all 
data extraction was performed in duplicate and a selection (20%) were 
checked by Dr Ojha.  
The data extracted includes:  
• All types and number of adverse effects related to ibuprofen 
administration  
•  Route of ibuprofen administration (IV or oral) 
•  Dose and frequency of ibuprofen 
• Number of courses of ibuprofen administered 
• Indication of ibuprofen given for PDA (treatment/prophylaxis) 
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• Comparator of ibuprofen used in the study (e.g. placebo, 
indomethacin, paracetamol, other ibuprofen formulations) 
•  Adverse effects that led to discontinuation of ibuprofen, and adverse 
effects of ibuprofen that resulted in prolonged hospital stay or hospital 
admission or death. Adverse effects were classified according to the 
organ system and tabulated with the corresponding numbers. 
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 Results  
5.3.1 Description of chracteristics of included studies 
Initial search returned 2458 titles and abstracts and after exclusions 93 
studies were included in the review. Reason of excluded studies and trials 
are given in appendix 9.33 and 9.34. 
Figure 54 represents the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) flow chart of the total number of references 
identified in the searched databases.  
This included 42 RCTs. Three publications, Pistulli et al., Eras et al. and 
Oncel et al. (280–282) were follow up publicaiton of the same RCT reported 
in Hoxha et al., Gokmen et al. and Oncel et al. (283–285) respectively. 
These three publications have been included with the first publication of 
resutls of their original RCTs.  
This review also includes non-randomised studies: 33 cohort studies, four 
case series, two case-control studies and nine case reports.  
In addition, ten ongoing trials awaiting results were reviewed (detailed in 
appendix 9.35).  
No study was excluded after quality assessment.    
Page | 233  
 
 
Figure 54. PRISMA flow chart of the total number of references 
identified in the searched databases 
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5.3.2 Sub-classification of included studies  
Ibuprofen was administered for PDA treatment in 35 RCTs 
(179,262,280,281,283–315) and in 44 observational studies (50,52–54,316–
353) (Figure 55). Ibuprofen was administered for PDA as prophylaxis in six 
RCTs (262,354–359) and in five observational studies (41,346,360–362) 
(Figure 56).There was one retrospective case series study with unclear 
reporting of the indication for use (43) and one RCT that compared ibuprofen 
when used as treatment vs. use as prophylaxis (44). 
The comparators are classified as: 
• Comparator 1:Ibuprofen vs. placebo/no treatment 
• Comparator 2:Ibuprofen vs. indomethacin 
• Compatrator 3:Ibuprofen vs. paracetamol 
• Comparator 4:Other studies (detailed in section 5.3.3.2.4) 
  




Figure 55. Included studies: Ibuprofen for prophylaxis of patent ductus 
arteriosus (PDA) 
 
Figure 56. Included studies: Ibuprofen for treatment of  
patent ductus arteriosus (PDA) 
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5.3.3 Quality assessment of included studies (RCTs) 
5.3.3.1 Studies of ibuprofen use for PDA prophylaxis 
Six RCTs (354–358) included in this review compared ibuprofen to placebo 
when used in PDA prophylaxis.  
Summary of ROB assessment, as per the Cochrane risk of bias tool (278) for 
RCTs is given in Figure 57 and Figure 58.
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Figure 57. Risk of bias graph of studies comparing ibuprofen vs. 
placebo (PDA prophylaxis) 
 
Figure 58. Risk of bias summary of studies comparing ibuprofen vs. 
placebo (PDA prophylaxis) 
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5.3.3.2 Studies of ibuprofen use for treatment of PDA  
5.3.3.2.1 Comparator 1: Studies comparing ibuprofen to placebo/no 
treatment  
There were three studies (286–288) included in this comparison. ROB is 
given in Figure 59 and Figure 60. 
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Figure 59. Risk of bias graph of studies comparing ibuprofen vs. 
placebo or no treatment (PDA treatment) 
 
Figure 60. Risk of bias summary of studies comparing ibuprofen vs. 
placebo or no treatment (PDA treatment) 
Page | 240  
 
5.3.3.2.2 Comparator 2: Studies compaing ibuprofen to indomethacin  
There were 16 studies (56–69, 82) included in this comparison. ROB is given 
in Figure 61 and Figure 62. 
 
 
Figure 61. Risk of bias graph of studies comparing ibuprofen vs. 
indomethacin (PDA treatment)




Figure 62. Risk of bias summary of studies comparing ibuprofen vs. 
indomethacin (PDA treatment) 
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5.3.3.2.3 Comparator 3: Studies comparing ibuprofen to paracetamol 
There were six studies (179,282,285,303,304,311,312) included in this 
comparison. ROB is given in Figure 63 and Figure 64. 
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Figure 63. Risk of bias graph of studies comparing ibuprofen vs. 
paracetamol (PDA treatment) 
 
Figure 64. Risk of bias summary of studies comparing ibuprofen vs. 
paracetamol (PDA treatment) 
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5.3.3.2.4 Comparator 4: Other studies 
This category includes studies where ibuprofen is used in different regimen, 
routes of administration and indications, including:   
• Oral ibuprofen vs. IV ibuprofen (four studies) 
(280,281,283,284,305,306) 
• Standard dose ibuprofen vs. high dose ibuprofen (two studies) 
(309,363) 
• Ibuprofen IV bolus vs. ibuprofen IV continuous infusion (one study ) 
(310) 
• Oral ibuprofen vs. rectal ibuprofen (one study) (313) 
In addition, El-Mashed et al. (2017) was a three arm study which compared 
ibuprofen, indomethacin and paracetamol (307). Dani et al. (2000) compared 
ibuprofen used as prophylaxis vs. treatment (44) while Bravo et al. (2014) 
compared ibuprofen used in standard doses vs. ibuprofen doses given only if 
the PDA persisted (on ECHO examination) after each dose (315). The ROB 
for these is given in Figure 65 and Figure 66.  
The detailed risk of bias assessment of all included RCTs is given in 
appendix 9.36 . 
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Figure 65. Risk of bias graph of studies comparing ibuprofen in 
different regimen, routes, and indications 
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Figure 66. Risk of bias summary of studies comparing ibuprofen in 
different regimen, routes, and indications 
  
Page | 247  
 
5.3.4 Quality assessment of non-RCTs 
5.3.4.1 Cohort studies of ibuprofen use for PDA prophylaxis 
Three cohort studies (41,360,361) compared ibuprofen when used in PDA 
prophylaxis to placebo. Only one cohort study (346) compared ibuprofen 
when used in PDA prophylaxis to indomethacin. 
Summary of risk of bias assessment, using the JBI tool (279) is given in 
Figure 67 . 




Figure 67. Risk of bias assessment for cohort studies comparing ibuprofen to placebo/no treatment and ibuprofen 
to indomethacin (PDA prophylaxis)  
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5.3.4.2 Cohort studies of ibuprofen use for treatment of PDA 
Twenty nine cohort studies were included in which ibuprofen was used for 
PDA treatment.  
5.3.4.2.1 Cohort studies comparing ibuprofen to placebo/no treatment 
and ibuprofen to indomethacin 
Thirteen cohort out of the 29 cohort studies compared ibuprofen to 
indomethacin (324,326,327,329–331,333–335,343–345,349). Only two 
compared ibuprofen to placebo (321,336).   
Summary of risk of bias assessment, using the JBI tool is given in Figure 68. 
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Figure 68. Risk of bias assessment for cohort studies comparing 
ibuprofen to placebo/no treatment and ibuprofen to indomethacin (PDA 
treatment)  
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5.3.4.2.2 Cohort studies comparing ibuprofen to paracetamol  
There were no cohort studies comparing ibuprofen (used for PDA treatment) 
to paracetamol that met the inclusion criteria.   
5.3.4.2.3 Other cohort studies included in this review  
There was 11 cohort studies 
(322,323,325,332,337,338,340,341,347,348,364) that compared ibuprofen in 
different dose regimens. Two cohort studies (339,342) did not report a 
comparison group while one (328) compared several arms (ibuprofen vs. 
indomethacin vs. control vs. no treatment). 
Summary of risk of bias assessment, using the JBI tool is given in Figure 69 
and Figure 70.
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Figure 69. Cohort studies comparing ibuprofen in different dose regimen (PDA treatment)




Figure 70. Other cohort studies where ibuprofen used for PDA treatment 
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5.3.5 Overview of adverse effects across all studies  
A total of 6,937 neonates received ibuprofen for PDA management and a 
total of 4,700 adverse effects were reported (Table 25). The largest number 
of neonates (3,831) receiving ibuprofen were recruited within the 26 
retrospective cohort studies. This group also reported the highest number of 
adverse effects (2,264 adverse effects). The 42 RCTs reported the second 
largest number of adverse effects (1,911 adverse effects). 

















42 2,200 (32%) 1,911 (40.7%) 
Prospective cohort 
studies 
7 681 (9.8%) 309 (6.6%) 
Prospective case series 1 22 (0.3%) 7 (0.1%) 
Retrospective cohort 
studies 
26 3,831 (55%) 2,264 (48.2%) 
Retrospective case 
series 
3 96 (1.4%) 99 (2.1%) 
Case-control studies 2 96 (1.4%) 99 (2.1%) 
Case reports 9 11 (0.1%) 11 (0.2%) 
Total 90 6,937 4,700 
*as a percentage of total number of neonates who received ibuprofen across all 
types of studies 
#as a percentage of total number of adverse effects among neonates who received 
ibuprofen across all types of studies 
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5.3.6 Risk of adverse effects from RCTs and prospective cohort 
studies  
The calculated risk of each adverse effect per 100 patients in the RCTs and 
prospective cohort studies included in this review is shown in Table 26. The 
most common adverse effects in GI and renal systems were NEC and 
oliguria, respectively. BPD was the most frequently reported respiratory 
adverse effect. There was hertrogenity in the defintion of BPD used in the 
studies.  
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Table 26. Calculated risk of adverse effects from RCTs and prospective cohort studies 
Adverse effects 











Risk per 100 
patient 
Gastro-intestinal system 
NEC 190 46 2548 7.5 
Intestinal/bowel perforation 23 17 1036 2.2 
GI bleeding 87 19 1047 8.3 
Feeding intolerance 34 4 120 28.3 
Renal system 
Oliguria* 146 21 1917 7.6 
Renal failure** 29 7 333 8.7 
Increase in serum creatinine  33 6 548 6.0 
Respiratory system 
BPD at 28 days 277 6 638 43.4 
BPD at 36 weeks 260 14 1039 25.0 
BPD (not defined) 170 18 749 22.7 
Pulmonary hypertension 17 9 616 2.8 
Pulmonary haemorrhage 20 9 455 4.4 
Hypoxaemia 15 1 65 23.1 
Nervous system 
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IVH (any grade) 313 26 1561 20.1 
IVH (grade III-IV) 44 8 595 7.4 
PVL 66 17 1103 6.0 
Neurodevelopmental impairment 88 2 288 30.6 
Blood system 
Thrombocytopenia 18 3 88 20.5 
Prolonged coagulogram 4 1 22 18.2 
Others 
Hyperbilirubinaemia 28 1 80 35 
Hypoglycaemia 35 1 60 58.3 
Jaundice 25 1 55 45.5 
Cholestasis 2 1 55 3.6 
All cause mortality 233 37 1919 12.1 
*study by Asadpour et al. (2018) reported abnormal urine output (unclear definition) and was not included 
**some studies reported acute kindney injury and were included in the calculation of this adverse event 
BPD, Bronchopulmonary dysplasia; GI, gastrointestinal; IVH, intraventricular haemorrhage; NEC, necrotising 
enterocolitis;  PVL, Periventricular leukomalacia 
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5.3.7 Meta-analyses of adverse effects of ibuprofen reported in RCTs 
Forty two RCTs were included in this review. In six RCTs, ibuprofen was 
used as a prophylaxis (354–357,359,365) and in 35 for treatment 
(179,262,280–307,309–315,363). Characteristics of the included RCTs and 
the reported adverse effects is given in appendix 9.37.   
The next sections summarise the results of the meta-analyses of the adverse 
effects reported in the included RCTs. 
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5.3.7.1 GI adverse effects  
NEC was the most frequently reported GI adverse effect among the included 
RCTs (40 RCTs), followed by GI bleeding (17 RCTs), intestinal/bowel 
perforation (15 RCTs), and feeding difficulties (four RCTs) (Table 27). 
The meta-analyses for NEC did not show any difference between ibuprofen 
when compared to placebo/no treatment or when compared to paracetamol. 
Ibuprofen had a lower risk of NEC when compared to indomethacin [16 
studies; 1125 patients; RR: 0.66, 95% CI: 0.47 to 0.93, p=0.02] (Figure 71). 
Other studies (ten RCTs) are discussed in section 5.3.7.7.  
Higher risk of GI bleeding was found with ibuprofen when compared to 
placebo/no treatment [three studies; 140 patients; RR: 2.09, 95% CI: 1.20 to 
3.66, p=0.010], and with paracetamol [two studies; 240 patients; RR: 7.00, 
95% CI: 1.91 to 25.61, p=0.003]. There was no difference in the risk of GI 
bleeding when ibuprofen was compared to indomethacin (Figure 72). Other 
studies (seven RCTs) are discussed in section 5.3.7.7.  
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Figure 71. Meta-analyses for the risk of NEC comparing ibuprofen to A. 
placebo/no treatment B. indomethacin C. paracetamol 
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Figure 72. Meta-analyses for the risk of GI bleeding comparing ibuprofen 
to A. placebo/no treatment B. indomethacin C. paracetamol 
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Table 27. Summary of meta-analyses of GI adverse effects following ibuprofen use in preterm neonates with PDA 
Outcome Intervention Comparator Studies 
Number of 
patients 








9 1039 1.00 [0.67, 1.49] ¶ 0.99 27 
Ibuprofen Indomethacin 16 1125 0.66 (0.47,0.93) 0.02 0 







4 338 1.78 (0.32, 9.85) ¶ 0.51 46 
Ibuprofen Indomethacin 7 591 0.60 (0.28, 1.30) 0.20 0 





3 140 2.09 (1.20, 3.66) ¶ 0.010 0 
Ibuprofen Indomethacin 5 291 1.06 (0.53, 2.11) ¶ 0.88 0 






2 88 1.77 (1.08, 2.91) ¶ 0.02 10 
Ibuprofen Indomethacin 1 40 
Not estimable as zero events in both 
groups 
Ibuprofen Paracetamol 1 110 0.89 (0.37,2.13) 0.79 n/a 
¶ RR value >1 denotes higher rates of adverse effects with ibuprofen compared with the comparator 
GI; gastrointestinal bleeding, NEC; necrotising enterocolitis, n/a; not applicable 
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5.3.7.2 Renal adverse effects  
Oliguria was the most frequently reported renal adverse effect in the included 
RCTs (18 RCTs) followed by renal failure (six RCTs) (Table 28).  
There was no difference in the risk of oliguria when ibuprofen was compared 
to placebo/no treatment (two RCTs) and when compared to paracetamol 
(three RCTs). However, lower risk of oliguria with ibuprofen was found in 
comparison to indomethacin [five studies; 626 patients; RR: 0.38, 95% CI: 
0.25 to 0.56, p<0.00001] (Figure 73). Other studies (eight RCTs) are 
discussed in section 5.3.7.7.  
The pre-defined cut off for definition of oliguria in this review was < 1 
ml/kg/hour. In studies with unclear definition of oliguria or that defined 
oliguria as urine output < 0.5 ml/kg/hr are also included. Therefore, a 
sensitivity analysis including only those studies that defined oliguria as < 1 
ml/kg/h was performed for the comparison between ibuprofen and 
indomethacin [four studies; 482 patients; RR: 0.27, 95% CI: 0.14 to 0.52, 
p<0.0001] and this did not change the outcome.   
Higher risk of renal failure was found with ibuprofen when compared to 
paracetamol [two studies; 270 patients; RR: 3.91, 95% CI: 1.63 to 9.37, 
p=0.002], and no difference in the risk of renal failure when ibuprofen was 
compared to placebo (one RCT) or indomethacin (two RCTs). One RCT is 
described in section 5.3.7.7.  
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Twenty two RCTs reported the absolute levels of serum creatinine following 
ibuprofen administration (18 RCTs detailed in Table 28, four RCTs detailed 
in section 5.3.7.7). In four RCTs, only the increase in serum creatinine 
following ibuprofen administration was reported (one RCT detailed in Table 
28, three RCTs detailed in section 5.3.7.7).  
265 | P a g e  
 
Table 28. Summary of meta-analyses of renal adverse effects following ibuprofen use in preterm neonates with 
PDA 
Outcome Intervention Comparator Studies 
Number of 
patients 






2 545 1.35 (0.96, 1.90) ¶ 0.09 24 
Ibuprofen Indomethacin 5 626 0.38 (0.25, 0.56) <0.00001 38 





1 36 4.50 (0.23, 87.61) ¶ 0.32 n/a 
Ibuprofen Indomethacin 2 110 0.26 (0.06, 1.10) 0.07 n/a 









1 131 8.12 (1.05, 63.13) 0.05 n/a 
Ibuprofen Indomethacin No eligible studies 








5 631 5.53 (-0.96, 12.02) 0.10 55** 
Ibuprofen Indomethacin 9 689 -1.65 (-9.13, 5.83) 0.67 71** 
Ibuprofen Paracetamol 4 377 1.43 (-2.32, 5.19) 0.45 21 
* Mean difference (95% CI) for serum levels (mmol/l) measured at 72 hours following the intervention 
** Used random effect model. All others are with fixed effects model. 
¶RR value greater than 1 denotes higher rates of adverse effects with ibuprofen compared with the comparator drug 
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Figure 73. Meta-analyses for the risk of oliguria comparing ibuprofen to 
A. placebo/no treatment B. indomethacin C. paracetamol 
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5.3.7.3 Respiratory adverse effects  
BPD (undefined) was the most frequently reported respiratory adverse effect 
in the included RCTs (15 RCTs), followed by BPD (at 36 weeks) (13 RCTs), 
pulmonary haemorrhage (eight RCTs), pulmonary hypertension (seven 
RCTs), BPD (at 28 days) (five RCTs), and hypoxaemia (one RCT) (Table 
29).  
From this table, the only statistically significant difference in those adverse 
effects was found to be for BPD (at 28 days) favouring indomethacin when 
compared to ibuprofen. All the other respiratory adverse effects were 
statistically insignificant regardless of the comparator to ibuprofen. Other 
studies are discussed in section 5.3.7.7.   
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Table 29. Summary of meta-analyses of respiratory adverse effects following ibuprofen use in preterm neonates 
with PDA 
Outcome Intervention Comparator Studies 
Number of 
participants 







3 170 1.01 (0.28, 3.60) ¶ 0.99 54* 
Ibuprofen Indomethacin 5 302 0.95 (0.80, 1.11) 0.97 0 
Ibuprofen Paracetamol 4 379 1.42 (0.67, 3.01) ¶ 0.36 0 
BPD 
(oxygen requirement 




4 408 1.01 (0.81, 1.25) 0.95 0 
Ibuprofen Indomethacin 3 357 1.12 (0.77, 1.61) ¶ 0.56 0 
Ibuprofen Paracetamol 1 80 1.00 (0.21, 4.66) 1 n/a 
BPD 
(oxygen requirement 




3 597 1.08 (0.94, 1.24) ¶ 0.28 0 
Ibuprofen Indomethacin 2 188 1.37 (1.01, 1.86) ¶ 0.04 0 







4 293 4.28 (0.76, 24.14) ¶ 0.10 0 
Ibuprofen Indomethacin 1 83 
Not estimable as zero events in both 
groups 






2 267 0.90 (0.09, 8.67) 0.92 65* 
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 Ibuprofen Indomethacin 2 68 0.38 (0.06, 2.30) 0.29 0 






1 131 1.69 (0.80, 3.59) ¶ 0.17 n/a 
Ibuprofen Indomethacin No eligible studies 
Ibuprofen Paracetamol No eligible studies 
* Used random effect in those forest plots instead of fixed effect model 
¶ RR value greater than 1 denotes higher rates of adverse effects with ibuprofen compared with the comparator drug  
BPD; Bronchopulmonary dysplasia 
270 | P a g e  
 
5.3.7.4 Central nervous system adverse effects  
IVH-any grade was the most frequently reported CNS adverse effect in the 
included RCTs (22 RCTs), followed by PVL (16 RCTs), severe IVH (grades 
3-4) (seven RCTs), and neurodevelopmental adverse effects outcomes 
(measured at 18-24 months) (two RCTs) (Table 30). Other studies (seven 
RCTs) are discussed in section 5.3.7.7. 
The meta-analyses for IVH (any grade) did not show any difference between 
ibuprofen when compared to placebo/no treatment; indomethacin; or 
paracetamol (Figure 74). Also, there was no difference in IVH (grade 3-4) 
when ibuprofen was compared to indomethacin. There were no studies that 
compared the risks of IVH (grade 3-4) between ibuprofen and paracetamol 
(Figure 75). 
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Table 30. Summary of meta-analyses of central nervous system adverse effects following ibuprofen use in preterm 
neonates with PDA 
 
Outcome Intervention Comparator Studies 
Number of 
participants 






7 868 0.94 (0.77,1.14) 0.52 0 
Ibuprofen Indomethacin 4 308 0.95 (0.58,1.55) 0.83 0 







1 105 0.81 (0.29,2.25) 0.69 n/a 
Ibuprofen Indomethacin 5 445 1.28 (0.73,2.23) ¶ 0.39 0 





6 899 1.00 (0.60,1.68) 0.99 0 
Ibuprofen Indomethacin 5 487 0.88 (0.47,1.65) 0.68 1 
Ibuprofen Paracetamol 2 182 0.83 (0.27,2.62) 0.76 n/a 
Neurodevelopmental  
Impairment  
Ibuprofen Paracetamol 1 61 1.08(0.51,2.27) ¶ 0.85 n/a 
Mental developmental 
index (MDI)<70 
Ibuprofen Paracetamol 1 61 0.97 (0.39,2.43) 0.94 n/a 
Moderate to severe 
cerebral palsy 
Ibuprofen Paracetamol 1 61 0.48 (0.10,2.45) 0.38 n/a 
Psychomotor 
developmental index<70 
Ibuprofen Paracetamol 1 61 0.97(0.31,3.01) 0.95 n/a 
¶ RR value greater than 1 denotes higher rates of adverse effects with ibuprofen compared with the comparator drug  
IVH, Intraventricular haemorrhage; PVL, Periventricular leukomalacia 




Figure 74. Meta-analyses for the risk of IVH (any grade) comparing 
ibuprofen to A. placebo/no treatment B. indomethacin C. paracetamol 
 
 














Figure 75. Meta-analyses for the risk of IVH (grade 3-4) comparing 
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5.3.7.5 All-cause mortality  
All-cause mortality was reported by 34 out of 42 RCTs and did not show any 
difference between ibuprofen as compared to placebo/no treatment; 
indomethacin; or paracetamol (Table 31, Figure 76).
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Table 31. Summary of meta-analyses of all-cause mortality reported in the included studies  










9 1049 0.90 (0.68, 1.19) 0.45 0 
Indomethacin 14 1087 0.90 (0.65, 1.25) 0.55 0 
paracetamol 4 372 1.00 (0.61, 1.62) 0.99 0 





2 130 0.75 (0.28, 2.01) 0.57 0 
Oral ibuprofen  
Rectal 
ibuprofen 







1 49 0.56 (0.14, 2.25) 0.42 n/a 
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Figure 76. Meta-analyses for the risk of all-cause mortality comparing 
ibuprofen to A. placebo/no treatment B. indomethacin C. paracetamol 
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5.3.7.6 Other adverse effects 
This includes adverse effects that are not classified under previous sections 
and were reported by individual RCTs such as, those related to the blood 
system (e.g. thrombocytopenia, hypoglycaemia, etc.) (Table 32).   
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Table 32. Summary of meta-analyses of other adverse effects reported in the included studies  
Outcome Intervention Comparator Studies 
Number of 
participants 








Hypoglycaemia Ibuprofen Indomethacin 1 119 0.88 (0.67,1.17) 0.38 n/a 






Ibuprofen Paracetamol 1 110 0.92 (0.44,1.90) 0.81 n/a 
Gastrointestinal 
complications 




Thrombocytopenia  Ibuprofen Paracetamol 1 110 0.94 (0.53,1.67) 0.84 n/a 
Jaundice  Ibuprofen Paracetamol 1 110 0.78 (0.54,1.13) 0.19 n/a 
Cholestasis  Ibuprofen Paracetamol 1 110 1.00 (0.15,6.85) 1 n/a 
¶ RR value greater than 1 denotes higher rates of adverse effects with ibuprofen compared with the comparator drug 
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5.3.7.7 Evidence of adverse effects from RCTs comparing ibuprofen in 
different regimen, routes, and indications 
5.3.7.7.1 Oral ibuprofen vs. IV ibuprofen  
Four RCTs compared ibuprofen administered via oral and IV routes when 
used in PDA management (Table 33). There was no significant difference in 
any of the adverse effects.  
5.3.7.7.2 Ibuprofen used in different regimen  
Four RCTs compared ibuprofen in different regimens; two RCTs compared 
standard dose vs. high dose of ibuprofen (309,363), one RCT compared IV 
ibuprofen when given as bolus vs. continuous infusion (310), and one 
compared ibuprofen given in standard doses vs. Echocardiography guided 
doses. Overall, there was no significant difference in any of the adverse 
effects (Table 34).  
5.3.7.7.3 Ibuprofen (prophylaxis) vs. ibuprofen (treatment) 
Only one RCT compared ibuprofen when used as prophylaxis vs. as 
treatment in neonates with PDA (44) (Table 35). Overall, there was no 
difference in any of the adverse effects. 
5.3.7.7.4 Oral ibuprofen vs. rectal ibuprofen  
One RCT compared ibuprofen given via the oral route with the rectal route of 
administration (313) (Table 36). Overall, there was no difference in any of the 
adverse effects.  
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Table 33. Summary of meta-analyses of adverse effects in studies comparing oral vs. IV ibuprofen used in preterm 
neonates with PDA 
Outcome Intervention Comparator Studies Number of 
participants 
RR (95% CI) P 
value 
I2 (%) 
GI adverse effects  
NEC Oral ibuprofen IV ibuprofen 4 304 0.98 (0.43,2.23) 0.95 0 
GI bleeding Oral ibuprofen IV ibuprofen 3 240 4.60 (0.55,38.72) ¶ 0.16 0 
Intestinal perforation  Oral ibuprofen IV ibuprofen 2 134 0.32 (0.01,7.48) 0.48 n/a 
Renal adverse effects  
Oliguria  Oral ibuprofen IV ibuprofen 4 304 0.14 (0.01,2.66) 0.19 n/a 
Increase in serum 
creatinine after 
treatment   




Oral ibuprofen IV ibuprofen 3 240 -1.80 (-8.27,4.67) 0.59 0 
Respiratory adverse effects  
BPD (oxygen 
requirement at 36 
weeks) 
Oral ibuprofen IV ibuprofen 3 236 0.82 (0.56,1.20) 0.31 0 
Pulmonary 
haemorrhage 
Oral ibuprofen IV ibuprofen 2 138 0.15 (0.02,1.25) 0.08 0 
Pulmonary HTN  Oral ibuprofen IV ibuprofen 2 172 Not estimable as zero events in both 
groups 
Central nervous system adverse effects  
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IVH (any grade) Oral ibuprofen IV ibuprofen 2 132 0.97 (0.62,1.52) 0.90 0 
PVL Oral ibuprofen IV ibuprofen 1 64 1.00 (0.15, 6.67) 1 n/a 
Moderate to severe 
cerebral palsy at 18-
24 months 








Oral ibuprofen IV ibuprofen 1 57 0.68 (0.27,1.7) 0.40 n/a 
* Mean difference (95% CI) is used instead of RR (95% CI) and serum levels (mmol/l) measured at 72 hours following the 
intervention 
¶ RR value greater than 1 denotes higher rates of adverse effects with ibuprofen compared with the comparator drug and a value 
less than 1 denotes vice versa 
BPD, Bronchopulmonary dysplasia; GI, gastrointestinal bleeding; IVH, Intraventricular haemorrhage; NEC, necrotising 
enterocolitis; PVL, Periventricular leukomalacia 
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RR (95% CI) P value I2 (%) 
Ibuprofen (standard dose) vs. ibuprofen (high dose) 
NEC 2 130 1.00 (0.40, 2.50) 1 0 
GI bleeding 1 60 0.50 (0.05,5.22) 0.56 n/a 
Oliguria 2 130 0.56 (0.12, 2.50) 0.44 0 
Renal failure 1 60 Not estimable as zero number of events in both groups 
Increase in serum creatinine 
after treatment 
1 70 0.33 (0.01, 7.91) 0.50 n/a 
BPD (oxygen requirement at 36 
weeks) 
1 70 0.63 (0.33, 1.18) 0.15 n/a 
IVH (any grade) 1 70 1.50 (0.46, 4.86) ¶ 0.50 n/a 
PVL 1 70 0.67 (0.12, 3.75) 0.65 n/a 
IV ibuprofen (bolus) vs. IV ibuprofen (continuos infusion) 
GI bleeding 1 111 1.96 (0.63, 6.15) ¶ 0.25 n/a 
NEC 1 111 2.29 (0.62, 8.41) ¶ 0.21 n/a 
Intestinal/ bowel perforation 1 111 0.49 (0.05, 5.26) 0.56 n/a 
Oliguria 1 111 4.91 (0.24, 100.05) ¶ 0.30 n/a 
BPD (oxygen requirement 
undefined) 
1 111 0.91 (0.45, 1.81) 0.78 n/a 
IVH (any grade) 1 111 1.38 (0.46, 4.07) ¶ 0.57 n/a 
IVH (grade 3-4) 1 111 2.95 (0.12, 70.82) ¶ 0.51 n/a 
PVL 1 111 1.96 (0.18, 21.04) 0.58 n/a 
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Ibuprofen (Echo guided) vs. ibuprofen (standard dose)  
NEC 1 49 0.38 (0.08, 1.86) 0.23 n/a 
Oligo-anuria  1 49 5.31 (0.29,97.57) 0.26 n/a 
BPD (oxygen requirement at 36 
weeks) 
1 49 1.35 (0.53, 3.44) 0.53 n/a 
IVH (any grade) 1 49 1.50 (0.60, 3.74) 0.38 n/a 
Severe ICH  1 49 0.75 (0.05, 11.31) 0.84 n/a 
Serum creatinine after 
treatment * 
1 49 -11.60 (-29.64, 6.44) 0.21 n/a 
Increase in serum creatinine 
after treatment  
1 49 2.28 (0.10, 53.23) 0.61 n/a 
* Mean difference (95% CI) is used instead of RR (95% CI) and serum levels (mmol/l) measured at 72 hours following the 
intervention 
¶ RR value greater than 1 denotes higher rates of adverse effects with ibuprofen compared with the comparator drug and a value 
less than 1 denotes vice versa 
BPD; Bronchopulmonary dysplasia, GI; gastrointestinal bleeding, IVH; Intraventricular haemorrhage, ICH; Intracranial 
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RR (95% CI) P value I2 (%) 
NEC 1 80 
Not estimable as zero number of events in 
both arms 




1 80 0.67 (0.12, 3.78) 0.65 n/a 
IVH  
(any grade) 
1 80 3.00 (0.64, 13.98) 0.16 n/a 
¶ RR value greater than 1 denotes higher rates of adverse effects with ibuprofen compared with the comparator 
drug  
BPD; Bronchopulmonary dysplasia, GI; gastrointestinal bleeding, IVH; Intraventricular haemorrhage, NEC; 
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Table 36. Summary of results of the study comparing oral ibuprofen vs. rectal ibuprofen 
 
 




RR (95% CI) P value I2 (%) 
NEC 1 72 1.50 (0.27, 8.45) ¶ 0.65 n/a 
GI bleeding 1 72 3.00 (0.13, 71.28) ¶ 0.50 n/a 
Intestinal/ bowel perforation 1 72 3.00 (0.13, 71.28) ¶ 0.50 n/a 
Oliguria 1 72 3.00 (0.13, 71.28) ¶ 0.50 n/a 
BPD  
(oxygen requirement undefined) 
1 72 1.20 (0.40, 3.58) ¶ 0.74 n/a 
IVH 
 (any grade) 
1 72 1.75 (0.56, 5.46) ¶ 0.34 n/a 
¶ RR value greater than 1 denotes higher rates of adverse effects with oral ibuprofen compared with rectal 
administration 
BPD; Bronchopulmonary dysplasia, GI; gastrointestinal bleeding, IVH; Intraventricular haemorrhage, NEC; necrotising 
enterocolitis 
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5.3.8 Adverse effects from cohort studies 
5.3.8.1 Adverse effects from prospective cohort studies  
A total of 309 adverse effects were extracted from seven prospective cohort 
studies (Figure 77). Three out of the seven included prospective cohort 
studies had a comparison group (321,324,361) while four studies did not 
(322,323,325,360). Characteristics of prospective cohort studies and the 
reported adverse effects are summarised in 9.38. 
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Figure 77. Adverse effects following ibuprofen use in preterm neonates with PDA reported in, prospective cohort 
studies (seven studies; 309 adverse effects; 681 patients received ibuprofen) 
288 | P a g e  
 
 
5.3.8.2 Adverse effects from retrospective cohort studies  
A total of 2,264 adverse effects were extracted from 26 retrospective cohort 
studies (Figure 78). Sixteen studies out of 26 compared ibuprofen to other 
treatment strategies, six studies compared different ibuprofen groups and 
four studies had no comparison group. Characteristics of retrospective cohort 
studies and the reported adverse effects are summarised in 9.39. 
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Figure 78. Adverse effects following ibuprofen use in preterm neonates with PDA in retrospective cohort studies 
(26 studies; 2,264 adverse effects; 3,831 patients received ibuprofen)
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5.3.9 Adverse effects from case series 
There were four case series [one prospective (320) and three retrospective 
(43,318,319) which reported adverse effects of ibuprofen when used in PDA 
management (Table 37). BPD (defined at 28 days) was the most frequently 
reported adverse effect in these studies (24/99 adverse effects), followed by 
BPD (defined at 36 weeks) and acute kidney injury/ renal failure (17/99 and 
15 /99 respectively).  
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Table 37. Characteristics of the included case series and the number of reported adverse effects 

















Nov 2000 to Apr 2002 
N=22 
Premature neonates <32 
weeks gestation and birth 
weight < 1500g with RDS 
and ECHO confirmed PDA 
Oral ibuprofen via feeding tube 
Three doses (10-5-5 mg/kg) every 
24 hr 
7  






Dec 2006 to July 2008 
N=18 
Premature neonates< 34 
weeks gestation 
IV ibuprofen 
Three doses (10-5-5 mg/kg) every 
24 hr for PDA treatment 
4 






Jan 2009 to Jan 2011 
N=35 
35 out of 1992 neonates 
have received ibuprofen 
Not mentioned 15 
The aim of this 







Centre Hong Kong 
Jan 2008 to Dec 2011 
N=43 
Premature neonates < 37 
weeks gestation 
IV ibuprofen 
Three doses (10-5-5 mg/kg) every 
24 hr for PDA treatment 
80 -- 
AKI, acute kidney injury; ECHO, echocardiography; PDA, patent ductus arteriosus; RDS, respiratory distress syndrome 
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5.3.10 Adverse effects from case-control studies 
Two case-control studies reported 99 adverse effects following ibuprofen use 
(316,317) (Table 38).  One was a single centre study in Italy which reported 
22 cases of acute renal failure (ARF). The second study was a multi-centre 
study in France which compared ibuprofen to control group (not receiving 
any treatment) in PDA treatment (317) and reported 77 adverse effects with 
37 of them were BPD (at 28 days). 
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Table 38. Characteristics of the included case-control studies and the reported adverse effects 



















22 cases of 
ARF 
This study looked at risk 










Ibuprofen used for 
PDA treatment 
Regimen: 10 mg/kg in 
first day; two following 
days: 5 mg/kg 
77 
Urine output values could 
not be extracted as values 
presented as a line graph 
with circles represents 
mean (SD) of the mean. 
ARF, acute renal failure; PDA, patent ductus arteriosus; SD, standard deviation 
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5.3.11 Adverse effects from case reports 
Nine case reports (50,52–54,350–353,362) reported 11 adverse effects 
following ibuprofen use (Table 39). There were five cases of pulmonary 
hypertension, three cases of intestinal perforation, two cases of reversible 
renal failure, and one case of GI haemorrhage.    
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Table 39. Reported adverse effects from individual case reports  
Study ID 
Gestational 





















After third dose 
IV L-Lysine 
preparation Three 
doses (dose not 
mentioned) given 24 hr 
apart 

















Does not mentioned 
given 24 hr apart 
















within an hour 
after second 
dose of ibuprofen 
which was 
administered at 
72 hours of life 
IV L-Lysine 
preparation Three 
doses Dose: 10 mg/kg 
then 2 doses of 5 
mg/kg after 24h & 48h 
respectively 
Death on day 5 
because of progressive 
worsening of clinical 
conditions attributed to 
generalized sepsis not 


















10mg/kg followed by 2 
doses of 5mg/kg at 
12h intervals 
Treated with IV fluids, 
dopamine infusion. 
Oliguria resolved on 
day 9 and renal 
function return to 
normal on day 12 












First incident: < 
18h after the 
second dose. 
Second incident: 
in the morning 
following the 
loading dose of 
which was given 
on day 12 due to 
continued 
presence of PDA 
IV ibuprofen Lysine 
10mg/kg followed by 
5mg/kg in 24h interval 
infused over 15 
minutes 
In both instances, 
intestinal perforation 
occurred within 24 
hours of ibuprofen 
administration. 
Ibuprofen was stopped 













After the third 
dose of ibuprofen 
(second course). 
IV ibuprofen Lysine 
Received in total 6 
doses of ibuprofen 
10mg/kg (first dose) 
followed by 2 doses of 
5 mg/kg /dose at 24 
hours interval 
Diagnosed with severe 
bronchopulmonary 
dysplasia (BPD) at 36 
weeks of 
postconceptional age. 











14 hours after 
the second dose 
of ibuprofen 
IV ibuprofen Lysine 
10mg/kg, then 5mg/kg 
and 5mg/kg with 24 
hours intervals 
Medication stopped 
before 3rd dose. 
Recovered and 
discharged on 27th day 
















after a total of 6 
doses. 
 
IV ibuprofen Lysine 
10mg/kg, then 5mg/kg 
and 5 g/kg at 24h 
intervals infused over 
15 minutes 
The infant was 
extubated to nasal 
CPAP on day 38 and 
was not given any 












on day 3 of life (8 
hours after the 
last dose of 
ibuprofen  
Oral ibuprofen Three 
doses 10mg/kg 
followed by 5 mg/kg at 
24h interval 
Survived and treated 
with drain; removed on 
day 6 and enteral 
feeding was started 5 
days later 









in 2 days after 




10mg/kg followed by 5 
mg/kg in 24 hours 
interval 
Survived and treated 
with drain; removed 













on day 3 of 
treatment 
(unclear if infant 




Three doses 10mg/kg 
followed by 5 mg/kg in 
24 hours interval 
Recovered full renal 
function after three 
days 
BW, birth weight; GA, gestational age; GI, gastrointestinal; PDA, patent ductus arteriosus. 
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5.3.12 Adverse effects that led to discontinuation of ibuprofen in 
preterm neonates with PDA 
Treatment of ibuprofen was stopped in 56 neonates as a result of ibuprofen 
toxicity (Table 40). Most cases (33 neonates) were reported within the 
included RCTs and were due to GI bleeding and renal adverse effects 
(303,315,355,356,359). Pulmonary hypertension necessitating the 
discontinuation of ibuprofen was reported by a prospective cohort study in 11 
neonates (360). One RCT (312) was stopped as the interim analysis 
revealed a high incidence of acute kidney injury (AKI) in the ibuprofen group 
compared to paracetamol group.   
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Table 40. Studies where ibuprofen was discontinued because of ibuprofen toxicity (56 cases) 
Study ID 









Randomised controlled trials 
Bravo (2013) 
(315) 




Echo guided treatment: 
received additional 
doses of ibuprofen (5 
mg/kg at 24-h intervals) 
only if the PDA was still 




received 2 additional 
doses of 5 mg/kg of 
ibuprofen at 24-h 
intervals after the initial 
dose of 10 mg/kg 
Treatment discontinued 
and no further treatment 
given. Except surgical 
ligation was indicated for 
one neonate. 
Rising in serum 









Renal failure 1 
Oral ibuprofen for PDA 
treatment :3 doses: 10 
mg/kg followed by 5 
mg/kg after 24 and 48 hr. 
Did not complete the 
treatment course and were 
withdrawn from the 
analysis 
NEC 2 
IVH grade III-IV 3 
GI bleeding 8 
Total 14 









IV ibuprofen Lysine for 
PDA treatment 
3 doses: 10mg/kg and 
then two doses 5mg/kg 
24h apart as continuous 
IV infusion over 20 
minutes. 
Trial was halted 
Kanmaz (2013) 
(359) 
GI bleeding 2 Oral ibuprofen for PDA 
prophylaxis: 10mg/kg 
within 12-24 h after birth 
followed by 5mg/kg at 24 
and 48 h. 
Trial was terminated earlier 
than planned 
SIP 2 




Oliguria/rising creatinine 5 IV ibuprofen lysine for 
PDA prophylaxis: 3 
doses 10mg/kg within 6 
hr of birth followed by 2 
doses of 5mg/kg at 24 hr 
and 48 hr 
Did not comple the full 
course 
Severe IVH 1 
Total 6 




Pulmonary hypertension 11 
IV ibuprofen for PDA 
prophylaxis within the 
first 2 hours of life (10-5-
5 mg/kg at 24h interval) 





Oral ibuprofen via 
feeding tube for PDA 
treatment at 48 to 120 hr 
as 3 doses: 10mg/kg 








Renal insufficiency 2 
IV ibuprofen: 3 doses 
(10-5-5 mg/kg) 24 hrly 








Oral ibuprofen for PDA 
treatment. Each course 











Intestinal perforation 2 
IV ibuprofen Lysine for 
PDA treatment 10-5-5 
mg/kg at 24h interval 





GI haemorrhage 1 
Oral ibuprofen  for PDA 
treatment 
Given as 3 doses: 10-5-
5mg/kg at 24h interval 
Second dose not given 
No cases of ibuprofen discontinuation were found in case series studies in this review 
GI, gastrointestinal; h, hour; IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; PDA, patent ductus arteriosus; SIP, 
spontaneous intestinal perforation. 
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 Discussion and conclusion 
The present systematic review provides the first comprehensive review of 
ibuprofen adverse effects following its administration in preterm neonates for 
management of PDA.  
5.4.1 The advantage of performing a comprehensive adverse effects 
review over that of the traditional Cochrane reviews 
Systematic reviews of adverse effects are of similar importance as 
systematic reviews of efficacy, and must be conducted with similar rigour 
(269). They are considered the determinant type of reviews in cases where 
different effective treatment strategies exist, or where the controversy 
includes the option to offer no pharmacological treatment as in the case of 
PDA management in preterm neonates (366). 
Inclusion of non-randomised studies is the distinctive characteristic of 
systematic reviews that focus on adverse effects as compared to those that 
are primarily designed to study the efficacy of an intervention such as the 
Cochrane reviews for ibuprofen. Unlike non-randomised (observational) 
studies, RCTs are known to be less useful in detecting uncommon/rare 
adverse effects/ADRs. This is due to their restrictive nature in the number of 
enrolled participants, time frame, and poor reporting of adverse effects/ADRs 
as most RCTs focus on efficacy outcomes (367). Among non-randomised 
studies, prospective study designs (including prospective cohort studies) are 
ranked higher in the hierarchy of evidence compared to retrospective 
designs (368). Both prospective and retrospective cohort studies are set to 
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explore the association between multiple exposures and multiple outcomes. 
However, retrospective cohort studies are limited due to potential 
incompleteness of records (i.e. adverse effects in this review). This is 
because of the nature of retrospective studies in which the outcomes are 
identified and analysed from previously collected records (369). Prospective 
cohort studies involve follow up of cohorts with an objective of investigating 
the association between exposure and the outcomes that are recorded as 
they occur and hence there is less chance of missing outcomes of interest 
(370). Hence prospective cohort study designs are useful in providing 
information about the incidence and the risk factors of common adverse 
effects/ADRs (371–373). Despite these advantages, prospective cohort 
studies are known to be limited by a loss to follow up and selection bias 
(367).  
New and rare adverse effects/ADRs can be only captured from individual 
case reports and case series. Their inclusion in any adverse effects 
systematic reviews is therefore crucial to paint the complete picture of 
potential harm form the use of any medicine (367).  
5.4.2 Summary of the results  
Adverse effects from randomised controlled trials: The most frequently 
reported GI and renal adverse effects were NEC and oliguria respectively. 
The most frequently reported respiratory and nervous system adverse effects 
cases were BPD, (including all definitions) and IVH respectively.  
It can be argued that these adverse effects were due to prematurity or were 
complications of PDA and may not be attributed to the direct effect of 
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ibuprofen. Several reviews pointed that PDA complications are due to two 
main reasons; fluid overload and the steal phenomenon (374). Prolonged 
ventilation, needed as a consequence of fluid overload, can lead to an 
increased risk of BPD and nosocomial infections. The steal phenomenon is a 
change in the blood flow movement in splanchnic and renal vessels due to 
left-to-right shunting. This phenomenon can result in an increased risk of 
NEC, bowel perforation, worsening in renal impairment and even 
intracerebral haemorrhage (ICH)/IVH (374,375).  
Adverse effects from non-randomised studies: The majority of adverse 
effects were captured within the retrospective cohort studies (2,264 adverse 
effects) as compared to prospective cohort studies (309 adverse effects). 
Among retrospective cohort studies, there are two studies reporting around 
40% of the total adverse effects extracted from all other retrospective cohort 
studies (1102 adverse effects /2264 total adverse effects) (327,329). This 
high number of adverse effects reported can be attributed to the fact that 
they were large multicentre studies that captured adverse effects, 
respectively. It is important to highlight that one retrospective cohort study by 
Gulack et al. reported an ambiguous outcome ‘any adverse event’ in 802 
neonates receiving ibuprofen compared to 3,395 in neonates receiving 
indomethacin (329). These data were not included in this review as the 
nature and type of these adverse effects could not be classified.   
Another important finding is the discontinuation of ibuprofen because of 
toxicity which was reported in 56 neonates. The majority of adverse effects 
that led to discontinuation of treatment in RCTs were GI bleeding and renal 
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adverse effects (including renal insufficiency, oliguria and an increase in 
serum creatinine) (303,315,355,356,359). Eleven neonates had pulmonary 
hypertension following ibuprofen administration in a prospective cohort study 
which necessitate discontinuation of the drug (360).  
5.4.3 Comparison with existing systematic reviews 
There are three recent Cochrane reviews assessing effectiveness and safety 
of ibuprofen in preterm neonates with PDA. Two were published in 2018 
where ibuprofen was used for PDA treatment with different comparators 
(47,244) whereas one published in 2019 where  ibuprofen was used for PDA 
prophylaxis (57).  
There were some differences in the studies included between this systematic 
review and the Cochrane reviews. Four RCTs that were included in this 
review and were not included in the Cochrane reviews (287,311,312,314). 
Those studies with the reasons for their exclusion were not stated in the 
Cochrane reviews. In contrast, there were 13 RCTs included in the Cochrane 
reviews and were not included in this review. Reasons for excluding these 
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Reason for inclusion in Cochrane 
reviews 
Reason for exclusion 
from this review 
Ding (2014) 
(376) 
Included in Ohlsson 2018 (47); PKPD study 
measure PDA closure only. 






Included in Ohlsson 2018 (47); measure 
physiologic effect of ibuprofen only 
(changes in cerebral blood volume, cerebral 
blood flow, and cerebral oxygen delivery). 





Included in Ohlsson 2018 (47); measure 
physiologic effect of ibuprofen only 
(cerebral blood flow velocity) 





Included in Ohlsson 2018 (47); measure 
physiologic effect of ibuprofen only 
(cerebral perfusion, and cerebral 
mitochondrial 
Oxygenation)  





Included in Ohlsson 2018 (47); measure 
physiologic effect of ibuprofen (cerebral 
blood flow velocities, blood pressure).  
Although mortality and 
serum creatinine were 
listed as outcome 
measures; no information 
was provided in the 
original publication about 
these outcomes. 
Therefore, it was 
excluded.  
Akar (2017)  
(380) 
Included in Ohlsson 2018 (47); measure 
physiologic effect of ibuprofen only (effect 
of different forms of ibuprofen treatment 
on the antioxidant and oxidant status of the 
patients) 





Included in Ohlsson 2018 (47); measure 
both efficacy and adverse effects 
outcomes.  
Article in Chinese. Could 




Included in Ohlsson 2018 (47); measure 
both efficacy and adverse effects 
outcomes. 
Article in Turkish. Could 




Included in Ohlsson 2018 (47); measure 
both efficacy and adverse effects 
outcomes. 
Article in Persian. Could 




Included in Ohlsson 2018 (47); measure 
both efficacy and adverse effects 
outcomes. 
Article in Polish. Could 




Included in Ohlsson 2019 (57); measure 
IVH (grade 2 to 4) at 7 days of life, PDA on 
day 3, BPD at 36 weeks’, NEC, sepsis 
(confirmed with positive blood culture) 
Ibuprofen was used to 
prevent IVH in preterm 
neonates and not PDA 
closure.  




Included in Ohlsson 2019 (57); measure 
IVH, PDA, NEC, GI bleeding, mortality, 
hospitalisation (days). 
Ibuprofen was used to 
prevent IVH in preterm 




Included in Ohlsson 2018 (47); measure 
failure to close a PDA, need for surgical 
ligation of the PDA, oliguria, NEC, 
creatinine 
and BUN before and after treatment, 
mortality at 28 days of life  
The original paper did not 
report the results of the 
adverse effects 
outcomes. Therefore, it 
was excluded.  
BPD, bronchopulmonary dysplasia; BUN, blood urea nitrogen; GI, gastrointestinal; IVH, 
intraventricular haemorrhage; NEC, necrotising enterocolitis; PDA, patent ductus arteriosus 
Despite these differences in the number of studies included, the overall 
meta-analyses result of this review are very similar to those of the Cochrane 
reviews.  
With regards to GI adverse effects, the meta-analyses in this review 
concluded that ibuprofen has a lower risk of NEC compared to indomethacin 
[16 studies; 1125 patients; RR: 0.66, 95% CI: 0.47 to 0.93, p=0.02] with no 
difference in this outcome when ibuprofen was compared to placebo or 
paracetamol. These results are consistent with the Cochrane reviews when 
comparing ibuprofen to indomethacin [18 studies; 1292 patients; RR: 0.68, 
95% CI: 0.49 to 0.94, p=0.02], placebo [nine studies; 1,028 patients; RR: 
0.96, 95% CI: 0.61 to 1.50] and paracetamol [five studies; 559 patients; RR: 
0.88, 95% CI: 0.46 to 1.70].  
In this review ibuprofen was found to have higher risk of GI bleeding when 
compared to placebo [three studies; 140 patients; RR: 2.09, 95% CI: 1.20 to 
3.66, p=0.010] and paracetamol [two studies; 240 patients; RR: 7.00, 95% 
CI: 1.91 to 25.61, p=0.003] with no difference in this outcome when 
compared to indomethacin. This was similarly reported in the Cochrane 
reviews when comparing ibuprofen to placebo [5 studies; 282 patients; RR: 
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2.05, 95% CI: 1.19 to 3.51, p<0.001], paracetamol [4 studies; 537 patients; 
RR: 0.28, 95% CI: 0.12 to 0.69, p<0.001] with no difference when compared 
to indomethacin.  
Among renal adverse effects, meta-analyses of this review concluded that 
there was no significant difference of oliguria when comparing ibuprofen to 
placebo or paracetamol. However, a significant difference of oliguria was 
found when ibuprofen was compared with indomethacin, with lower risks in 
the ibuprofen group [five studies; 626 patients; RR: 0.38, 95% CI: 0.25 to 
0.56, p<0.001] was similarly reported in the Cochrane review [6 studies; 576 
patients; RR: 0.28, 95% CI: 0.14 to 0.54, p<0.001].  
Finally, there was no difference in the risk of IVH when comparing the three 
pharmacological agents in this review and in the Cochrane reviews.  
5.4.4 Comparisons with other adverse effects systematic reviews  
Previous adverse effects systematic reviews in paediatrics have highlighted 
that most adverse effects are reported in prospective cohort studies rather 
than RCTs (277,388). For instance, a safety systematic review on the use of 
lamotrigine in paediatrics identified 12 prospective cohort studies (1,524 
adverse effects) and nine RCTs (549 adverse effects) (388). The other 
review that explored the safety of use of levetiracetam in paediatrics also 
reported more adverse effects from 20 prospective cohort studies (897 
adverse effects) vs. six RCTs (415 adverse effects) (277). Contrary to these 
expectations, the present systematic review revealed that most adverse 
effects were found in RCTs rather than prospective cohort studies. Thirty-
nine RCTs reported forty per cent (1,841 adverse effects) of the total number 
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of adverse effects whereas only seven prospective cohort studies reported 
five per cent (232 adverse effects) of the total adverse effects in this review.  
While different to the trend in paediatric studies, this distribution is similar to 
other systematic reviews in neonates (389). A recent systematic review with 
an aim to investigate the safety of azithromycin in neonates yielded more 
adverse effects in RCTs compared to cohort studies. Four RCTs in this 
review reported 340 adverse effects following azithromycin use compared to 
three cohort studies that reported only 16 adverse effects (389). This may be 
because in neonatal medicine, there is possibly a move towards more RCTs 
with fewer publications of prospective cohort studies. Additionally, a number 
of recent RCTs have adopted the recommendation of more carefully 
reporting adverse effects of the intervention as compared to older RCTs.  
This is due to the updates on the Consolidated Standards of Reporting Trials 
(CONSORT) statement to include harms which was published in 2010 (390). 
This update has added ten further new recommendations into the original 
CONSORT statement to address harms-related issues and improve the 
quality of reporting harms in RCTs (391). Despite this, change is slow. A 
recent systematic review highlighted the inconsistency in reporting of harms 
in RCTs with an obvious heterogeneity between the included studies for 
each recommendation(390). This review pointed out that almost half of 
health research journals (19/41 (46%)) provided online instructions to 
authors about the CONSORT guideline without a referral to the CONSORT-
harms statement. This would suggest a need for further adherence to the 
CONSORT-harms by both researchers and editorial team of medical/health 
journals.  
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The improvement in the practice of reporting adverse effects should make an 
assessment of the toxicity of new drugs easier to perform and more robust. 
This can be useful when assessing ADRs in neonates (especially premature 
neonates) where a definite conclusion about the causality of the events as a 
result of a drug or prematurity might be difficult to differentiate.  
The high number of adverse effects captured from retrospective cohort 
studies in this review is due to the larger number of patients than those 
included in RCTs. Such large retrospective database derived reports are 
expected to be published more and more due to the establishment of large 
neonatal databases of routinely collected data such as the National Neonatal 
Research Database in the UK. These data, although a wealthy repository of 
very useful information, must be interpreted with caution because 
retrospective studies are more prone to reporting bias when compared to 
prospective studies.  
The methodology followed in this systematic review is consistent with the 
framework proposed by Loke et al. for conducting systematic reviews of 
adverse effects. A recent systematic review of levetiracetam toxicity in 
children followed a similar methodological approach (277). Unlike the 
levetiracetam systematic review, this review has included all non-randomised 
studies following quality assessment without any requirements to fulfil certain 
quality criteria. This is in keeping with the recommendation for using the JBI 
tool for quality assessment which has been used here. This assessment is 
subjective and it is considered appropriate to include all the data of adverse 
effects from non-randomised studies (279). Until a validated tool for non-
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randomised studies is developed, it is better to include all the non-
randomised studies when conducting adverse effects systematic reviews.  
5.4.5 Strengths and limitations  
In addition to inclusion of all types of study designs and a comprehensive 
documentation of all reported adverse effects of ibuprofen in preterm 
neonates, the strengths of this systematic review include the clear definition 
of the research question (using PICO model), and adherence to an explicit 
protocol that was developed and registered prior to the analysis (Prospero 
[CRD 42018067600]). The robust nature of the search strategy also added 
strength to the review. This included expert input into selecting the search 
terms, searching several electronic databases and the grey literature, and 
including all study designs with no restriction of languages. Another strength 
is that all studies (RCTS and non-RCTs) were reviewed by two reviewers 
(and a third one where there was a conflict).   
There are some limitations that need to be highlighted. First, some studies 
were retrieved in non-English language (Chinese, Turkish, Polish, and 
Iranian) that could not be translated (384,382,383,381,392,393). Another 
limitation is that the tool used for quality assessment of non-randomised 
studies is not standardised.  However, currently there is no perfect tool for 
assessment of non-randomised studies and the tool developed by JBI was 
used. This is used widely to assess the quality of many types of study 
designs (cohort, case-control, case report) (279) and was therefore selected 
for this review. A new tool, the ROBINS-I,  which is under assessment by 
Cochrane group, may provide a more rigorous conclusion when assessing 
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risk of bias of non-randomised studies compared to the tool used in this 
review (394).  
It must also be noted that this systematic review is limited by the difficulty of 
assessing adverse effects in preterm neonates. This is due to the fact that 
those events may be attributed to prematurity or the haemodynamic 
consequences of PDA or they might have been due to the direct effect of 
ibuprofen (273).  
5.4.6 Conclusion 
There are still many unanswered questions about the best available 
treatment strategy when managing PDA, especially in extremely preterm 
neonates who are more resistant to treatment and more prone to harm. This 
systematic review has identified the most common and some rare adverse 
effects encountered following ibuprofen administration in preterm neonates 
with PDA across all study designs, with quantification of their risks in RCTs 
and prospective cohort studies. This can assist neonatologists and other 
healthcare providers in their daily clinical judgement making when it comes 
to weighing the risks and benefits associated with ibuprofen use and prevent 
unnecessary exposure to ibuprofen in a cohort of neonates who may be 
managed conservatively and who have a high risk of adverse outcomes.   
Combined results from RCTs and prospective cohort studies in our review 
show that oliguria is the most commonly reported adverse effect among the 
renal adverse effects. However, the high number of rising serum creatinine 
after treatment from retrospective studies should also be considered when 
treating preterm neonates with ibuprofen for PDA.  
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Following the count of ibuprofen and indomethacin adverse effects in 
retrospective cohort studies that compared both agents, ibuprofen was 
associated with a smaller number of adverse effects compared to 
indomethacin (1691 vs. 3586 adverse effects). So, this can highlight the fact 
that ibuprofen might be favourable to indomethacin in terms of its safety.  
Paracetamol, a new emerging pharmacological option, might be favoured 
when compared to ibuprofen as it is found to be associated with less risk of 
GI bleeding. However, there is a need for more studies that aim towards its’ 
long-term benefits when used in preterm neonates with PDA.
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CHAPTER 6 REVIEW OF NEONATAL DRUG 
FORMULARIES AND OTHER PRACTICE GUIDELINES 
USED IN NEONATAL UNITS IN THE UK 
 Introduction 
In the previous chapters, I have focussed on the pattern of drug use in 
neonatal units in England and Wales by applying quantitative methods on 
data in a national database. These analyses; however, do not give any 
insight into how these drugs are used, e.g. there is no information in the 
National Neonatal Research Database (NNRD) about the indications and 
recommended doses for any of these drugs. Quality, which is a determinant 
of irrational practice, can be assessed through an evaluation of current 
practices by investigating the use of local guidelines. This will enable us to 
identify whether prescribing information in the drug formularies and available 
practice guidelines are consistent across different units.  
Tools to detect inappropriate prescribing have been developed widely in the 
elderly. However, there are few in paediatrics and none in neonates. After 
scoping the literature, only three tools were found to be developed for the 
paediatric population (395–397). The first was proposed in France and was 
named Pediatric: Omission of Prescriptions and Inappropriate Prescriptions 
(POPI) to identify inappropriate prescribing in this population (395). However, 
the use of this tool would be inappropriate to aid prescribers in neonatal 
medicine, as most of the criteria are for children, not neonates. Another study 
in UK and Ireland attempted to develop indicators of potentially inappropriate 
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prescribing in children (PIPc) in a primary care setting (396), which also have 
not included criteria for neonates. The most recent tool in the paediatric 
population was conducted in the UK by Corrick et al. with the aim of 
evaluating the applicability of the POPI tool to UK practice and modified, 
where necessary, to apply it in paediatric practice (397). This tool is also 
inappropriate to be used for the neonatal population as it was mainly directed 
for infants and children. It is worth considering the creation of such a tool to 
tackle irrational prescribing in the neonatal population, especially with the 
inconsistencies that are found across the collected neonatal drug information 
resources.  
This study will aim to explore the information held in current neonatal 
formularies and practice guidelines used in the UK and compare prescribing 
information extracted from them. The British National Formulary for Children 
(BNF-C) is considered the standard dosing information that meets the WHO 
standards for national formularies (28) and is widely used in the UK. 
However, it is worth exploring if there are any further resources used across 
neonatal units in the UK and whether prescribing information in those 
formularies and other clinical practice guidelines is similar or different. 
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6.1.1 Study aim and objectives 
The aim of this study was to review the neonatal drug formularies and any 
other existing neonatal practice guidelines used in different neonatal units in 
the UK.  
This was a multi-centre observational study conducted over 12 months from 
1st April 2018 to 1st April 2019 and set out to address two main questions with 
the following objectives:  
• Objective 1: Is the prescribing information of the frequently prescribed 
drugs stated in neonatal drug formularies and or local practice 
guidelines used in UK neonatal units similar, or do they differ? 
• Objective 2: Is the prescribing information of the drugs used in PDA 
management (indomethacin, ibuprofen, and paracetamol) stated in 
neonatal drug formularies and or local practice guidelines used in UK 
neonatal units similar, or do they differ? 
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 Methods  
6.2.1 Study design  
A prospective multi-centre study was conducted over 12 months (1/4/2018 to 
1/4/2019) to obtain drug formularies and or practice guidelines used in 
neonatal units in the UK, or drug formularies that are exclusively aimed for 
the use of prescribing in older children were excluded. 
This study was reviewed and approved by the Faculty of Medicine and 
Health Sciences (FMHS) Research Ethics Committee (FMHS Ref no: 283-
1803) (attached in 9.40).   
 
6.2.2 Data collection  
Drug resources were requested electronically via two main networks; the 
Neonatal and Paediatric Pharmacists Group (NPPG) and the British 
Association of Perinatal Medicine (BAPM). NPPG is a professional network 
formed in 1994, to improve the care of neonates, infants and children by 
advancing the personal development of pharmacists and the provision of 
quality pharmacy services. BAPM is the UK’s leading organisation of 
clinicians in perinatal medicine and has representation in every neonatal unit 
in the UK, founded in Bristol since 1976.  
Data collection was done by the researcher of the study (myself). This was 
conducted by circulating an invitation letter electronically to the members of 
those two networks. A copy of the participation invite letter is attached in  
9.41. However, because the NPPG network is an establishment of the UK 
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National Health Service (NHS) network, it was necessary to contact a 
member of the NPPG as an initial step to prompt the post of the invite letter 
at the NPPG network message board. The initial message was posted by Dr 
Sharon Conroy (SC) (associate professor at school of medicine, UoN) who is 
also an active member at the NPPG network. The initial invite letter was 
posted on 28th April 2018 by SC and resulted in two responses from the 
members by May 2018. Following this initial step, I then followed the data 
collection process. Since there were no further responses by June 2018, an 
attempt was made to contact the NNPG network administrator, Peter 
Polland, to circulate the invite letter. The invite letter was then emailed to all 
NPPG members by the network administrator, which resulted in nine further 
responses by mid-November 2018. At that time, an email was sent to BAPM 
to circulate the invite letter to their members; there was no response so a 
reminder was sent in March 2019 and again no response was received. A 
final contact was made with the NPPG to collate further responses. However, 
an email received from the administrator indicated that the timing was difficult 
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Figure 79. Data collection during the study period and the responses 
gained 
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6.2.3 Data extraction and analysis  
The contents of all collected drug resources were analysed descriptively 
using Microsoft Excel (version 16, 64 bit).  
For objective 1: relevant information about the most frequently prescribed 
drugs were extracted. The drugs were chosen based on the results of 
Chapter 3. These drugs were the ten most frequently prescribed drugs 
identified across neonatal units in England and Wales: benzylpenicillin, 
gentamicin, cefotaxime, caffeine, morphine (IV), flucloxacillin and pulmonary 
surfactants. However, sodium, phosphate and iron, which are also amongst 
the ten frequently prescribed drugs were not included in this analysis, as they 
are used in neonatal units as supplements. The data extracted from the 
formularies were the following:  
• Indication of use 
• Dosing regimen  
• Instruction for administration 
• Contraindications  
• Cautions  
• Monitoring for adverse effects  
Similarly, this was also done for objective 2, with the above categories of 
information on the drugs used in PDA (ibuprofen, indomethacin, and 
paracetamol) extracted. 
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 Results  
6.3.1 Participating units’ characteristics 
Eleven neonatal units responded to the participation letter during the study 
period. Only eight units shared their neonatal drug formularies or guidelines 
or both. The total number of shared neonatal formularies/guidelines was 
nine, as one unit shared two local formularies (Table 42).  
As can be seen from the table, seven out of eight responding units were from 
different places in England, and one was from West-Scotland. Four of the 
units were level three neonatal units (NICUs), while two were level two (LNU) 
units. However, two participants shared the formularies/ guideline of the trust 
or several hospitals, so the level of the unit cannot be assigned. Most of the 
units shared electronic links to their formularies/neonatal guidelines. 
However, three out of eight units shared an electronic copy of their 
formularies.   
A total of nine shared documents that include six drug formularies, and three 
clinical practice guidelines were received and included for the descriptive 
analysis. 
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Table 42. Characteristics of the participating neonatal units and an overview of the neonatal formularies/drug 
guidelines  
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- - - 
LNU, local neonatal unit; NICU, neonatal intensive care unit; ODN, operational delivery networks 
*The unit level cannot be determined as the shared document covers a trust or several hospitals in that region 
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6.3.2 Objective 1: Is the prescribing information of the frequently 
prescribed drugs stated in neonatal drug formularies and or local 
practice guidelines used in the UK neonatal units similar? 
Antibiotics included in the list of ten most frequently prescribed drugs were: 
benzylpenicillin, gentamicin, cefotaxime, and flucloxacillin. 
6.3.2.1 Benzylpenicillin  
Benzylpenicillin is the most frequently prescribed drugs across neonatal units 
in England and Wales. This drug was cited across all the collected 
formularies and practice guidelines as being used for sepsis or meningitis. 
According to the BNF-C, this antibiotic is prescribed for neonatal sepsis as 25 
mg/kg every 12 hours (increased every 8 hours) in those up to 7 days and as 
25 mg/kg every 8 hours (increased to 50 mg/kg every 8 hours) in neonates 7 
to 28 days (398).  
Five out of the nine shared drug resources stated its use in sepsis. However, 
there are different dose regimens used which varied between 25 to 100 
mg/kg either twice or three times per day depending on the severity of the 
infection and the gestational age of the neonate. Resources from four units 
have mentioned the dosage regimen according to the postnatal age of the 
neonate (Table 43) whereas the fifth unit did not state the specific dose for 
sepsis. Three units out of four (units 2,3, and 6) use 50 mg/kg twice daily for 
neonates < seven days and 50 mg/kg three times daily for neonates seven to 
28 days. The fourth unit halved the above-mentioned dosage regimens for 
those ages.  
Page | 324  
 
Similarly, for meningitis different dose regimens were cited across the shared 
drug information resources, which varied between 50 to 100 mg/kg twice or 
three times per day.  
The detailed prescribing information of benzylpenicillin obtained from the 
participating units is in 9.42.
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Table 43. The dosage regimen of benzylpenicillin in sepsis  




Sepsis (suspected at birth) 
<7 days of age 50mg/kg 12 hourly 
7 to 28 days of age 50mg/kg 8 hourly 




Sepsis (suspected at birth) 
<7 days of age 50mg/kg 12 hourly 
7 to 28 days of age 50mg/kg 8 hourly 
>28 days of age 50mg/kg 6 hourly 
Unit 6 Early-onset sepsis 
Preterm 50mg/kg/dose 12 hourly 
Term < 7 days 50mg/kg/dose 12 hourly 
Term 7 to 28 days 50mg/kg /dose 8 hourly 
Unit 7 Early-onset sepsis 
< 7 days 
25 mg/kg every 12 hours; 
change to 25mg/kg every 8 
hours 
7 to 28 days 
25 mg/kg every 8 hours; 
increased if necessary, to 50 
mg/kg every 8 hours in 
severe infection 
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6.3.2.2 Gentamicin  
Gentamicin is usually administered with benzylpenicillin for the management 
of neonatal sepsis, particularly early-onset sepsis (EOS). According to the 
BNF-C, the recommended dose is 5 mg/kg every 36 hours in neonates up to 
7 days of age, and every 24 hours in neonates 7 to 28 days of age (399). It 
was the second most frequently prescribed drug in neonatal units in England 
and Wales. Four out of nine shared drug information resources stated the 
use of gentamicin for sepsis, with three of them in EOS. The remaining five 
indicated the use of gentamicin in infections as general without specifying the 
type of infection. Also, similarly to benzylpenicillin, various doses were found 
to be used that ranged between 3 to 5 mg/kg every 24 or 36 hours and 
started at different gestational ages. However, two units used the same 
regimen of gentamicin in sepsis for neonates < seven days of age 
(5mg/kg/dose once every 36 hours) and neonates ≥ seven days 
(5mg/kg/dose once every 24 hours).  
Gentamicin requires regular therapeutic drug monitoring due to its potential 
ototoxicity and nephrotoxicity. Eight out of the nine information resources 
stated the gentamicin therapeutic monitoring protocol. All of the eight 
resources indicated that trough levels should be taken with seven of them 
stated that this should be before the second dose. Peak levels were required  
by five out of the eight formularies while three of them indicated that it is 
required only if there was no response to the treatment (Figure 80).  
The detailed prescribing information of gentamicin obtained from the 
participating units is in 9.43. 
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Figure 80. Therapeutic gentamicin monitoring from eight neonatal care units
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6.3.2.3 Cefotaxime  
Cefotaxime is a third-generation cephalosporin frequently used among 
neonates. According to the BNF-C, this antibiotic is used in infections 
sensitive to Gram-positive and Gram-negative bacteria and severe 
infections/meningitis. The doses vary according to neonatal age and type of 
infection, for example, 25mg/kg every 12 hours is prescribed for neonates up 
to 7 days in Gram-positive and Gram-negative infections and increased to 50 
mg/kg every 12 hours in severe infections and meningitis (400).   
One out of the nine resources indicated the use of cefotaxime as first-line in 
late-onset sepsis, three stated its broad term use in infections, four indicated 
its use in infections and meningitis, and one indicated its use only in 
meningitis. The doses were stated by seven units and were mostly similar, 
with six units using it at 50 mg/kg at different hours based on the neonatal 
age (Figure 81).  
The detailed prescribing information of cefotaxime obtained from the 
participating units is in 9.44. 
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Figure 81. Cefotaxime variability in dosage regimen (stated by seven units)
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6.3.2.4 Flucloxacillin  
According to the BNF-C, flucloxacillin is indicated for use in neonates with 
infections related to staphylococcal (e.g. meningitis), skin (e.g. impetigo), and 
osteomyelitis. The doses vary according to the neonatal age and the type of 
infection. For instance, the recommended dose in neonates up to 7 days of 
age with osteomyelitis is 50-100 mg/kg every 12 hours (every 8 hours in 
neonates 7 to 20 days). Whereas in neonates up to 7 days of age with 
impetigo, the recommended dose is 25mg/kg every 12 hours (every 8 hours 
in neonates 7 to 20 days) (401). 
 Four out of the nine drug information resources stated the use of 
flucloxacillin in infections, whereas four were more specific and stated its use 
in staphylococcal infections, and one indicated its use in skin and systemic 
infections. The doses of flucloxacillin also varied between units, ranges 
between 25 to 100 mg/kg administered at different intervals based on 
different neonatal gestational ages (Figure 82). 
The detailed prescribing information of flucloxacillin obtained from the 
participating units is in 9.45. 




Figure 82. Number of units using different dosage regimen of 
flucloxacillin to treat infection
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6.3.2.5 Caffeine (citrate)  
Caffeine is a respiratory stimulant used for apnoea of prematurity. As per 
BNF-C, the recommended dose of caffeine citrate in neonatal apnoea is 
20mg/kg (loading dose), then maintenance dose of 5mg/kg once daily (may 
increase above 20mg/kg) and started 24 hours post the loading dose (402). 
As of August 2013 and due to safety information, all licensed preparations of 
caffeine are required to be labelled as caffeine citrate to minimise the risk of 
dosing errors as a recommendation by the Medicines and Healthcare 
products Regulatory Agency (MHRA) (193). All units participating in this 
study have stated caffeine as caffeine citrate in their formularies and or 
clinical practice guidelines and had the same indication for its use which is 
apnoea of prematurity. Eight out of the nine resources stated the doses of 
caffeine citrate as a loading and maintenance dose, whereas one resource 
did not state any dose recommendation for caffeine citrate. The loading dose 
is given as 20 mg/kg in all the participating units. However, the maintenance 
dose varied between units (Figure 83).  
Also, all the resources highlighted the fact that monitoring of caffeine levels is 
unnecessary unless adverse symptoms persist, or there is evidence of 
toxicity. An interesting observation is that caffeine is usually advised to be 
given via intravenous (IV) infusion as a bolus injection is associated with 
sudden changes in blood pressure. Most of the resources have stated that 
the direction for its use is via slow IV infusion. However, one practice 
guideline stated a direction of using bolus infusion of caffeine citrate when 
given as a maintenance dose.    
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The detailed prescribing information of caffeine obtained from the 
participating units is in 9.46.  
 
 
Figure 83. Number of units using different maintenance dosage regimen 
of caffeine citrate
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6.3.2.6 Morphine (IV) 
Morphine (sulphate) has a few different indications in the neonatal 
population. It is used primarily as a sedative and analgesic. Also, it has been 
used to treat neonates with Neonatal Abstinence Syndrome (NAS), which 
refers to a collective set of withdrawal symptoms that neonates can develop 
following birth if their mothers have taken addictive drugs such as narcotics, 
antidepressants, or potentially addictive drugs. According to the BNF-C, the 
recommended dose of IV morphine as analgesic is 50 mcg/kg every 6 hours 
and adjusted later according to response. Whereas, if used for NAS, the 
recommended dose of morphine is 40 mcg/kg every 4 hours (orally), and 
increased if necessary (403).   
Seven resources out of nine have reported the dosage of morphine 
according to the indication, whereas the remaining two stated general dosing. 
The dosing for morphine, when used as pre-medication for intubation, was 
similar in four out of seven resources given as 100 mcg/kg. However, the 
loading dose of morphine when indicated for analgesia or sedation varied 
between 50-100 mcg/kg (Figure 84).  
Regarding Neonatal Abstinence Syndrome (NAS), the doses were mostly 
given at 40 mcg/kg every 4 hours, and morphine was given as an oral 
preparation in most of the formularies for this indication.  
The detailed prescribing information of morphine obtained from the 
participating units is in 9.47.  
 





Figure 84. Number of units using a different loading dose of morphine 
when used as analgesic or sedation 
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6.3.2.7 Pulmonary surfactants  
Pulmonary surfactants are used primarily in preterm neonates who develop 
respiratory distress syndrome (RDS) as a result of their lungs’ immaturity, 
which affects surfactants production (196). Six out of the nine shared 
documents cited poractant as a pulmonary surfactant used in their units for 
preterm neonates with RDS. According to the BNF-C, the recommended 
dose of poractant alfa when treating RDS in neonates is 100-200 mg/kg, then 
100 mg/kg every 12 hours if required (404). The remaining three units had no 
information regarding pulmonary surfactants in their shared documents. 
Doses were similar and ranged from 100 to 200 mg/kg/dose as an initial dose 
for RDS treatment. 
The detailed prescribing information of poractant obtained from the 
participating units is in 9.48.
Page | 337  
 
6.3.3 Objective 2: Is the prescribing information of the drugs used in 
PDA management (indomethacin, ibuprofen, and paracetamol) 
stated in neonatal drug formularies and or local practice 
guidelines used in UK neonatal units similar?  
6.3.3.1 Indomethacin  
Five out of nine drug information resources included indomethacin 
prescribing information when used in PDA. Indomethacin is one of the drugs 
used in PDA closure. However, BNF-C does not list any doses for its’ use in 
PDA closure.   
One resource indicated that indomethacin is used as a second-line agent 
after ibuprofen, whereas another one stated its use as a first-line drug. Three 
resources out of five listed the dose regimen of indomethacin used in PDA 
with two of them (UNIT-1 and UNIT 5-A) using the same regimen of either 
100mcg/kg every 24 hours intravenously for six doses or as a short courses 
regimen detailed in (Figure 85). 
The detailed prescribing information of indomethacin obtained from the 
participating units is in 9.49.  
 




Figure 85. The dosage regimen of indomethacin for PDA treatment as stated in the drug information resources
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6.3.3.2 Ibuprofen  
Eight out of nine shared drug information resources had information about 
ibuprofen use in PDA. According to the BNF-C, ibuprofen is used in PDA 
closure at an initial dose of 10mg/kg, followed by 5mg/kg every 24 hours for 
two doses and the course maybe repeated after 48 hours if necessary (405).  
One of the resources indicated the use of ibuprofen as a second-line drug 
instead of indomethacin for PDA. Interestingly, all of the shared resources 
had unified dosage regimens for ibuprofen in PDA, which is: three doses 
given as slow IV infusion of 10-5-5 mg/kg at 24 hours intervals. Also, they all 
suggested a repeated course in case the ductus reopens or has not closed 
after 48 hours after the first course. Monitoring for renal, hepatic function and 
urine output were amongst the monitoring parameters during ibuprofen 
treatment that were cited in the shared resources.   
The detailed prescribing information of ibuprofen obtained from the 
participating units is in 9.50.  
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6.3.3.3 Paracetamol  
Only two out of the nine shared resources listed paracetamol to be used for 
PDA in addition to its use as an analgesic. The other seven resources listed 
the indication of paracetamol as an analgesic only.  
In the BNF-C, there are no doses listed for paracetamol when used in PDA. 
However, there are doses listed when it is used for pain/pyrexia with 
discomfort. Paracetamol is indicated at a dose of 7.5 mg/kg every 8 hours for 
neonates of 32 weeks corrected GA and above as IV infusion (406).   
The doses were different as one has specified the doses per neonatal age at 
the time of the treatment, whereas the other listed one fixed-dose for all age 
groups (Table 44).
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Table 44. Paracetamol comparison when used in PDA as stated in neonatal formularies 
Comparison UNIT-6 UNIT-8 
Dose regimen 
Five day course; given as IV infusion.  
Gestation and age based 
• 23 0/7 to 25 6/7 and ≤ 7days at time of 
treatment: 12.5mg/kg every 6 hours 
• 23 0/7 to 25 6/7 and > 7days at time of 
treatment: 15mg/kg every 6 hours 
• ≥ 26 0/7: 15mg/kg every 6 hours 
• Maintenance dose to commence six hours 
after loading dose 
15mg/kg 6 hourly for 5-7 days 
Instruction for 
administration 
Check Paracetamol trough level, immediately 
before the third maintenance dose. Given by IV 
infusion over 15 minutes 
Not stated 
Contraindications Not stated Not stated 
Cautions Caution in hepatic impairment Not stated 
Monitoring for 
adverse effects 
Monitor hepatic function 
Liver function tests should be 
checked daily 
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 Discussion 
In neonatal medicine, the use of drug formularies and clinical practice 
guidelines is vital to provide comprehensive guidance on the safe and 
effective use of drugs in this population. This is due to the vast array of 
neonatal ages and birth weights, in addition to the immaturity of their organs 
if born preterm that could affect their response to medicines. All of this can 
add challenges to clinicians when prescribing and requires referral to such 
resources, in addition to their clinical judgment, to provide the best 
therapeutic plan to their patients.  
The results of this study have shown that there are some similarities in the 
extracted drug information from the obtained resources, as well as some 
inconsistencies and these are discussed in the following sections.  
6.4.1 Antibiotics 
I found several differences in the prescribing recommendations for the most 
frequently prescribed antibiotics, benzylpenicillin and gentamicin. 
Benzylpenicillin and gentamicin are used as a first line for sepsis and were 
stated in four resources to be explicitly used for sepsis. The dosage regimen 
of benzylpenicillin reported in three out of these four resources was double 
that recommended by the National Institute for Health and Care Excellence 
(NICE) clinical guidelines for the treatment of early-onset sepsis/suspected 
sepsis at birth. One unit only had the same dose recommended by NICE, 
which is 25 mg/kg 12 hourly for neonates less than a week of age and 
increased to 8 hourly for neonates between 7 and 28 days (407).  
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The gentamicin starting dose for early-onset neonatal sepsis is 5mg/kg and 
repeated every 36 hours in which the interval can be shortened depending on 
the severity of the illness and the results of the blood culture as per NICE 
guidelines (407). Four obtained resources from the neonatal units have 
stated the use of gentamicin for sepsis with two of them indicating the 
starting dose of 5mg/kg as per NICE guidelines but with different dosing 
intervals depending on the neonatal age. All units have stated the use of 
gentamicin as a once daily dosage regimen, which is supported by the 
literature. The most recent Cochrane systematic review by Rao et al. 
conducted with the aim of comparing and safety of once-daily regimen to 
multiple dosage regimen of gentamicin in suspected or proven sepsis (408). 
This systematic review has supported the superiority of the ‘once-daily 
regimen’ of gentamicin compared to the ‘multiple daily regimen’ based on the 
pharmacokinetic profile. PK of gentamicin varies widely in neonates with a 
longer half-life and smaller clearance in preterm neonates compared to term 
ones (409). The general recommendation is to attain lower troughs and 
higher peaks to reduce the toxicity and achieve the efficacy. This can be 
attained by the ‘one dosage regimen’ with a high loading dose to increase the 
peak concentration (409). However, the review suggested the need for 
further studies that investigates the clinical safety and efficacy of gentamicin. 
Gentamicin is known to be nephrotoxic and ototoxic with severe toxicity seen 
after 7 to 10 days of use. Hence, a trough concentration level must be 
measured, which must be less than 2 mg/l to avoid the toxicity. All units have 
recommended trough levels of gentamicin to be measured and where stated 
the level was suggested to be < 2mg/l before commencing the next dose. 
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Cefotaxime is known to be used for late-onset sepsis (LOS) or meningitis in 
neonates. The participating units have listed the dosage regimen of 
cefotaxime for meningitis and severe infections. Only one resource stated the 
use of cefotaxime for LOS with a dose of 50mg/kg at different frequencies, 
according to GA. According to the NICE guidelines on neonatal infections, 
there is still uncertainty and lack of evidence-based guidelines to treat LOS 
(410). However, the BNFc stated the dose of cefotaxime for LOS as 25mg/kg 
at different frequencies, according to GA. The latest national surveillance 
from the UK indicated that 95-97% of isolated organisms from LOS blood 
samples were susceptible to gentamicin and flucloxacillin/ penicillin (411). 
Cefotaxime dosage regimen in neonatal meningitis and severe infections 
were stated in all units per the BNFc and National Institute for Health and 
Care Excellence (NICE) as 50mg/kg at different frequencies, according to 
GA.  
6.4.2 Caffeine  
The prescribing of caffeine as caffeine citrate with a loading dose of 20 mg/kg 
was standardised across sources. This loading dose is equivalent to the dose 
used in several studies across the literature, and it is the licensed loading 
dose as per the summary of product characteristics of caffeine citrate for the 
treatment of apnoea of prematurity (AOP) (203). Apnoea of prematurity, 
defined as a cessation of breathing for 20 seconds or longer or a shorter 
pause accompanied by bradycardia, cyanosis, or pallor in preterm neonates 
(194). The maintenance dose of caffeine citrate varied between units. One 
resource stated higher maintenance dosage regimen of caffeine of 10 mg 
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twice daily compared the other units stating the maintenance dose of caffeine 
as once daily. The BNFc stated that the maintenance dose of caffeine citrate 
up to 20mg/kg daily can be considered if therapeutic efficacy was not 
achieved, taking into consideration the toxicity levels (412). To date, 
inconsistencies in the dosage regimen for caffeine citrates still exist. A recent 
review by Moschino et al. summarised the available evidence about the 
different dosage regimen of caffeine citrate (192). Moschino et al. pointed out 
that based on the suggestions of the available evidence from recent 
systematic reviews, a higher dosage regimen of caffeine citrate may be 
better in improving neonatal outcomes which include reducing episodes of 
apnoea, extubating failure, and BPD at 36 weeks. However, higher rates of 
tachycardia were observed. The range of dosage regimen stated in the 
systematic reviews varied for the loading dose between 10 to 80 mg (or > 
20mg) and for the maintenance dose between 5 to 30 mg (or > 10mg) (413–
415). What is less clear is the long-term outcomes and safety data on the 
high dosage regimen of caffeine which may have led to the continual use of 
the standard dosage regimen of caffeine citrate (loading dose: 20 mg/kg, 
maintenance dose: 5-10 mg/kg). This dosage regimen has been used in one 
of the landmarks randomised controlled trials of caffeine when used in 
preterm neonates, which is the ‘Caffeine for Apnoea of Prematurity’ (CAP) 
(203). None of the resources indicated the duration of caffeine citrate when 
used in AOP, but one unit has stated that the treatment should be held for 
five days before the actual date of the discharge. This is done to allow for the 
continuous monitoring for the toxicity of caffeine as the half-life of caffeine in 
neonates is between 60-140 hours. All units highlighted the importance of 
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labelling and prescribing caffeine as caffeine citrate as this can avoid dosing 
errors. This is due to the fact that the dose of caffeine citrate is equivalent to 
twice that of caffeine when expressed as caffeine base (193).  
6.4.3 Pulmonary surfactants  
Pulmonary surfactants are vital in the management of neonates with RDS. 
There were three different animal-derived surfactant preparations licensed in 
Europe in 2016. Two are bovine minced pulmonary surfactant (beractant and 
bovactant), and one is porcine minced pulmonary surfactant (poractant alfa) 
(416). Evidence has shown that those preparations also differ in their clinical 
outcomes. Recent Cochrane Systematic review concluded that poractant alfa 
is associated with a better survival rate and improved pulmonary outcomes 
when compared with beractant (417). This could explain the use of poractant 
alfa as a surfactant and not beractant across the collected resources in the 
present study. The recent European Consensus guidelines on the 
management of RDS have recommended the use of poractant alfa as an 
initial dose of 200mg/kg as it is also found to be associated with better clinical 
outcomes when compared to the 100mg/kg of beractant or proactant alfa 
(416). However, there is uncertainty whether this advantage is related to the 
dose or the source of surfactant preparations. Despite the available evidence 
and recommendations, only one resource in the present study stated the 
initial dosage regimen of poractant alfa as 200mg/kg whereas others stated 
the initial dos as a range of 100-200mg/kg. A recent systematic review and 
meta-analysis by Foligno and Luca (2020) have compared the porcine and 
bovine surfactant therapy on extra-pulmonary outcomes (418). Interestingly, 
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this meta-analysis showed a lower risk of PDA with porcine preparation when 
compared with bovine preparation [12 studies; 1472 patients; OR: 0.655; 
95% CI: 0.460 to 0.931; p = 0.018]. No differences were observed in other 
extra-pulmonary outcomes. 
6.4.4 PDA drugs  
Generally, indomethacin and ibuprofen are used in preterm infant only as 
agents to close the PDA. This study demonstrates this consistency. Also, the 
dosing of ibuprofen was found to be similar in the collected resources and 
was given as three doses 24 hours apart. This dosage regimen is the 
recommended and licensed dose of ibuprofen to be used for PDA (45). The 
findings from the systematic review of ibuprofen adverse effects presented in 
this thesis (Chapter 5) also indicated that nearly all studies have used the 
same dosage regimen of ibuprofen in PDA. However, the doses of 
indomethacin varied across the units. This is was not unexpected as the 
dosage regimen of indomethacin when used in PDA differs widely across the 
literature (245). So, until a consensus regarding the optimal dose of 
indomethacin for PDA closure to be used, the variety in doses used across 
several drug formularies will remain. Paracetamol was used by most of the 
units as an analgesic rather than for PDA, despite the lack of evidence of 
using it as an analgesic and the latest evidence of using it for PDA as 
detailed in Chapter 4.  
6.4.5 Limitations of the presented study 
The study has captured a small number of drug information resources. Only 
eight units (with nine drug information resources) responded to the letter of 
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participation to the study out of approximately 195 neonatal units across the 
UK (22,23). This can affect the generalisability of the data and hinder, 
reaching a definite conclusion about the actual practice in neonatal unit 
settings. Even with such small numbers, I found inconsistencies in practice 
for the use of frequently used medicines. This is of particular note for those 
drugs that have a potential to cause harm if used inappropriately such as 
gentamicin and caffeine.  
In conclusion, despite the limitations of this study, this is an attempt to 
provide an initial overview of the available neonatal drug formularies and 
clinical practice guidelines in the UK. This initiative highlights the need to 
reach consensus in the prescribing information of some drugs (e.g., 
benzylpenicillin and caffeine), and reinforces the similarities of others (e.g., 
ibuprofen in PDA). Future implications of the findings are discussed in 
Chapter 7. 
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CHAPTER 7 DISCUSSION  
The main goal of this thesis was to assess the rational use of drugs in 
neonates admitted to neonatal units in the UK. This was done by exploring 
the patterns and quality of prescribing. To further explore the complexities of 
rational drug use in neonates, one example, i.e. patent ductus arteriosus 
(PDA) in preterm neonates was explored further. As a result, several findings 
of the work presented have emerged. I found some answers but in addition, 
my work has raised several questions that need to be addressed in future 
research. These are discussed at the end of each chapter. Here, I provide a 
summary of my findings and put them together to give a combined view 
obtained from the work and the wider implications of the findings.   
 Summary of findings 
The complexity of prescribing in neonates necessitates essential measures 
to ensure safe and effective use of drugs in neonates. Drug utilisation 
research is considered an explorative key tool used to investigate the 
patterns of drug prescribing and the extent to which the drugs are used. This, 
in turn, will provide an overall picture of the impact of guidelines' 
implementation and whether they can affect the prescribing behaviour of the 
clinicians. The up-to-date literature review detailed in chapter two of drug 
utilisation studies has highlighted the similarities and differences of drug 
prescribing patterns on a global scale. It has concluded that antibiotics 
remain the most frequently prescribed drugs globally and a need to 
rationalise the use of those agents worldwide due to the ongoing concerns of 
anti-microbial resistance. Also, this review found similarities of prescribing 
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patterns in some regions like Europe and highlighted a lack of drug utilisation 
studies in others such as Africa and China. The review also revealed the 
paucity of drug utilisation research in the UK with so far three studies 
conducted with limitations that hinder an overall conclusion of the prescribing 
patterns across neonatal units in the UK (28,29,63). These limitations 
triggered the need for the study described in Chapter 3, which explored the 
drug utilisation patterns across the neonatal units in England and Wales. This 
was done using a retrospective data analysis approach of a national 
database (NNRD). Several points were highlighted from this study that was 
either related to the drug use profile or the usefulness of the NNRD database 
in drug utilisation research.  
My findings support the evidence from two studies in the USA that similarly 
utilised large databases in investigating drug utilisation patterns in their 
NICUs (66,185). All have reported penicillin and gentamicin to be the most 
frequently prescribed drugs in their NICUs. Consistent with Clark et al., 
caffeine was amongst the most frequently prescribed drug in preterm 
neonates (gestational age (GA) < 37 weeks) and the most frequently 
prescribed drugs in low, very low and extremely low birth weight neonates. 
Drug use in preterm neonates is challenging due to the burden of co-
morbidities that lead to polypharmacy, consequently exposing them to a 
higher risk of adverse effects. I found a high burden of drug use with 
extremely preterm and very preterm neonates exposed to a median of 17 
and 8 unique drugs, respectively. Interestingly, I found a large group of 
neonates who were admitted to a neonatal unit but did not have records of 
having received drugs. These neonates were more mature and had a greater 
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BW at birth and had shorter length of stay compared to those who received 
drugs. This group has not been looked at previously.  
Drug use over time can undergo change and I found some interesting 
variations over the study period. Across the entire cohort, ranitidine, 
domperidone and ocular chloramphenicol use decreased while the use of 
benzylpenicillin, gentamicin, amikacin, and pulmonary surfactants increased.  
Some of these changes may be explained by the changing demographics of 
the population included in the NNRD – from 2010 to 2017 there is an 
increase in the number of term born neonates whose data are entered into 
the NNRD which may inflate the number of those who received drugs such 
as benzyl penicillin. The NNRD, a rich repository of real-life data, allows large 
national studies such as mine possible. However, it has some limitations and 
I have discussed them in detail in the chapter. 
In my exploration of drugs used for management of PDA in very and 
extremely preterm neonates, I found that ibuprofen was the most frequently 
used. However, a firm conclusion about paracetamol use in PDA could not 
be reached as NNRD data available to me did not allow me to make a direct 
linkage between the drugs and its indication for use. It is therefore possible 
that some use of paracetamol may be for its analgesic effect or its indication 
for preterm neonates for post-immunisation.   
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The popularity of ibuprofen compared to indomethacin is due to the evidence 
that ibuprofen is safer to use, However, this relative safety does not preclude 
the fact that it too has several adverse effects. My systematic review of 
ibuprofen adverse effects when used in preterm neonates with PDA captured 
all new and rare adverse effects that are usually found in observational 
studies rather than randomised trials. I found that half of the total reported 
adverse effects were in retrospective cohort studies. Although results of such 
studies should be interpreted with caution as they are more prone to bias, 
these large numbers of adverse effects are worthy of note.  
As a final step in my journey to explore rational drug use in neonates in the 
UK, I explored the current neonatal drug formularies and practice guidelines 
in the UK. Despite the descriptive nature of this study and the small number 
of the drug information resources I was able to access, the results are 
interesting. They revealed some inconsistencies in prescribing information 
most notably in those drugs which have the potential of causing harm such 
as gentamicin and caffeine. To continue the theme, I also looked at the drugs 
used in PDA. While the recommendations for ibuprofen were fairly uniform, 
indomethacin doses and regimens varied. The dosing regimen of 
paracetamol, interestingly, was listed for analgesic in most of the units. 
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 Implications of findings and caveats for future research 
This thesis has re-asserted the adage that 'it requires much to treat the too 
little'. The implications of my findings and the caveats for future research can 
be broadly described below.  
7.2.1 Towards a better understanding of drug utilisation research in 
neonates through the usage of large databases  
Drug utilisation research is an eclectic discipline that gathers quantitative and 
qualitative measures to answer specific questions about drug use in a 
healthcare setting. In the UK, such large studies can be conducted easily and 
at low cost by using the NNRD. However, there are some gaps that need to 
be filled to allow this. Firstly, the way in which prescribed drugs are recorded 
should be standardised so that clinicians can enter the drug names uniformly. 
Use of a standardised classification system of the drugs and diseases will 
allow aggregation of data and meaningful comparison and analysis at 
national and international levels. The most preferred system is the Anatomic 
Therapeutic Classification (ATC) as this system provides one unique code for 
each drug (419). The application of such a system in neonatal drug utilisation 
studies has been observed in several studies across the literature (5,420–
422). However, these studies were all prospective using primary data 
sources and hence laborious and expensive to replicate. Incorporation of 
such standardisation into databases such as the NNRD will facilitate DUR 
without the need for such resource-intensive prospective studies. A recent 
expert review published by Allegaert et al., reported that the application of 
this classification is possible in neonates with the availability of specific 
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indication for each drug (423). With this step, the data related to the drugs 
can be aggregated easily. Another system that can be used in the UK to 
facilitate unified coding of drug nomenclature is the use of an existed unified 
dictionary of drugs named the 'dictionary of medicines and devices (dm+d)' 
(424). This electronic dictionary of unified codes represents medicines and 
devices in use across the NHS in a consistent way to facilitate sharing of 
information pertaining to medicines and devices between organisations. This 
dictionary is contained within a widely used database in the UK, the Clinical 
Practice Research Database (CPRD), which contains data routinely recorded 
in primary care. Incorporating such a system into Badger.net, and hence into 
the NNRD, will aid clinicians in prescribing, sharing information, and 
facilitating the analysis process when used by researchers through those 
standardised codes (425). 
Another point that can be used to improve the NNRD for drug utilisation 
research purposes is having records of the timing of the drugs, dosage 
regimen and concurrent drugs used. This may be achieved by linking 
electronic prescribing software with NNRD platforms such as Badger.net. 
The availability of such information will allow for better evaluation and 
assessment of the adverse effects of the drugs, especially in preterm 
neonates, where polypharmacy exists.  
Record linkage to other electronic databases is another area that could be 
applied to improve the quality of the NNRD when used in DUR. For example, 
Hospital Episode Statistics (HES), as mentioned in Chapter 3, does not 
capture any neonatal drug information, but does captures some data items 
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related to a neonate's time in hospital that might be useful for record linkage 
to the NNRD. This includes NHS maternity statistics, such as data from the 
Maternity Service Data set (MSDS) (426) which captures records of each 
stage of the maternity service and have been updated lately to include more 
neonatal data items. Some of those are related to birth complications, 
admission and transfer dates, and diagnosis details. However, it must be 
noted that this data captures information in England only.  
My findings also suggest the importance of establishing neonatal networks in 
regions such as Africa and Middle East, in addition to those in Europe (e.g. 
Task Force in Europe for Drug Development for the Young (TEDDY)), with 
the aim of conducting drug utilisation research to evaluate the current 
prescribing practices, to develop and implement guidelines, and finally to 
monitor their success (10). This suggestion emerged as per the DUR review 
in Chapter 2, only two studies were found to be conducted in Africa; one 
aimed towards exploring most frequently prescribed antibiotics in Zimbabwe 
(132) whereas the other one was conducted to assess the prevalence of off-
label and unlicensed drugs in an Ethiopian NICU (140). This paucity of 
research in Africa, known to have the highest neonatal mortality rate warrants 
further research to explore the pattern of drug use across their NICUs. 
Similarly, the paucity of drug utilisation studies in the Middle East was found 
in Chapter 2 prompting such networks or research groups to be established.  
Another point to note is that I was unable to include data from Scotland and 
Northern Ireland. While the data from Scotland were not available to me due 
to research governance rules, data from Northern Ireland is not included in 
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the NNRD. Also, an additional problem with the current NNRD is that some 
neonates are transferred between the UK nations for the purpose of receiving 
care in different units and this may result in incomplete records of their care 
in the current database.  Any further study claiming to be representative of all 
of the UK needs to take data from devolved nations into consideration, and 
research governance around access to these data should be streamlined.   
Some interesting clinical questions also arise from my work. My findings re-
iterate the need for improvement in prescribing practices to tackle the high 
usage of antibiotics across different neonatal settings worldwide. Neonatal 
sepsis and other severe infections contribute to large numbers of neonatal 
morbidity and mortality (9). This somewhat justifies the high use of antibiotics 
in but there remains a need to establish some measures to rationalise 
antibiotics use to avoid unnecessary drug exposure to vulnerable neonates. 
The results of my NNRD data analysis and systematic review of global DUR 
both show that antibiotics are, by far, the largest group of drugs given to 
neonates. Turner et al. (28) highlighted gaps in knowledge of therapeutic 
treatment of bacterial sepsis, and further work might be useful in this area. 
There should be an attempt to investigate and monitor the management of 
sepsis and implement strategies to reduce irrational use. Several strategies 
can be implemented, such as anti-microbial stewardship to promote safe and 
effective use of antibiotics and reduce possible anti-microbial resistance (10). 
These programs should focus on education, continuous monitoring of the 
current prescribing and resistance patterns, and antibiotics surveillance to 
promote the use of antibiotics (4,9,78).  
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Another area for future research is expanding the use of surfactants. My 
analyses miss out surfactant use in the delivery suite. In addition, more 
recently, new methods of administering surfactant such as the least invasive 
surfactant administration have become popular and such details should be 
recorded and analysed.  
The rational use of caffeine in very and extremely preterm neonates also 
needs attention. Caffeine was entered in three different ways in the 
database; caffeine, caffeine base, and caffeine citrate. This is concerning, 
from a pharmacology point of view, caffeine base and citrate differ greatly in 
terms of their dosage, prompting warnings from the Medicine and Healthcare 
Products Regulatory Agency (MHRA) (193). Caffeine use should, therefore, 
be standardised and monitored to avoid unintended adverse effects.  
In research, especially drug utilisation studies, combining both quantitative 
and qualitative methods, complement each other and enhance the 
interpretation of the findings. Providing an in-depth understanding of 
clinicians' prescribing behaviour in neonatal medicine is vital, as prescribing 
in this population is not only guided by rational decisions but also 
psychosocial factors (7,427). This area is rarely explored in drug utilisation 
research in neonates, and there is scope for qualitative research, including 
methods such as focus group discussions, open-ended questionnaires, and 
in-depth interviews to explore these.  
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7.2.2 Pharmacological management of PDA: Room for improvement 
Taken together, my findings from studies in Chapters 4, 5, and 6 suggest a 
need for continued research in PDA therapeutics. Ibuprofen is the preferred 
agents across neonatal units. I was unable to explore whether the use was 
as a treatment or prophylactic, or if it was guided by ECHO. Using ibuprofen 
prophylactically is not recommended (55–58,428) due to the increased risk of 
adverse effects without any benefit in long term outcomes. The patterns of 
paracetamol prescribing in PDA could also be analysed in more details if 
linkage between the drugs, and their indications was available. 
The systematic review of adverse effects of ibuprofen highlighted in an 
analytical and quantitative method all the adverse effects of this drug when 
used in PDA highlighting the need to continue to monitor drug use and the 
search of alternatives with fewer side effects and trials comparing treatment 
with no treatment and/or placebo. Further systematic reviews of ibuprofen 
adverse effects, which take stratification according to different gestational 
age groups into account, will provide a full picture of ibuprofen adverse 
effects and will aid neonatologists to weigh the risks and benefits before 
prescribing ibuprofen.  
Another future area of research is the causality assessment of adverse 
effects in neonates. Surprisingly, none of the studies included in this review 
has assessed the causality of the adverse effects reported. Assessing the 
causality of adverse effects in neonates is an ongoing challenge, especially 
in premature ones. This is due to the difficulty in differentiating the 'true' 
adverse effects from the confounding variables (e.g. organ dysfunction and 
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immaturity) in such sub-population of neonates. A new validated algorithm 
consisting of 13 scored items have been suggested to detect ADRs in 
neonatal population by Du et al. which may be reliable and tailored to 
neonates as compared to Naranjo algorithm (268,429). Although not yet 
tested in a larger neonatal population, the adaptation of such an algorithm in 
future neonatal studies would be beneficial.   
Research questions that could be asked include the factors that affect the 
response of preterm neonates with PDA to cyclooxygenase (COX) inhibitors, 
including ibuprofen. There are several predicting factors highlighted in the 
literature that affect PDA response to COX inhibitors (256) such as 
gestational age and birth weight, antenatal glucocorticoids, respiratory 
distress syndrome, and infections. However, there are no large multi-centre 
trials that address this to help avoid unnecessary pharmacological treatment 
(256). With the emergence of the perception that paracetamol may be as 
effective as ibuprofen in PDA management in a recent Cochrane review 
(244), a further systematic review with more focus on adverse effects of 
paracetamol is suggested as a future area for research.  
7.2.3 Neonatal formularies 
Finally, the findings in Chapter 6 has shown inconsistencies in the 
recommended dosage regimens of indomethacin and paracetamol when 
used in PDA in the drug information resources. There is a need to reach a 
consensus in terms of dosage regimen of those agents. This can be possibly 
addressed by using randomised trial or consensus and expert opinion such 
as the Delphi method (430). Even with the small numbers available to me, I 
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found important inconsistencies in prescribing recommendations highlighting 
the need for a rational prescribing tool for neonates. A larger, more 
comprehensive review of neonatal formularies could help gather more 
information to support this. Several tools have been developed for 
inappropriate prescribing in the elderly population (431). The fact that many 
tools have been designed for the elderly is due to the burden of comorbidities 
and polypharmacy in this population (395), characteristics that the elderly, 
rather interestingly, share with preterm neonates. There are few tools to 
detect inappropriate prescribing in paediatrics and none in neonates 
(432,433). A large body of work, including evidence synthesis incorporated 
into consensus building with the Delphi technique, will be needed to tackle 
this difficult but essential task. A national, or ideally, international 
collaboration is required to do this. A summary of all those discussed caveats 
for future research that came to light following the findings of this thesis is 
shown in Figure 86.




Figure 86. Summary of the caveats for future research emerged from this thesis 
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CHAPTER 9 APPENDICES 
 Copy of the published paper: Review of drug utilisation 
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 Search strategy for drug utilisation review  
Database  
(Total hits 715) 
Search terms Combination of search terms 
(A combination between title abstract free text keywords and Mesh terms 
was done for a compressive search from the inception of the database to 
July 2020 using OR , AND) 
EMBASE 
(provided by Ovid) 
 
From 1974 to  July 
2020   
 
Number of hits 
320 
Population search terms:  
Free text words:  
Infant*-newborn*-neonate* 
MeSH terms:  
INFANT-NEWBORN 
Drug utilisation search terms: 
Free text words:  




Setting search terms: 
Free text words:  
neonatal intensive care unit*-
neonatal unit* 
MeSH terms:  
NEWBORN INTENSIVE CARE- 
NEONATAL INTENSIVE CARE 
UNIT 
~"(((infant*).ti,ab OR (newborn*).ti,ab OR (neonate*).ti,ab OR *INFANT/ OR exp 
INFANT/ OR *NEWBORN/) AND (("drug use").ti,ab OR ("drug utili?ation").ti,ab OR 
*"DRUG UTILIZATION"/ OR exp "DRUG UTILIZATION"/ OR *"DRUG USE"/ OR 
exp "DRUG USE"/)) AND (*"NEWBORN INTENSIVE CARE"/ OR *"NEONATAL 






Population search terms:  
Free text words:  
Infant*-newborn*-neonate* 
MeSH terms:  
INFANT-INFANT, NEWBORN 
~"(((infant*).ti,ab OR (neonate*).ti,ab OR (newborn*).ti,ab OR *INFANT/ OR exp 
INFANT/ OR *"INFANT, NEWBORN"/ OR exp "INFANT, NEWBORN"/) AND 
(("drug use").ti,ab OR (drug utili?ation).ti,ab OR *"DRUG UTILIZATION"/ OR exp 
"DRUG UTILIZATION"/ OR *"DRUG UTILIZATION REVIEW"/ OR exp "DRUG 
UTILIZATION REVIEW"/)) AND ((neonatal intensive care unit*).ti,ab OR (neonatal 
unit*).ti,ab OR *"INTENSIVE CARE UNITS, NEONATAL"/ OR exp "INTENSIVE 
CARE UNITS, NEONATAL"/)" 
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From 1946 to July 
2020   
 
Number of hits 
292 
Drug utilisation search terms: 
Free text words:  
“drug use”- drug utili?ation 
MeSH terms: 
DRUG UTILISATION 
Setting search terms: 
Free text words:  
neonatal intensive care unit*-
neonatal unit* 
MeSH terms:  
Care,neonatal intensive- intensive 
care units,neonatal 
infant,newborn,intensive care-
neonatal intensive care-neonatal 





From 1937 to July 
2020 
 
Number of hits 
103 
Population search terms:  
Free text words:  
Infant*-newborn*-neonate* 
MeSH terms:  
INFANT- INFANT,NEWBORN 
Drug utilisation search terms: 
Free text words:  
“drug useinfa”- drug utili?ation 
MeSH terms: 
DRUG UTILIZATION 
Setting search terms: 
Free text words:  
neonatal intensive care unit*-
neonatal unit* 
MeSH terms:  
INTENSIVE CARE 
UNITS,NEONATAL 
Combination of search terms 
(A combination between title abstract key words, and Mesh terms was done for a 
compressive search from inception of the database to February 2019 using OR , 
AND) 
~"(((infant*).ti,ab OR (newborn*).ti,ab OR (neonate*).ti,ab OR *INFANT/ OR exp 
INFANT/ OR *"INFANT, NEWBORN"/ OR exp "INFANT, NEWBORN"/) AND 
(("drug use").ti,ab OR (drug utili?ation).ti,ab OR *"DRUG UTILIZATION"/)) AND 
((neonatal unit*).ti,ab OR (neonatal intensive care unit*).ti,ab OR *"INTENSIVE 
CARE UNITS, NEONATAL"/ OR exp "INTENSIVE CARE UNITS, NEONATAL"/)" 
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 Description of drug utilisation studies on drug use in general (60 studies studies) 
Studies of drug utilisation in Europe (27 studies) 
Study ID Study period 
 
Inclusion and exclusion criteria Number of 
neonates 
(%female) 
Gestation age (weeks) 
















Inclusion: All admitted neonates 
Exclusion: Fluids and electrolytes, 





GA (mean, range): 
33.3, 26-36 










Inclusion: All admitted neonates 
Exclusion: Not stated 
N=34 
(not stated) 







Inclusion: All admitted neonates 
receiving drugs 













Inclusion: All admitted neonates 
with at least one drug 
Exclusion: Not stated 
N=126 
(not stated) 
GA (median, range): 
31, 23-36 











Inclusion: All admitted neonates 
with at least one drug 
Exclusion: Not stated 
N=220 
(41%) 











Inclusion: All admitted neonates 








Not stated Not stated 
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Exclusion: Died within first 48 
hours after birth 
26 (22-33) 




Oct-Dec 2003 Inclusion: All admitted neonates 
Exclusion: Not stated 
N=48 
(not stated) 










Not stated N=52 
(48%) 
GA: 0-48 days 
BW (range): 550-3920 









Inclusion: Admitted neonates with 
at least one drug 
Exclusion: Not stated 
N=48 
(41%) 
GA (mean (SD)): 
34.5 (4.2) 










Inclusion: All admitted neonates 
Exclusion: Blood products, TPN, 
fluids and oxygen 
N=84 
(38%) 










Inclusion: All neonates with first 
prescription before 28th day of life 
and at least one electronic 
medical prescription 
Exclusion: No prescriptions, or 
none in first 28 days 
N=27382 
(55%) 
GA (mean (SD)): 
35.4 (4.3) 













Inclusion: Premature neonates 
with a need of intubation and 
mechanical ventilation 




GA (mean (SD)): 
27.2 (1.2) 
BW (mean (SD)): 
970 (145) 
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(96) Exclusion: TPN, IV fluids, oxygen 












Inclusion: All admitted neonates 
with at least one drug 
Exclusion: Blood products, 
oxygen, enteral and parenteral 




GA (median (IQR)): 
34 (31-37) 
BW (median (IQR)): 











Inclusion: All admitted neonates 
Exclusion: Blood products, TPN, 
oxygen therapy, IV fluids 
N=64 
(50%) 








Not stated N=4054 
(45%) 
GA (median, range): 
32 ,23+6 - 42 +2 
BW (median, range): 
1800, 360 -5400) 








Inclusion: All admitted neonates 
Exclusion: Electrolytes, TPN, 
vaccines, dermatological 
products, contrast media 
N=1491 
(48%) 
GA (median, IQR):  
32+5, 29+6 to 37+6 













Inclusion: All neonates with 
GA<32 




GA (mean (SD)): 
26.9 (1.65) 
BW (mean (SD)): 
930 (253) 





Oct 2005  
(11 months) 
Inclusion: All admitted neonates 
for > 24 hours 
Exclusion: IV infusions (glucose 
or chloride), TPN and oxygen 
N=183 
(44%) 
GA (mean (SD)): 
33.6 (4.66) 
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Inclusion: All admitted neonates 
Exclusion: IV fluids, flushes of 
sodium chloride 0.9% or heparin, 
blood products (other than 
albumin) and oxygen  
N=70 
(not stated) 
GA of preterm only 









Dec 2007-  
Apr 2008 
 
Inclusion: All admitted neonates 
Exclusion: Blood products, IV 
fluids, TPN 
Not stated Not stated Not stated Not stated 






Inclusion: All admitted neonates 





GA (mean (SD)): 
35 (5) 
BW (median (IQR)): 











Inclusion: All admitted neonates 
Exclusion: Oxygen, IV fluids and 
flushes, drugs used in surgeries, 
contrast agents, vaccines, blood 
products (except albumin and 
immunoglobulins), basic creams, 
research drugs  
N=218 
(45%) 
GA (mean (SD)): 
36.07 (4.0) 














Inclusion: All admitted neonates 
Exclusion: IV fluids, blood 
products, oxygen, nutritional and 
technical products, basic creams 




GA: Not stated 




4 (2-7, 27) 
Median (IQR): 
10 (5-18.75) 
Slovak Republic (one study) 







Inclusion: All admitted neonates 
Exclusion: IV replacement 
solutions, TPN, vaccines, blood 
products and oxygen 
N=202 
(49%) 
GA (mean (SD)): 
36 (3.4) 













Inclusion: All admitted neonates 
Exclusion: Standard IV solutions, 
sodium chloride 0.9% infusions, 
TPN, blood products (except 
albumin), and oxygen 
N=93 
(not stated) 
GA (mean (SD)): 
32.5 (4.7) 












Jan–Jun 2012 Inclusion: All neonates in 
neonatal unit receiving 
prescription on the day (at 8 AM) 
Exclusion: Blood products, 
glucose and electrolyte solutions, 
vaccines, nursery care topical 
agents, herbal medicines and 




GA (median, (IQR)): 
34 (30–38) 
BW (median, (IQR)): 
1993 (1356–3006) 
Not stated Not stated 
Studies of drug utilisation in Middle East (2 studies) 






Inclusion: All admitted neonates 
Exclusion: Saline, heparin flush, 
blood transfusions, and oxygen 
N=105 
(not stated) 











Inclusion: All admitted neonates 
Exclusion: TPN, blood products, 
fluids, oxygen therapy, nasal 
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Studies of drug utilisation in North America (12 studies) 














Inclusion: All admitted neonates 
for > 24 hour 
Exclusion: Vitamin K and topical 
products (silver nitrate) 
N=2690 
(43%) 
GA: Not stated 











Inclusion: All neonates in 
database 
Exclusion: Not stated 
N=253651 
(44%) 
GA (median, IQR): 
35 (33-38) 
BW (median, IQR): 
2460 (1790-3200) 














Inclusion: All admitted neonates 
with at least one drug 
Exclusion: TPN, oxygen, vitamin 
K prophylaxis, erythromycin 
ophthalmic prophylaxis, routine 
cord care, vaccinations, blood 















































Inclusion: All admitted neonates 
with at least one drug 
N=6839 
(46%) 
GA (mean (SD)): 
35 (5) 
BW (mean (SD)): 
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 Exclusion: Blood and blood 
products (except fresh frozen 
plasma), TPN, oxygen, vitamin K 
prophylaxis, erythromycin 
ophthalmic prophylaxis, routine 
cord care, vaccinations, normal 










Inclusion: All admitted neonates 
Exclusion: TPN, nutritional 
supplements such as vitamins, 
standard IV fluids, immunizations, 
and research drugs 
N=2304 
(43%) 
GA (mean (SD)): 
34.1 (4.6) 
















Inclusion: All admitted neonates 
Exclusion: After a day of life 120, 
and all vitamins (except vitamin 
A), nutritional supplements, 




GA (median, IQR): 
35 (33-38) 
BW (median, IQR): 



















Inclusion: All VLBW  
Exclusion: Volume boluses, blood 




GA (median, IQR): 
28 (26-30) 













Inclusion: 22–24 week admitted 
to NICU  
Exclusion: Missing or incomplete 
discharge data or discharge 
home at GA < 32 weeks. All 
nutritional supplements, vitamins 
(except Vitamin A), vaccines, eye 
drops and topical 
N=7578 
(47%) 
GA: Not stated 




13 (8, 18) 
Median (IQR): 
91 days (7, 
119) 
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Inclusion: All admitted neonates 
Exclusion: Drugs for routine 




GA (mean (SD)): 
36.4 (0.25) 














Jul1974 –  
Feb 1975 
Second period: 
Feb 1977– Nov 
1977 
Inclusion: All admitted neonates 
Exclusion: Vitamin K, ophthalmic 
preparations, fluids and 
electrolytes, IV amino 
acids/intralipids and/or glucose 
(except if for neonatal 
hypoglycaemia, phototherapy   
and oxygen 
Not stated First period: 
GA (mean (SD)): 
36.9 (0.2); 
BW (mean (SD)):  
2612 (51) 
Second period: 
GA (mean (SD)): 
36.42 (0.25); 























Inclusion: All admitted neonates 




Not stated 5.7 Not stated 
Studies of drug utilisation in Asia (11 studies) 
China (one study) 
Yue 2020          
(106)     
Mar-Apr 2018 Inclusion: All inpatients 
Exclusion: IV solutions (0.9% 
sodium chloride, 5% / 10% 
glucose, sterile solution for 
injection), blood products (except 
albumin), 1% silver nitrate eye 
drops, parenteral nutrition, 
heparin for venous access, 
oxygen, electrolytes (calcium 
gluconate, sodium bicarbonate, 




GA (mean (SD)): 
35.8 (3.9) 




3 (1, 5.5) 
median (IQR): 
5 (3-10) 
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Inclusion: All admitted neonates 
Exclusion: Not stated 
N=176 
(37%) 
GA: not stated 









Not stated N=100 
(not stated) 






Feb 2014  
(one year) 
 
Inclusion: All admitted neonates 
Exclusion: Discharged or die 




GA (mean (SD)) in days: 
3.36 (4.16) 
BW (mean (SD)):  
2160 (600) 







Not stated N=528 
(39%) 
GA (mean (SD)): 
35 (3) 














Inclusion: All admitted neonates 
with at least one drug 
Exclusion: Blood, blood products, 
vitamin K prophylaxis, 
prophylactic ophthalmic 
treatment, vaccines or IV fluids 
N=460 
(41%) 
GA (median, range) in 
days: 
1,1-27 












Inclusion: All admitted neonates 
Exclusion: IV fluids, parenteral 
nutrition, nutritional supplements, 
blood and blood products, 


















Inclusion: All admitted neonates 
Exclusion: IV fluids, TPN, routine 
oral nutritional supplements, 
vaccines, vitamin K, topical 




GA (mean (SD)): 
34 (2.75) 
















Not stated N=70 
(39%) 
GA (mean (SD)):  
35 (3.14) 
BW mean (SD)):  
2200 (730) 








Inclusion: All admitted neonates 
Exclusion: IV fluids, vaccines, 




















Inclusion: All admitted neonates 
Exclusion: Topical medication, 




GA (median, range): 
33, 26-35 







Studies of drug utilisation in Latin America and Caribbean (6 studies) 










Not stated N=827 
(not stated) 
Addressed drug 
utilisation in neonates 
with different birth 
weight 
Group a (<1000 g) 
Group b (1000-1499 g) 
Group c (1500 to 2499) 




Group b: 6 
Group c: 1.7 
Group d: 1.2 
Not stated 







Inclusion: All admitted neonates 
Exclusion: Blood and blood 
products, parenteral nutrition, 
oxygen and other gases, vitamin 












Inclusion: All admitted neonates > 
24 hours 
Exclusion: sodium chloride, 5 % 
glucose, blood products (except 
albumin), heparin for venous 
access, vaccines, phytonadione, 
1 % silver nitrate eye drops, TPN, 
















De Souza Jr 
2016 
(108) 




Inclusion: Neonates with 
electronic records of > 24 hours 
with drug 
Exclusion: Neonates with 
incomplete clinical data, 
prescriptions or prescriptions 
containing only vaccines, blood 
products, TPN, silver nitrate eye 
drops or IM administration of 
phytonadione in the delivery 
room, or IV fluids 
N=192 
(50%) 
GA (mean (SD)): 
 33.3 (4.3) 







De Lima Costa 
 2018 
(82) 
Aug 2015-  
Jul 2016 
 
Inclusion: All admitted neonates 
Exclusion: TPN, IV fluids, oxygen, 
blood products or electrolytes 
N=220 
(46%) 
GA (mean (SD)):  
32.4 (4.4) 













Inclusion: Not stated 
Exclusion: Compounded 
preparations made by local 
division of neonatology and drugs 
Not stated Not stated Not stated Not stated 
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donated or acquired by family 
members 
Studies of drug utilisation in Australasia (two studies) 








Inclusion: All admitted neonates 
Exclusion: IV glucose, TPN, 
oxygen, blood products, sodium 




GA (mean (SD)): 
34 (0.6) 
















Inclusion: All admitted neonates 
Exclusion: TPN, IV fluids, oxygen, 
and research drugs 
N=97 
(not stated) 
GA (median, range):  
31, 22.7-41.1 
BW (median, range): 
1560, 414- 4790 
Not stated Not stated 
BW, birthweight; GA, gestation age; SD, standard deviation; TPN, total parenteral nutrition 
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Amikacin     √ √       √   √ √   √  √ √     
Amoxicillin          √       √       √  √  
Ampicillin  √   √      √ √ √   √  √ √ √ √ √ √  √   
Ampicillin- 
Sulbactam  
    √  √            √      √ √ 
Benzyl-
penicillin 
 √    √   √  √  √ √         √  √ √ 
Cefixime       √                    
Cefotaxime    √            √    √     √  
Ceftazidime       √                    
Flucloxacillin  √                         
Gentamicin √ √  √  √ √   √ √  √ √ √  √ √ √ √   √ √ √ √ 
Meropenem     √       √               
Netilmicin            √       √        
Penicillin            √               
Piperacillin √       √                   





                    √      
Rifamycin                √         √  
Tobramycin √  √  √   √               √    
Vancomycin     √       √       √ √       
Analgesics 
Fentanyl           √ √        √ √ √ √     
Morphine   √           √ √    √     √    
Paracetamol       √    √     √  √     √  √  
Piritramide         √                   
Antifungals 
Clotrimazole                 √ √         
Fluconazole          √         √  √ √     
Ketocon-
azole 
                √          
Nystatin   √         √               
Antimuscarinics 
Atropine                      √     
Cyclo-
pentolate 
             √             
Cardiovascular agents 
Dobutamine        √  √                 
Dopamine                    √       
Furosemide √ √  √    √  √ √    √   √  √ √ √     
Heparin          √ √                




                    √      
Spirono-
lactone 
   √                 √      
Corticosteroids 
Budesonide       √                    
Methyl-
prednisolone 
                   √       
Other 
steriods 
      √                    
Electrolytes and minerals 
Calcium 
gluconate 
                       √   
Calcium 
(oral) 
                       √   
Ferrous 
fumarate 
        √                  
Ferrous 
sulphate 




                 √       √  
Endocrine agents 
Methimazole        √                   
Pyridoxine                 √   √       
Gastro-intestinal agents 
Domperidone         √                  
Ranitidine     √                      
Simeticone          √ √                
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Neurological agents 
Midazolam           √         √       
Pheno-
barbital 




√                          
Caffeine 
citrate*** 




  √        √                
Surfactant        √     √  √       √ √    
Theophylline    √    √    √               
Vitamins and supplements 
Calcifediol                      √     
Calcitriol                     √ √     
Chole-
calciferol 
                √ √     √    
Citicoline √                          
Folic acid  √               √          
Multi-
vitamins 




    √          √           √ 
Vitamin D3 
and E 
  √      √                  
Vitamin K √ √    √  √ √     √  √ √      √  √ √ 
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Vitamin D                         √ √ 
Others 
Albumin  √                         
Anti-
diarrhoeal  
                √          
Calcium 
folinate 
    √    √       √           
Carnitine    √                       
Chlor-
hexidine 
             √             
Dextriferrone          √                 





         √                 
Octeniding 
wash 
             √             
Phenyl-
ephrine 
             √             
Sodium 
chloride 
        √                  
*group A: neonates with birth weight < 1000g 
**group B: neonates with birth weight 1000-1500 grams 
***some studies reported it as caffeine only 
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Ampicillin √ √ √ √ √ √   √ √ √ √ 
Cefotaxime      √ √ √ √    
Chloramphenicol   √          
Gentamicin √ √ √ √ √ √    √ √ √ 
Kanamycin √  √ √         
Penicillin √ √ √ √ √        
Vancomycin      √ √ √ √  √ √ 
Analgesics 
Fentanyl        √  √ √ √ 
Cardiovascular agents 
Aldactone         √    
Dobutamine       √ √     
Dopamine  √       √ √ √ √ 
Epinephrine  √           
Furosemide √ √ √ √  √    √ √  
Heparin     √     √   
Indomethacin       √ √  √  √ 
Corticosteroids 
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Dexamethasone       √      
Hydrocortisone            √ 
Electrolytes and minerals 
Calcium 
gluconate 
√ √ √ √         
Calcium     √        
Electrolytes     √        
Potassium 
chloride 
    √        
Sodium chloride     √        
Gastro-intestinal agents 
Metoclopramide      √ √ √     
Neurological agents 
Midazolam           √  
Phenobarbital  √     √ √     
Respiratory agents 
Aminophylline       √      
Caffeine citrate*       √  √ √ √ √ √ 
Surfactant      √ √ √ √ √ √ √ 
theophylline       √ √ √    
Anti-fungal 
Fluconazole            √ 
Vitamins and supplements 
Ferrous sulphate      √       
Iron   √ √     √    
Multivitamins √  √ √  √       




    √        
Vitamin K  √            
Others 
Erythropoietin          √   
Fresh frozen 
plasma 
    √        
Fat supplement    √         
Glycerine √            
Naloxone  √           
Plasma protein          √    
Sodium 
bicarbonate 
√ √ √ √         
*some studies reported caffeine instead of caffeine citrate 
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Ampicillin     √  
Amikacin  √ √  √  
Ampicillin/sulbactam   √    
Antibiotics √   √   
Ceftriaxone  √   √  
Ceftazidime     √  
Cefotaxime   √    
Gentamicin   √  √  
Metronidazole   √    
Cefoperazone-
sulbactam 
     √ 
Pipracillin/tazobactam      √ 
Analgesics 
Paracetamol     √  
Pentazocin    √   
Anti-Fungals 
Fluconazole      √ 
Cardiovascular agents 
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Adrenaline   √    
Captopril     √  
Furosemide      √ 
Electrolytes and minerals 
Calcium gluconate   √    
Neurological agents 
Phenobarbitone  √ √ √ √  
Phenytoin    √ √  
Respiratory agents 
Aminophylline  √  √ √  
Caffeine      √ 
Vitamins and supplements 
Vitamin K √ √ √ √  √ 
Vitamin AD      √ 
Others 
carnitine   √    
IV fluids √      
Others    √   
Hepatitis B vaccine      √ 
Endocrine agents 
levothyroxine      √ 
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Amikacin √ √ √ √ √   
Ampicillin √ √ √ √ √  √ 
Gentamicin     √ √ √ 
Vancomycin √    √  √ 
Analgesics  
Fentanyl    √ √ √ √ 
Morphine     √   
Metamizole    √    
Paracetamol     √   
Cardiovascular agents  
Dobutamine       √ 
Furosemide √   √    
Heparin       √ 
Indomethacin  √      
Gastro-intestinal drugs 
Domperidone   √     
Gastrointestinal 
drugs  
√ √      
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Ranitidine   √     
Neurological agents  
Midazolam    √    
Phenobarbital     √   
Aminophylline √ √     √ 
Caffeine √ √ √     
Surfactant √ √ √     
Vitamins and supplements  
Folinic acid       √ 
Multivitamins     √ √ √ 
Vitamin K        √ 
Glycerine     √   
Filgrastim √       
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 Description of drug utilisation on antibiotics only (11 studies) 
Study ID Study period 
 









Number of drugs 
prescribed per 
neonate 
Asia -India (four studies) 
Gandra 2018  
(128) 
Feb 2016-Feb 2017 
(one year) 
Inclusion: All admitted 
neonates with active 
antimicrobial prescriptions 
Exclusion: Not stated 
N=403  
(32%) 
GA (median, IQR): 
34.5 (31-38) 





Apr 2008-Mar 2010 (3 
years) 
Inclusion: Neonates with 
sepsis 












Oct 2011- Sept 2012 Inclusion: Neonates with 
sepsis 
Exclusion: Discharged or 
transferred to other hospital 
or died within 2 days in NICU 
N= 84  
(29%) 
GA: Not stated 
BW (mean (SD)): 
2000 (620) 
Not stated 
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Subash 2015  
(131) 
Feb-Apr 2013 Inclusion: Neonates with 
suspected or confirmed 
sepsis 
Exclusion: Neonates with 
surgical problems, major 
congenital malformations, on 
antibiotics or those whose 
mothers received antibiotics 
before delivery 
N= Not stated 
(42%) 
Not stated Not stated 
Latin America and Caribbean-Trinidad and Tobago (one study) 
Hariharan 2013 
(125) 
Sept-Nov 2008 Inclusion: All neonates 
receiving antimicrobials 




GA: < 40 days 




Latin America and Caribbean-Chile (one study) 
Jimenez 2017 
(126) 
Four years Inclusion: All neonates 
admitted within study period 
Exclusion: Not stated 
N=5,619 
(46.5%) 
GA (mean (SD)): 
36.2 (3.6) 
BW: Not stated 
Not stated 
North America-USA (two studies) 
Cantey 2015 
 (127) 
Oct 2011-Nov 2012  
(4 months) 
Inclusion: All neonates 
admitted to NICU 
Exclusion: Not stated 
N1 
(retrospective 




period) = 1014 
(43%) 
Retrospective: 
GA (median, IQR): 
38 (34.5-39.4) 
BW (median, IQR): 
2860 (2145-3457) 
Prospective: 
GA (median, IQR): 
37.4 (34.1-39.1) 








Aug 1999 -Feb 2000 Inclusion: Neonates admitted 
at NICU at each participating 
hospital on study dates 
Exclusion: Not stated 
N=1580 
(45%) 
Not stated Median (range): 
2 (1-5) 




Oct 2012–Jun 2013 
(33 months) 
Inclusion: <16 years (data on 
neonates reported separately) 
received at least one 
antimicrobials 
Exclusion: Antimicrobial by 




Not stated Not stated 




May–Nov 2018 Inclusion: All admitted 
neonates 
Exclusion: Not stated 
N=459 
(49%) 
GA: Not stated 
BW (median, (IQR)): 
2800 (2–3.4) 
Not stated 







Inclusion: Neonatal or 
paediatric ICU admissions, 
had antimicrobial for 
>24hours 




Not stated Not stated 
BW, birthweight; GA, gestation age; NICU; neonatal intensive care unit; SD; standard deviation 
 
Page | 438  
 
 Description of drug utilisation on off-label and/unlicensed drugs only (six studies) 









Number of drugs 
prescribed per  
neonate 
Europe- Spain (one study)  
Casan 2017 
(139) 
Nov 2015-Feb 2016 Inclusion: All admitted neonates  
Exclusion: Crystalloid fluids, 
plasma-expanding serums 
(except for albumin), TPN, 




GA (mean (SD)): 
35.9 (4.22) 










Inclusion: All admitted neonates 
Exclusion: Not stated 
N=38 
(53%) 
Not stated Not stated 
Asia-India (one study) 
Jain 2014  
(435) 
Jun-Aug 2009 Inclusion: All neonates in NICU 
for >6 hours and had any drug 
Exclusion: Nutritional 
supplements, IV fluids, 
inotropes, vaccines, vitamin K, 
topical anaesthetic cream, fluid 
or heparin for flushing lines, 
oxygen and blood products 
N=156 
(not stated) 
GA (median, IQR): 
32 (30-35) 
BW (median, IQR): 
1348 ,1076 - 1800 
Median (IQR): 
6 (1-6) 





Inclusion: Neonates admitted for 
at least 24 hours received at 
least one drug 
Exclusion: Oxygen therapy, 
vaccines, blood products (except 
N=193 
(41%) 
GA (mean (SD)): 
34 (4.4) 
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immunoglobulin), vitamins, 
electrolytes, TPN, and IV 
hydration 
Middle East-Saudi Arabia (one study)  




Inclusion: All admitted neonates 
for minimum of 24 hours and 
prescribed at least one drug 
N=138 
(48%) 
GA (median, IQR): 
35 (35-39) 
BW: Not stated 
Mean (SD): 
3.5 (2.3) 




Mar–Apr 2019 Inclusion: Admitted for at least 
24 hours; prescribed at least one 
drug 
Exclusion: Oxygen therapy,PN, 
blood products, antiseptics, 
vaccines and IV fluid (normal 




GA: Not stated 




BW, birthweight; GA, gestation age; IV; intravenous; NICU; neonatal intensive care unit; SD; standard deviation 
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 Description of studies on specific pharmacologic groups only (seven studies) 









Number of drugs 
prescribed per  
neonate 
North America -USA (one study)- Antiepileptics   
Ahmad 2017 
(436) 
Jan 2005-Dec 2014 Inclusion: All neonates with 
data entered with diagnosis of 
seizure or seizure disorder 
and received one of following: 
phenobarbital, phenytoin/ 
levetiracetam, topiramate, 
lidocaine or carbamazepine 
Exclusion: Benzodiazepine as 
used for sedation  
N=9,134 
(42%) 
GA (mean (SD)): 
34.8 (5.8) 
BW (mean (SD)): 
2500 (1200) 
Not stated 
North America-Canada (one study)-Sedatives and narcotics 
Toye 2018  
(67) 
2004-2009 Inclusion: GA <35 weeks 
admitted to NICUs 
contributing data to  
Canadian Neonatal 
Network during 2004-2009 
Exclusion: Not stated 
N=12,415 
(not stated) 
Not stated Not stated 
Europe-Spain (one study)-Sedatives and analgesics 
Avila-Alvarez 2015 
(141) 
Nov 2012  
(one month) 
Inclusion: all neonates 
admitted during study 
period with corrected age 
of 44 
Exclusion: Not stated 
N=468 
(45%) 
GA (mean (SD)): 
34.3 (4.6) 
BW (mean (SD)): 
2182 (9764) 
Not stated 
Europe-France (one study)-Analgesics 





Jan 2012-Jun 2013 Inclusion: All neonates 
undergoing surgery during 
the study period 
Exclusion: Not stated 
N=168 
(40%) 
GA (mean (SD)): 
35.1 (4.6) 








Not stated Not stated N=726 
(not stated) 
GA (median, range): 
34 (23-42) 
BW (median, range): 
1993 (400-4720) 
Not stated 
North America-USA (one study)-Drugs used in bronchopulmonary dysplasia (BPD) 






Exclusion: GA ≥32 weeks, 
admitted after 36 weeks 
postmenstrual age; 
admitted for <1 week 
N=3252 
(40%) 
GA (median, (IQR)): 
26 (24–28) 








Jan–Feb 2018 Not stated Not stated Not stated Not stated 
BW, birthweight; GA, gestation age; NICU; neonatal intensive care unit; SD; standard deviation 
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 Drugs coding and categorisation  
Broad group: Agents for metabolic disorders 
Drug ID 
(as appeared in database) 
Individual drug 
Drug ID 
(as appeared in database) 
Individual drug 
allopurinol allopurinol imiglucerase enzyme (imiglucerase) 
carnitine amino acid derivative (carnitine) rasburicase rasburicase 
cysteamine (mercaptamine) amino acid derivative 
(mercaptamine) 
sodium benzoate sodium benzoate 
ubidecarenone co-enzyme Q10 sodium benzoate infusion sodium benzoate  
cyclic pyranopterin monophosphate (1) cyclic pyranopterin 
monophosphate 
sodium dichloroacetate sodium dichloroacetate 
agalsidase beta (galactosidase) enzyme (agalsidase beta) sodium phenylbutyrate sodium phenylbutyrate 
  sodium phenylbutyrate infusion sodium phenylbutyrate  
(1) https://www.sps.nhs.uk/medicines/cyclic-pyranopterin-monophosphate/:) 
Broad group: Agents for pulmonary hypertension 
bosentan bosentan sildenafil sildenafil 
nitric oxide nitric oxide silfanadil sildenafil 
Broad group: Agents used in anaesthesia 
atracurium atracurium Orabase (1) benzocaine (topical) 
Orobase (1) benzocaine (topical) bupivicaine bupivacaine 
Dantrolene (2) dantrolene ketamine ketamine 




oxybuprocaine 0.4% oxybuprocaine 0.4% (ocular) pancuronium pancuronium 
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propofol propofol proxymetacaine hydrochloride proxymetacaine 
hydrochloride (ocular) 
proxymetocaine proxymetacaine hydrochloride 
(ocular) 
rocuronium rocuronium 
sevoflurane sevoflurane suxamethonium suxamethonium 
ametop tetracaine vecuronium vecuronium 
vecuronium infusion vecuronium   
(1) https://www.drugs.com/mtm/orabase.html 
(2) https://medlineplus.gov/druginfo/meds/a682576.html 
Broad group: Agents used in PDA 
ibuprofen ibuprofen indometacin (indomethacin) indomethacin 
indometacin indomethacin indomethacin indomethacin 
Broad group: alkalising agents  
sodium bicarbonate sodium bicarbonate Tricitrate (1) tricitrates oral solution 
tham (trometamol) trometamol   
(1): https://www.medicinesforchildren.org.uk/sites/default/files/content-type/leaflet/pdf/20141107132738_0.pdf 
Broad group: Analgesics 
alfentanil alfentanil alfentanyl alfentanil 
benzydamine benzydamine buprenorphine buprenorphine 
codeine codeine diclofenac diclofenac 
diamorphine diamorphine morphine morphine (iv) 
methadone methadone morphine sulphate morphine (iv) 
iv morphine morphine (iv) morphine - iv morphine (iv) 
morphine infusion morphine (iv) morphine - oral morphine (oral) 
oral morphine morphine (oral) oral morphine - level 1 morphine (oral) 
oral morphine - level 3 morphine (oral) oral morphine - level 4 morphine (oral) 
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oramorph morphine (oral) oromorph morphine (oral) 
oxycodone oxycodone remifentanil remifentanil 
sucrose (1) sucrose (oral) sucrose (oral) (1) sucrose (oral) 
sweetease (1) sucrose (oral) calpol paracetamol 
paracetamol paracetamol   
(1)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590075/ 
Broad group: Antibiotics 
amikacin amikacin amoxicillin amoxicillin 
amoxycillin amoxicillin ampicillin ampicillin 
azithromycin azithromycin azithromycin oral azithromycin 
aztreonam aztreonam benzyl penicillin benzylpenicillin 
cefaclor cefaclor cefalexin cefalexin 
cefotaxime cefotaxime cefradine cefradine 
ceftazidime ceftazidime ceftriaxone ceftriaxone 
cefuroxime cefuroxime chloramphenicol chloramphenicol (ocular) 
chloramphenical eyedrops chloramphenicol (ocular) chloramphenicol eye ointment chloramphenicol (ocular) 
ciprofloxacin ciprofloxacin clarithromycin clarithromycin (iv/oral) 
clarithromycin iv clarithromycin (iv/oral) clarithromycin oral clarithromycin (iv/oral) 
clindamycin clindamycin augmentin co-amoxiclav 
co-amoxiclav co-amoxiclav co-amoxiclav (augmentin) co-amoxiclav 
colistimethate sodium colistimethate sodium colistin colistimethate sodium 
colomycin colistimethate sodium cotramoxizole co-trimoxazole 
co-trimoxazole co-trimoxazole daptomycin daptomycin 
erthromycin erthromycin erthromycin erythromycin 
flucloxacillin flucloxacillin fosfomycin fosfomycin 
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fusidic acid fusidic acid sodium fusidate fusidic acid 
sodium fusidate / fusidic acid fusidic acid fucidin ointment fusidic acid (topical) 
fusidic acid eye drops fusidic acid (ocular) fucidine cream fusidic acid (topical) 
gentamicin gentamicin gentamicyn eye drops gentamicin (topical) 
gentamicin - topical gentamicin (topical) imipenem (primaxin) imipenem + cilastatin 
levoflaxacin levofloxacin levofloxacin levofloxacin 
linezolid linezolid meropenem meropenem 
metronidazole metronidazole bactraban mupirocin 
bactroban mupirocin bactroban ointment mupirocin 
bactroban ointment (mupirocin) mupirocin mupirocin mupirocin 
neomycin neomycin neomycin 0.5% eye drops neomycin 0.5% (ocular) 
netilmicin netilmicin nitrofurantoin nitrofurantoin 
ofloxacillin ofloxacin ofloxacin eye drops ofloxacin (ocular) 
phenoxymethylpenicillin phenoxymethylpenicillin piperacillin piperacillin + tazobactam 
piptazocin piperacillin + tazobactam rifampicin rifampicin 
flamazine cream silver sulfadiazine cream spiramycin spiramycin 
sulphadiazine sulfadiazine teicoplanin teicoplanin 
tetracycline hydrochloride tetracycline hydrochloride trimethoprim trimethoprim 
tobramycin tobramycin vancomycin vancomycin 
Broad group: Antidotes and chelators 
calcium resonium calcium polystyrene sulfonate flumazenil flumazenil 
methylene blue methylthioninium chloride naloxone naloxone 
Broad group: Antiemetics 
ondansetron ondansetron ondansetrone ondansetron 
Broad group: Anti-fungals  
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amphotericin amphotericin (liposomal) ambisome (liposomal 
amphoteracin) 
amphotericin (liposomal) 
ambisone amphotericin (liposomal) amphotericin - liposomal amphotericin (liposomal) 
amphotericin liposomal amphotericin (liposomal) liposomal amphoteracin amphotericin (liposomal) 
caspofungin caspofungin clotrimazole clotrimazole (topical) 
canestan cream (clotrimazole) clotrimazole (topical) clotrimazole cream clotrimazole (topical) 
fluconazole fluconazole flucytosine flucytosine 
itraconazole itraconazole micafungin micafungin 
daktarin (see miconazole) miconazole (topical) miconazole miconazole (topical) 
miconazole gel / cream miconazole (topical) nystatin nystatin (topical) 
nystatin suspension nystatin (topical) nystatin cream nystatin (topical) 
nystatin ointment nystatin (topical) voriconazole voriconazole 
Broad group: Antihistamines 
alimemazine tartrate alimemazine tartrate vallergan alimemazine tartrate 
chlorphenamine chlorphenamine chlorpheniramine chlorphenamine 
hydroxyzine hydroxyzine promethazine promethazine 
Broad group: Antimalarials 
pyrimethamine pyrimethamine   
Broad groups: Antimuscarinics 
atropine atropine cyclopentolate eye drops 0.5% cyclopentolate  0.5% 
(ocular) 
glycopyrrolate glycopyrronium bromide glycopyrronium glycopyrronium bromide 
glycopyrronium bromide glycopyrronium bromide hyoscine patch hyoscine (patch) 
ipratropium ipratropium ipratropium (atrovent) ipratropium 
oxybutin oxybutynin trihexyphenidyl trihexyphenidyl 
tropicamide 0.5% tropicamide (ocular) tropicamide eye drops tropicamide (ocular) 
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Broad group: Anti-mycobacterials 
isoniazid isoniazid pyrozinamide pyrazinamide 
Broad group: Antineoplastic agents  
cytarabine cytarabine etoposide etoposide 
chemotherapy agents chemotherapy agents   
Broad group: Agents for fluids and electrolyte imbalances  
dextrogel glucose (oral) glucose gel 40% (oral) glucose (oral) 
glycogel glucose (oral) hypostop glucose (oral) 
Broad group: Antivirals 
abacavir abacavir aciclovir aciclovir 
acyclovir aciclovir adefovir adefovir 
enfuvirtide enfuvirtide ganciclovir ganciclovir 
gancyclovir ganciclovir lamivudine lamivudine 
kaletra lopinavir with ritonavir nevirapine nevirapine 
oseltamivin oseltamivir oseltamivir oseltamivir 
tamiflu / oseltamivir oseltamivir ribavirin ribavirin 
valganciclovir valganciclovir zidovudin zidovudine 
zidovudine (azt) zidovudine   
Broad group: Blood and related products 
human albumin solution 20% albumin (human albumin 
solution 20%) 
human albumin solution 4.5% albumin (human albumin 
solution 4.5%) 
albumin albumin (unclassified) cryoprecipitate cryoprecipitate 
gelofusin gelatin   
Broad group: Blood and blood forming organs  
darbopoetin alfa epoetins epoetin alfa and beta epoetins 
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erythropoeitin epoetins   
Broad group: Cardiovascular agents  
aprotinin aprotinin tranexamic acid tranexamic acid 
adenosine adenosine alteplase alteplase 
amiloride amiloride amiodarone amiodarone 
amlodipine amlodipine aspirin aspirin 
atenelol atenolol atenolol atenolol 
bendrofluazide bendroflumethiazide captopril captopril 
catopril captopril chlorothiazide chlorothiazide 
chrlorthiazide chlorothiazide clonidine clonidine 
clopidogrel clopidogrel defibrotide defibrotide 
digoxin digoxin dipyridamole dipyridamole 
disopyramide  disopyramide enalapril enalapril 
enoximone enoximone esmolol esmolol 
factor 8 factor VIII factor vlla (novo 7) factor Vlla 
flecainide flecainide frusemide furosemide 
glyceryl trinitrate glyceryl trinitrate dalteparin heparin 
clexane heparin enoxaparin heparin 
tinzaparin heparin hydralazine hydralazine 
hydralazine infusion hydralazine hydrochlorthiazide hydrochlorothiazide 
isoprenaline isoprenaline labetalol labetalol 
lisinopril lisinopril metolazone metolazone 
nifedipine nifedipine phentolamine phentolamine 
potassium canrenoate potassium canrenoate potassium conreonate potassium canrenoate 
prozocin prazocin propranolol propranolol 
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recombinant activated protein c protein C concentrate sodium nitroprusside sodium nitroprusside 
sotalol sotalol aldactone spironolactone 
spironolactone spironolactone tenecteplase tenecteplase 
tolazoline tolazoline warfarin warfarin 
adrenaline adrenaline dopamine dopamine 
adrenaline (epinephrine) adrenaline dopamine 2 double dopamine 
adrenaline infusion adrenaline dopamine infusion dopamine 
dobutamine dobutamine milrinone milrinone 
dobutamine 2 double dobutamine noradrenaline noradrenaline 
dobutamine infusion dobutamine noradrenaline infusion noradrenaline 
alprostadil (prostaglandin e1) prostaglandins prostin e2 prostaglandins 
alprostadil (prostaglandin e2) prostaglandins epoprostenol prostaglandins 
dinoprosone prostaglandin e2 prostaglandins epoprostenol (prostacyclin) prostaglandins 
dinoprostine (prostaglandin e2) prostaglandins iloprost prostaglandins 
dinoprostone (prostaglandin e2) prostaglandins latanoprost prostaglandins 
prostin prostaglandins dinoprostone prostaglandin e2 
(see alprostadil) 
prostaglandins 
Broad group: Corticosteroids 
beclomethasone beclomethasone beclomethasone (inhaler) beclomethasone (inhaler) 
beclomethasone (nasal spray) beclomethasone (nasal) beconase nasal drops beclomethasone (nasal) 
betamethasone betamethasone betnesol betamethasone 
betamethasone eye drops betamethasone (ocular) budesonide budesonide 
budesonide inhaler budesonide (inhaler) dexamethasone dexamethasone 
dexamethasone eye drops dexamethasone (ocular) fludrocortisone fludrocortisone 
fluocinolone fluocinolone flixotide fluticasone (inhaler) 
hydrocortisone hydrocortisone methylprednisolone methylprednisolone 
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prednisolone prednisolone prednisolone acetate 1% eye 
drops 
prednisolone acetate 1% 
(ocular) 





Broad group: Electrolyte replacement agents  
dioralyte oral rehydration solution   
Broad group: Electrolytes and minerals  
calcium sandoz calcium supplements calcium calcium supplements 
calcium gluconate 10% calcium supplements magnesium magenesium supplements 
magnesium glycerophosphate magenesium supplements magnesium sulphate magenesium supplements 
buffered phosphate phosphate supplements buffered po4 phosphate supplements 
phosphate - buffered phosphate supplements phosphate phosphate supplements 
joules phosphate phosphate supplements phosphate - potassium acid 
phosphate 
phosphate supplements 
phosphate - sodium acid phosphate phosphate supplements polyfusor phosphates phosphate supplements 
potassium acid phosphate phosphate supplements potassium phosphate phosphate supplements 
sodium acid phosphate phosphate supplements sodium dihydrogen phosphate phosphate supplements 
sodium glycerophosphate phosphate supplements sodium phosphate phosphate supplements 
potassium potassium supplements potassium bicarbonate potassium supplements 
potassium chloride potassium supplements sodium sodium 
sodium + potassium sodium and  potassium sodium chloride sodium 
zinc sulphate zinc sulfate   
Broad group: Endocrine agents  
carbimazole carbimazole somatropin growth hormone 
(somatropin) 
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growth hormone growth hormone (unclassified) acth hormone 
(adrenocorticotrophic 
hormone) 
desmopressin (ddavp oral) hormone (desmopressin) desmopressin acetate 
intranasal solution 
hormone (desmopressin) 
diazoxide hormone (diazoxide) glucagon hormone (glucagon) 
glucagon infusion hormone (glucagon ) gonadorelin hormone (gonadorelin) 
beta hch (pregnyl) hormone (human chorionic 
gonadotrophin) 
insulin - actrapid hormone (insulin) 
human chorionic gonadotrophin hormone (human chorionic 
gonadotrophin) 
insulin 1 single hormone (insulin) 
humulin i hormone (insulin) insulin actrapid hormone (insulin) 
insulatard hormone (insulin) insulin infusion hormone (insulin) 
insulin hormone (insulin) novorapid hormone (insulin) 
lanreotide hormone (lanreotide) tetracosactrin (tetracosactide) hormone (tetracosactide) 
levothyroxine sodium (thyroxine) hormone (levothyroxine sodium) vasopressin hormone (vasopressin) 
liothyronine sodium hormone (liothyronine sodium) metformin metformin 
octreotide hormone (octreotide) disodium pamidronate pamidronate disodium 
teriparatide hormone (teriparatide) lugols iodine potassium iodide with 
iodine 
propylthiouracil propylthiouracil   
Broad group: Feed supplements  
maxijul high energey supplement 
(carbohydrates) 
duocal high energy supplement 
(fat and carbohydrate) 
polycal high energey supplement 
(carbohydrates) 
calogen high energy supplement 
(fat) 
protifar high energy supplement 
(protein) 
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Broad group: Gastro-intestinal agents  
chenodeoxycholic acid chenodeoxycholic acid carobal feed thickener 
domperidone domperidone carobel feed thickener 
creon enzyme (pancreatin) nutilis feed thickener 
pancrex v capsules enzyme (pancreatin) thixo-d feed thickener 
vitaquick feed thickener lanzoprazole lansoprazole 
glycerin (glycerol) suppository glycerol suppository lonsorprazole lansoprazole 
glycerine chip glycerol suppository loperamide loperamide 
lactulose lactulose movicol macrogol 3350 with 
potassium and sodium 
salts 
lansoprazole lansoprazole metoclopramide metoclopramide 
omeprazole omeprazole infracol simeticone 
ranitidine ranitidine gaviscon feed thickener 
senokot senna sucralfate sucralfate 
infacol simeticone ursodeoxycholic acid ursodeoxycholic acid 
Broad group: Immunoglobulins 
hepatitis b immunoglobulin immunoglobulin (hepatitis b) vigam immunoglobulin (normal) 
flebogamma immunoglobulin (normal) immunoglobulin - human 
normal immunoglobulin 
immunoglobulin (normal) 
human normal immunoglobulin immunoglobulin (normal) immunoglobulin immunoglobulin 
(unclassified) 




sandoglobulin immunoglobulin (normal) zoster immunoglobulin immunoglobulin (varicella-
zoster) 
Broad group: Immunostimulants  
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filgrastim G-CSF (filgrastim) glatiramer glatiramer 
lenograstim G-CSF (lenograstim) interferon alfa interferon alfa 
granulocyte colony stimuating factor G-CSF (unclassified) beta interferon interferon beta 
peginterferon alpha peginterferon alfa   
Broad group: Immunosuppressants 
adalimumab adalimumab palivizumab palivizumab 
alemtuzumab alemtuzumab rituximab rituximab 
avastin bevacizumab tacrolimus tacrolimus 
Broad group: Minerals and trace elements 
ferrous fumarate iron supplements sodium feredate (sytron) iron supplements 
fersamal iron supplements sodium ferederate iron supplements 
fersamal (ferrous fumarate) iron supplements sytron iron supplements 
fersamal (ferrous fumurate) iron supplements sytron - sodium ironedetate 
(sodium feredate) 
iron supplements 
ferrous sulphate iron supplements iron iron supplements 
iron (sytron) iron supplements   
Broad group: Miscellaneous 
saliva replacement gel artificial saliva products emulsifying ointment emollients 
chlorhexidine chlorhexidine hydomol ointment emollients 
chlorhexidine powder chlorhexidine ilex skin protection emollients 
chlorohexidine powder chlorhexidine hyaluronidase (hyalase) enzyme (hyaluronidase) 
dextrometaphan dextromethorphan carmellose ocular lubricants 
aquamax cream emollients celluvisc ocular lubricants 
aqueous cream emollients gel tears ocular lubricants 
cavalon spray (1) emollients hylo-forte ocular lubricants 
cavilon cream (1) emollients hypromellose eye drops ocular lubricants 
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cavilon stick (1) emollients lacri-lube (eye ointment) ocular lubricants 
Cetraban (2) emollients lacrilube ointment / drops ocular lubricants 
derma (3)s emollients viscotears ocular lubricants 
diprobase cream emollients timolol 0.1% gel timolol 0.1% (ocular) 
e45 cream emollients Aquacel (4) wound dressing 
emollin spray emollients flaminal hydro gel wound dressing 
jelonet dressing (7) wound dressing Hydrosorb(5) wound dressing 
leptospermum honey wound dressing elfin-imp research drug (ELFIN) 







Broad group: Musculoskeletal agents  
baclofen baclofen hydroxycholoroquin hydroxycholoroquin 
edrophonium chloride (1) edrophonium chloride neostigmine neostigmine 
edrophonium chloride (tensilion) edrophonium chloride pyridostigmine pyridostigmine 
(1) https://www.medicinescomplete.com/#/content/martindale/4516-v?hspl=edrophonium 
Broad group: Neurological agents  
acetazolamide acetazolamide midazolam midazolam 
carbamazepine carbamazepine midazolam 2 double midazolam 
chloral hydrate chloral hydrate midazolam infusion midazolam 
chlorpromazine chlorpromazine nitrazepam nitrazepam 
clobazam clobazam paraldehyde paraldehyde 
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clonazepam clonazepam phenobarbital phenobarbital 
co-careldopa co-careldopa phenobarbital 
(phenobarbitone) 
phenobarbital 
diazepam diazepam phenobarbitone phenobarbital 
dorzolamide dorzolamide phenobarbitone - loading dose phenobarbital 
gabapentin gabapentin phenobarbitone - maintenance phenobarbital 
haloperidol haloperidol phenytoin phenytoin 
lamotrigine lamotrigine risperidone risperidone 
levatiracetam (keppra) levatiracetam sodium valporate sodium valproate 
levetiracetam levatiracetam sodium valproate sodium valproate 
lorazepam lorazepam temazepam temazepam 
melatonin melatonin thiopentone thiopental sodium 
metaclopramide metaclopramide topiramate topiramate 
triclofos triclofos vigabatrin vigabatrin 
Broad group: Nutritional supplement 
anamix infant amino acid (amino acid mix) glutamine amino acid (glutamine) 
arginine amino acid (arginine) isoleucine powder amino acid (isoleucine) 
carglumic acid (carbaglu) amino acid (carglumic acid) valine powder amino acid (valine) 
human milk fortifier breast milk fortifier docosohexanoic acid docosohexanoic acid 
Broad group: probiotics 
acidophillus probiotics infloran probiotics 
bifidobacterium probiotics labinic (probiotic) probiotics 
bio-kult probiotics lb2 (probiotic) probiotics 
Broad group: Prostaglandins and oxytocics 
oxytocin/ergometrine ergometrine with oxytocin   
Broad group: Respiratory agents  
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acetylcystene acetylcysteine survanta pulmonary surfactants 
aminophylline aminophylline curosurf pulmonary surfactants 
caffeine caffeine curosurf - poractant pulmonary surfactants 
caffeine base caffeine poractant alfa - curosurf pulmonary surfactants 
caffeine citrate caffeine surfactant pulmonary surfactants 
dnase dornase alfa salbutamol salbutamol 
dornase alfa dornase alfa salbutamol (ventolin) salbutamol 
doxapram doxapram salbutamol iv salbutamol (iv) 
montelukast montelukast salmeterol salmeterol 
beractant - survanta pulmonary surfactants theophylline theophylline 
Broad group: Retinoid and related drugs 
acitretin acitretin   
Broad group: Vaccines 
bcg vaccine vaccine (BCG) meningococcal c vaccine vaccine (meningococcal c) 
diptheria vaccine (diphtheria) mmr vaccine (MMR) 
infanrix vaccine (DPT) polio - oral vaccine (oral polio) 
pediacel vaccine (DTTPH) prevenar vaccine (pneumococcal 
conjugate) 




influenza immunisation vaccine (influenza) pneumococcal vaccine vaccine (pneumococcal) 
rotarix vaccine (live attenuated 
rotavirus) 
polio vaccine vaccine (polio) 
meningococcal b vaccine vaccine (meningococcal b) tetanus toxoid vaccine (tetanus toxoid) 
pertussis (whooping cough) vaccine (whooping cough)   
Broad group: Vasoconstrictors  
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ephedrine ephedrine xylometazoline-paediatric xylometazoline (paediatric) 
phenylephrine hydrochloride 2.5% phenylephrine hydrochloride 
2.5%  (ocular) 
  
All drugs’ classification are based on BNF for children (online version), unless otherwise indicated  
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 Calculated Z scores bounds for boys and girls  
Z scores bounds for boys  
Gestation age 
Z scores (minus 4SD) for birth weight 
(grams) 
Mean birth weight        
(grams) 
Z scores (plus 4 SD) for birth weight 
(grams) 
22 weeks 198 614 990 
23 weeks 198 614 990 
24 weeks 222 714 1163 
25 weeks 246 817 1344 
26 weeks 270 924 1538 
27 weeks 295 1036 1743 
28 weeks 324 1158 1966 
29 weeks 358 1290 2208 
30 weeks 401 1436 2474 
31 weeks 458 1605 2775 
32 weeks 535 1799 3111 
33 weeks 634 2016 3471 
34 weeks 757 2247 3839 
35 weeks 906 2486 4196 
36 weeks 1077 2726 4527 
37 weeks 1503 3500 5497 
38 weeks 1503 3500 5497 
39 weeks 1503 3500 5497 
40 weeks 1503 3500 5497 
41 weeks 1503 3500 5497 
42 weeks 1503 3500 5497 
43 weeks 1503 3500 5497 
44 weeks 1503 3500 5497 
   
 
Page | 467  
 
 
Z scores bounds for girls  
Gestation age 
Z scores (minus 4SD) for birth 
weight (grams) 
Mean birth weight  
(grams) 
Z scores (plus 4 SD) for birth 
weight(grams) 
22 weeks 82 559 914 
23 weeks 82 559 914 
24 weeks 104 658 1090 
25 weeks 129 761 1276 
26 weeks 154 867 1473 
27 weeks 183 978 1683 
28 weeks 218 1093 1905 
29 weeks 263 1217 2141 
30 weeks 323 1359 2408 
31 weeks 401 1525 2710 
32 weeks 498 1712 3039 
33 weeks 618 1916 3386 
34 weeks 758 2134 3739 
35 weeks 920 2361 4086 
36 weeks 1103 2590 4411 
37 weeks 1468 3360 5252 
38 weeks 1468 3360 5252 
39 weeks 1468 3360 5252 
40 weeks 1468 3360 5252 
41 weeks 1468 3360 5252 
42 weeks 1468 3360 5252 
43 weeks 1468 3360 5252 
44 weeks 1468 3360 5252 
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 List of excluded drugs from the analysis  




heparin sodium (used to 
open lines) 
metanium cream/ dermol/ miconazole cream hc 
nystaform hc ointment/ octenisan 
polyfax/ prontoderm/ timodine /tri-adortyl 
trimovate cream /naseptin cream 
topical agents with 
combination 
sodium chloride for 
flush 
used to flush lines dextrose (see glucose 10% or glucose any conc) 
dextrose 10% /dextrose 5% / glucose 10% 
glucose 50% 
glucose infusion 
cling film eye wrap used to flush lines Abidec /dalavit /dalivit 
healthy start – vitamins /ketovite /multivitamins 
vitamins (abidec) /folic acid 
folinic acid (calcium folinate) /arovit 
vitamin a / thiamine 
riboflavin /pyridoxal /pyridoxal phosphate 
pyridoxine /biotin /vitamin d / alfacaladol 
alfacalcidol / alphacalcidol / calciferol 
cholecalciferol 
vitamin e / vitamin e (alphatocopheryl acetate) 
vitamin k / vitamin k (phyomenadione) 
vitamin k (phytomenadione) 
vitamin k - 2nd dose / vitamin 
vitamins /vitamins (other) 
vitamins 
eye drops unspecified name of the 
drops 






perfluorocarbon used for liquid ventilation 
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none  
10% special k 
5% special k 
bunesconide puffer 
k 
liquid paraffin 50% in 








fluids and electrolytes 
replacement infusions 
Page | 470  
 










Sodium 16.6 20.4 22.8 24.7 25.8 26.5 27.3 27.3 27.3 16.6 10.7 
Benzylpenicillin 51.0 51.1 50.6 53.7 56.9 58.6 59.9 59.4 59.9 50.6 9.3 
Gentamicin 51.9 50.8 50.8 52.7 54.7 56.3 58.1 57.1 58.1 50.8 7.3 
Cefotaxime 15.6 15.4 14.4 13.2 11.9 11.4 11.9 12.1 15.6 11.4 4.2 
Iron 
supplements 
11.8 10.9 10.2 9.9 9.3 9.2 8.3 7.7 11.8 7.7 4.1 
Pulmonary 
surfactants 
3.9 2.6 3.9 5.8 6.4 6.5 6.4 6.0 6.5 2.6 3.9 
Domperidone 4.0 3.7 3.4 3.2 1.8 0.7 0.5 0.4 4.0 0.4 3.6 
Amoxicillin 6.4 7.0 7.0 6.1 4.7 4.2 4.5 3.8 7.0 3.8 3.2 
Flucloxacillin 7.6 7.2 6.5 6.4 6.0 5.7 5.3 4.9 7.6 4.9 2.7 
Ranitidine 5.1 4.9 4.2 4.1 3.1 2.7 2.6 2.5 5.1 2.5 2.6 
Feed thickeners 5.1 4.7 4.4 4.1 3.9 3.7 3.3 3.0 5.1 3.0 2.1 
Caffeine 11.8 11.5 11.1 11.1 10.6 10.7 10.2 10.0 11.8 10.0 1.8 
Phosphate 
supplements 
6.6 6.3 6.0 6.0 5.8 5.6 5.0 4.8 6.6 4.8 1.8 
Probiotics 0.2 0.2 0.3 0.8 1.1 1.6 0.9 1.3 1.6 0.2 1.4 
Nystatin (topical) 5.2 5.1 5.2 5.3 5.1 4.7 4.5 3.9 5.3 3.9 1.4 
Vancomycin 4.5 4.3 3.9 3.8 3.8 3.6 3.4 3.1 4.5 3.1 1.4 
Metronidazole 3.9 3.8 3.4 3.3 2.8 2.7 2.6 2.5 3.9 2.5 1.4 
Amikacin 1.4 1.9 2.0 2.1 2.5 2.7 2.6 2.5 2.7 1.4 1.3 
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Chlorhexidine 1.1 1.2 1.2 1.2 1.9 1.9 2.2 1.0 2.2 1.0 1.2 
Chloramphenicol 
(ocular) 
2.6 2.4 2.1 2.0 1.9 1.7 1.6 1.5 2.6 1.5 1.1 
Furosemide 3.4 3.3 3.1 3.0 2.9 2.8 2.8 2.5 3.4 2.5 0.9 
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 Full list of range values of the drugs selected to describe their change in use over time (very 
preterm) 








17.4 19.5 19.7 30.5 34.2 34.9 35.1 34.7 35.1 17.4 17.7 
Sodium*  51.0 57.4 61.0 65.2 66.3 65.3 66.8 67.8 67.8 51.0 16.9 
Domperidone 17.8 17.3 17.5 17.0 10.4 3.8 3.0 2.6 17.8 2.6 15.2 
Caffeine* 76.5 79.8 81.1 84.4 84.6 87.0 88.9 91.0 91.0 76.5 14.5 
Probiotics 0.7 1.1 2.0 5.8 9.5 13.8 8.6 13.7 13.8 0.7 13.2 
Benzylpenicillin 76.4 76.7 76.6 81.4 86.7 86.4 88.9 88.3 88.9 76.4 12.5 
Gentamicin 79.1 78.2 79.8 81.9 85.0 84.1 88.1 86.4 88.1 78.2 9.8 
Cefotaxime 30.5 32.0 29.3 26.9 24.4 24.2 24.3 24.9 32.0 24.2 7.8 
Ranitidine 19.6 19.6 17.9 19.3 14.6 12.7 13.4 13.9 19.6 12.7 6.9 
Nystatin (topical) 13.0 14.6 15.8 17.9 18.0 17.7 19.1 18.3 19.1 13.0 6.1 
Paracetamol 6.1 6.5 6.5 6.8 6.7 7.8 11.0 11.6 11.6 6.1 5.5 
Amoxicillin 10.7 12.9 13.6 11.7 9.6 8.8 9.5 8.1 13.6 8.1 5.5 
Vaccine 
(meningococcal b) 




0.0 0.0 0.0 0.0 2.9 3.1 4.0 4.9 4.9 0.0 4.9 
Morphine (iv) 21.1 22.2 22.8 24.5 25.9 25.5 25.3 24.9 25.9 21.1 4.7 
Fuconazole 4.6 6.1 6.0 6.7 8.1 7.4 8.3 8.7 8.7 4.6 4.1 
Chlorhexidine 1.9 2.1 2.2 2.5 4.2 4.5 6.0 3.1 6.0 1.9 4.0 
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Fentanyl 1.7 2.2 2.4 2.6 2.7 3.6 4.4 5.7 5.7 1.7 4.0 
Atropine 3.6 4.8 5.2 6.5 5.8 6.2 6.4 7.6 7.6 3.6 4.0 
Suxamethonium 4.9 5.6 6.2 7.7 7.6 7.8 8.3 8.7 8.7 4.9 3.8 
Cyclopentolate  
0.5% (ocular) 
6.2 6.9 7.2 8.1 9.2 8.9 8.7 9.8 9.8 6.2 3.5 
Iron supplements 65.1 65.3 66.6 67.6 67.8 68.5 68.6 67.4 68.6 65.1 3.5 
Phosphate 
supplements 
37.2 36.3 36.6 37.6 39.1 38.4 38.3 39.8 39.8 36.3 3.5 
Metronidazole 12.5 14.5 13.8 13.4 12.9 11.2 11.8 11.9 14.5 11.2 3.2 
Glycerol 
suppository 




7.0 7.8 8.3 9.2 9.6 9.3 9.5 10.2 10.2 7.0 3.2 
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 Full list of range values of the drugs selected to describe their change in use over time 
(extremely preterm)  
Prescribed 
drugs 








33.6 35.0 34.2 52.5 61.4 63.1 61.9 59.4 63.1 33.6 29.6 
Domperidone 31.2 30.8 29.8 30.9 16.7 9.1 7.4 5.8 31.2 5.8 25.4 
Paracetamol 18.8 19.3 20.1 20.9 20.7 27.0 36.5 37.8 37.8 18.8 19.0 
Fluconazole 34.0 36.9 41.5 46.9 45.8 49.1 48.6 51.8 51.8 34.0 17.8 
Benzylpenicillin 75.4 76.2 77.7 82.7 90.2 88.7 92.1 91.8 92.1 75.4 16.7 




0.0 0.0 0.0 0.2 8.9 12.4 14.4 14.7 14.7 0.0 14.7 
Caffeine 79.5 80.9 84.1 86.2 86.9 89.4 92.8 93.6 93.6 79.5 14.1 




0.0 0.0 0.0 0.0 0.0 0.3 13.0 13.9 13.9 0.0 13.9 
Indomethacin 14.7 6.6 13.0 2.2 1.5 1.7 1.6 1.1 14.7 1.1 13.6 
Phosphate 
supplements 
57.0 59.0 60.9 64.0 64.9 67.6 68.2 69.4 69.4 57.0 12.5 
Ranitidine 39.7 39.2 36.9 37.4 28.8 28.3 27.4 30.1 39.7 27.4 12.4 
Sodium*  78.9 84.1 84.1 85.6 86.2 88.5 89.8 90.2 90.2 78.9 11.3 
Chlorothiazide 25.4 28.1 29.6 33.3 33.8 36.6 34.8 35.3 36.6 25.4 11.2 
Gentamicin 81.6 80.3 82.4 84.7 89.1 88.7 91.4 90.7 91.4 80.3 11.1 
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Nystatin (topical) 28.2 29.7 31.8 35.2 34.7 33.6 39.1 36.7 39.1 28.2 10.9 
Ibuprofen  14.3 21.0 17.8 22.5 23.3 22.5 24.6 22.2 24.6 14.3 10.3 
Vaccine (DPT) 0.0 0.0 0.0 0.0 2.7 5.4 5.1 9.0 9.0 0.0 9.0 
Iron supplements 70.4 71.2 74.6 76.2 77.2 78.9 78.6 79.2 79.2 70.4 8.9 
Cefotaxime 47.6 47.5 43.9 43.2 40.0 39.9 38.8 43.9 47.6 38.8 8.9 
Spironolactone 36.0 36.5 39.5 41.8 43.3 44.8 43.1 44.1 44.8 36.0 8.8 
Cyclopentolate  
0.5% (ocular) 
12.9 14.7 13.8 17.7 19.0 19.6 20.0 21.7 21.7 12.9 8.8 
Morphine (oral) 7.2 8.1 10.5 11.6 11.7 13.3 13.2 15.8 15.8 7.2 8.6 
Morphine (iv) 62.1 63.7 61.5 65.4 68.5 69.7 69.9 70.0 70.0 61.5 8.5 
Nitric oxide  5.8 5.3 7.5 9.4 11.8 12.9 13.2 13.7 13.7 5.3 8.4 
Fentanyl 6.1 8.2 8.2 8.3 8.5 10.5 11.6 14.0 14.0 6.1 7.9 
Dobutamine 23.2 24.5 22.0 24.1 29.9 27.7 29.7 29.2 29.9 22.0 7.8 
Dopamine 35.5 37.8 35.8 37.4 42.0 42.4 42.7 43.1 43.1 35.5 7.7 
Adrenaline 9.9 9.8 9.1 6.5 12.3 14.1 13.9 13.3 14.1 6.5 7.6 
Phenylephrine 
hydrochloride 
2.5%  (ocular) 
13.6 15.1 14.9 18.5 18.9 19.1 20.0 21.0 21.0 13.6 7.4 
Furosemide 44.9 45.4 49.0 48.8 50.3 50.2 51.9 50.6 51.9 44.9 7.0 
Dexamethasone 13.3 13.5 16.8 18.3 18.6 18.7 18.8 20.2 20.2 13.3 6.9 
Suxamethonium 12.1 13.2 13.7 16.0 15.8 17.0 16.1 18.6 18.6 12.1 6.6 
Omeprazole 7.1 8.5 9.2 8.0 9.8 10.1 10.9 13.6 13.6 7.1 6.4 
Vecuronium 6.8 7.1 3.9 4.0 7.2 9.6 9.4 9.1 9.6 3.9 5.7 




6.4 8.1 7.4 8.1 8.7 10.2 11.8 11.7 11.8 6.4 5.4 
Page | 476  
 
Atracurium 7.4 9.7 11.9 11.8 12.0 12.7 11.8 11.7 12.7 7.4 5.4 
Chlorhexidine 2.0 2.2 1.8 3.7 4.1 5.0 7.1 3.7 7.1 1.8 5.3 
Sodium 
bicarbonate 
26.3 29.8 29.0 29.7 30.8 30.2 31.2 31.6 31.6 26.3 5.3 
Flucloxacillin 51.2 49.6 49.3 54.5 50.9 53.5 52.3 51.8 54.5 49.3 5.2 
Metronidazole 33.8 31.6 32.1 33.3 28.6 28.6 28.7 30.8 33.8 28.6 5.2 
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 Neonatal demographics according to different birth weight categories 
Demographic comparison 
All birth weight 
categories 
ELBW 
< 1000 g 
VLBW 
1000 to 1499 g 
LBW 
1500 to 2499 g 
Normal 
birth weight >2500 g 
Number of neonates 
 n (%) 
638,843 (99.3) 20,339 (3) 35,639 (6) 177,023 (28) 405,842 (63) 
Female  
n (%) 
283,553 (44) 10,165 (50) 17,513 (49) 85,956 (49) 169,919 (42) 
Length of hospital stay in days 
median (IQR) 




Home 419,671 (66) 14,467 (71) 33,185 (93) 141,430 (80) 230,589 (56.5) 
Died 8,666 (1) 4,311 (21) 1,131 (3.2) 1,335 (1) 1,889 (0.5) 
Ward 192,766 (30) 415 (2) 457(1.3) 30,838 (17) 161,056 (39.7) 
Transfer 16,022 (3) 1,049 (5) 797 (2.3) 3,130 (1.8) 11,049 (3) 
Missing 1,715 (0.0) 97 (1) 69 (0.2) 290 (0.2) 1,259 (0.3) 
ELBW, extremely low birth weight; VLBW, very low birth weight; LBW, low birth weight  
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Drug  n (%) Drug  n (%) 
Benzylpenicillin 355,679 (56%) Domperidone 12,850 (2%) 
Gentamicin 347,713 (54%) Fluconazole 12,740 (2%) 
Sodium 156,109 (24%) Chloramphenicol (ocular) 12,416 (2%) 
Cefotaxime 83,281 (13%) Dobutamine 12,224 (2%) 
Caffeine 69,060 (11%) Chlorothiazide 10,365 (2%) 
Iron supplements 60,488 (9%) Atropine 10,228 (2%) 
Morphine (iv) 53,147 (8%) Insulin 10,220 (2%) 
Flucloxacillin 38,716 (6%) Chlorhexidine 9,392 (1%) 
Phosphate supplements 36,258 (6%) Teicoplanin 9,327 (1%) 
Pulmonary surfactants  35,118 (5%) Co-amoxiclav 9,041 (1%) 
Amoxicillin 33,838 (5%) Meropenem 8,879 (1%) 
Nystatin (topical) 30,841 (5%) Glycerol suppository 8,779 (1%) 
Feed thickeners 25,044 (4%) Phenobarbital 8,269 (1%) 
Paracetamol 24,704 (4%) Phenylephrine hydrochloride 2.5% (ocular) 8,005 (1%) 
Vancomycin 23,706 (4%) Cyclopentolate  0.5% (ocular) 7,627 (1%) 
Ranitidine 22,339 (3%) Atracurium 7,550 (1%) 
Metronidazole 19,566 (3%) Nitric oxide 7,442 (1%) 
Dopamine 19,227 (3%) Aciclovir 7,278 (1%) 
Furosemide 18,729 (3%) Morphine (oral) 6,979 (1%) 
Miconazole (topical) 18,665 (3%) Pancuronium 6,825 (1%) 
Potassium supplements 17,343 (3%) Adrenaline 6,766 (1%) 
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Amikacin 14,520 (2%) Hydrocortisone 6,631 (1%) 
Spironolacton 13,593 (2%) Ceftazidime 6,625 (1%) 
Suxamethonium 13,130 (2%) Fentanyl 6,451 (1%) 












Drug  n (%) Drug  n (%) 
Benzylpenicillin 189,413 (50%) Sodium bicarbonate 3,211 (1%) 
Gentamicin 183,602 (48%) Feed thickeners 3,159 (1%) 
Sodium 66,144 (17%) Potassium supplements 2,980 (1%) 
Cefotaxime 41,605 (11%) Atracurium 2,819 (1%) 
Morphine (iv) 19,399 (5%) Adrenaline 2,718 (1%) 
Amoxicillin 16,485 (4%) Atropine 2,675 (1%) 
Paracetamol  11,624 (3%) Pancuronium 2,656 (1%) 
Nystatin (topical) 9,347 (2%) Trimethoprim 2,571 (1%) 
Flucloxacillin 8,454 (2%) Sucrose (oral) 2,544 (1%) 
Amikacin 7,526 (2%) Furosemide 2,368 (1%) 
Miconazole (topical) 6,457 (2%) Vecuronium 2,217 (1%) 
Phenobarbital 6,097 (2%) Midazolam 2,182 (1%) 
Dopamine 6,045 (2%) Chloramphenicol (ocular) 2,165 (1%) 
Aciclovir 5,254 (1%) Hydrocortisone 1,956 (1%) 
Pulmonary surfactants 4,989 (1%) Domperidone 1,796 (0%) 
Ranitidine 4,476 (1%) Chloral hydrate 1,782 (0%) 
Co-amoxiclav 4,411 (1%) Calcium supplements  1,756 (0%) 
Prostaglandins 4,250 (1%) Fentanyl 1,725 (0%) 
Metronidazole 4,035 (1%) Iron supplements 1,583 (0%) 
Dobutamine 3,842 (1%) Magnesium supplements  1,420 (0%) 
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Chlorhexidine 3,823 (1%) Phenytoin 1,388 (0%) 
Suxamethonium 3,666 (1%) Teicoplanin 1,337 (0%) 
Vancomycin 3,606 (1%) Meropenem 1,217 (0%) 
Morphine (oral) 3,460 (1%) Ocular lubricants 1,169 (0%) 
























Drug  n (%) Drug  n (%) 
Benzylpenicillin 115,236 (58%) Sucrose (oral) 2,629 (1%) 
Gentamicin 112,699 (57%) Emollients 2,599 (1%) 
Sodium 47,087 (24%) Domperidone 2,558 (1%) 
Cefotaxime 22,059 (11%) Dopamine 2,302 (1%) 
Caffeine 16,341 (8%) Furosemide 1,993 (1%) 
Iron supplements 16,095 (8%) Clotrimazole (topical) 1,925 (1%) 
Morphine (iv) 10,892 (5%) Glycerol suppository 1,846 (1%) 
Amoxicillin 9,979 (5%) Co-amoxiclav 1,729 (1%) 
Flucloxacillin 8,696 (4%) Calcium supplements  1,610 (1%) 
Pulmonary surfactants 8,551 (4%) Sodium bicarbonate 1,581 (1%) 
Nystatin (topical) 7,950 (4%) Fentanyl 1,566 (1%) 
Phosphate supplements 7,289 (4%) Teicoplanin 1,458 (1%) 
Feed thickeners 6,311 (3%) Trimethoprim 1,432 (1%) 
Miconazole (topical) 5,924 (3%) Dobutamine 1,417 (1%) 
Paracetamol  4,911 (2%) Atracurium 1,372 (1%) 
Chloramphenicol (ocular) 4,597 (2%) Aciclovir 1,211 (1%) 
Ranitidine 4,590 (2%) Prostaglandins 1,061 (1%) 
Metronidazole 4,250 (2%) Spironolactone 1,026 (1%) 
Amikacin 3,930 (2%) Nitric oxide  1,022 (1%) 
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Suxamethonium 3,521 (2%) Phenobarbital 1,015 (1%) 
Chlorhexidine 3,453 (2%) Meropenem 1,009 (1%) 
Vancomycin 3,448 (2%) Pancuronium 965 (0%) 
Potassium supplements 3,184 (2%) Erythromycin 951 (0%) 
Benzocaine (topical) 3,105 (2%) Ceftazidime 942 (0%) 
















Drug  n (%) Drug  n (%) 
Caffeine 35,482 (84%) Paracetamol  3,332 (8%) 
Gentamicin 34,905 (83%) Dopamine 3,290 (8%) 
Benzylpenicillin 34,857 (83%) Teicoplanin 3,145 (7%) 
Iron supplements 28,280 (67%) Suxamethonium 3,003 (7%) 
Sodium 26,404 (63%) Fluconazole 2,957 (7%) 
Phosphate supplements 15,970 (38%) Probiotics 2,946 (7%) 
Pulmonary surfactants 11,952 (28%) Chlorothiazide 2,812 (7%) 
Flucloxacillin 11,673 (28%) Sodium bicarbonate 2,484 (6%) 
Cefotaxime 11,366 (27%) Atropine 2,443 (6%) 
Morphine (iv) 10,137 (24%) Insulin 2,343 (6%) 
Feed thickeners 9,619 (23%) Dobutamine 1,926 (5%) 
Nystatin (topical) 7,091 (17%) Meropenem 1,886 (4%) 
Ranitidine 6,870 (16%) Ceftazidime 1,847 (4%) 
Vancomycin 6,763 (16%) Omeprazole 1,693 (4%) 
Metronidazole 5,360 (13%) Amikacin 1,635 (4%) 
Furosemide 4,991 (12%) Erythromycin 1,583 (4%) 
Domperidone 4,644 (11%) Clotrimazole (topical) 1,453 (3%) 
Amoxicillin 4,453 (11%) Chlorhexidine 1,404 (3%) 
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Potassium supplements 4,395 (10%) Fentanyl 1,343 (3%) 
Phenylephrine hydrochloride 2.5% 
(ocular) 
3,743 (9%) Piperacillin + tazobactam 1,250 (3%) 
Spironolactone 3,716 (9%) Atracurium 1,220 (3%) 
Miconazole (topical) 3,534 (8%) Co-amoxiclav 1,195 (3%) 
Glycerol suppository 3,480 (8%) Research drug (ELFIN) 1,145 (3%) 
Chloramphenicol (ocular) 3,450 (8%) Nitric oxide  1,082 (3%) 





















Drug  n (%) Drug  n (%) 
Caffeine 16,622 (87%) Meropenem 4,767 (25%) 
Gentamicin 16,507 (86%) Ibuprofen  4,037 (21%) 
Sodium 16,474 (86%) Domperidone 3,852 (20%) 
Benzylpenicillin 16,173 (84%) Teicoplanin 3,387 (18%) 
Iron supplements 14,530 (76%) Phenylephrine hydrochloride 2.5% (ocular) 3,382 (18%) 
Morphine (iv) 12,719 (66%) Cyclopentolate 0.5% (ocular) 3,343 (17%) 
Phosphate supplements 12,250 (64%) Dexamethasone 3,320 (17%) 
Flucloxacillin 9,893 (52%) Hydrocortisone 3,015 (16%) 
Vancomycin 9,889 (52%) Suxamethonium 2,940 (15%) 
Pulmonary surfactants 9,626 (50%) Amoxicillin 2,921 (15%) 
Furosemide 9,377 (49%) Gycerol suppository 2,833 (15%) 
Fluconazole 8,509 (44%) Ceftazidime 2,783 (15%) 
Cefotaxime 8,251 (43%) Miconazole (topical) 2,750 (14%) 
Spironolactone 7,890 (41%) Piperacillin + tazobactam 2,664 (14%) 
Dopamine 7,590 (40%) Atropine 2,465 (13%) 
Insulin 7,041 (37%) Pancuronium 2,209 (12%) 
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Potassium supplements 6,784 (35%) Chloramphenicol (ocular) 2,204 (12%) 
Nystatin (topical) 6,453 (34%) Morphine (oral) 2,195 (11%) 
Ranitidine 6,403 (33%) Atracurium 2,139 (11%) 
Chlorothiazide 6,163 (32%) Adrenaline 2,133 (11%) 
Feed thickeners 5,955 (31%) Nitric oxide  1,193 (10%) 
Metronidazole 5,921 (31%) Omeprazole 1,855 (10%) 
Sodium bicarbonate 5,719 (30%) Fentanyl 1,817 (9%) 
Dobutamine 5,039 (26%) Vaccine (DTTPH) 1,806 (9%) 
Paracetamol 4,837 (25%) Probiotics 1,758 (9%) 
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 Number of unique drugs per patient in median (range, IQR) by year of admission 
Year of admission 
Total 
 
Extremely preterm Very preterm 
Moderate to late 
preterm 
Term 
2010 2 (0-55, 0-3) 15 (0-55, 10-22) 7 (0-50, 4-10) 2 (0-36, 0-3) 2 (0-37, 0-2) 
2011 2 (0-69, 0-3) 16 (0-69, 10-23) 7 (0-46, 5-11) 2 (0-32, 0-3) 2 (0-34, 0-2) 
2012 2 (0-54, 0-3) 16 (0-54, 11-24) 7 (0-45, 5-11) 2 (0-39, 0-3) 2 (0-40, 0-3) 
2013 2 (0-54, 0-3) 17 (0-54, 12-24) 8 (0-40, 5-12) 2 (0-41, 0-3) 2 (0-40, 0-3) 
2014 2 (0-47, 0-3) 18 (0-57, 12-25) 8 (0-50, 5-12) 2 (0-41, 0-3) 2 (0-42, 0-3) 
2015 2 (0-57, 0-3) 18 (0-57, 13-26) 8 (0-47, 5-11) 2 (0-41, 0-3) 2 (0-46, 0-3) 
2016 2 (0-63, 0-3) 19 (0-61, 13-26) 8 (0-63, 5-12) 2 (0-57, 1-3) 2 (0-47, 2-3) 
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 The top 50 drugs in terms of their calculated total number of days of use 
Drugs 
Number of neonates 
prescribed the drug at 
least once 
Average number of 
days of exposure in 
median 
Total number of days of use 
Caffeine* 69060 20 1381200 
Benzylpenicillin 355679 3 1067037 
Gentamicin 347713 3 1043139 
Iron supplements 60488 15 907320 
Phosphate supplements 36258 19 688902 
Sodium*  156109 4 624436 
Cefotaxime 83281 4 333124 
Spironolactone 13593 24 326232 
Feed thickeners 25044 12 300528 
Ranitidine 22339 10 223390 
Domperidone 12850 17 218450 
Chlorothiazide 10365 21 217665 
Morphine (iv) 53147 3 159441 
Flucloxacillin 38716 4 154864 
Nystatin (topical) 30841 5 154205 
Vancomycin 23706 6 142236 
Probiotics 5490 19 104310 
Fluconazole 12740 8 101920 
Amoxicillin 33838 3 101514 
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Omeprazole 5318 17 90406 
Potassium supplements 17343 5 86715 
Metronidazole 19566 4 78264 
Ursodeoxycholic acid 3522 22 77484 
Morphine (oral) 6979 11 76769 
Furosemide 18729 4 74916 
Miconazole (topical) 18665 4 74660 
Paracetamol  24704 3 74112 
Meropenem 8879 7 62153 
Chloramphenicol (ocular) 12416 5 62080 
Dopamine 19227 3 57681 
Teicoplanin 9327 5 46635 
Erythromycin 4490 10 44900 
Dexamethasone 4848 9 43632 
Amikacin 14520 3 43560 
Insulin 10,220 4 40880 
Research drug (ELFIN) 1778 22 39116 
Chlorhexidine 9392 4 37568 
Co-amoxiclav 9041 4 36164 
Pulmonary surfactants 35118 1 35118 
Ceftazidime 6625 5 33125 
Piperacillin + tazobactam 5515 6 33090 
Trimethoprim 4858 6 29148 
Aciclovir 7278 4 29112 
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Clotrimazole (topical) 5790 5 28950 
Sodium bicarbonate 12995 2 25990 
Dobutamine 12224 2 24448 
Benzocaine (topical) 5798 4 23192 
Nitric oxide  7442 3 22326 
Loperamide 866 25 21650 
Emollients 5244 4 20976 
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 Percentage of very preterm neonates prescribed a particular drug each year (drugs with 
fluctuating trends) 
Drugs with fluctuating 
trends 
2010 2011 2012 2013 2014 2015 2016 2017 
Probiotics 0.7 1.1 2.0 5.8 9.5 13.8 8.6 13.7 
Gentamicin 79.1 78.2 79.8 81.9 85.0 84.1 88.1 86.4 
Cefotaxime 30.5 32.0 29.3 26.9 24.4 24.2 24.3 24.9 
Ranitidine 19.6 19.6 17.9 19.3 14.6 12.7 13.4 13.9 
Nystatin (topical) 13.0 14.6 15.8 17.9 18.0 17.7 19.1 18.3 
Amoxicillin 10.7 12.9 13.6 11.7 9.6 8.8 9.5 8.1 
Morphine (iv) 21.1 22.2 22.8 24.5 25.9 25.5 25.3 24.9 
Fluconazole 4.6 6.1 6.0 6.7 8.1 7.4 8.3 8.7 
Chlorhexidine 1.9 2.1 2.2 2.5 4.2 4.5 6.0 3.1 
Atropine 3.6 4.8 5.2 6.5 5.8 6.2 6.4 7.6 
Cyclopentolate 0.5% 
(ocular) 
6.2 6.9 7.2 8.1 9.2 8.9 8.7 9.8 
Iron supplements 65.1 65.3 66.6 67.6 67.8 68.5 68.6 67.4 
Phosphate supplements 
37.2 36.3 36.6 37.6 39.1 38.4 38.3 39.8 
Metronidazole 12.5 14.5 13.8 13.4 12.9 11.2 11.8 11.9 
Glycerol suppository 6.5 7.1 8.1 8.4 8.6 8.2 9.4 9.7 
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 Percentage of extremely preterm neonates prescribed a particular drug each year (drugs with 
fluctuating trends) 
Drugs with fluctuating 
trends 
2010 2011 2012 2013 2014 2015 2016 2017 
Fluconazole 34.0 36.9 41.5 46.9 45.8 49.1 48.6 51.8 
Benzylpenicillin 75.4 76.2 77.7 82.7 90.2 88.7 92.1 91.8 
Probiotics 3.1 2.2 2.6 9.1 10.8 18.0 9.6 17.7 
Vaccine (meningococcal b) 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 
Indomethacin 14.7 6.6 13.0 2.2 1.5 1.7 1.6 1.1 
Ranitidine 39.7 39.2 36.9 37.4 28.8 28.3 27.4 30.1 
Sodium*  78.9 84.1 84.1 85.6 86.2 88.5 89.8 90.2 
Chlorothiazide 25.4 28.1 29.6 33.3 33.8 36.6 34.8 35.3 
Gentamicin 81.6 80.3 82.4 84.7 89.1 88.7 91.4 90.7 
Nystatin (topical) 28.2 29.7 31.8 35.2 34.7 33.6 39.1 36.7 
Ibuprofen  14.3 21.0 17.8 22.5 23.3 22.5 24.6 22.2 
Cefotaxime 47.6 47.5 43.9 43.2 40.0 39.9 38.8 43.9 
Spironolactone 36.0 36.5 39.5 41.8 43.3 44.8 43.1 44.1 
Cyclopentolate 0.5% (ocular) 12.9 14.7 13.8 17.7 19.0 19.6 20.0 21.7 
Morphine (iv) 62.1 63.7 61.5 65.4 68.5 69.7 69.9 70.0 
Nitric oxide  5.8 5.3 7.5 9.4 11.8 12.9 13.2 13.7 
Dobutamine 23.2 24.5 22.0 24.1 29.9 27.7 29.7 29.2 
Dopamine 35.5 37.8 35.8 37.4 42.0 42.4 42.7 43.1 
Adrenaline 9.9 9.8 9.1 6.5 12.3 14.1 13.9 13.3 
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Phenylephrine hydrochloride 
2.5%  (ocular) 
13.6 15.1 14.9 18.5 18.9 19.1 20.0 21.0 
Furosemide 44.9 45.4 49.0 48.8 50.3 50.2 51.9 50.6 
Suxamethonium 12.1 13.2 13.7 16.0 15.8 17.0 16.1 18.6 
Omeprazole 7.1 8.5 9.2 8.0 9.8 10.1 10.9 13.6 
Vecuronium 6.8 7.1 3.9 4.0 7.2 9.6 9.4 9.1 
Atropine 9.9 11.2 12.2 13.5 12.9 14.3 13.3 15.4 
Vaccine (pneumococcal 
conjugate) 
6.4 8.1 7.4 8.1 8.7 10.2 11.8 11.7 
Atracurium 7.4 9.7 11.9 11.8 12.0 12.7 11.8 11.7 
Chlorhexidine 2.0 2.2 1.8 3.7 4.1 5.0 7.1 3.7 
Sodium bicarbonate 26.3 29.8 29.0 29.7 30.8 30.2 31.2 31.6 
Flucloxacillin 51.2 49.6 49.3 54.5 50.9 53.5 52.3 51.8 
Metronidazole 33.8 31.6 32.1 33.3 28.6 28.6 28.7 30.8 
 
Page | 491  
 
  Average duration of drug exposure in days for the 10 most frequently prescribed drugs 
according to gestational age group 
Most frequently prescribed 
drugs across all gestation age 
Average duration of drug exposure in days reported in median (IQR) 
Term Moderate to late preterm Very preterm Extremely preterm 
Benzylpenicillin 3 (2-4) 3 (2-4) 4 (3-5) 4 (3-6) 
Gentamicin 3 (2-4) 3 (2-4) 4 (3-6) 8 (4-14) 
Sodium  3 (2-4) 3 (2-5) 13 (5-27) 39 (7-22) 
Cefotaxime 3 (2-5) 3 (2-5) 5 (3-8) 7 (4-12) 
Caffeine* 1 (1-3) 7 (4-10) 22 (14-31) 48 (37-60) 
Iron supplements 6 (2-14) 5 (2-11) 16 (8-28) 47 (29-67) 
Morphine (IV) 3 (2-5) 2 (1-4) 3 (1-5) 8 (3-19) 
Flucloxacillin  3 (2-5) 4 (2-6) 5 (3-7) 7 (4-12) 
Phosphate supplements 5 (2-11) 8 (5-14) 19 (10-31) 40 (20-61) 
Pulmonary surfactants  Not included as they are given in one dose  
*caffeine results reported by merging caffeine, caffeine citrate and caffeine base data  
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 Average duration of drug exposure in days for the 10 most frequently prescribed drugs 
according to birth weight group 
Most frequently prescribed 
drugs across all gestation 
age 
Average duration of drug exposure in days reported in median (IQR) 
Normal birth weight Low birth weight Very low birth weight 
Extremely low birth 
weight 
Benzylpenicillin 3 (2-4) 3 (2-4) 4 (3-5) 4 (3-6) 
Gentamicin 3 (2-4) 3 (2-4) 4 (3-7) 7 (4-14) 
Sodium  3 (2-5) 3 (2-6) 14 (6-28) 37(15-62) 
Cefotaxime 3 (2-5) 3 (3-5) 5 (3-8) 7 (4-12) 
Caffeine* 2 (1-5) 10 (5-16) 25 (15-35) 45 (30-59) 
Iron supplements   5 (2-12) 6 (3-13) 17 (9-30) 44 (26-66) 
Morphine (IV) 3 (2-5) 2 (1-5) 3 (2-6) 8 (3-9) 
Flucloxacillin  3 (2-5) 4 (3-6) 5 (3-7) 7 (4-12) 
Phosphate supplements 4 (2-10) 9 (5-15) 18 (10-30) 38 (19-60) 
Pulmonary surfactants  Not included as they are given in one dose 
*caffeine results reported by merging caffeine, caffeine citrate and caffeine base data  
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 Variables used to calculate the number of neonates with PDA 
Neonates (GA< 32 weeks) with PDA records in the NNRD n (%) 
1. PDA diagnosis variables 
1.1 Neonates with records of PDA in ‘diagnosis day’ variable 14,455 24 
1.2 Neonates with records of PDA in ‘diagnosis at admission’ variable 3,968 6 
1.3 Neonates with records of PDA in ‘diagnosis at discharge’ variable 15,714 26 
A) All neonates with records of PDA diagnosis in any of the fields ‘1.1’ or ‘1.2’ or 
‘1.3’  
17,703 29 
2. Neonates without records of PDA diagnosis but had pharmacological treatment or surgical 
2.1 Neonates without records of PDA diagnosis but had indomethacin   189 0.4 
2.2 Neonates without records of PDA diagnosis but had ibuprofen   280 0.6 
2.3 Neonates without records of PDA diagnosis but had PDA surgery  27 0.1 
B)  All neonates without records of PDA diagnosis but had pharmacological or 
surgical treatment in any of the fields ‘2.1’ or ‘2.2’ or ‘2.3’ 
478 1 
Total number of neonates who had PDA in the NNRD are those with records in A) 
and B) 
18,181 30 
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 Variables used to calculate the number of neonates who 
had a treatment for PDA 
 
 
Neonates with various treatment strategies n (%) 
1. Neonates with indomethacin records  
1.1 Neonates with records of indomethacin from ‘drugs 
day’ or ‘treatment for pda’ variables 
1,417 8 
1.2 Neonates with records of indomethacin and 
ibuprofen 
324 2 
1.3 Neonates with records of indomethacin and surgery   137 1 
1.4 Neonates with records of indomethacin and 
ibuprofen and surgery  
61 0.3 
All neonates with any records of indomethacin from 1.1 
or 1.2 or 1.3 or 1.4 
1,417 8 
2. Neonates with ibuprofen records  
2.1 Neonates with records of ibuprofen from ‘drugs day’ 
or ‘treatment for pda’ variables 
4,926 27 
2.2 Neonates with records of indomethacin and 
ibuprofen 
324 2 
2.3 Neonates with records of ibuprofen and surgery   596 3 
2.4 Neonates with records of indomethacin and 
ibuprofen and surgery 
61 0.3 
All neonates with any records of ibuprofen from 2.1 or 
2.2 or 2.3 or 2.4 
4,926 27 
3.Neonates with surgery records  
3.1 Neonates with records of surgery from ‘treatment for 
pda’ variable  
1,037 6 
3.2 Neonates with records of surgery and indomethacin 
and ibuprofen  
61 0.3 
All neonates with records of surgery from 3.1 or 3.2  1,037 6 
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 Variables used to extract records of paracetamol across the entire cohort  
Neonates with paracetamol records n (%) 
1. Neonates with any record of paracetamol from ‘drugs day’ variable 8,169 13 
2. Neonates with a record of paracetamol only  5,877 10 
3. Neonates with any records of paracetamol and ibuprofen  1,733 3 
4. Neonates with any records of paracetamol and indomethacin  545 1 
5. Neonates with any records of paracetamol and surgery  558 1 
6. Neonates with any records of paracetamol and indomethacin and 
ibuprofen  
176 0.3 
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Prevalence (%) of 












of PDA in each 
month* 
Jan-10 160 595 27 Jan-14 189 651 29 
Feb-10 149 523 28 Feb-14 179 561 32 
Mar-10 148 563 26 Mar-14 177 601 29 
Apr-10 169 603 28 Apr-14 198 630 31 
May-10 186 606 31 May-14 211 654 32 
Jun-10 164 581 28 Jun-14 188 619 30 
Jul-10 189 663 29 Jul-14 236 698 34 
Aug-10 149 614 24 Aug-14 190 647 29 
Sep-10 167 572 29 Sep-14 170 586 29 
Oct-10 163 694 23 Oct-14 216 655 33 
Nov-10 143 625 23 Nov-14 204 626 33 
Dec-10 175 658 27 Dec-14 176 597 29 
Jan-11 179 624 29 Jan-15 194 642 30 
Feb-11 183 574 32 Feb-15 173 597 29 
Mar-11 148 591 25 Mar-15 209 640 33 
Apr-11 197 683 29 Apr-15 209 658 32 
May-11 188 693 27 May-15 210 714 29 
Jun-11 171 646 26 Jun-15 192 610 31 
Jul-11 174 600 29 Jul-15 200 651 31 
Aug-11 167 635 26 Aug-15 188 654 29 
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Sep-11 182 607 30 Sep-15 201 652 31 
Oct-11 187 662 28 Oct-15 200 687 29 
Nov-11 203 633 32 Nov-15 203 608 33 
Dec-11 165 620 27 Dec-15 192 632 30 
Jan-12 182 621 29 Jan-16 198 659 30 
Feb-12 200 615 33 Feb-16 217 652 33 
Mar-12 179 635 28 Mar-16 202 717 28 
Apr-12 202 638 32 Apr-16 196 642 31 
May-12 183 615 30 May-16 209 722 29 
Jun-12 193 600 32 Jun-16 180 622 29 
Jul-12 191 670 29 Jul-16 179 623 29 
Aug-12 225 698 32 Aug-16 205 688 30 
Sep-12 185 601 31 Sep-16 204 634 32 
Oct-12 206 681 30 Oct-16 192 659 29 
Nov-12 186 623 30 Nov-16 191 675 28 
Dec-12 164 666 25 Dec-16 197 661 30 
Jan-13 183 628 29 Jan-17 197 638 31 
Feb-13 161 564 29 Feb-17 171 614 28 
Mar-13 197 655 30 Mar-17 211 635 33 
Apr-13 214 672 32 Apr-17 220 707 31 
May-13 207 705 29 May-17 213 673 32 
Jun-13 180 600 30 Jun-17 212 674 31 
Jul-13 194 640 30 Jul-17 181 656 28 
Aug-13 210 672 31 Aug-17 214 706 30 
Sep-13 195 635 31 Sep-17 195 630 31 
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Oct-13 209 666 31 Oct-17 193 645 30 
Nov-13 212 629 34 Nov-17 170 661 26 
Dec-13 188 609 31 Dec-17 177 599 30 
*prevalence of PDA calculated by dividing number of records of neonates who have PDA by the number of neonates admitted each month and 
multiplied by 100 
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22 27 0 0 0 0.0 8 30 1 3.7 0 0.0 
23 997 37 3.7 23 2.3 170 17 63 6.3 10 1.0 
24 2,339 77 3.3 49 2.1 429 18 130 5.6 12 0.5 
25 2,636 82 3.1 38 1.4 396 15 132 5.0 18 0.7 
26 2,900 49 1.7 28 1.0 312 11 98 3.4 10 0.3 
27 2,807 40 1.4 20 0.7 221 8 60 2.1 6 0.2 
28 2,479 29 1.2 13 0.5 120 5 37 1.5 3 0.1 
29 1,772 7 0.4 4 0.2 51 3 18 1.0 1 0.1 
30 1,276 2 0.2 1 0.1 18 1 5 0.4 1 0.1 
31 948 1 0.1 0 0.0 8 1 1 0.1 0 0.0 
22-27 weeks 11,706 39 0.3 18 0.2 197 2 61 0.5 5 0.0 
28-31 weeks 6,475 285 4.4 158 2.4 1536 24 484 7.5 56 0.9 
22-31 weeks  18,181 324 1.8 176 1.0 1733 10 545 3.0 61 0.3 
PDA, patent ductus arteriosus 
N.B: treatment combination is not exclusively limited to those as a neonate might be receiving any additional treatment strategy in addition 
to each combination   
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Percentage of neonates with 
indomethacin records 
Jan-10 160 33 13 Jan-14 189 1 29 
Feb-10 149 32 13 Feb-14 179 1 28 
Mar-10 148 39 18 Mar-14 177 3 31 
Apr-10 169 28 15 Apr-14 198 1 19 
May-10 186 27 16 May-14 211 2 29 
Jun-10 164 23 16 Jun-14 188 1 27 
Jul-10 189 18 21 Jul-14 236 3 27 
Aug-10 149 13 23 Aug-14 190 2 28 
Sep-10 167 11 29 Sep-14 170 2 28 
Oct-10 163 7 26 Oct-14 216 3 30 
Nov-10 143 4 27 Nov-14 204 1 27 
Dec-10 175 6 31 Dec-14 176 1 28 
Jan-11 179 4 30 Jan-15 194 2 24 
Feb-11 183 6 32 Feb-15 173 0 27 
Mar-11 148 3 36 Mar-15 209 4 27 
Apr-11 197 2 40 Apr-15 209 4 26 
May-11 188 6 29 May-15 210 1 25 
Jun-11 171 7 30 Jun-15 192 2 30 
Jul-11 174 10 36 Jul-15 200 1 28 
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Aug-11 167 10 28 Aug-15 188 4 29 
Sep-11 182 14 25 Sep-15 201 2 22 
Oct-11 187 17 23 Oct-15 200 3 27 
Nov-11 203 16 29 Nov-15 203 0 29 
Dec-11 165 19 25 Dec-15 192 2 28 
Jan-12 182 24 25 Jan-16 198 1 27 
Feb-12 200 21 25 Feb-16 217 3 28 
Mar-12 179 18 16 Mar-16 202 1 35 
Apr-12 202 21 21 Apr-16 196 3 34 
May-12 183 17 23 May-16 209 2 31 
Jun-12 193 13 24 Jun-16 180 4 31 
Jul-12 191 17 21 Jul-16 179 1 31 
Aug-12 225 21 24 Aug-16 205 1 30 
Sep-12 185 11 27 Sep-16 204 1 31 
Oct-12 206 13 26 Oct-16 192 2 29 
Nov-12 186 8 25 Nov-16 191 7 31 
Dec-12 164 6 34 Dec-16 197 13 34 
Jan-13 183 4 26 Jan-17 197 6 32 
Feb-13 161 3 27 Feb-17 171 9 25 
Mar-13 197 3 37 Mar-17 211 10 30 
Apr-13 214 4 23 Apr-17 220 8 27 
May-13 207 1 26 May-17 213 8 27 
Jun-13 180 4 24 Jun-17 212 8 25 
Jul-13 194 4 31 Jul-17 181 14 30 
Aug-13 210 4 29 Aug-17 214 7 22 
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Sep-13 195 3 26 Sep-17 195 10 29 
Oct-13 209 2 26 Oct-17 193 10 30 
Nov-13 212 0 29 Nov-17 170 14 31 
Dec-13 188 2 28 Dec-17 177 8 26 
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 Detailed search strategy used in the systematic review 
Database 
(Total hits 2458) 
Search terms 
Combination of the search 
terms 
(A combination of title 
abstract key words, and Mesh 







(1946 to present) 
Number of hits 
836 
Population Search Terms (Defined as infants <37 weeks gestational age): 
prematurity – preterm – premature*- 
premmie*- preemie* 
Mesh Terms (INFANT, PREMATURE- INFANT, EXTREMELY PREMATURE- 
PREMATURE BIRTH) 
Intervention Search Terms (Ibuprofen and most commonly used brands ) 
ibumetin – motrin – nuprin – advil – nurofen – brufen 
Mesh Terms (IBUPROFEN – ANTI-INFLAMMATORY AGENTS, NON-STERIODAL) 
Comparison Search Terms (not applicable, as no specific comparator according to the 
objective of this systematic review) 
Outcome Search Terms (Toxicity related terms) 
Adverse effect*- side effect*- adverse drug reaction*- tolerabil* - complication* - harm* 
Mesh Terms (ABNORMALITIES,DRUG-INDUCED,  DRUG-RELATED SIDE EFFECTS 
AND ADVERSE REACTIONS-LONG TERM ADVERSE EFFECTS - IBUPROFEN/-ae - 
IBUPROFEN/-tu - IBUPROFEN/-to) 
(((exp IBUPROFEN/ OR exp 
"ANTI-INFLAMMATORY 
AGENTS, NON-STEROIDAL"/ 
OR (ibumetin).ti,ab OR 
(motrin).ti,ab OR (nuprin).ti,ab 
OR (advil).ti,ab OR 
(nurofen).ti,ab OR (brufen).ti,ab) 
AND (exp "DRUG-RELATED 
SIDE EFFECTS AND 
ADVERSE REACTIONS"/ OR 
exp "LONG TERM ADVERSE 
EFFECTS"/ OR IBUPROFEN/-
ae OR IBUPROFEN/-tu OR 
IBUPROFEN/-to OR (adverse 
effect*).ti,ab OR (side 
effect*).ti,ab OR (adverse drug 
reaction*).ti,ab OR 









(preemie*).ti,ab OR exp 
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"INFANT, PREMATURE"/ OR 
exp "INFANT, EXTREMELY 
PREMATURE"/ OR exp 






(1974 to present) 
 
Number of hits 
747 
Population Search Terms (Defined as infants less than 37 weeks gestational age) 
Prematurity – preterm – premature* - premmie* – preemie* 
Mesh terms(PREMATURITY) 
Intervention Search Terms (Ibuprofen and most commonly used brands) 
Mesh terms ( IBUPROFEN) 
N.B: The other brands were included in embase as subheadings of Ibuprofen; 
therefore, they were not searched individually. 
Outcome Search Terms (Toxicity related terms) 
Side effect* - Tolerabil* - complication* - harm* 
Mesh terms (IBUPROFEN/ae -IBUPROFEN/to - IBUPROFEN/dt - ADVERSE DRUG 
REACTION - DRUG INDUCED MALFORMATION 
N.B: Adverse effect in Embase thesaurus is subheading of adverse drug reaction 
((exp IBUPROFEN/ AND (exp 
IBUPROFEN/ae OR exp 
IBUPROFEN/to OR exp 
IBUPROFEN/dt OR exp 
"ADVERSE DRUG REACTION"/ 
OR (side effect*).ti,ab OR 
(tolerabil*).ti,ab OR exp "DRUG 
INDUCED MALFORMATION"/ 














(1981 to present) 
Number of hits  
163 
Population Search Terms (Defined as infants less than 37 weeks gestational age) 
Prematurity – preterm – premature* - premmie* - preemie* 
Mesh terms (INFANT, PREMATURE - CHILDBIRTH, PREMATURE) 
N.B: INFANT, PREMATURE from CINAHL thesaurus of infant. CHILDBIRTH, 
PREMATURE from CINAHL thesaurus of premature. 
Intervention Search Terms (Ibuprofen and most commonly used brands) 
Ibumetin – motrin – advil – nuprin – nurofen – brufen 
Mesh terms (IBUPROFEN- ANTIINFLAMMATORY AGENTS, NON-STEROIDAL) 
Outcome Search Terms (Toxicity related terms) 
(((exp IBUPROFEN/ OR exp 
"ANTIINFLAMMATORY 
AGENTS, NON-STEROIDAL"/ 
OR (ibumetin).ti,ab OR 
(motrin).ti,ab OR (advil).ti,ab OR 
(nuprin).ti,ab OR (nurofen).ti,ab 
OR (brufen).ti,ab) AND (exp 
"ADVERSE DRUG EVENT"/ OR 
exp "DRUG TOXICITY"/ OR 
IBUPROFEN/ae OR 
IBUPROFEN/tu OR 
IBUPROFEN/de OR (adverse 
effect*).ti,ab OR (side 
effect*).ti,ab OR (adverse drug 
reaction*).ti,ab OR 
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Adverse effect* - side effect* - adverse drug reaction* - complication* - harm* - 
tolerabil* 
Mesh terms (ADVERSE DRUG EVENT- DRUG TOXICITY- IBUPROFEN/ae - 








(preemie*).ti,ab OR exp 








(1992 to present) 
Number of hits 
11 
Population Search Terms (Defined as infants less than 37 weeks gestational age) 
Prematurity – preterm – premature* - premmie* - preemie* 
Mesh terms (NEONATES:BIRTHWEIGHT) 
N.B: NEONATES: BIRTHWEIGHT from BNI thesaurus of preterm-preterm babies 
Intervention Search Terms (Ibuprofen and most commonly used brands) 
Ibuprofen – Non-steroidal anti-inflammatory –" Non-steroidal anti-inflammatory" - motrin 
– advil – nuprin – nurofen – brufen – ibumetin 
N.B: no Mesh terms for any of the intervention terms in this database 
Outcome Search Terms (Toxicity related terms) 
Adverse effect* - side effect* - adverse drug reaction* - tolerabil* -complication* -harm* 





(ibumetin).ti,ab OR (motrin).ti,ab 
OR (nuprin).ti,ab OR (advil).ti,ab 
OR (nurofen).ti,ab OR 
(brufen).ti,ab) AND (exp 
"DRUGS : ADVERSE 
REACTIONS"/ OR (adverse 
effect*).ti,ab OR (side 

















Provided by US 
national library of 
medicine 
Number of hits 
473 
N.B: PubMed uses same Mesh as Medline 
Population Search Terms (Defined as infants less than 37 weeks gestational age): 
prematurity – preterm – premature* 
premmie*- preemie** 
Mesh Terms (INFANT, PREMATURE- INFANT, EXTREMELY PREMATURE- 
PREMATURE BIRTH) 
Intervention Search Terms (Ibuprofen and most commonly used brands ) 
ibumetin – motrin – nuprin – advil – nurofen – brufen 
Mesh Terms (IBUPROFEN – ANTI-INFLAMMATORY AGENTS, NON-STERIODAL) 
Outcome Search Terms (Toxicity related terms) 
Adverse effect*- side effect*- adverse drug reaction*- tolerabil* - complication* -harm* 
Mesh Terms (ABNORMALITIES,DRUG-INDUCED,  DRUG-RELATED SIDE EFFECTS 
AND ADVERSE REACTIONS-LONG TERM ADVERSE EFFECTS - IBUPROFEN/-ae - 
IBUPROFEN/-tu - IBUPROFEN/-to) 
(((((ibuprofen[MeSH Terms]) OR 
anti-inflammatory agents, non-







((((((((drug-related side effects 
and adverse reactions[MeSH 
Terms]))) OR long term adverse 
effects[MeSH Terms]) OR 
((("ibuprofen/adverse 
effects"[MeSH Terms]) OR 
"ibuprofen/therapeutic 
use"[MeSH Terms]) OR 
"ibuprofen/toxicity"[MeSH 
Terms])) OR ((((adverse 






induced[MeSH Terms]) OR 
((complication*[Title/Abstract]) 
OR harm*[Title/Abstract]))) AND 
(((((((prematurity[Title/Abstract]) 





Terms]) OR infant, extremely 
premature[MeSH Terms]) OR 
premature birth[MeSH Terms])) 
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Provided by Ovid 
(1970 to 31 
January 2019 ) 
Number of hits 
7 
   
N.B: There is no Mesh terms in this database so the search run in all fields as key 
words and use same terms as Embase because it is a drug database 
Population Search Terms (Defined as infants less than 37 weeks gestational age) 
prematurity – preterm – premature* 
premmie*- preemie* af 
Intervention Search Terms (Ibuprofen and most commonly used brands ) 
Ibuprofen.af 
Outcome Search Terms (Toxicity related terms) 
"Adverse drug reaction" – side effect* - tolerabil* -" drug induced malformation"- 
complication* - harm* 
1 (adverse drug reaction xy or 
side effect* or tolarabil* or drug 
induced malformation xy or 
complication* or harm*).af. 
2. (prematurity or preterm or 
premature* or premmie* or 
preemie*).af. 
3. 1 and 2 and 3 
limit 4 to yr="1967 - 2017" 
Cochrane library  





N.B: uses same Mesh as Medline 
Population Search Terms (Defined as infants less than 37 weeks gestational age): 
prematurity – preterm – premature* 
premmie*- preemie* 
Mesh Terms (INFANT, PREMATURE- INFANT, EXTREMELY PREMATURE- 
PREMATURE BIRTH) 
Intervention Search Terms (Ibuprofen and most commonly used brands ) 
ibumetin – motrin – nuprin – advil – nurofen – brufen 
Mesh Terms (IBUPROFEN – ANTI-INFLAMMATORY AGENTS, NON-STERIODAL) 
Outcome Search Terms (Toxicity related terms) 
Adverse effect*- side effect*- adverse drug reaction*- tolerabil* - complication* - harm* 
Mesh Terms (ABNORMALITIES,DRUG-INDUCED,  DRUG-RELATED SIDE EFFECTS 
AND ADVERSE REACTIONS-LONG TERM ADVERSE EFFECTS - IBUPROFEN/-ae - 
IBUPROFEN/-tu - IBUPROFEN/-to) 
(((exp IBUPROFEN/ OR exp 
"ANTI-INFLAMMATORY 
AGENTS, NON-STEROIDAL"/ 
OR (ibumetin).ti,ab OR 
(motrin).ti,ab OR (nuprin).ti,ab 
OR (advil).ti,ab OR 
(nurofen).ti,ab OR (brufen).ti,ab) 
AND (exp "DRUG-RELATED 
SIDE EFFECTS AND 
ADVERSE REACTIONS"/ OR 
exp "LONG TERM ADVERSE 
EFFECTS"/ OR IBUPROFEN/-
ae OR IBUPROFEN/-tu OR 
IBUPROFEN/-to OR (adverse 
effect*).ti,ab OR (side 
effect*).ti,ab OR (adverse drug 
reaction*).ti,ab OR 











(preemie*).ti,ab OR exp 
"INFANT, PREMATURE"/ OR 
exp "INFANT, EXTREMELY 
PREMATURE"/ OR exp 
"PREMATURE BIRTH"/)) [DT 
1964-2017] 
Clinical trials.gov 
Number of hits  
42 
Keyword search by typing in the advanced search bar : Ibuprofen and premature infants 
Grey literature 
Number of hits 
 0 
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  Studies excluded after full text review with reasons 
(n=64) 
Study ID Reason(s) for exclusion 
Adamska (2005) Polish; could not be translated 
Adamska(2000) Polish; could not be translated 
Akisu (2001) Turkish; could not be translated 
Alba (2015) Conference abstract -treatment not clear 
Antonucci (2009) PKPD study 
Arslan (2010) Turkish; could not be translated  
Babayigit (2018) No adverse effects  
Bagnoli (2013) Unable to extract adverse effects data) 
Bagheri (2016) not measure adverse effects 
Bhatt (2012) Evaluated regional tissue oxygenation only 
Bixler (2017) No adverse effects  
Boghossian (2017) No adverse effects 
Brunner (2013) Unclear which Cox inhibitor was associated with IVH  
Calkavur(2010) Conference abstract - insufficient data  
Chinta(2015) Conference abstract - insufficient data  
Concheiro-Guisan(2014) Conference abstract - insufficient data  
Constance (2017) No adverse effects mentioned 
Cooper-Peel(1996) PKPD study 
Dani (2018) No adverse effects mentioned 
De Carolis (2000)* Evaluated effect on cerebral and renal hemodynamic 
De Albuquerque Botura (2017) No study group received ibuprofen only 
Demirel (2012) PKPD study 
Ding (2018) No adverse effects mentioned 
Ethington (2011) 
Unclear if the adverse effects were related to 
ibuprofen or indomethacin 
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Fesharaki (2012) Iranian; could not be translated 
Fonseca (2014) Unclear reporting of adverse effects 
Gimeno (2007) Spanish - translation showed to be a review article 
Gorman(2015) 
Evaluated effect on cerebral and somatic regional 
tissue oxygenation 
Gournay (2002) Case report included in Gournay 2004 
Goudjil(2012) 
Conference abstract - insufficient reported data on 
ibuprofen adverse effects 
Guimaraes (2009) No adverse effects mentioned 
Härkin (2018) No adverse effects mentioned 
Hochwald et al., 2018 No study group received ibuprofen only 
Hariprasad (2002) Letter to editor – no adverse effect reported  
Hoxha (2012) 
Conference abstract - insufficient data. Primary 
publication included (Hoxha 2013) 
Jansen (2017) No adverse effects mentioned 
Kang (2017) No adverse effects mentioned 
Kaur (2018) Not included ibuprofen as intervention 
Kim(2015) 
Conference abstract. Primary publication (Kim 2016) 
included 
Letshwiti (2017) No adverse effects mentioned 
Lin (2012) Chinese; could not be translated 
Mehralizadeh (2011) Conference abstract - insufficient data  
Mian(2016) 
Unclear if the adverse effects were related to 
ibuprofen or indomethacin 
Mitra (2016) Systematic review protocol  
Morley (2003) Letter to editor-no adverse effects reported  
Mosca(1997) 
Evaluated effect on cerebral perfusion and 
oxygenation 
Naulaers (2005) 
Evaluated effect on cerebral perfusion and 
oxygenation 
Nimiri(2010) No adverse effects mentioned 
Olgun (2014) Conference abstract - insufficient data  
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Pacifici (2014) Review article  
Patel (2000) Evaluated effect on cerebral hemodynamic  
Raaijmakers (2018) Measure long term renal adverse effects 
Rheinlaender(2010) No adverse effects mentioned 
Richards (2009) No adverse effects mentioned 
Romagnoli (2018) No adverse effects mentioned 
Sari (2013) Letter to editor – no adverse effects reported 
Sedsikaite(2014) Conference abstract - insufficient data  
Shin(2017) 
Letter to editor. Primary publication (Kim-2016) 
included 
Terek (2014) No adverse effects mentioned 
Thibaut (2011) Review article  
Vanhaesebrouck(2007) No adverse effects mentioned 
Woodhead(2015) Conference abstract - insufficient data  
Zanardo (2005) PKPD study 
Zecca (2009) PKPD study 
*This study ‘Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very 
preterm neonates ‘published in Clinical Pharmacology and Therapeutics 67(6): 676-683 
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 Trials excluded as no results posted (n=2) 
1.NCT02602054 
Trial name 
The Best Treatment Strategy: Surgical Versus 
Pharmacological, to Close the Ductus Arteriosus Persistent 
in Preterm Infants. A Randomized Controlled Trial 
Methods RCT, setting: NICU, Mexico 
Participants 40 premature neonates with PDA 
Interventions 
Experimental group: Surgical treatment 
Control group: one of the following drugs to be administered 
-Indomethacin: 3 doses (1 dose every 12 hours) for 2 days. 
Dose: 0.1 - 0.25 mg / kg 
-Ibuprofen: 3 doses (1 dose every 24 hours) for 2 days. 
Dose 05 - 10 mg / kg 
-Acetaminophen: 12 doses (1 dose every 6 hours) for 3 
days Dose 15 mg / kg 
Outcomes 
Success rate of closure patent ductus arteriosus 
Adverse effects and complications of treatment Death 
before discharge  
Starting date October 2015 
Contact information 
Esaú Luis Nieto, Pediatrician 5564787736 
dresauln@gmail.com 
Notes 
Primary estimated completion date: October 2017 
Contacted on: 09 Feb 2018  
2.NCT01149564 
Trial name  
Comparison of Oral and Intravenous Ibuprofen for 
Treatment of Patent Ductus Arteriosus in Extremely 
Premature Infants: A Randomized Controlled Trial 
Methods  
RCT 
Setting: NICU, Taiwan 
Participants  
70 neonate< 28 weeks, RDS requiring assisted ventilation, a 
PDA without other cardiac anomalies 
Interventions  
Intervention group: Oral ibuprofen  
Placebo group: IV ibuprofen  
Dose (both): initial 10 mg/kg then 5 mg/kg at 24-hour 
intervals as indicated by PDA flow pattern. 
Outcomes 
Number with PDA closed or adverse effects as a measure of 
efficiency and safety. 
Starting date  December 2009 
Contact information  
Bai-Horng Su, MD, PhD 886-4-22052121 ext 2061 
bais@ms49.hinet.net 
Notes  
Primary estimated completion date: June 2012 
Contacted on: 09 Feb 2018  
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  Ongoing trials awaiting results (n=10)  
1.NCT 02422966 
Trial name  Efficacy and safety of intravenous paracetamol in 
comparison to ibuprofen for the treatment of patent 
ductus arteriosus in preterm infants: study protocol for a 
randomized control trial 
Methods  Multicentre RCT 
Settings: NICUs (Italy) 
Participants  110 neonates (GA 24 - 31 weeks) with PDA (ECHO)   
Interventions Group I: IV paracetamol,15mg/kg/dose every 6 hours for 
a total of 12 doses  
Group II: IV ibuprofen, initial dose of 10mg/kg followed 
by 5mg/kg after 24 and 48 hours 
Outcomes PDA closure rate, need for surgical ligation, reopening 
of the duct, renal failure, NEC, liver failure 
Starting date Dec 2015 
Contact information  Angelini S.p.A. - Piazzale della Stazione, 
00071S. Palomba - Pomezia (Roma) Italy. Tel. 
+3906910451.Website: 
http://www.angelini.it/wps/wcm/connect/it/home 
Notes  Estimated completion: Dec 2017  
2.NCT 02056223 
Trial name  Paracetamol versus Ibuprofen for Patent Ductus 
Arteriosus Closure in Preterm Infants. A Prospective, 
Randomized, Controlled, Double Blind, Multicenter 
Clinical Trial 
Methods  Multicentre RCT, Double Blind, Settings: NICUs (Italy) 
Participants  120 neonates ≤ 31+ 6 days weeks with Hs PDA 
Interventions Group A: Boluses of paracetamol 15 mg/kg four time a 
day for three consecutive days 
Group B: Boluses of ibuprofen 10-5-5-mg/kg/dose once 
daily for three consecutive days 
Outcomes PDA closure, oliguria (first 14 days of life), NEC (first 14 
days of life), IVH (within 28 days of life) 
Starting date  Feb 2014 
Contact information  Paola Lago, MD    0039 049 821 ext 3545    
paola.lago@aopd.veneto.it      
Sabrina Salvadori, MD    0039 049 821 ext 3546    
sabrina.salvadori@aopd.veneto.it      
Notes  Estimated completion: Jul 2019  
3. NCT 01630278     
Trial name  Impact of Early Targeted Ibuprofen Treatment of Patent 
Ductus Arteriosus (PDA) on Long Term 
Neurodevelopmental Outcome in Very Premature 
Infants (TRIOCAPI) 
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Methods  RCT 
Setting: France 
Participants  363 neonates with GA< 28 weeks and postnatal age < 
12 hours 
Interventions  Ibuprofen group: Ibuprofen before 12 hours of life 
 Placebo group:  Placebo before 12 hours of life 
Outcomes  2-year survival without cerebral palsy, other prematurity-
related morbidities (pulmonary, digestive, neurological, 
renal) 
Starting date Mar 2012 
Contact information  Not mentioned 
Notes  Estimated completion: Feb 2019  
4. NCT02884219 
Trial name Multi-centre, Randomized Non-inferiority Trial of Early 
Treatment Versus Expectative Management of Patent 
Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial 
Belgium Netherlands Ductus Trial 
Methods  RCT 
Setting: Belgium 
Participants  564 neonates GA <28 weeks with PDA 
Interventions  Active Comparator: Early Treatment with ibuprofen or 
indomethacin within the first 3 days of life  
Expectative Treatment: No intervention  
Outcomes  Mortality, and/or NEC, and/or BPD (day 1 to 3 months) 
Short term adverse effects (day 1 to 3 months) 
Long-term neurodevelopmental consequences (at 
corrected age of 2 years) 
Starting date  Dec 2016 
Contact information  Willem P de Boode, MD PhD +31 24 361 44 30 
willem.deboode@radboudumc.nl 
Notes  Estimated completion: December 2019  
5. NCT02128191 
Trial name Efficacy and Safety of No Treatment Compared With 
Oral Ibuprofen Treatment for Patent Ductus Arteriosus 
in Preterm Infants: a Randomized, Double-blind, 
Placebo-controlled, Non-inferiority Clinical Trial 
Methods RCT, non-inferiority trial 
Setting: Samsung Medical Centre, Seoul 
Participants  142 neonates with GA ≤ 30 weeks or BW ≤ 1250 g with 
PDA during 5 to 14 days of life 
Interventions  Ibuprofen group: Initial dose of 10 mg/kg, then two 
doses of 5 mg/kg at 24 and 48 hours (oral)  
Placebo group: Initial dose of normal saline, then 
second and third dose at 24 and 48 hours  
Outcomes Moderate to severe BPD or mortality at 36 weeks 
postmenstrual age, IVH (grade 3 or greater), retinopathy 
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of prematurity, NEC (stage 2b or greater), duration of 
PDA and intubation, adverse effects, growth velocity 
Starting date Jul 2014 
Contact information  Se In Sung, M.D. 82-2-3410-1775 
sein.sung@samsung.com   
Notes  Estimated completion: Apr 2019  
6. NCT 02884219 
Trial name/title Early Treatment Versus Expectative Management of 
PDA in Preterm Infants (BeNeDuctus) 
Methods Multi-centre, RCT 
Participants 564 neonates with GA < 28 weeks or BW ≤1000g 
Interventions Ibuprofen vs. Indomethacin (dosage not mentioned) 
Outcomes Primary outcome: composite of mortality, and/or NEC 
(Stage > IIa), and/or BPD (all at a postmenstrual age of 
36 completed weeks) 
Secondary outcome: cardiovascular failure, adverse 
effects and long-term neurodevelopmental 
consequences  
Starting date Dec 2016 
Contact information Willem Boode, MD, PhD, Netherland 
Phone: +31243614430 
Email: willem.deboode@radboudumc.nl 
Note ClinicalTrials.gov identifier: NCT 02884219 
As of Jan 2019, this trial was still ongoing 
7. NCT 03103022 
Trial name/title Combination of Acetaminophen and Ibuprofen in the 
Management of Patent Ductus Arteriosus 
Methods Prospective cohort studies 
Participants 30 neonates with GA <30 weeks 
Interventions Oral ibuprofen:10mg/kg/dose for the first dose, then 
5mg/kg/dose at 24 and 48 hours 
Oral acetaminophen:15mg/kg/dose every 6 hours for 3 
days 
Outcomes Primary outcome: Efficacy of ductal closure and safety 
Secondary outcome: Ductal reopening, sepsis, NEC, 
BPD, IVH, periventricular leukomalacia, retinopathy of 
prematurity and ventilator days and developmental 
status  
Starting date Jun 2017 
Contact information Sanket D Shah, MD, University of Florida, United States 
Phone: 904-244-3508 
Email: sanket.shah@jax.ufl.edu 
Note ClinicalTrials.gov identifier: NCT 03103022 
As of January 2019, this trial was still ongoing 
8. NCT 03648437 
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Trial name/title Paracetamol and Ibuprofen in Closing Patent Ductus 
Arteriosus (PDI) 
Methods RCT 
Participants 20 neonates with GA <37 weeks 
Interventions Ibuprofen: IV every 24h for 3 days, dosages: 10-5-5 
mg/kg 
Paracetamol: IV for 3 days: loading dose 20mg/kg, then 
7.5mg/kg every 6h (up to12 doses) 
Outcomes Primary outcome: Efficacy of the ductal closure and 
safety 
Secondary outcome: Complications (not mentioned), 
need for ductal therapies, cardiac ultrasound findings, 
duration of ventilation assist, long-term complications of 
prematurity  
Starting date Sept 2018 
Contact information Outi Aikio, MD, PhD, Finland 
Phone: +35883155810 
Email: outi.aikio@ppshp.fi 
Note  ClinicalTrials.gov identifier: NCT 03648437 
As of January 2019, this trial was still ongoing 
9. NCT 03701074 
Trial name/title Randomized Controlled Trial to Evaluate the Safety and 
Efficacy of Acetaminophen in Preterm Infants Used in 
Combination with Ibuprofen for Closure of the Ductus 
Arteriosus 
Methods RCT 
Participants 80 neonates with GA ≤27 6/7 weeks 
Interventions Ibuprofen and placebo: Ibuprofen18 mg/kg/dose then 2 
doses (9 mg/kg/dose) at 24 hours. Placebo sterile 
water, with similar volume and colour as ibuprofen for 3 
days at 6 hours intervals 
Ibuprofen and acetaminophen: Ibuprofen 18 mg/kg/dose 
then 2 doses (9 mg/kg/dose) at 24 hours. Oral 
Acetaminophen at 15 mg/Kg/dose every 6 hours for 3 
days  
Outcomes Primary outcome: Efficacy for the ductal closure and 
safety 
Secondary outcome: Liver injury, renal injury, 
haematological adverse effects, BPD, retinopathy of 
prematurity, intestinal perforation, NEC, GI 
haemorrhage, late onset sepsis, periventricular 
leukomalacia 
Starting date Dec 2018 




Note ClinicalTrials.gov identifier: NCT 03701074 
As of January 2019, this trial was still ongoing 
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10. CTRI/2014/08/004805 
Trial name/title Oral Paracetamol vs. Oral Ibuprofen for closure of 
Hemodynamically significant Patent Ductus Arteriosus 
in Preterm Neonates (32 weeks): A Blinded 
Randomized Controlled Non-Inferiority Trial 
Methods RCT 
Participants 196 neonates with GA ≤32 weeks 
Interventions Ibuprofen: 10mg/kg followed by 5mg/kg at 24 and 48 
hours  
Paracetamol:15mg/kg every 6 hours for 3 days in first 
course and same dose in second course until PDA is 
patent 
Outcomes Primary outcome: Efficacy of the ductal closure and 
safety 
Secondary outcome: azotaemia, oliguria, hepatitis, 
deranged coagulogram, IVH, periventricular 
leukomalacia, NEC, BPD and retinopathy of prematurity, 
reopening of PDA, need for surgical ligation and 
mortality rate 
Starting date Apr 2014  
Contact information Dr Ashutosh Kumar, Senior Resident, Newborn unit 
(Dept. of Pediatrics), Nehru Hospital PGIMER 
Chandigarh 160012, India 
Phone: 08194951444 
Email: ashuarnav@gmail.com 
Note Clinical Trials Registry – India CTRI number: 
CTRI/2014/08/004805  
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 Risk of bias of the included randomised controlled trials (n=42) 
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ECH, echocardiography; ISRCTN, International standard randomised controlled trial number 
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 Characteristics of the included RCTs (n=42) 
Characteristics of the included RCTs: ibuprofen vs. placebo for PDA prophylaxis (six studies) 















• GA < 31 weeks 
Exclusion criteria 
• BW < 500 g 
• Antenatal indomethacin 
• Persistent PHT 





5 mg/kg every 24 
hours within 2 
hours of birth 
N=23; mean (SD) 
28.1 (1.1) weeks 
and 934 (288) g 
No treatment 
N=23; mean (SD): 
28.0 (1.9) weeks and 





















• GA < 28 weeks 
Exclusion criteria 
• Maternal use of 
nephrotoxic medication 
within 3 days before 
delivery 
• Congenital malformations 
• Shock or life-threatening 
infection 
• Hydrops fetalis 
• IVH (3-4) 
IV ibuprofen: 10-5-
5 mg/kg every 24 
hours within 6 
hours of birth 
N= 65; mean (SD) 
26 (0.9) weeks and 
844 (181) g 
 
IV placebo: Saline in 
volumes and 
schedule same as 
ibuprofen within 6 
hours of birth 
N= 66; mean (SD): 
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• Neurological dysfunction 
• Substantial right-to-left 
shunt  














• GA of < 28 weeks and/or 
BW of <1000 g enrolled 12 
to 24 hours after birth 
Exclusion criteria 
• Major congenital 
abnormalities 
• Life threatening infection 
• IVH (3-4) 
• Urine output <1 mL/kg/h 
during the preceding 8 h 
• Serum creatinine level of 
>1.6 mg/dL 
• Platelet count of <60000 
mm3 




• Persistent PHT 
Oral ibuprofen: 10-
5-5 mg/kg every 24 
hours within 12–24 
hours of birth N=23; 
mean (SD): 25.6 
(1.6) weeks and 
775 (131) g 
No treatment 
N=23; mean (SD): 
26.4 (1.7) weeks and 




















• GA 24-30 weeks within 6 
hours of birth 
Exclusion criteria 
• Major congenital 
malformation  
IV ibuprofen:10-5-5 
mg/kg within first 6 
hours of life 
N=205; mean (SD): 
28.1 (1.7) weeks 
and 1048 (315 g) 
 
IV saline in similar 
volume and regimen 
N=210; mean (SD) 
28.1 (1.6) weeks and 









course [5 rise 
in 
creatinine/oli
guria, 2 died, 
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• IVH > grade 1 
• Congenital infection or 
septicaemia 
• Uncontrolled hypotension 
• Serum creatinine 
>115µmol/l 
• Bilirubin >85 µmol/l 














• GA 28-32 weeks 
• BW ≤1500g 
Exclusion criteria 
• Maternal prenatal infection 
• Maternal drug abuse 
• Maternal NSAIDs use 
• Hydrops fetalis 
• Unstable clinical 
conditions 
• Congenital heart disease  
• Persistent PHT 
• Serum creatinine > 1.5 
mg/dL 
• Platelet count <75,000 
cells/L 
• Abnormal coagulogram 
Oral ibuprofen:10-
5-5 every 24 hours  
N= 22; mean (SD): 
30.6 (1.8) weeks 
and 1280 (80) g 
Placebo (orange 
starch): three doses 
with the same 
method and time 
schedule of 
ibuprofen 
N=20; mean (SD): 
30.2 (2.1) weeks and 


















• BW <1500g 
• PDA (ECHO) 
Oral ibuprofen:10-
5-5 mg/kg every 24 
hours 
N=31; mean (SD): 
Placebo (orange 
starch): same 













• Congenital heart disease  
• Symptomatic PDA 
• Maternal prenatal infection 
• Maternal drug abuse 
• Maternal NSAIDs 
• Hydrops fetalis 
• Other major congenital 
anomalies 
• Persistent PHT 
• Serum creatinine > 1.5 
mg/dL and or BUN> 30 
mg/dL 
• Platelet count < 75,000 
cells/mm3 
• Abnormal coagulogram 
29.3 (1.9) weeks 
and 1157 (264) g 
 
N= 31; mean (SD): 
29.3 (2.2) weeks and 
1163 (261 g) 










• GA < 34 weeks 
• Nasal CPAP with >30% 
oxygen 
• Platelet count >75000/mL 
• Serum creatinine< 1.5 mg/dL 
• Absence of IVH (3-4) before 
randomisation 
Exclusion criteria 
• Congenital malformations  
• Persistent PHT 
IV prophylactic 
ibuprofen: 10-5-5 
mg/kg every 24 
hours within 24 
hours of life 
N=40; mean (SD): 





treatment but after 
PDA (ECHO) 
N=40; mean (SD): 
29.6 (5.6) weeks 










Characteristics of the included RCTs: Ibuprofen vs. placebo for PDA treatment (three studies) 
















• GA ≤ 30 weeks, BW: 500-1000g, 
<72 hours old 
• Non symptomatic PDA (ECHO) 
Exclusive criteria: 
• Congenital bacterial infection 
• Maternal antenatal NSAIDs 
exposure <72 hours before 
delivery 
• Treatment with a steroid at any 
time since birth 
• Unremitting shock 
• Renal failure or oliguria 
• Platelet count <75,000/mm3 
• Bleeding tendency 
• Expected survival <48 hours  
IV Ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N= 68; mean (SD): 
26.1 (1.3) weeks and 
798.5 (128.7) g 
Placebo: 
indistinguishable 
solution at same 
volumes 
N=68; mean 
(SD): 26.2 (1.4) 
weeks and 





















• GA <32 weeks and BW <1500 g 
• Postnatal age (48-96 hours) 
• RDS necessitating treatment 
• Hs-PDA (ECHO) 
Exclusion criteria: 
• Congenital anomalies 
• IVH (grade 3)  
• Serum creatinine ≥ 1.5 mg% 
• Platelet count 660,000/mL3 
• Tendency to bleed 
• Hyperbilirubinemia  
Oral ibuprofen: 
10mg/kg 
ECHO performed at 
24 hours, 48 hours- if 
PDA present, 2nd 
dose and 3rd dose  
(5mg/kg) given. 
N=33; mean (SD): 
28.8 (2.8) weeks and 
1035 (353) g 






(SD) 28.9 (2.7) 





















• BW: 500 - 1250 g 
• GA: 23 - 32 weeks 
• >24 hours old but ≤14 days old 
Exclusion criteria 
• Severely small for GA 
• Congenital malformations 
• Proven sepsis 
• Serum creatinine >1.7 
•  Oliguria (urine output <1 
cc/kg/hr) 
• Pulmonary hypertension 
• Abdominal pathology 
• Bleeding diathesis 




90th centile) 26 (23-
28) weeks and mean 
(SD) 854 (204) g 
[If Hs-PDA 
developed in either 
group before 28 
days, neonates 
received un-blinded, 













2) weeks and 























• GA: 27-35 weeks 
• Postnatal age (2-7) days 
with PDA (ECHO) 
• Moderate to severe RDS 
Exclusion criteria: 
• Congenital anomalies 
• Hydrops fetalis 
• Hyperbilirubinemia 
• Life threatening infections 
• Platelet count < 60.000/ml 
• Bleeding tendency 
Oral ibuprofen: 
(10-5-5 mg/kg) 
 every 24 hours 
N=12; mean (SD): 
31.2 (2.5) weeks and 









N=9; mean (SD): 
32.9 (1.6) weeks 




















• GA<34 weeks 
• RDS 
• Age <10 days 
• PDA (ECHO) 
Exclusion criteria: 
• Congenital anomaly  
• IVH (within 24 hours) 
• Urine output <1ml/kg/hour 
• Serum creatinine ≥1.6mg/dl  
• Tendency to bleed 
• NEC 
• Hyperbilirubinemia  
Oral ibuprofen: three 
doses at 24 hours  
N=15; mean (SD): 
30.8 (2.3) weeks and 
1412 (354) g 
 
Indomethacin: 
three doses at 12 
hours 
N=15; mean (SD): 
29.86 (2.92) 































• GA <34 weeks 
• Age ≤ 14 days 
• Platelet count ≥ 
100,000/µmol 
• Serum creatinine ≤ 1.6 
mg/dL 
• Absence of clinical 
abnormal clotting 
• IVH 
• PDA (ECHO) 
Exclusion criteria: 
• Congenital anomalies 
• Hydrops fetalis 
Oral ibuprofen: 
(10-5-5) at 24 hours  
N=18; mean (SD): 
31.5 (1.4) weeks and 




doses at 24 hours 
N=18; mean (SD): 
30.9 (2.0) weeks 
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• Urine output < 1ml/kg/hr in 
the preceding 12 hours 
• Bleeding tendency 












• GA ≤ 33 weeks 
• BW ≤ 1750 g 
Exclusion criteria 
• Congenital heart lesions 
• Documented infection 
• Thrombocytopenia  
• IVH (grade 4) 
IV ibuprofen:10-5-5 
every 24 hours 
N=32; mean (SD): 
27.8 (2.6) weeks and 
1060 (350) g 
Continuous 
indomethacin: 
infused for 36 
hours 
N= 31; mean 
(SD): 27.8 (2.8) 


















• GA ≤ 34 weeks 
• Postnatal age 48–72 hour 
• RDS with mechanical 
ventilation 
• PDA (ECHO) 
Exclusion criteria 
• Congenital anomalies 
• Persistent PHT 
• Recent bleeding (< 48 
hours) 
• Platelet count of 
<50,000/mm3 
• Urine output <1 ml/kg/hour 
during the previous 12 
• Serum creatinine > 140 
mmol/l and BUN >14 mmol/l 
IV Ibuprofen:10-5-5 
mg/kg every 24 
hours, repeated if 




N=94; mean (SD): 
 28 (2) weeks and 
1126 (412) g 
IV indomethacin: 
0.2-0.2-0.2 mg/kg 
at 12 hours 
N=81; mean (SD) 
29 (3) weeks and 

















– not given 
N=150 
Inclusion criteria 
• BW <1000g 
• RDS on X-ray 
• PDA (ECHO) 
Exclusion criteria 
• Evidence of infection or 
sepsis 
• Congenital anomaly 
• Oliguria (urine output 
<1ml/kg/h) or serum 
creatinine > 2 mg/dl 
• Low platelet count 
(<50,000/mm cube) or 
bleeding tendency 
IV Ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N=71; mean (SD): 
26.2 (1.7) weeks and 




every 24 hours  
N=73; mean (SD): 
26.3 (1.6) weeks 


























• GA <34 weeks 
• First week of life 
• Hs-PDA (ECHO) 
Exclusion criteria 
• Urine output <1ml/kg/h in 
last 8 hours 
• Creatinine > 1.8mg/dl 
• Platelet count < 
60,000/µmol 
• Active bleeding 
• IVH (3-4) 
• Severe hyperbilirubinemia 
IV Ibuprofen: 10-5-5 
every 24 hours 
N=23; mean (range): 
28.5 (27 to 30) 






N= 24; mean 
(range or SD): 
 28 (26 to 31) 




















• GA < 33 weeks  
• RDS  
• Postnatal age 48 - 72 hours 
Exclusion criteria 
• Congenital malformations 
• Persistent PHT 
• Hydrops fetalis 
• IVH (<48 h)  
• Clinical bleeding 
• Thrombocyte count < 60 
000/mm3 
• Oliguria of <1 ml/kg/hour in 
preceding 8 hours 
• BUN > 14 mmol/l, serum 
creatinine > 140 mmol/l 
• Hyperbilirubinemia needing 
transfusion 
IV ibuprofen:10-5-5 
mg/kg every 24 
hours 
N=20; mean (SD): 
29.0 (2.4) weeks and 
1270 (450) g 
Indomethacin: 0.2 
mg/kg at 12 hours 
(three doses) 
N=20; mean (SD): 
28.7 (1.9) weeks 





















• GA ≤ 32 weeks 
• Age of 2 to 4 days 
• PDA (ECHO) 
• RDS necessitating 
respiratory support 
Exclusion criteria 
• Major congenital anomalies 
• Life-threatening infection 
• Hydrops fetalis 
IV ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N=74; mean (SD): 
29.0 (2.3) weeks and 
1230 (390) g 
IV indomethacin: 
0.2mg/kg every 
12 hours (three 
doses)  
N=74; mean (SD): 
29.0 (2.1) weeks 
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• IVH (in 24 hours) 
• Urine output < 1 ml/kg/hr 
• Serum creatinine ≥ 1.6 
mg/dl or BUN > 40 mg/dl 
• Platelet count < 60,000mm3 
• Tendency to bleed 











• GA <33 weeks 
• RDS  
• Hs-PDA (second day of life) 
IV ibuprofen: 10-5-5 
mg/kg every 24 
hours  
N=9; mean (SD): 
 29.1 (2.2) weeks 
and 1151 (426) g 
IV indomethacin: 
0.2-0.1-0.1 mg/kg 
every 24 hours  
N=8; mean (SD): 
29.5 (2.6) weeks 

















• GA < 34 weeks 
• BW < 2500 g 
• Hs-PDA (ECHO) with a 
diameter > 1.5 mm 
Exclusion criteria 
• Congenital anomalies 
• Serum creatinine ≥140 
umol/l, BUN > 14 mmol/l 
• Platelet count <50,000/mm3 
• NEC, abdominal distention, 
feeding intolerance 
• Tendency to bleed 
• Hyperbilirubinemia requiring 
transfusion 
• Anuria < 0.5 ml/kg/hour in 
preceding 8 hours 
Oral ibuprofen:10-5-5 
mg/kg every 24 
hours. If PDA persist, 
a second course of 
ibuprofen given. If 
PDA persist, a 
course of 
indomethacin given 
N=21; mean (SD): 
27.7 (2.5) weeks and 
1094 (480) g 
IV Indomethacin: 
0.2 mg/kg/dose 
every 24 hours. If 
PDA persist, a 
second course 
given 
N= 20; mean 
(SD): 27.7 (2.5) 
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• GA <32 weeks 
• BW <1500g with hs-PDA 
• RDS requiring respiratory 
support 
Exclusion criteria 
• Congenital heart defect 
• Life-threatening infection 
• NEC 
• Bleed, or platelet counts 
<60,000/mL 
• Liver failure 
• Severe intracerebral 
haemorrhage 
• Severe hyperbilirubinemia 
• Creatinine >1.5  
• Obvious bleeding 
• Mother/infant treated with 
NSAIDs or drugs 
contradicted to ibuprofen 
Oral ibuprofen: 
Doses according to 
age and weight of 
neonates at 24 hours 
intervals for three 
doses 
N=40; mean (SD): 
29.2 (1.8) weeks and 
1182.37 (197.25) g 
Indomethacin: 
Doses according 
to age and weight 
of neonates 
N=40; mean (SD): 




















• GA< 32 weeks 
• BW<1500g 
• On CPAP 
• Platelet count ≥100, 000/μL 
• Serum creatinine ≤1.5 
mg/dL 
IV ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N=32; mean (SD): 
28.7 (2.2) weeks and 
1134 (200 g) 
Indomethacin: 
0.2-0.2-0.2 mg/kg 
every 12 hours  
N=31; mean (SD): 
28.2 (2.4) weeks 






Page | 539  
 
• Absence of abnormal 
clotting function 
•  IVH (3-4) 
• PDA (ECHO) 
Exclusion criteria 
• Congenital anomalies 
• Life threatening infection 
• Hydrops fetalis 
• Recent IVH (within 24 
hours) 
• Urine output < 1 mL/kg/h 
during the preceding 8 h 













• GA ≤28 weeks 
• RDS  
• PDA (ECHO) 
Exclusion criteria 
• Severe congenital 
anomalies 
• Lethal cardiopulmonary 
conditions 
IV Ibuprofen:10-5-5 
mg/kg every 24 
hours 
N=60; median 
(range) 25 (23-28) 
weeks and 825 (550-
990) g 
Indomethacin: 
initial dose and 
then 0.1 mg/kg in 
neonates < 48h 
old, 0.2 mg/kg in 
neonates > 48h 
every 24 hours 
N=59; median 
(range): 25 (23-





























• GA <34 weeks 
• Symptomatic PDA 
Exclusion criteria 
• Congenital anomalies  
• CHD or PHT 
Oral ibuprofen: 
10mg/kg daily for 
three days 
N=9; mean (SD): 
30.1 (2.7) weeks and 
1447 (38) g 
Indomethacin 
(oral/IV):0.2mg/kg 
every 12 hours 
(three doses) 
N=9; mean (SD): 
30.4 (2.6) weeks 
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• Congenital infection  
• IVH 
• Bleeding 
• Thrombocytopenia  












• GA<37 weeks 
• BW< 2500g up to 28 days of 
age 
• PDA (ECHO) 
Exclusion criteria 
• Congenital heart disease 
• Severe PHT 
• Hydrops fetalis 
• Multiple congenital 
anomalies 
• Maternal prenatal infection 
• Critical illness 
• IVH (3-4) 
• Platelet count <50,000/cu 
mm 
• Abnormal coagulogram 
• Serum creatinine > 1.5 
mg/dl 
Oral ibuprofen: 10-5-
5 mg/kg every 24 
hours 
N=48; mean (SD): 
29.6 (3.1) weeks and 




every 24 hours for 
three doses-
based on GA  
N=35; mean (SD): 
30.3 (3.1) weeks 
























• GA ≤32 weeks 
Oral ibuprofen: 
10mg/kg/dose once 
daily for three days 
Oral paracetamol: 
10mg/kg/dose 
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Mar 2015 – 
Oct 2016 
• BW ≤1500g 
Exclusion criteria: 
• Congenital heart diseases 
• Major congenital 
malformation 
• IVH (3-4) 
• Renal impairment  
• Pulmonary haemorrhage 
• Thrombocytopaenia 
•  Elevated alanine 
transaminase 
N=9; mean (range): 
28 (25-35) weeks; 




32) weeks; mean 














• GA < 37 weeks 
Exclusion criteria: Not stated 
Oral ibuprofen: 10-5-
5 mg/kg every 24 
hours 
N=25; mean (SD): 
not stated 
Oral paracetamol: 
10mg/kg every 6 
hours for three 
days 

















• GA ≤ 37 weeks 
• BW ≤ 2500g 
• Symptomatic hs-PDA 
Exclusion criteria: 
• Other cardiac anomalies or 
duct dependent lesions 
• Major congenital 
malformations 
• Oliguria (urine output 
<1ml/kg/hour in preceding 
24 hours) 
• Serum creatinine >1.6mg/dl 
Oral ibuprofen: (10-
5-5 mg/kg every 24 
hours) 
N=75; mean (SD): 
31.54 (2.9) weeks 
and 1513.4 (414.9) g 
Oral paracetamol: 
15mg/kg/dose 
every 6 hours 
N=75; mean (SD): 
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• IVH (within 24 hours) 
• NEC 
• Jaundice requiring 
transfusion 
• Platelet counts 
<50,000/mm3 










• GA < 34 weeks  
• Postnatal age < to 14 days 
• Hs-PDA (ECHO) 
Exclusion criteria: 
• CHD  
• Life-threatening infection 
• IVH (3–4) 
• Urine output < 1 ml/kg/hour 
in preceding 8 hours 
• Serum creatinine > 88.4 
µmol/L 
• Platelet count of <50x109 /L 
• Hyperbilirubinemia  
• NEC and/or intestinal 
perforation 
• Liver dysfunction 
Oral ibuprofen: 10-5-
5 mg/kg every 24 
hours 
N=80; mean (SD): 
30.9(2.2) weeks and 
1531(453.5) g 
Oral paracetamol: 
15mg/kg every 6h 
for three days 

























• GA≤ 30 weeks 
• BW ≤ 1250 g 
• Postnatal age 48-96 hours 
Oral Ibuprofen: 10-5-
5 every 24 hours 
N=40; mean (SD): 
27.3 (2.1) weeks and 
973 (224) g 
Oral paracetamol: 
15mg/kg every 6 







is a follow up 
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• PDA (ECHO) 
Exclusion criteria 
• Congenital abnormalities 
• Right-to-left ductal shunting 
• Life-threatening infection 
• IVH (3-4) 
• Urine output < 1 mL/kg/h in 
last 8h 
• Serum creatinine >1.6 
mg/dL 
• Platelet count <60 000/mm3 
• Liver failure 
• Hyperbilirubinemia 
• Persistent PHT 
N=40; mean (SD): 
27.3 (1.7) weeks 













• GA <3 7 weeks admitted 
within 24 hour of birth 
• PDA (ECHO 15 hours-10 
days after birth) 
Exclusion criteria 
• Thrombocytopenia  
• Haemorrhagic disease 
• Oliguria 
• NEC 
• Intestinal perforation 
• Serum creatinine >159.1 
μmol/l 




5 mg/kg every 24 
hours 
N= 43; mean (SD): 
33.4 (2.1) weeks and 
2091 (657) g 
Oral paracetamol: 
15 mg/kg every 6 
hours for three 
days 
N=44; mean (SD): 
33.6 (2.1) weeks 
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• GA < 32 weeks 
• BW <1500 g 
• Respiratory distress  
• PDA (ECHO) 
Exclusion criteria: 
• Right-to-left shunting 
• Major congenital anomalies 
• IVH (3–4) 
• Tendency to bleed 
• Serum creatinine level >16 
mg/dL; serum BUN >9 
mg/Dl 
Oral ibuprofen:10-5-5 
mg/kg every 24 
hours 
N = 32; mean (SD): 
29.3 (1.2) weeks and 
1227.2 (188) g 
IV ibuprofen: 10-
5-5 mg/kg every 
24 hours 
N=32; mean (SD): 





















• GA ≤28 weeks 
• BW <1000 g 
• Postnatal age 48–96 hours  
• PDA (ECHO) 
Exclusion criteria 
• Congenital abnormalities 
• Life-threatening infection 
• IVH (3-4) 
• Urine output < 1 ml/kg/h in 
last 8 hours, serum 
creatinine level >1.6 mg/dl 




N=34; mean (SD): 
26.3 (1.3) weeks and 
872 (123) g 
Oral ibuprofen : 
10-5-5mg/kg 
N=36;mean (SD): 
26.4 (1.1) weeks 















route if PDA 
persisted. 
10 [6 in IV 
and 4 in oral] 
excluded as 
of death 
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• Tendency to bleed 
• Hyperbilirubinemia 


















• GA ≤ 32 weeks 
• BW ≤1500 g 
• 48 to 96 hours 
• PDA (ECHO) 
Exclusion criteria: 
• Congenital abnormalities 
• Life-threatening infection 
• IVH (3-4) 
• Urine output <1 mL/kg/h in 
last 8h 
• Creatinine level >1.6 mg/dL 
• Platelet count <60 000/mm3 
• Tendency to bleed 
• Hyperbilirubinemia 
• Persistent PHT 
IV ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N=50; mean (SD): 
28.7 (2.1) weeks and 
1205 (366) g 
Oral Ibuprofen: 
10-5-5mg/kg 
every 24 hours  
N= 52; mean 
(SD): 28.5 (1.9) 








*Eras 2013 is 

























Jan 2010 – 
Dec  2012 
N=80 [94 neonates assessed. 
14 not included (reasons 
given).80 randomised] 
Inclusion criteria 
• GA (28-32 weeks) 
• BW ≤ 2000g 
• Age 48 to 96h 
• PDA (ECHO) 
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Exclusion criteria 
• Congenital malformations  
• IVH (3-4) 
• Congenital bacterial 
infection 
• Renal failure or oliguria  
• Platelet count < 60,000/mL3 
• Bleeding tendency 
• Serum creatinine <1.6 mg/l; 





hours if PDA 
still present. 
 












• GA ≤ 32 weeks 
• BW ≤ 1500 g 
• Hs-PDA 
Exclusion criteria: 
• Major congenital anomalies 
• Right-to-left ductal shunts 
• Life threatening infections 
• IVH (3-4) 
• Urinary output <1mL/kg/hour 
• Serum creatinine levels 
>1.6mg/dL 
• Thrombocyte count 
<60,000/mm3 
• Hyperbilirubinemia 
• Persistent PH 
Oral ibuprofen: 10-5-
5 mg/kg every 24 
hours 
N=36; mean (SD): 
30.2 (2.04) weeks 
and 1435 (343) g 
Rectal ibuprofen: 
10-5-5 mg/kg 
every 24 hours 
N=36; mean (SD):  
29.7 (2.3) week 










Characteristics of the included RCTs: Ibuprofen vs. indomethacin vs. paracetamol (3 arm trial); (one study) 













• GA< 28 weeks or 
• BW< 1500 g 
• First 2 weeks of life 
• Hs-PDA (ECHO and clinical 
examination) 
Exclusion criteria 
• Congenital anomalies 
• Life threatening sepsis 
• NEC 
• IVH 
• Urine output <1ml/kg/h in 
the last 24 h 
• Serum creatinine >1.5 mg/dl 
• Platelet count <100,000/ml 
• Congenital heart, or duct-
dependent lesions 
IV Ibuprofen: 10-5-5 
mg/kg/day  
N=100; mean (SD): 
25 (2.1) weeks and 
1000 (120) g 
IV Paracetamol: 
15 mg/kg infusion 
followed by 15 
mg/kg/6 hours for 
three days 
N=100; mean 
(SD): 26 (1.9) 
weeks and 1100 
(130) g 
IV Indomethacin: 
0.2 mg/kg infusion 
(three doses) 
every 12 hours  
N=100; mean 
(SD): 26 (2.1) 























• GA: 24 - 34 weeks 
• PDA (ECHO) 
Exclusion criteria: 
• Life-threatening congenital 
defects 
• Congenital heart disease 
• Contraindication for 
ibuprofen 





doses of ibuprofen (5 
mg/kg at 24-hours) 
only if the PDA was 
still 1.5mm at the 











of 5 mg/kg at 24-
hours following 
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• Severe intracranial 
haemorrhage 
• Intestinal ischaemia or 
severe PH 
N=28; mean (SD): 
27.2 (2.2) 













• GA <29 weeks 
• PDA (ECHO) 
• Age 12–24 h 
• RDS  
Exclusion criteria 
• Congenital anomalies 
• Life-threatening infection 
• Pulmonary hypertension 
(ECHO) 
• Death before end of first 
course of ibuprofen 
• Urine output <1 ml/kg /h last 
12 hours  
• Serum creatinine ≥1.5 mg/dl 
• Platelet count ≤50,000/mm3 
• Tendency to bleed 
Low dose IV 
ibuprofen:10-5-5 
mg/kg every 24 
hours 
N=35; mean (SD): 
26(1.7) weeks and 
835 (215) g 
High dose IV 
ibuprofen: 20-
10-10 mg/kg 


























• GA≤ 37 weeks  
• Postnatal age 3-7 days 
• PDA (ECHO) 
Exclusion criteria 
• Major CHD 
• Persistent PHT 
High dose 
ibuprofen:20-10-10 
mg/kg every 24 
hours 
N= 30 ; mean 
(SD): 30 (2.6) 




5 mg/kg every 
24 hours 
N= 30; mean 
(SD): 31.3 (2.1) 
weeks and 








Three in high and 
two in standard 
dose group died 
before end of the 
first course of 
treatment.  
In both groups, 
second course 
(20-10-10) given if 
PDA persisted 
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• Life-threatening infections 
• Severe bleeding 
• Death before the first course 
of ibuprofen 
• Urine output (<1ml/kg/h); 
serum creatinine≥1.8mg/dl 
• Platelet count ≤50,000/mm3 













• GA< 32  
• RDS on ventilation 
Exclusion criteria: 
• Renal impairment  
• Thrombocytopenia  
• Bleeding disorders 
• IVH (3-4) 
• Severe hyperbilirubinemia 
• Sepsis 
• Birth asphyxia 




of 10, 5 and 5 
mg/kg every 24 
hours  
N= 56; mean (SD): 
27.4 (2.7) weeks 
and 1027 (346) g 
Continuous 
infusion: 10-5-5 
mg/kg every 24 
hours 
N=55; mean 











In both groups, 
second course 
was given if PDA 
persisted. 
AE, adverse effects; BW, birth weight; BUN, blood-urea nitrogen; ECHO, echocardiography; CHD, congenital heart disease; CPAP, continuous 
positive airway pressure; GA, gestational age; GI, gastrointestinal; hsPDA, haemodynamically significant PDA; IVH, intraventricular 
haemorrhage; NEC, necrotising enterocolitis; NSAIDs, non-steroidal anti-inflammatory drugs; PDA, patent ductus arteriosus; PHT, pulmonary 
hypertension; RDS, respiratory distress syndrome; SD, standard deviation 
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 Characteristics of the prospective cohort studies (n=7) 
Characteristics of the included prospective cohort studies with comparison group(s) and the reported adverse effects (three studies) 









Jan 2003-Dec 2011 
GA: 24-28 weeks  hs-PDA (ECHO) 
10-5-5 mg/kg (route 
not mentioned) 
N = 248 
No hs-PDA 




N = 104 
Ibuprofen= 146 






Single centre Iran 
2001  
Over six months 
period 
GA: < 37 weeks 




mg/kg every 24 hours;  
two further courses if 
needed  
N = 10 
Oral indomethacin 
0.2mg/kg for three 
doses at 24 hours 
intervals; two 
further courses if 
needed 
N = 10 
Ibuprofen = 1 







Feb 1993 - Aug 
1993 
BW: < 1500g and 
GA: < 32 weeks 
IV ibuprofen:10-5-5 
mg/kg every 24 hours  
within three hours of 
birth 
N= 12 
Single dose of IV 
ibuprofen (10mg/kg) 






doses = 5 
Ibuprofen one dose 
 =8 
Saline = 10 
 
Characteristics of the included prospective cohort studies without comparison group(s) and the reported adverse effects (four studies) 
Study ID Setting Inclusion criteria Ibuprofen protocol Adverse 
effects (n) 
Notes 









GA: <28 weeks 
 
PDA prophylaxis within two hours 
of birth: 10-5-5 mg/kg every 24 
hours. Second course if PDA 
persisted after 72 hours; if still 
persistent: indomethacin 
72 Treatment 









GA: <32 weeks and BW: 
<2000g, 48-96 hours old, 
RDS + PDA (ECHO) 
PDA treatment: Oral 10-5-5 mg/kg 








GA: < 33 weeks with hs-PDA 
(ECHO) 
 
PDA treatment: Oral 10-5-5 mg/kg 
every 24 hours. Three courses 







Jan 2009 – 
Sept 2009 
GA< 34 weeks 
RDS+PDA (ECHO) 
 
PDA treatment: Oral 10-5-5 mg/kg 
every 24 hours. Second course of 
20-10-10mg/kg every 24 hours if 
PDA persisted 
15  
ECHO, echocardiography; hs, hemodynamically significant; PDA, patent ductus arteriosus; RDS, respiratory distress syndrome 
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 Characteristics of the retrospective cohort studies (n=26) 
Characteristics of the included retrospective cohort studies with comparison group(s) (16 studies) 













N = 99 
 
Indomethacin 















BW <1000 g 
Neonates with 
clinical symptoms 
and PDA (ECHO) 
N = 306 Indomethacin 











1995 - 2001 
GA < 30 weeks, 
BW ≤ 1300 g  
IV ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N = 20 
Indomethacin: three 
doses 0.2 mg/kg every 
12 hours 
N = 20 
No treatment 





No treatment  
=1 
Second course of 
same treatment if PDA 







GA < 28 weeks 
received either 
drug between 
days 2 and 14 












PDA (ECHO) Oral ibuprofen:10-5-
5 mg/kg every 24 
hours 
N = 22 
IV Indomethacin: three 
doses every 12 hours (< 
48 hours of life, 0.2 -0.1-
0.1mg/kg; 2–7 days of 
life 0.2 mg/kg; and > 7 







Study all included 
“mature infants” 
defined as ≥37 weeks 
gestational age. These 
were excluded from 
the review 










PDA (ECHO) with 
at least one dose 
of ibuprofen or 
indomethacin  
Oral ibuprofen:10-5-
5 mg/kg every 24 
hours 
N = 57 
Indomethacin: three 
doses every 12 hours 
intervals (< 48 hours of 
life, 0.2 -0.1 -0.1 mg/kg; 
2–7 days of life 0.2 
mg/kg; and > 7 days of 
life, 0.2 - 0.25 - and 0.25 
mg/kg). 
N = 65 
Ibuprofen 
 = 25 
Indomethacin 











treatment for PDA 
Ibuprofen:10-5-5 
mg/kg every 24 
hours 
N = 182 
 
Indomethacin: (< 750 g:  
0.2-0.1-0.1 mg/kg/dose 
; 750 g to 1 kg: 0.2-0.2-
0.2 mg/kg/dose 
; > 1kg: 0.2 
mg/kg/dose). 














BW <1500g, age 
48-96 hr, hs-PDA  
(ECHO) 
Oral ibuprofen:10-5-
5 mg/kg every 24 
hours 
N = 52 
IV indomethacin:(<48 
hours of life, 0.2 -0.1- 
0.1 mg/kg; 2-7 days of 
life, 0.2 mg/kg; & > 7 
days of life, 0.2 - 0.25 - 
0.25 mg/kg) 











Jan 2000 – 
June 2003 
PDA (ECHO)  IV ibuprofen:10-5-5 










 = 62 
No prophylactic 
indomethacin used. 









GA ≤ 32 weeks  Hs-PDA treated with 
ibuprofen 
N = 9 
PDA (not hs-PDA)- No 
treatment  




















doses every 12 hours of 
0.2 mg/kg, then 0.1 
mg/kg daily for six days; 













GA 24 -31 weeks; 
BW 500 - 1500 g, 
and survival > 7 
days 
IV ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N=96 
IV indomethacin: three 














Mar 2009- Feb 
2011 
GA < 32 weeks 
received at least 




IV ibuprofen: 10-5-5 
mg/kg every 24 
hours 
N=70 
IV indomethacin: three 













Jan 2005 – 
June 2008 
BW: < 1500 g  Early treatment: at 
day one of life: IV 
ibuprofen 10-5-5 
mg/kg every 24 
hours 
N=80 
A second course 
given, if ECHO 
confirmed PDA at 
day three 
IV indomethacin in 
neonates with PDA 















PDA after 48 




IV ibuprofen in three 
different cycles. 
Each cycle: 10-5-5 
mg/kg every 24 
hours 
N=201 












ECHO 24 hours after 
last dose of first cycle 
to determine 
subsequent courses 
and/ surgical ligation 










Jan 2007 – 
June 2011 
BW <1000 g with 
PDA (ECHO) 
Oral ibuprofen: 10-5-
5 mg/kg every 24 
hours 
N=22 
IV indomethacin: three 






ECHO performed after 
first dose to determine 
subsequent doses 
Characteristics of the included retrospective cohort studies compared different ibuprofen regimen (six studies) 








GA ≤ 28 weeks received 
course of prophylactic 
ibuprofen of 10-5-5 mg/kg 
every 24 hours 
Ibuprofen lysine 
N = 156 
Ibuprofen sodium 
N = 60 
Ibuprofen lysine = 41 
Ibuprofen sodium = 32 







Jan 2010–Dec 2013 
All neonates received IV 
ibuprofen 
Low-dose ibuprofen: 
10-5-5 mg/kg daily 
N = 44 
High dose ibuprofen: 
20-10-10 mg/kg daily 
N = 33 
Low dose= 45 
High dose = 32 








All neonates received 
ibuprofen for PDA  
High dose ibuprofen: 
20-10-10 mg/kg daily 
N = 23 
Low-dose ibuprofen: 
10-5-5 mg/kg daily 
N = 19 
Low dose= 3 
High dose = 3 
Total = 6 
 







Jan 2010 – Dec 
2014 
GA <37 weeks with clinical 
and/or PDA (ECHO) and 
received three doses of 
ibuprofen 
Standard:10-5-5 mg/kg 
every 24 hours 
N = 63 
High dose: 10-10-10 
mg/kg every 24 hours  
N = 63 
Low dose= 11 
High dose = 12 







Apr 2009 – Jun 2010 
hs-PDA (ECHO) at 24-48 
hours of age 
Oral = 24  
IV = 42 
10-5-5 mg/kg every 24 
hours. Second or third 
doses given if PDA 
persisted 
Oral = 39 
IV= 70 
Total = 109 
 





Nov 2005-sept 2011 
GA <32 weeks treated with 
ibuprofen 
IV ibuprofen: (10-5-5 
mg/kg every 24 hours) 
N=164 received one 
course; then 43 
received second 
course and 11 received 
third course 
First course= 14 
Second course=1 




ECHO performed 24 
hours after third dose 
to determine 
subsequent courses / 
ligation 
Characteristics of the included retrospective cohort studies without comparison group(s) (four studies) 
Study ID Setting Inclusion criteria 
 







Jan 2010-Dec 2014 
BW < 1500 g received 
ibuprofen for 
symptomatic PDA 
IV or oral: 10-5-5 mg/kg 
every 24 hours 







All neonates treated 
with ibuprofen 
Dose regimen not stated 
N = 227 
49 Conference abstract 






2008 – 2010 
Neonates with hs-
PDA 
Oral: 10-5-5 mg/kg 
every 24 hours 
ECHO after 3rd dose – 
if hs-PDA persists 
second and third course 







Jan 2007 – Oct 2009 
Neonates with PDA 
treated with ibuprofen 
IV ibuprofen: (10-5-5 
mg/kg every 24 hours)  
136  
BW, birth weight; ECHO, Echocardiography; GA, gestational age; hs, hemodynamically significant; PAH, pulmonary arterial hypertension; PDA, 
patent ductus arteriosus; RDS, respiratory distress syndrome 
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 A copy of the invite email letter to participate in the study  
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 Benzylpenicillin in neonatal drug formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-2 UNIT-3 UNIT-4 UNIT-5A UNIT-5B UNIT-6 
Indication  Treatment of 
infections for term 
and preterm 
neonates 
First line antibiotic if 
streptococcal infections 
suspected or proven 
Initial treatment of 
suspected sepsis 











 regimen  





• GA (< 30 weeks) 
and postnatal 
age > 28 days:  
50mg/kg 8 hourly 






• GA (30-36 
weeks) and 
postnatal age > 
14 days: 50 
mg/kg 8 hourly 
• GA (37-term) 
and postnatal 
age 0-28 days: 
50 mg/kg 8 
• <7 days: 50mg/kg 
12 hourly 
• 7 to 28 days: 
50mg/kg 8 hourly 
• >28 days: 50mg/kg 
6 hourly 





< 7 days: 
100 mg/ kg 
IV 12 hourly. 
If > 7 days: 8 
hourly. If > 28 
days: 6 
hourly 
• < 7 days: 
50mg/kg 
twice daily 





















daily, Term < 
7 days: 
50mg/kg/dose 
2 times daily. 
Term 7 to 28 
days: 
50mg/kg 











postnatal age > 
28 days: 
50mg/kg 6 hourly 
Instruction for 
administration  
IV over 5-30 minutes IV over 3-5 minutes 
Doses > 50mg/kg give 
IV infusion over 15 
minutes to avoid CNS 
toxicity 
Over 15 - 30 
minutes 
Not stated Not stated Slow IV Bolus / 





Cautions Avoid cephalosporins 
and other beta-
lactams in penicillin 
allergy 
For incompatible drugs 
use separate line. 
Flush between drugs 
Not stated Not stated Not stated Longer 
administration 
time in high doses 




adverse effects  
CNS toxicity and 
convulsions 
Not stated Not stated Adjust in renal 
impairment 




Comparison UNIT-7 UNIT-8 





Dosage regimen  • EOS: < 7 days: 25 mg/kg every 12 hours; 
change to 25mg/kg every 8 hours. 7-28 
days: 25 mg/kg every 8 hours (50 mg/kg 
every 8 hours in severe infection) 
50mg/kg 12 hourly up to 7 days 
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• Meningitis: < 7 days: 50 mg/kg every 12 
hours. Neonate 7-28 days: 50 mg/kg every 
8 hours 
Instruction for administration IV bolus over 3 - 5 minutes (peripheral) or IV 
infusion over 30 minutes 
IV 
Contraindications Not stated 
Cautions  high doses/severe renal impairment (CNS 
toxicity, convulsions)  
Not stated 
Monitoring for adverse effects  Not stated 
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  Gentamicin in neonatal drug formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-2 UNIT-3 UNIT-4 UNIT-5A UNIT-5B UNIT-6 UNIT-7 UNIT-8 
















<7 days: 5mg/kg 
36 hourly 






























< 7 days:  
5mg/kg/dose 36 hourly  
≥7 days: 









IV bolus over 3-5 
minutes 










Slow IV over 
at least 3 
minutes 
Contraindications  Not stated Not stated 





Not stated Not stated Not stated Not 
stated 
Ototoxicity Ototoxicity 
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Monitoring for 
adverse effects  
Trough: 6 
hours before 
3rd dose (6 
hours before 






































EOS, early onset sepsis; LOS, late onset sepsis  
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 Cefotaxime in neonatal drug formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-2 UNIT-3 UNIT-4 UNIT-5A UNIT-
5B 
UNIT-6 UNIT-7 UNIT-8 

























< 7 days: 50mg/kg 12 
hourly 
≥7 days: 50mg/kg 6-8 
hourly 
21-28 days: 50mg/kg 
6 hourly 
< 7 days: 50 
mg/kg 12 
hourly 
> 7 days: 
50mg/kg 8 
hourly 
> 21 days: 
50mg/kg 6 
hourly 
< 7 days: 25-
50 mg/kg 12 
hourly 
7-21 days: 25-
50 mg/kg 8 
hourly 
21-28 days: 




























































Not stated Not stated Not stated Not stated Not stated 
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Not stated Not stated Not stated Not stated Not stated 
Monitoring for 






Not stated Not stated Adjust in renal 
impairment 
 Not stated Not stated 
LOS, late onset sepsis; IV, intravenous  
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 Flucloxacillin in neonatal drug formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-2 UNIT-3 UNIT-4 UNIT-5A UNIT-5B UNIT-6 UNIT-7 UNIT-8 















Infections Skin and 
systematic 
infection   















50mg/kg 8 hourly 
 































Not stated < 7 days: 
25 mg/kg 
12 hourly 





















IV over 3-5 
minutes 


























Contraindications Not stated Not stated Not stated Not stated Not stated 
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Not stated Caution in 
hepatic 
impairment 
Not stated Cholestatic 
jaundice 
Monitoring for 
adverse effects  
Cholestatic 
jaundice 
Not stated Adjust in 
renal 
impairment 
Not stated Not stated 
IV, intravenous         
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 Caffeine (citrate) in neonatal formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-
2 
UNIT-3 UNIT-4 UNIT-5A UNIT-
5B 
UNIT-6 UNIT-7 UNIT-8 
Indication  Neonatal Apnoea 















Loading:                 
20 mg/kg 
(IV/oral)             
Maintenance 
(24 hour post 


































once daily IV 
infusion over 
10 minutes 



















10mg/kg daily  
Instruction for 
administration  
Slow IV over 30 
minutes.  
IV or oral 
centrally due 
to low pH but 

















Slow IV over 





slow IV over 
10 minutes 
Not stated 
Contraindications Not stated Not stated Not stated Not stated Not stated Not stated 
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GA of 34 
weeks 



















adverse effects  
if levels required, 
trough taken 
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 Morphine in neonatal drug formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-2 UNIT-3 UNIT-4 UNIT-5A UNIT-5B 













Dose regimen  • Analgesia: IV, 









Continue for at 
least a week. 
Reduce 
frequency at 2-7 
day basis to 6, 
8,12, and 24 
hourly. 












• Pain/sedation: IV: 
50-100 mcg/kg  
• NAS: 40 mcg/kg 








• NAS: 0.5 
mg/kg/day 





Bolus: 50 - 
100 mcg/kg 




• Sedation: 50 
mcg/kg over 
5 minutes, 
follow by  
infusion 
















IV over at least 5-10 
minutes 
Not stated Not stated Slow IV bolus Not stated Not stated 
Contraindications Not stated Not stated Not stated Not stated Not stated Not stated 
Cautions Increased 
susceptibility to 
Not stated Not stated Not stated Not stated Not stated 





adverse effects  
Respiration Not stated Not stated Do not use if 
hypotensive 
Not stated Not stated 
Comparison UNIT-6 UNIT-7 UNIT-8 









Dose regimen  • Sedation/analgesia: 
continuous IV in neonate-6 
months: 5-40mcg/kg/hour. 
• Intubation: IV 
100mcg/kg/dose One dose 
only. Repeated once if 
necessary  
• Intubation: IV 100 mcg/kg/dose, repeat if 
required 
• Pain: loading IV 50 mcg/kg/dose over at 
least 5 minutes then continuous IV 
infusion 5 - 20 mcg/kg/hour adjusted 
according to response 
• NAS: Oral 40mcg/kg 4 hourly,30mcg/kg 4 
hourly then 20mcg/kg 4 hourly then 
10mcg/kg 4 hourly. Reduced every 24-48 
hours if feeding well and settling between 
feeds 
• General dosing; IV bolus of 
25 – 100mcg/kg/dose over at 
least 5 – 10 minutes. 
Infusion: Loading 50 – 
100mcg/kg IV over 30 
minutes then 5-40 mcg/hour 
• Oral short-term pain relief: 
200mcg/kg orally, then 




Pain: IV preferred, IM used when 
no IV access.  
Not stated Not stated 
Contraindications Not stated Not stated Not stated 
Cautions  Do not flush a line containing 
morphine (potent drug) 
Not stated Not stated 
Monitoring for adverse 
effects  
Not stated Neonates with increased susceptibility to 
respiratory depression, have increased 
sensitivity and decreased metabolism of 
morphine 
Not stated 
NAS, neonatal abstinence syndrome; IV, intravenous 
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 Poractant in neonatal drug formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-2 UNIT-3 UNIT-4 UNIT-5A UNIT-5B UNIT-6 UNIT-7 UNIT-8 


































Dosage regimen  Treatment: 
200mg/kg, then 
100mg/kg 12, 
























































:120 mg in 
delivery 
suite to all 
neonates 















Not stated Intra-tracheal Not stated 
Contraindications  Not stated  Not stated  Not stated  
Cautions  
Monitoring for 
adverse effects  
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 Indomethacin in neonatal drug formularies and clinical practice guidelines 






































Indication  PDA-second line after ibuprofen PDA PDA PDA PDA-first line  
Dose regimen  All doses IV at 12-24 hours. 
Depending on the age at time of 
first dose: 
<48 hours: 200-100 -100 mcg/kg 
2-7 days: 200 - 200 - 200 mcg/kg 
> 7 days: 200-250-250 mcg/kg 
 
Or IV injection 100mcg/kg 24 
hourly for six doses 
 
IV: 100 mcg/kg 
once daily for six 
doses 
Alternative short 
course (if normal 











Prophylaxis: IV 200mcg/kg, 
then 100mcg/kg 12, 24, 48 
hourly 
Early symptoms (2-6 days): 
IV 200 mcg/kg -100 mcg/kg 
12, 24, 48 hourly. If PDA 
persisted after 4th dose, 
continue with 5th and 6th 
dose at 100mcg/kg 24 and 
48 hourly 
Late symptomatic (> 7 
days): IV 200mcg/kg , 
repeated every 12, 24, 48 












Over 20 minutes Not stated Over 20 – 30 minutes 
Contraindications History of asthma, angioedema, 
urticaria and rhinitis to aspirin or 
any other NSAID or with 
coagulation defect 
Not stated Not stated 
Cautions Reduces in cerebral blood flow (20-
minute infusion preferred to bolus) 






Reduces glomerular filtration Monitor renal 
function 
Withhold dose if urine output 
<1 ml/kg/hr during the 
preceding 8 hours 
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 Ibuprofen in neonatal drug formularies and clinical practice guidelines 
Comparison UNIT-1 UNIT-2 UNIT-3 UNIT-5A UNIT-5B UNIT-6 UNIT-7 UNIT-8 
Indication  PDA PDA PDA PDA PDA PDA  PDA PDA (2nd line) 
Dose regimen  IV doses 10-5-5 mg/kg 24 hourly. 
Repeat if PDA persisted after 48 hours of first course 
Not 
stated 
 IV doses 10-5-5 mg/kg 24 hourly. Repeat if PDA 
persisted after 48 hours of first course 
Instruction for 
administration  










Not stated Short 
infusion over 
15 minutes 









urticaria or rhinitis 












Cautions Use in renal, 


































Bleeding. If anuria or 
oliguria 
(<0.5ml/kg/hour) after 
1st or 2nd dose, 
withhold next dose 
until urine output rises 
at least 0.5ml/kg/hr 






No available information from UNIT-4 
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THE END 
